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Abstract
This thesis addresses abnormal Pap smears and clinical practice from three 
perspectives: a population perspective, the perspective of women who have 
abnormal Pap smears and from a health economic perspective. Exploring 
these perspectives reveals contradictions between them that inhibit the 
implementation of public health policy and amplify women's distress.
If a woman is found to have an abnormal Pap smear she may be referred for 
colposcopy or a repeat Pap smear may be recommended. This thesis 
considers the consequences of referring women who have an abnormal Pap 
smear for a colposcopy. The research was conducted in the Australian 
Capital Territory (ACT).
In 1989/90, in the ACT, an estimated one in forty women between ages 15 
and 74, had a colposcopy. On a lifetable simulation of a hypothetical cohort, 
it is estimated that if current patterns of referral for colposcopy continue 
three quarters of women will have a colposcopy by age 75. There is a 
mismatch between current clinical practice and population derived risks of 
cervical cancer.
To explore women's perspectives, 29 detailed individual interviews with 
women who had abnormal Pap smears were conducted. Following 
diagnosis, women experienced their risk of cervical cancer as part of 
themselves. They felt vulnerable and sought to manage their newly defined 
state of risk. Women felt that their risk required ongoing medical 
surveillance. This defined their cervix as an ongoing site of potential 
disorder.
Some women made sense of their state of risk by linking it to various life 
pressures. For example, several women associated their abnormality with 
stress or diet which offered avenues for reasserting control over their own 
health. They often found their gynaecological care unsatisfactory as their 
gynaecologists failed to engage with the meanings their abnormality held fo 
them. Often clinicians did not explain their approach and hence women 
lacked a conceptual framework within which to make sense of their 
treatment and its after-effects. There were conflicts between the way
clinicians approached women's abnormalities and the women's own 
accounts.
To explore abnormal Pap smears from a health economic perspective, I 
conducted a case note audit of 502 women who attended a Canberra 
colposcopy service because of an abnormal Pap smear between January 1 
1989 and April 30 1990. Women who had minor cytological abnormalities 
(CIN 1 or less) constituted the majority of the financial costs to government 
and women. In multiple linear regression analyses the severity of cytology 
was associated with costs to government and women however, other 
variables such as a woman's age also influenced costs. If implemented, new 
policy recommendations for the clinical care of women who have abnormal 
Pap smears would be less costly than the current approach. However, the 
new policy recommendations may not be effective because they do not 
recognise the complexity of clinical decision-making.
Twenty per cent of the clinic sample did not complete the follow-up 
recommended by their clinicians. In a multivariate analysis, women who had 
had treatment were more likely to discontinue attending than women who 
had not had treatment. Women younger than 25 were also less likely to 
continue attending. For women who had no past history of abnormal Pap 
smears, attendance was less likely if they did not have private health 
insurance. Out-of-pocket expenses may be a barrier to attendance for some 
women. Conflicts between the way women conceive their abnormality and 
the way gynaecological care is delivered may discourage some women from 
continuing to attend.
The thesis concludes with a discussion of how the research findings can 
contribute to public health policy and clinical practice. Directions for future 
research are also indicated.
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Part A
Opening the accounts
Chapter One
Introduction
This thesis considers current clinical practice and abnormal Papanicolaou 
(Pap) smears from a population perspective, from the perspective of women 
who have abnormal Pap smears and from a health economic perspective. I 
believe that each perspective should contribute to shaping public health 
policy and clinical practice.
Each perspective provides an account of abnormal Pap smears. The accounts 
may be descriptive, narrative or financial. To gather the accounts I have used 
methods from different disciplines. The population account employs 
demographic and epidemiological methods; women's accounts draw on the 
disciplines of sociology and anthropology; and the economic account uses 
health-economic and epidemiological methods.
Throughout the thesis 'abnormal Pap smear' refers to any cytological 
abnormality except invasive cancer. 'Abnormal', rather than 'positive', is 
used because cytological findings such as inflammation, mild atypia, human 
papillomavirus (HPV) infection and cervical intraepithelial neoplasia (CIN) 
are clinically conceptualised, understood and treated as deviations from 
normal.
For women's accounts I use the term cervical abnormality. All the women I 
interviewed had had a colposcopy and biopsy. Their 'abnormal' Pap smear 
had been investigated and defined in colposcopic and histological terms. The 
term 'cervical abnormality’ better encapsulates the characteristics of a 
condition defined using these different tests.
This thesis:
• describes age-specific patterns of Pap smear and colposcopy use
• considers the cumulative risk of colposcopy if current patterns of referral 
for colposcopy continued
describes the consequences for women of cervical abnormalities
• explores how women understand their cervical abnormality and the 
consequences they identify
• documents women's experiences of current clinical practice
• compares the costs of current gynaecological care on the basis of the level 
of presenting smear1
• documents the contribution of different levels of presenting smear to the 
total cost of the gynaecological care of women who have abnormal Pap 
smears
• computes the likely cost savings of alternative approaches to the treatment 
of abnormal Pap smears
• identifies the socio-demographic and clinical factors which predict 
economic costs
• identifies the socio-demographic and clinical factors which predict 
whether women complete the follow-up recommended by their clinicians.
Two economic costs are examined: costs to government and costs to women. 
Costs to government tend to drive policy while costs to women are of social, 
political and personal importance. The out-of-pocket expense of a service 
influences whether an individual can access that service. If costs are high 
some women may be unable to afford a particular service, such as 
colposcopy. Such a service would be inequitable and hence politically, 
socially and personally unfavourable. Clinicians are also concerned about 
costs to the users of their services. Hence costs to government and women 
are presented separately rather than as a total cost to society because they 
have different implications for policy and clinical practice.
The research for this thesis was conducted in Canberra in the Australian 
Capital Territory (ACT). In June 1992 the ACT had 295,700 residents, 1.7 per 
cent of Australia's population. The ACT has a higher than average per capita 
wage, lower unemployment rate, higher workforce participation rate and
1 By 'presenting smear' I mean the cervical cytological report that resulted in women's 
referral to a gynaecologist for colposcopy.
higher levels of education, than the rest of Australia. (Australian Bureau of 
Statistics 1993a).
The Commonwealth government funds a national universal system of health 
care financing called Medicare. The Health Insurance Commission manages 
the Medicare scheme. The Health Insurance Commission (HIC) provides 
benefits (under the Medicare scheme) for private inpatient and outpatient 
medical services. Individuals may also purchase private health insurance 
which covers some of the costs of inpatient services. Other ancillary health 
services may also be covered by private health insurance. Private health 
insurance also enables the choice of inpatient service provider. Public 
hospitals are managed by state and territory governments and are partially 
funded by grants to the states from the Commonwealth. Individuals 
admitted as public patients to public hospitals have no out-of-pocket expense 
but have no choice of doctor. Most public hospitals have outpatient services. 
There are no out-of-pocket costs to individuals attending public outpatient 
services.
The ACT has two public hospitals but no public colposcopy service. All 
colposcopy services are provided on a private outpatient basis. Most cervical 
cancer screening is performed by private general practitioners. Medical and 
nurse practitioners also provide cervical cancer screening services at 
community health centres, a women's health service and a family planning 
service.
Structure
The thesis is comprised of eleven chapters. In Chapter Two, I review the 
epidemiological and social science literature on abnormal Pap smears. I also 
describe Australian public health policy relevant to abnormal Pap smears.
Chapter Three details the population account of abnormal Pap smears. Using 
Medicare and laboratory statistics I describe current patterns of Pap smear 
and colposcopy use and simulate the population effects of current patterns of 
use.
In Chapter Four, I describe the methods used for the research on women's 
accounts of cervical abnormalities. Chapters Five through Seven describe 
the results of this inquiry. Chapter Five examines how women experienced 
their cervical abnormality as neither a state of health nor illness — rather it
was a state that defined them as being at ongoing risk of cervical cancer and 
death. In Chapter Six, I explore how women sought to manage this newly 
defined state of risk. Women's accounts of their interactions with the health 
system are detailed in Chapter Seven.
Chapters Eight through Ten present a clinical and economic account of 
abnormal Pap smears. The methods of this inquiry, sample characteristics 
and concordance between cytology, colposcopy and histology are described 
in Chapter Eight. The economic costs, for government and women, of 
current practice and new policy recommendations, are considered in Chapter 
Nine. In this chapter, I also examine how cost is influenced by various socio­
demographic and clinical variables. As 20 per cent of the clinic sample did 
not complete the recommended follow-up I use survival models to estimate 
how socio-demographic and clinical factors might be associated with non- 
attendance. The results of this analysis are reported in Chapter Ten.
Finally, in Chapter Eleven I overview the research findings and consider how 
they might reshape clinical practice and public health policy. I also 
recommend directions for future research.
Chapter Two
Setting the scene
This chapter describes the scientific and policy context in which the research 
conducted for this thesis was located.
The chapter examines the following questions: what is the historical context 
of cervical cancer screening; is cervical cancer a significant public health 
problem in Australia; are Pap smears efficacious; how should a screening 
program be organised; how are Pap smears reported; what is the natural 
history of cervical cancer; and, what is the appropriate clinical approach to 
abnormal Pap smears? Epidemiological literature is the main source of 
information. The chapter concludes with an overview of current Australian 
policy and abnormal Pap smears and a description of the relevant health 
economic and social science literature that address the economic and non­
economic costs of abnormal Pap smears.
Historical context
Although the Pap smear is well accepted as an efficacious screening test, 
previous uses of both the speculum and Pap smear have been harmful for 
some women.
Dr J Marion Sims 'invented' the speculum in the mid 1800s. When he 
inserted it into the vagina of a woman positioned 'all fours', he is purported 
to have said:
Introducing the bent handle of a spoon, I saw everything as no 
man had ever seen before...The speculum made it perfectly clear 
from the beginning... I felt like an explorer in medicine who first 
views a new and important territory. (Barker-Benfield 1976). p95
Sims, who had a self-declared hatred of the female pelvis, developed the 
speculum to perform operations on women who had fistulas between their 
bladder and vagina. These were initially performed on black slaves whom 
he housed in a building in his backyard. (Barker-Benfield 1976).
The vaginal speculum has been an instrument of women's oppression and a 
tool of women's resistance to that oppression. The speculum was used to 
examine Parisian prostitutes for signs of venereal disease in the 1830s. Any 
identified lesions were then treated with caustic solutions. When British 
gynaecologists tried to introduce the speculum to their practice in the mid 
nineteenth century they met with resistance because such examinations were 
regarded as inappropriate for 'virtuous' women. Such treatment was 
believed to change a woman's 'purity' and 'delicacy'. Further, it was thought 
that some women became addicted to these examinations and were 'uterine 
hypochondriacs'. (Walkowitz 1980).
In 1864 the British Parliament passed the first Contagious Diseases Act which 
enabled plain-clothes policemen to identify women who were 'common 
prostitutes' and require them to undergo fortnightly internal examinations. 
The Ladies' National Association, which formed with the leadership of 
Josephine Butler, fought the introduction of the Act on the basis that it 
constituted class and sex discrimination. (Walkowitz 1980).
George Papanicolaou originally collected vaginal cytology specimens from 
guinea pigs. Later he discovered that cervical carcinoma cells could be found 
on scrapings from the human female cervix and vagina. He first presented a 
paper on his findings at a 'race betterment conference' in Michigan in 1928. 
His work was initially poorly received and he did not publish his research 
until 1941. (Papanicolaou and Traut 1941; Barter 1992).
Since the 1960s the Pap smear (named after George Papanicolaou) has been 
widely used in the secondary prevention of cervical cancer through screening 
women who do not have symptoms of cervical cancer. The advent of cervical 
screening, the use of the speculum in routine gynaecological examinations 
and in pregnancy and childbirth means that most Australian women are now 
familiar with the vaginal speculum.
In the 1970s the speculum became part of the feminist self-help groups. It 
became a symbol of women seizing technology from medicine and gaining 
greater control over their own bodies. (Ehrenreich and English 1973). Some 
women's health books contain accounts of how to perform self-examination 
with a vaginal speculum.1
1 For example, for an account of vaginal self examination see The Boston Women's Health 
Collective 1971. p270
In the 1980s the work of Professor Herb Green, at the Royal Hospital for 
Women in Auckland, was exposed as unethical. It became a subject of 
international controversy. Professor Green believed that carcinoma in situ 
was not a precursor to cervical cancer. Women who had persistent 
carcinoma in situ after treatment were followed without any further 
treatment and without their consent for withholding treatment. Twenty-two 
per cent developed cervical cancer and five died. Colleagues, who were 
concerned about his practice, published the results of his clinical practice in a 
medical journal in 1984. (Mclndoe, McLean et al. 1984). The work was first 
brought to public attention by two feminists — Sandra Coney and Phillida 
Bunkle (a journalist and an academic) (Coney and Bunkle 1987). A national 
inquiry was subsequently held (Committee of Inquiry into Allegations 
Concerning Treatment of Cervical Cancer at the National Women's Hospital 
and into Related Matters 1988).
Our current understanding of cervical cancer screening has been made at 
considerable cost to women in the past two centuries.
Cervical cancer incidence and mortality
In 1988,1061 women in Australia developed cervical cancer and 345 women 
died from it. Cervical cancer was the seventh most frequent cause of cancer 
death for Australian women. The highest incidence of cervical cancer was 
among those aged 65 to 69 years. The incidence rates were similar for 
women aged between 35 and 84. Based on 1987 incidence rates, a woman's 
lifetime risk of developing cervical cancer was one in 90. (Australian Institute 
of Health and Welfare and the Australasian Association of Cancer Registries 
1994). In New South Wales in 1991 there were 361 new cases of cancer of the 
cervix and 105 cancer deaths. (Coates, McCredie et al. 1994).
In Australia, between 1950-1954 and 1975-1979 the age-standardised 
mortality rate from cancer of the cervix fell from 12.5 to 7.5 per 100,000 
person years. These rates were adjusted for the number of women who had 
undergone hysterectomy in each age group (and hence are no longer at risk 
of dying from cervical cancer). However, women bom after 1940 seem to 
have experienced increased rates of cervical cancer mortality at ages 30-34, 
35-39 and 40-44. Mortality rates may be decreasing for women bom after 
1955. (Holman and Armstrong 1987).
Between 1973 and 1982 in New South Wales the incidence and mortality rate 
from cancer of the cervix fell by 1.3 and 3.6 per cent per year respectively 
(McCredie, Coates et al. 1989). Thirty-five per cent of women who had 
cervical cancer in a series of 237 cases referred to a Sydney hospital had never 
had a smear (Wain, Farnsworth et al. 1992). Of 100 women referred to a 
Perth based hospital 61 had not had a smear prior to the diagnosis of their 
cancer (Holman, McCartney et al. 1981).
Overview of screening
Morrison (1992) describes screening as:
...the examination of asymptomatic people to classify them as 
likely, or unlikely, to have the disease that is the object of 
screening.
In the case of cervical cancer, screening should identify individuals who are 
likely to develop cervical cancer. The Pap smear test detects cervical 
cytological abnormalities that may develop into cervical cancer during a 
woman's lifetime. Morrison calls abnormalities that would not progress to 
cancer 'pseudodisease'. (Morrison 1992). The purpose of the Pap smear is to 
prevent invasive cervical cancer. It does not prevent preclinical disease. This 
distinction must be borne in mind when considering the natural history of 
cervical cancer discussed later in this chapter. (Morrison 1992).
Morrison (1992) provides a framework for considering screening. He 
identifies the characteristics of a disease suitable for screening and the 
characteristics of a suitable screening test. Diseases which pass through a 
preclinical phase, which do not produce symptoms, are suited to screening 
techniques. Screening identifies asymptomatic individuals in the preclinical 
phase of the disease. The preclinical phase begins when the pathological 
process first occurs. This is often indistinct. The preclinical phase finishes 
when a person develops symptoms that would lead to identifying the 
disease. A long preclinical phase makes a disease even more suitable for 
screening.
Another precondition for a screening test is that a diagnostic procedure is 
available to investigate people who have a positive result. For screening to 
be effective, treatment in the preclinical phase must confer an advantage over 
treatment at a later stage. That is, early treatment must reduce morbidity and 
mortality from the screened disease. (Morrison 1992).
8
A suitable test must distinguish between those with and those without 
preclinical disease. This distinction is often difficult to make because there 
may be considerable overlap in test measurements. For example, atypical 
cells on a cervical cytology specimen may occur in both women who do and 
do not have preclinical stages of cervical cancer. Whether a woman who has 
atypical cervical cells is considered screen-test positive depends on the 
criterion of positivity. This criterion is somewhere between clearly normal and 
clearly abnormal. If the criterion of positivity is low the test will have high 
sensitivity for preclinical disease, as most people with the disease will be 
detected. However, a lot of people without preclinical disease will be 
labelled screen test-positive and the test will have low specificity. On the 
other hand, a high criterion of positivity will result in low sensitivity and 
high specificity. A screening test should also be reliable. That is, it should 
produce similar results when repeated on the same person at a similar time. 
Once a possible screening test has been identified it should be evaluated.
Evidence for the efficacy of cervical cancer screening
Ideally a screening test should be evaluated in a randomised controlled trial 
in which a group is randomly invited to participate in a particular screening 
schedule. This schedule includes screening at specified intervals, protocols 
for the assessment of people who screen positive and treatment of those 
identified with preclinical disease. Another group is also randomly assigned 
to a control group, which receives no intervention or an alternative 
intervention with which one wants to compare the screening schedule. This 
alternative is usually the previously accepted best practice schedule. Groups 
are followed over many years to ascertain whether the screening program 
reduces morbidity or mortality from the screened disease. There have been 
no randomised controlled trials of the Pap smear in which the cervical cancer 
incidence and mortality of women who are offered screening is compared 
with women who are not screened. This is because Pap smears were 
introduced before such evaluation was considered necessary and it is now 
considered unethical not to offer screening to all women.
Other evidence for the efficacy of screening tests comes from non- 
experimental studies. Correlational and analytical studies provide the 
evidence for the efficacy of cervical cancer screening.
Time trend and geographical correlational studies from Canada and British 
Columbia (Miller, Lindsay et al. 1976; Anderson, Boyes et al. 1988), the 
United States (Cramer 1974), Norway (Magnus, Langmark et al. 1987), 
Denmark (Lynge 1983; Lynge, Madsen et al. 1989), Sweden (Pettersson, 
Bjorkholm et al. 1985), Iceland (Sigurdsson, Adalsteinsson et al. 1989) and 
Finland (Timonen, Nieminen et al. 1974) have demonstrated that cervical 
cancer screening can reduce the incidence of and mortality from cervical 
cancer. In contrast, cervical screening in the United Kingdom has been less 
effective in reducing incidence and mortality from cervical cancer (Murphy, 
Campbell et al. 1987). A comparison of cervical cancer mortality rates in the 
Nordic countries showed reductions in mortality between 1965 to 1982 of 
between 40 and 80 per cent for Sweden, Iceland and Finland. Denmark and 
Norway, who had less extensive 'organised' programs, did not experience as 
large a reduction in mortality. (Laara, Day et al. 1987).
Various case-control studies have demonstrated the preventive effect of 
cervical cancer screening. They have shown that women who participate in 
cervical screening have a reduced incidence of cervical cancer. Protective 
effects of between 40 and 90 per cent have been reported. (Clarke and 
Anderson 1979; Aristizabal, Cuello et al. 1984; La Vecchia, Franceschi et al. 
1984; Berrino, Gatta et al. 1986; Wangsuphachart, Thomas et al. 1987; 
Celentano, Klassen et al. 1988; Olsen 1988; Palli, Carli et al. 1990; Herrero, 
Brinton et al. 1992).
About 85 per cent of all cervical carcinomas are of the squamous cell type. 
The remainder are adenocarcinoma, adenosquamous and a mixture of other 
types. Most epidemiological studies have only demonstrated a protective 
effect of cervical cancer screening for squamous cell cancers.
An international collaborative study based on ten screening programs related 
the risk of invasive cancer to time elapsed since the last negative smear and 
the number of previous negative results. They concluded that smears 
performed up to three years previously provided 90 per cent protection 
against invasive cancer. They recommended that screening programs should 
be aimed at women between 35 and 60 years of age and the smears should be 
taken at least every three years. Annual or biennial smears did not offer 
much greater protection than triennial smears. (LARC Working Party on the 
Evaluation of Cervical Cancer Screening Programmes 1986). There were 
various methodological problems associated with that study, however. 
Individual studies used different definitions for a negative smear from that
initially agreed upon by the collaborating group. Some women without 
symptoms, who were detected as a consequence of screening, were included 
as cases. Inclusion of these women as cases will underestimate the beneficial 
effect of screening. Analytical studies may also be subject to bias because 
women who are screened are less likely to have cervical cancer. This is 
because women screened more frequently are less likely to have preclinical 
disease or a false negative test. To be screened frequently means one cannot 
have the disease the screen is designed to detect. Someone who has been 
screened frequently is also more likely to have been screened more recently. 
Therefore, case-control studies may overestimate the benefit of recent smears. 
(Morrison 1992).2
A screening program
A 'screening program' is the application of a screening test in a population 
and the diagnosis and treatment of the early disease. The Nordic countries, 
which have introduced organised screening programs for cervical cancer, 
have experienced the greatest reductions in incidence and mortality. Based 
on the Nordic experience, the International Agency for Research on Cancer 
(LARC) outlined the essential elements of an organised cervical cancer 
screening program. These are:
• the target population is identified
• individual women are identifiable
• measures are available to guarantee high coverage and attendance, such as
a personal letter of invitation
• there are adequate facilities for taking Pap smears and adequate laboratory
facilities to examine them
• there is an organised program for quality control of the taking of Pap
smears and their interpretation
\
• adequate facilities exist for the diagnosis and appropriate treatment and
follow-up of women who have confirmed neoplastic lesions
2 For a review of the methodological difficulties associated with case-control studies of 
screening see: Morrison 1982; Weiss 1983; Morrison 1992.
• there is a carefully designed and agreed upon referral system, an agreed
link between the women, the laboratory and the clinical facility for 
diagnosis of the abnormal screening test, for the management of the 
abnormality found and for providing information about normal screening 
tests
• there is evaluation and monitoring of the total program; that is, incidence
and mortality rates among those attending and not attending are 
described and there is quality control of epidemiological data. (Hakama, 
Miller et al. 1986), p289
Thus there are numerous steps involved in a population-based cervical 
cancer screening program. This thesis focuses on the final steps in a cervical 
screening program — what happens when women have an abnormal Pap 
smear result. In the remainder of this chapter I concentrate on issues directly 
relevant to abnormal Pap smears.
Cervical cytology, colposcopy and histology
The reporting of cervical cytology
Since the introduction of the Pap smear in the 1960s, several systems for 
reporting cytology have been used. These are presented in Table 2.1.
Initially Pap smears were divided into classes. (McKay, Terjanian et al. 1959). 
Govan et al. (1969) described the histological criteria for defining dysplasia 
(Govan, Haines et al. 1969). Because of the difficulty in differentiating 
between severe dysplasia and carcinoma in situ, Richart (1966) introduced a 
system in which precancerous smears were classified as cervical 
intraepithelial neoplasia (CIN) grades 1 to 3. CIN 3 corresponded with 
severe dysplasia and carcinoma in situ. Classification into grades of CIN 
depended on the proportion of the epithelium that had atypical nuclear 
changes. CIN 1 corresponded with one third of epithelial involvement and 
CIN 2 and 3 with two thirds and full thickness respectively. Previously 
dysplastic lesions and in situ lesions had been classified by the degree of 
cellular atypia or the proportion of the epithelium occupied by atypical cells. 
The CIN system of classification also accommodated a conceptual shift in 
thinking about the natural history of cervical cancer. At the time Richart 
introduced the CIN classification, the progression of precancer to cancer was 
thought to be a continuous process rather than occurring in discrete stages.
(Richart 1966; Buckley, Butler et al. 1982). Buckley (1982) also argued that the 
CIN classification made clinical sense because the distinction between benign 
atypical lesions and CIN provided a guide to clinicians. All CIN lesions 
should be considered as having similar prognoses and hence the approach to 
clinical care of women who had any grade of CIN should be similar. CIN 
should be considered as signifying a significant future risk of cervical cancer. 
(Buckley, Butler et al. 1982).
Table 2.1 Reporting systems for cervical cytological specimens
C la s s  s y s te m  (M cK ay, (R ich art 1 966). B e th e s d a  (N ational (C o m m o n w e a lth
T e rja n ia n  e t  al. 1 9 5 9 ). C a n c e r  Ins titu te D e p a rtm e n t of H u m an
W o rk sh o p  198 9 ). S e rv ic e s  a n d  H ealth  
1 9 9 4 ).
1. S p e c im e n  a d e q u a c y 1. R e p o rt c a te g o ry
C la s s  1 - N orm al
N orm al
2. G e n e ra l c a te g o ry N o rm a l
In c lu d e s  s m e a r s  w ith no
3. D esc rip tiv e  d ia g n o s is a b n o rm a litie s  a n d  th o s e
C la s s  2  - S u s p ic io u s (i) In fection w ith m in o r re a c tiv e  
c h a n g e s  only)
(ii) R e a c tiv e  o r 
re p a ra tiv e  c h a n g e s L o w  g ra d e  e p ith e lia l 
a b n o rm a litie s
(iii) Low  g ra d e  ep ith e lia l ( In c lu d e s  c h a n g e s  of
C la s s  3A  - V ery  m ild cell a b n o rm a litie s : H PV  a n d  CIN 1. A lso
d y s p la s ia CIN 1 (e q u iv a le n t to  mild S q u a m o u s in c lu d e s  e n d o c e rv ic a l
d y sp la s ia ) (e q u iv a le n t to  CIN 1 a n d ce lls  d e m o n s tra tin g
C la s s  3B  - Mild H PV  a n d  mild d y sp la s ia ) m inor g la n d u la r
d y s p la s ia G la n d u la r c h a n g e s )
C la s s  3 C  - M o d e ra te CIN 2 (e q u iv a le n t to (iv) H igh g ra d e In co n c lu s ive
d y s p la s ia m o d e ra te  d y sp la s ia ) ep ith e lia l ab n o rm a litie s : 
S q u a m o u s H ig h  g ra d e  n o n -
CIN 3  (e q u iv a le n t to (e q u iv a le n t to e p ith e lia l les ion s
C la s s  3D  - S e v e re s e v e r e C IN 2/C IN 3 a n d e g  s a r c o m a s
d y s p la s ia d y sp la s ia /c a rc in o m a  in m o d e r a te /s e v e re
situ) d y s p la s ia /c a rc in o m a  in H ig h  g ra d e  e p ith e lia l
situ) a b n o rm a litie s
C la s s  4  - C a rc in o m a  in G la n d u la r (i) In traep ith e lia l le s io n s
s itu
(v) In v as iv e  c a rc in o m a
(th is in c lu d e s  s q u a m o u s  
a n d  g la n d u la r  ce lls
S q u a m o u s c h a n g e s  e q u iv a le n t to
C la s s  5  - In v as iv e  
c a rc in o m a
G la n d u la r CIN 2 o r 3)
(vi) N o n -ep ith e lia l 
m a lig n a n t n e o p la s m
(ii) In v as iv e  le s io n s
Recently the Bethesda system has been introduced. In this system 
precancerous changes are divided into two distinct groups: low and high 
grade squamous intraepithelial lesions (LGSIL and HGSIL). Low grade 
abnormalities are equivalent to CIN 1 and HPV infection (koilocytosis); high 
grade abnormalities correspond with CIN 2 and 3. (National Cancer Institute 
Workshop 1989; Broder 1992). The amalgamation of HPV change and CIN 1
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into one reporting category is logical because they have a similar natural 
history and in practice it has been difficult to differentiate HPV and CIN 1. In 
contrast, CIN 2 and 3 are associated with different HPV types than CIN 1 and 
are more likely to progress to cancer. (Richart 1990; Kurman, Malkasian et al. 
1991). Low grade squamous intraepithelial lesions (LGSIL) appear to be 
associated with HPV types that are not associated with invasive cancer 
whereas high grade squamous intraepithelial lesions (HGSIL) are more 
commonly associated with virus types that have been related to cervical 
cancer (Kiviat, Critchlow et al. 1992). It is suggested that LGSILs are 
transient HPV infections which confer women with a higher risk of 
developing a HGSIL. LGSIL and HGSIL are considered to be distinct entities 
rather than part of a disease continuum. (Kiviat, Critchlow et al. 1992).
The Bethesda system was introduced to improve reproducibility; achieve 
better concordance between cytological, colposcopic and histologic findings; 
to represent more accurately current understandings of the natural history of 
cervical cancer; and, to improve communication between clinician and 
pathologist (Kurman, Malkasian et al. 1991). The Papanicolaou and CIN 
reporting systems have poor inter- and intra-observer reliability. In contrast, 
the Bethesda system appears to have better reproducibility (Sherman, 
Schiffman et al. 1992).
Until recently there were no uniform guidelines for the reporting of cytology 
in Australia. Both the Papanicolaou and CIN systems were used. The 
frequency of minor abnormalities reported by laboratories has varied. In 
Victoria, in 1992 the frequency of abnormalities showing minor reactive or 
inflammatory changes ranged from one to 44 per cent (Mitchell and Higgins 
1993). Guidelines have recently been released for the reporting of cervical 
abnormalities in Australia. These guidelines follow a similar format to the 
Bethesda system. (Commonwealth Department of Human Services and 
Health 1994).
Concordance between cytology, colposcopy and histology
Inter- and intra-observer reliability for cervical cytology, colposcopy and 
histology is poor. Concordance between cytology and colposcopy and 
histology is also low.
In 1992 in Victoria 86 per cent of women who received a cytology report of 
CIN had a subsequent histologic or colposcopic report that was the same or
within one grade of their cytology report. (The colposcopic findings were 
used if no biopsy was taken.) Fifty-seven per cent of women had cytology 
and histology or colposcopy reports of equivalent grade. (Mitchell and 
Higgins 1993).
Usually, cytology results are compared with the histology report (and 
occasionally the colposcopy findings) to determine the accuracy of cervical 
cytology. Colposcopy and histology can also be inaccurate, however. For 
example, colposcopy and direct punch biopsies may miss significant lesions 
found on cone biopsy (Skehan, Soutter et al. 1990). Inter-observer reliability 
for histology is often poor, particularly for low grade CIN. CIN 1 is not easily 
distinguished from reactive squamous proliferations of the epithelium. 
(Ismail, Colclough et al. 1989; Robertson, Anderson et al. 1989).
A major concern is that women with low grade cytology reports may have 
more significant disease when a biopsy is taken. For example, a small 
proportion of women with cytology reports of inflammatory or squamous 
atypia may have histologic reports of CIN. Another concern is that women 
with CIN 1 on Pap smear may have a higher grade lesion on biopsy. Studies 
examining the proportion of women with minor cytological abnormalities 
who have histological evidence of a higher grade lesion are reviewed later in 
the chapter.
In clinical practice, the reliability of cytology and histology might be even 
poorer. Studies of reliability of particular measures use agreed-upon 
classification systems. Most studies involve experienced pathologists. Until 
recently there has not been uniform criteria for the reporting of pathology in 
Australia. Pathologists and cytotechnicians with a range of experience report 
on specimens.
The accuracy of cervical cytology
The reported inaccuracies of cervical cytology have been of concern. Recent 
court cases have brought this to public attention.3
Of most concern is the frequency of false negative reports. That is, the 
sensitivity of cervical cytology is poor. False negative reports can be a 
consequence of reporting or sampling error. Although the concept of 
sensitivity (the probability that someone with the disease will have it 
detected on a screening test) appears to be straightforward, dilemmas arise 
when one attempts to define what constitutes a positive screening test and 
disease. In theory, in order to calculate the sensitivity of a test in a particular 
setting all participants should have a diagnostic test which establishes 
whether or not the disease is present; then, those with falsely negative 
screening tests can be identified. In the context of an ongoing program this is 
impractical. Measures of sensitivity are also likely to be falsely elevated in 
these circumstances since women with symptoms may be screened and are 
more likely to be followed up regardless of their screening test result and 
cytotechnicians may pay more attention to smears from a woman where 
symptoms are reported (Mitchell 1989).
A positive screening test might be defined as one that results in referral of the 
woman for further investigation. Practice has varied in this regard. Some 
clinicians and their clients might chose to seek further investigation for minor 
levels of abnormalities; others might consider referral only if the smears 
report is of CIN 2 or greater.
3 Two actions have recently been taken against a private and a public laboratory. One court 
case involved a woman with invasive disease who had symptoms of intermenstrual and 
postcoital bleeding. Pap smears were reported as normal. The woman, who lived in Sydney, 
sued the pathology laboratory for missing significant pathology on her smear and her 
general practitioner for failing to refer her when she had symptoms. She was awarded over 
$400,000. She died soon after the court case.
Action was recently taken against a public laboratory by a woman who received a false 
negative report and subsequently developed cervical cancer. There was an out of court 
settlement for an amount similar to the Sydney case.
In cervical cancer screening emphasis is on detecting precursor lesions. In 
this situation, precursor lesions might be conceived as disease. The definition 
of precursor lesions is unclear, however. The sensitivity of the Pap smear 
varies for different grades of abnormality and large lesions are more readily 
detected than smaller lesions (Giles, Hudson et al. 1988; Barton, Jenkins et al. 
1989).
Later in the chapter I discuss how many women with CIN or HPV would 
never develop cervical cancer. The lower the grade of CIN, the less likely the 
lesion will progress to invasive cancer. Those women who have lesions that 
will not progress have what Morrison refers to as 'pseudodisease'. Can these 
women be considered 'true positives' even though they have precursor 
lesions that would not develop into invasive disease?
The aim of a cervical cancer screening program is to reduce morbidity and 
mortality from cervical cancer in the population. It is not to prevent 
precursor lesions. Therefore, sensitivity may be better considered in the 
context of the program itself. Program sensitivity is 'the proportion of cases 
found as a result of screening among cases that arise during the screening 
program' (Morrison 1992). Does the screening test detect disease in those 
participating in the screening program or does it prevent disease amongst the 
population to whom it is offered? In Australia, it is estimated that screening 
prevents 46 per cent of cervical cancers (Australian Health Ministers' 
Advisory Council. Cervical Cancer Screening Evaluation Committee 1991). 
One might consider, therefore, the sensitivity of Australia's cervical cancer 
screening program to be 46 per cent. Uptake of the screening tests, the 
interval for screening and screening test sensitivity all affect the above 
calculation.
The interval cancer rate is related to program sensitivity. Interval cancers are 
those cases of cancer detected in women who have negative results within a 
specified time period after a screening test, for example, three years. These 
women might be considered to be false negatives of the screening program. 
They include women who have a false negative test (reporting or sampling 
error) or those who develop rapidly growing new cancers. For established 
screening programs, the interval cancer rate also gives an indication of a 
screening test's accuracy (Mitchell 1989). Between 1982 and 1986 in Victoria, 
the interval cancer rate for women younger than 35 and between 35 and 69 
years was 10 per 100,000 women years and 16 per 100,000 women years, 
respectively (Mitchell, Medley and Giles 1990).
Specificity is another measure of a screening test's validity. Specificity refers 
to the probability that someone who does not have the screened disease has a 
negative screening test. The false positive rate is one minus the specificity.
Pap smears may be specific for preclinical disease. They may accurately 
discern those who do not have precursor lesions. However, because most 
women would not develop cervical cancer in their lifetime, the specificity of 
the program for cervical cancer may not be high enough. That is, a large 
proportion of women who would not develop the disease will be referred for 
further investigation (screen-test positive with 'pseudodisease'). These 
women could be considered to have false positive results because they would 
never develop cervical cancer.
The quality of cervical cytology
A satisfactory smear should sample sufficient cellular material from the 
transformation zone, be maintained in a good state of preservation and have 
clearly visualised cellular material unobscured by blood or inflammatory 
material. (Commonwealth Department of Human Services and Health 1993).
Endocervical cells are used to judge whether cells have been sampled from 
the transformation zone or above. Because neoplastic changes occur in the 
transformation zone it is imperative that adequate cells are sampled from this 
area. It is also suggested that smears with endocervical cells are more likely 
to detect precursors of adenocarcinoma.
Smears lacking an endocervical component are often judged suboptimal and 
re-screening earlier than the regular interval is recommended. The concern is 
that if smears lack an endocervical component then precursors of cervical 
cancer may be missed. However, this concern may not be substantiated 
empirically. Mitchell and Medley (1991) performed a longitudinal study 
comparing the rate of subsequent abnormalities amongst women whose 
smears lacked an endocervical component with a control group of women 
who had negative smears and endocervical cells. They hypothesised that if 
smears lacking an endocervical component were more likely to miss 
important abnormalities, then this group of women should have a higher rate 
of CIN on subsequent smears than the control group. No significant 
difference in the rate of CIN was found between the two groups. (Mitchell 
and Medley 1991).
Rates of abnormal Pap smears
Between 1970 and 1988 the crude rate of CUM reported on cytology in Victoria 
increased almost sevenfold, from 4.6 per 1000 to 17.7 per 1000. The age- 
adjusted increase was 390 per cent. The rate of CIN 3 decreased. CIN 
became more prevalent in younger age groups in the later years of the study. 
(Mitchell and Medley 1990). Mitchell and Medley (1990) estimated that the 
ratio of women receiving a report of CIN in their lifetime to women who 
would develop cervical cancer is 148:1. Proposed explanations for the 
change in the rates of CIN were that the natural history of CIN had changed 
and that there had been a shift in reporting practices towards more frequent 
reporting of CIN. A South Australian hospital-based laboratory study also 
reported increases in CIN between 1977 and 1981, particularly in the younger 
age groups. (MacCormack, Lew et al. 1988). Until recently Victoria was the 
only state in which there were population-based figures on cervical cytology. 
However, it is likely that the trends in CIN reported in Victoria also occurred 
in other parts of Australia.
In 1992,12.9 per cent of smears registered with the Victorian Cervical 
Cytology Registry were abnormal; 9.6 per cent showed minor reactive, 
inflammatory or mildly atypical changes only. CIN 1 and CIN 2/3 were each 
reported on one per cent of smears. Large variations (of orders of 
magnitude) between the rate of reporting of abnormalities was found 
between laboratories. The rate of abnormal smears reported by laboratories 
ranged from 4.4 to 47.3 per cent. The reporting of minor abnormalities with 
no evidence of CIN ranged from 1.4 to 43.9 per cent. There was less variation 
in the reporting of CIN. (Mitchell and Higgins 1993). Clearly these 
differences cannot only be explained by different populations of women.
Such differences would not explain the forty fold difference in the reporting 
of minor abnormalities. Differences in reporting practice probably affect the 
varying rates of abnormal Pap smears found in laboratories.
Syrjanen et al. (1990) modelled the lifetime risk of receiving a cytology report 
indicating HPV infection based on current incidence rates. He estimated that 
79 per cent of women would receive a cytology report indicating wart virus 
infection based on current reporting practices and incidence rates for 22-year- 
old women in Finland. (Syrjanen, Hakama et al. 1990). Even if this were 
inflated by a factor of ten, many more women will receive a cytology report 
of HPV than will ever develop cervical cancer.
Richart and Wright (1993) suggests that the increase in the reporting of 
abnormalities of uncertain significance may have occurred because 
pathologists are increasingly concerned about missing an abnormality in 
women who later develop cervical cancer. In contrast, they believe clinicians 
would prefer fewer reports of minor abnormalities so that they increase the 
probability that women they refer have significant disease and hence are 
likely to benefit from further treatment. (Richart and Wright 1993).
The role of human papillomavirus
Cervical cancer has been related to smoking, age of first sexual intercourse, 
number of sexual partners (both the woman and her male partner/s), 
socio-economic status, HPV infection, herpes simplex virus infection and the 
oral contraceptive pill. Recently, intake of vitamins A, C and E have received 
research attention. I do not review the literature for all the risk factors for 
cervical cancer and its precursors. Instead, I provide a brief overview of the 
current state of knowledge about wart virus infection since this condition 
presents clinical dilemmas regarding appropriate care.
Wart virus infection (HPV) has different morphological manifestations. It 
can present as frank warts resulting in condyloma acuminatum or flat 
condyloma (clinical infection) or it may only be evident on cervical cytology 
or colposcopy (subclinical infection). It may also be latent. Latent infection 
can only be identified virologically, using techniques that detect viral DNA. 
Someone with HPV infection may move between the clinical, subclinical and 
latent phases of infection.
Human papillomavirus is a DNA virus that inserts into the nucleus of human 
cells. About 70 types of HPV have been identified, some of these have been 
related to anogenital cancers (penile, vulval, anal and cervical cancer).
Early epidemiological studies of cervical cancer concentrated on the link 
between sexual activity and cervical cancer. Studies that compared the rates 
of cervical cancer of nuns with other women (Rigoni-Stem 1842 reprinted 
1987; Gagnon 1950; Fraumeni, Lloyd et al. 1969) have become folklore. In 
fact, Rigoni-Stem, the earliest of the researchers, compared the ratios of 
uterine to breast cancer in 'nubile' women (nuns included) and married 
women. The ratio was 1 to 4 for women who had never married and 1 to 2 
for married women. Cancer of the breast was much more common in nuns. 
He did not separate cancer of the body of the uterus from the cervix. (Rigoni-
Stern 1842 reprinted 1987). The misquoted lower rate of cervical cancer (or 
uterus) amongst nuns has been taken to suggest that sexual activity was 
related to cervical cancer because nuns were, presumably, celibate.
Griffiths (1991) reviewed the evidence relating to cervical cancer among 
nuns. He found that many of the studies had been misquoted. Some had 
even concluded that nuns had rates of cervical cancer similar to other women 
but had been quoted as supplying evidence in support of the low risk of 
cervical cancer among nuns. Most studies had serious methodological flaws. 
He concludes:
there is no substantial objective evidence for the dogma that 
cervical cancer is rare among nuns. (Griffiths 1991). p802
Yet the studies on nuns still influence practice. New regulations in Britain 
require general practitioners (GPs) to achieve 80 per cent participation of the 
women registered in their practice in cervical cancer screening. Payments are 
linked to them achieving this target. A conservative MP raised the issue in 
the House of Commons, concerned that GPs may be unable to reach their 
target because they had nuns, virgins and spinsters on their books: a GP with 
a convent on the books stood to lose £1000 or more. The conservative party 
supported a motion to exclude nuns and spinsters from the group of women 
targeted for cervical screening. (Warden 1990).
Recent studies have found that sexual activity is associated with cervical 
cancer and CIN (Cuzick, De Stavola et al. 1989; Slattery, Overall et al. 1989; 
Cuzick, Singer et al. 1990; Herrero, Brinton et al. 1990; Jones, Brinton et al. 
1990; Parazzini, Hildescheim et al. 1990; Parazzini, LaVecchia et al. 1992; de 
Vet, Knipschild et al. 1993). The most popular explanation for the consistent 
relationship between sexual activity and cervical cancer or CIN has been that 
cervical cancer is related to a sexually transmitted agent. Lately HPV 
infection has been identified as the probable link between sexual activity and 
cervical cancer.
Measuring HPV
The greatest barrier to assessing the relationships between HPV infection, 
sexual activity and cervical cancer has been with problems in accurately 
measuring HPV infection. Recent advances in molecular biology have 
contributed to this field; it is now possible to detect HPV DNA in human 
tissue.
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A variety of techniques have been used, most popular of which have been the 
Southern blot, dot blot, filter in-situ hybridisation (FISH) and, most recently, 
PCR-based techniques. Serological tests are also being developed but have 
not yet been used in large-scale epidemiological studies. The different 
techniques have variable validity and reliability. Often, the sensitivity and 
specificity of the techniques are tested against clean model systems such as 
purified DNA which do not reflect the clinical conditions or field conditions 
under which they are used (Lorincz 1992). Alternatively the validity of the 
techniques is tested against Southern blot which has been used as the ’gold 
standard'. The Southern blot requires biopsy specimens. This is not possible 
in epidemiological studies where control subjects do not have any evidence 
of disease. Schiffman (1992) reviewed the validation of different 
hybridisation assays. In his review he cites unpublished work which 
illustrates the relatively poor reliability of all methods. Between laboratory 
and within laboratory comparisons demonstrate poor reproducibility. Slight 
differences in the use of the same techniques in different settings make it 
difficult to compare the results. He concludes that Southern blot is superior 
to all but the polymerase chain reaction (PCR) based methods which are 
capable of detecting one HPV DNA molecule in 105 cells (Young, Bevan et al. 
1989). Schiffmann concludes that while a Southern blot requires a large 
sample to be sufficiently sensitive, both the PCR and dot blot methods are 
useful techniques for epidemiological studies. In contrast, the sensitivity and 
specificity of FISH too low. However, he maintains that there is a critical 
need for a reference centre to develop standards to enable comparisons 
between laboratories. Another study which compared Southern blot, dot blot 
and PCR found that the intra- and inter-test reliability was reasonable. They 
found that Southern blot and dot blot were less sensitive for women without 
neoplasia than women with invasive cervical cancer. (PCR was the gold 
standard used to assess the sensitivity of these tests.) (Guerroro, Daniel et al. 
1992).
It is important to have a valid and reliable technique to measure HPV 
because misclassification of HPV status can significantly bias the results of 
epidemiologic investigations (Munoz, Bosch et al. 1988; Franco 1991; Franco 
1992; Schiffman and Schatzkin 1994). Poor specificity is likely to overestimate 
the prevalence of HPV in the general population. In case-control studies of 
cervical cancer and HPV, poor specificity and sensitivity of HPV 
hybridisation techniques, which result in non-differential misclassification of 
exposure status for case and controls, will underestimate the strength of the
relationship between HPV and cervical cancer. (Franco 1991). This form of 
misclassification error was postulated as a reason why early analytic studies 
failed to demonstrate a consistent relationship between HPV infection and 
cervical cancer (Munoz, Bosch et al. 1988). Franco (1992) suggests, however, 
that misclassification of HPV status may not have been random between 
cases and controls. Instead, the techniques may be more sensitive for HPV in 
cases than controls partly because different specimens are collected from 
cases and controls. Schiffman and Schatzkin (1994) show how two similar 
case-control studies designed to assess the relationship between HPV and 
CIN found odds ratios of different orders of magnitude because of the 
different techniques used to assess HPV exposure.
Studies that investigated the relationships between HPV infection and 
cervical cancer, CIN and sexual activity in the 1980s, were hampered by the 
difficulties in measuring HPV infection. Hence the findings of these studies 
are now questioned.
The nature of the association between HPV and cervical cancer
An international workshop, organised by the International Agency for 
Research on Cancer, considered that the association between HPV and 
cervical cancer was causal. (Munoz, Bosch, Shah et al. 1992). In a review of 
the evidence, Munoz and Bosch drew this conclusion for five reasons: the 
relationship between HPV and cervical cancer was strong and consistent 
across several case-control studies; risk appeared to be related to a limited 
number of viral types; the viral load risk was related to cervical cancer risk 
implying a dose-response relationship; indirect evidence suggested that the 
presence of HPV DNA in neoplastic cells pointed to prior infection with 
HPV, indicating the temporality of the relationship (which cannot be 
established in case-control studies); and, the risk of progression to cervical 
cancer is higher for HPV types 16 and 18, both associated with cervical cancer 
in the case-control studies (Munoz and Bosch 1992). Since 1992 further 
evidence has emerged to support this conclusion. This is reviewed below.
A recent case-control study demonstrated that HPV infection was strongly 
related to the number of the woman's sexual partners (Kataja, Syrjanen et al. 
1993). Another study has failed to demonstrate such a clear link (Villa, 
Franco et al. 1989). Case-control studies of HPV and sexual activity have used 
cytology or the less sensitive HPV DNA hybridisation methods to define
HPV status. These methods may have resulted in some misclassification of 
cases and controls.
In a case-control study of women who reported only one lifetime male sexual 
partner, their male partner's sexual history was associated with a much 
higher risk of cervical neoplasia. A history of male genital wart virus 
infection and non-use of condoms was also associated with a higher risk of 
cervical cancer. The association between women's male partners' sexual 
history and risk of cervical cancer was not statistically significant when male 
genital wart virus infection, condom use and age were controlled for in a 
multivariate analysis. This finding suggests that the association between a 
male partner's sexual history and women's risk of cervical cancer is likely to 
be due to a sexually transmitted agent, probably of wart virus infection. This 
was a small case-control study, however. (Kjaer, de Villiers et al. 1991).
Recent case-control studies using more sensitive PCR-based techniques for 
detecting HPV DNA consistently demonstrate a very strong relationship 
between cervical neoplasia (both cervical cancer and CIN 3) and HPV 
infection. (Munoz, Bosch, de Sanjose et al. 1992; Bosch, Munoz et al. 1993; 
Morrison, Ho et al. 1991; Schiffman, Bauer et al. 1993; Eluf-Neto, Booth et al. 
1994; Peng, Liu et al. 1991). Odds ratios of between ten and 70 are reported. 
Such high odds ratios are rare in cancer epidemiology and suggest a causal 
relationship between HPV infection and cervical cancer. These findings are 
consistent with biological evidence that shows that particular proteins 
produced by HPV deactivate human tumour suppressor genes (Scheffner, 
Munger et al. 1991; Crook, Wrede et al. 1992).
HPV 16 has been most commonly implicated. Other types such as 18, 31, 33, 
35 are also associated with higher risk of cervical cancer. After controlling for 
HPV status, the number of a woman's sexual partners became insignificant, 
suggesting that HPV infection explained the relationship between sexual 
activity and cervical cancer (Bosch, Munoz, de Sanjose et al. 1992; Schiffman, 
Bauer et al. 1993; Eluf-Neto, Booth et al. 1994). There also appears to be a 
relationship between risk of cervical neoplasia and viral load, implying a 
dose-response relationship (Reeves, Brinton et al. 1989; Morrison, Ho et al. 
1991; Munoz, Bosch, de Sanjose et al. 1992). Two methods were used to assess 
viral load: an assessment of intensity of the HPV signal and the number of 
different HPV DNA hybridisation assays (PCR, Southern blot and ViraPap) 
which were positive. If the specimens were positive on all of the tests it was 
assumed that the viral load was high, whereas if the specimens were positive
only on PCR-based tests then the viral load was assumed to be low. None of 
the studies discusses the reliability and validity of the techniques used to 
assess viral load. The association between viral load and risk of cervical 
cancer needs further exploration. Previous use of oral contraceptives was 
associated with increased risk of cervical neoplasia in the IARC case-control 
studies. This was specific to women who had evidence of HPV infection on 
PCR-based detection techniques. A possible explanation for this finding is 
that oral contraceptives promote the oncogenic potential of HPV. (Munoz, 
Bosch et al. 1994).
Thus far I have reported evidence from retrospective case-control studies 
demonstrating a link between HPV infection, CIN and cervical cancer. One 
possible explanation for this association is that cervices with neoplastic 
change are more liable to HPV infection or that HPV DNA detection 
techniques are more sensitive to HPV infection in neoplastic tissue.
Longitudinal studies that follow women with HPV infection will give further 
insight into the natural history of HPV infections. A recent study followed a 
cohort who had negative cytology. Women who were HPV DNA positive on 
dot blot hybridisation had a cumulative incidence of CIN 2 or 3 of 28 per cent 
at two years compared with a cumulative incidence at two years of 3 per cent 
amongst HPV negative women. Women testing positive for HPV types 16 
and 18 had the highest risk of progression. (Koutsky, Holmes et al. 1992). 
Other prospective studies using HPV DNA hybridisation methods are in 
progress. In a cohort of Finnish women with evidence of HPV infection on 
biopsy but with no CIN, 5.8 per cent developed CIN 1 or greater in a mean 
follow-up time of 45 months (Kataja, Syrjanen et al. 1989). In an Australian 
study, 13 per cent of women with cytological evidence of HPV infection in 
1979 developed cytological or histological evidence of CIN over a six year 
follow-up period. Their risk of developing carcinoma in situ was 16 times 
greater than that expected on population incidence figures. (Mitchell, Drake 
et al. 1986). These studies use cervical intraepithelial neoplasia as an 
endpoint because following women until they develop cervical cancer is 
unethical. They do not, therefore, give us information about risk of cervical 
cancer associated with HPV infection. Such information is extrapolated from 
information we already have regarding the natural history of CIN.
Prevalence of HPV infection
With the advent of new HPV detection techniques several studies have 
examined the prevalence of different HPV types in women with normal 
cytology, mild atypia, CIN and cervical cancer. An increasing prevalence of 
HPV is apparent as the severity of the Pap smear abnormality increases 
(Zhang, Coppleson et al. 1988; van den Brule, Walboomers et al. 1991; de 
Roda Husman, Walboomers et al. 1994). Low grade lesions demonstrate a 
greater degree of heterogeneity of HPV types than higher grade lesions 
(Lungu, Sun et al. 1992; de Roda Husman, Walboomers et al. 1994). Several 
studies have shown that CIN 2 and 3 and cervical carcinoma are most 
commonly associated with HPV types 16 and 18 (Fuchs, Girardi et al. 1988; 
van den Brule, Walboomers et al. 1991; Lungu, Sun et al. 1992; Cusick, Terry 
et al. 1994; de Roda Husman, Walboomers et al. 1994). In contrast, CIN 1 
and HPV atypia are most commonly associated with types 6 and 11 (Fuchs, 
Girardi et al. 1988; de Roda Husman, Walboomers et al. 1994). A 
considerable proportion of low grade lesions also have a HPV 16 and 18 
infection (van den Brule, Walboomers et al. 1991; Lungu, Sun et al. 1992; 
Schiffman, Bauer et al. 1993; de Roda Husman, Walboomers et al. 1994). The 
proportion of women with CIN or cervical cancer who are HPV positive 
depends on the assay used to assess HPV DNA and the number of HPV 
types that are tested for. Studies using PCR-based analyses to detect HPV 
have reported prevalences of HPV for CIN 3 and invasive cancer from 63 to 
100 per cent (van den Brule, Walboomers et al. 1991; Cusick, Terry et al. 1994; 
de Roda Husman, Walboomers et al. 1994; Eluf-Neto, Booth et al. 1994; 
Munoz, Bosch et al. 1994).
Table 2.2 shows the point prevalence of HPV infection among groups of 
women who have normal cytology. The table includes subjects included as 
controls in the case-control studies described earlier. A wide range of 
prevalence rates has been reported. The variation can partly be attributed to 
differences in the techniques used, samples collected and the number and 
types of HPV virus that were tested. The populations from which the 
samples are drawn also vary. For example, in the Spanish and Columbian 
case-control study of invasive cancer and HPV infection the prevalence of 
HPV positivity amongst control subjects was 4.6 per cent in Spain and 13.3 
per cent in Columbia. Identical methods were used to determine HPV 
positivity amongst these control subjects. The authors suggest that the higher 
prevalence of HPV infection in Columbia may explain why Columbia has a
much higher incidence of cervical cancer than Spain. (Munoz, Bosch et al. 
1994).
The samples in the studies shown in Table 2.2 vary with regard to age and 
other risk factors for HPV infection. Nonetheless it is evident that an 
appreciable proportion of the population may have infection with one or 
more HPV types. The prevalence of the high risk types 16 and 18 in women 
without cervical cancer has been reported as between zero and 75 per cent 
(see Table 2.2). Even if one takes the high estimates (32 and 75 per cent) to be 
falsely elevated (perhaps due to problems with hybridisation such as 
contamination or non-specific techniques) prevalence rates of 5 and 6 per cent 
are still reasonable. These are point prevalence estimates; the cumulative 
lifetime risk of a woman developing HPV DNA positivity for a high risk type 
is probably much higher. Most of these women would not develop cervical 
cancer. Although the relative risk of infection with high risk HPV types is 
extremely high the absolute risk of developing cervical cancer in the presence 
of these infections may be low.
HPV infection appears to be dynamic and often transient in nature. Using 
Southern blot hybridisation, Rosenfeld et al. (1991) found that 57 per cent of 
adolescents (n=51) had at least one HPV infection, on two tests taken six to 36 
months apart. Only one young woman had infection with the same HPV 
virus on both occasions. Eight per cent of young women were HPV positive 
on both occasions. The authors conclude that self-limiting transient infection 
may be part of the natural history of cervicovaginal HPV infection in young 
women. (Rosenfeld, Rose et al. 1991).
Clearly, HPV infection can only be considered part of a multifactorial 
causation for cervical cancer. Other factors such the oral contraceptive pill or 
herpes simplex virus infection may also play a role.
Table 2.2 Point prevalence of HPV infection in women with normal cytology
Authors Description of sample HPV detection method and types 
tested for*
Prevalence of 
HPV positivity
(positive for 
high risk 
types 16 and 
18)
(van den Brule, 1346 asymptomatic women with PCR. Types 6, 11, 16, 18, 31, 33 3.5%
Walboomers et 
al. 1991).
normal cytology and unspecified types (0.9%)
(Fuchs, Girardi 102 women with normal epithelial Southern blot of cervical 14.7%
et al. 1988). changes (includes 71 women 
with metaplastic changes)
biopsies. Types 6, 10, 11,16, 18
(Eluf-Neto, 225 age matched controls in the PCR of cervical cytology. Types 16.8%
Booth et al. Brazilian hospital-based case- 6, 11, 16, 1 8 ,3 1 ,3 3  and (6.4%)
1994). control study unspecified types
(Bosch, Munoz A random sample of 130 women PCR, Virapap and Southern 4.6%
et al. 1992). selected as controls for the 
Spanish case-control study
98 women randomly selected as
hybridisation. Types 6, 11,16, 
18, 31 ,33 , and 35.
controls for the Columbian case- 
control study
PCR, Virapap and Southern 
hybridisation. Types 6, 11,16, 
18, 31 ,33 , and 35.
3.3%
(Reeves, 1467 randomly selected hospital Filter in situ hybridisation. Types (32.0%
Brinton et al. 
1989).
controls 6, 11, 16 and 18.
(Schiffman, 500 controls selected from within PCR. Types 6, 11, 42, 31, 33, 17.7%
Bauer et al. a cohort of women who are part 35, 39, 45, 51,52, 16, 18 or (2.9%)
1993). of a Kaiser-Permante HMO study 
on the natural history of cervical 
cancer.
unspecified types.
(Peng, Liu et 
al. 1991).
146 hospital-based controls PCR. Types 16 and 33. 1.4%
(de Villiers, 8755 women attending Filter in situ hybridisation. Types 9%
Schneider et 
al. 1987).
gynaecology outpatients with 
normal cytology
6, 11, 16, 18.
(Fischer, 107 women undergoing pelvic Southern Blot. Types 6, 11, 16, 32.1%
Rosenfield et examinations at an adolescent 18, 31, 33, 35, 39, 42, 45, 56 and (18% HPV 18,
al. 1991). health centre unspecified types. 3 %  HPV 16)
(Borg, Medley 318 women with normal cytology Dot blot hybridisation. Types 6, 9%
et al. 1993). attending a Melbourne STD clinic 
population
11, 18, 31 ,35. (5.2 %)
(Rakoczy, 510 normal smears in a Western Dot blot hybridisation and PCR. (74.8% HPV
Sterrett et al. 
1990).
Australian laboratory in 1987 Type 16. 16)
(Martinez, 68 adolescent women with Southern hybridisation. Types 6, 2.9%
Smith et al. 
1988).
normal cytology who had pelvic 
examinations at an adolescent 
clinic
11, 16, 18, 31 and 45. (0%)
* Unless otherwise specified the cytology or cervicovaginal lavage specimens were used for the HPV 
DNA hybridisation.
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HPV DNA typing and screening
In light of new molecular biological and epidemiological evidence linking 
infection with particular HPV types with cervical cancer, some authors have 
suggested that HPV typing be included in screening (Ritter, Kadish et al.
1988; Meijer, van den Brule et al. 1992). Ritter et al. (1988) found that the 
sensitivity of both HPV typing and cytology for histological evidence of 
dysplasia was 89 per cent. Cytology and HPV typing alone yielded 
sensitivities of 74 and 68 per cent respectively. The authors concluded that 
the two tests combined were a better screening test than either technique 
alone. However, the false positive rate was 41 per cent with the two 
screening tests combined compared with 27 per cent for cytology alone. 
Therefore, although the combined tests may improve the sensitivity of 
screening, the increase in the false positive rate would increase drastically the 
number of women referred for biopsy. It would be premature to include 
HPV typing in cervical screening. It has not yet been formally evaluated as a 
screening technique. Such an evaluation would require a randomised 
controlled trial in different populations. Some HPV typing techniques have 
poor reproducibility in field studies and are likely to be even worse in a 
clinical setting. There is also a reasonable prevalence of high risk HPV types 
among women with normal cytology and some women with HGSIL or 
cervical cancer may not be positive for high risk types. HPV typing would 
also increase the cost of cervical screening.
Others have suggested that HPV typing be used to assess women who have 
LGSIL (Beral and Day 1992). Testing in this proposal might enable the 
identification of those women who have lesions at high risk of progressing, 
since it is postulated these women who have infection with high risk types 
are more likely to develop cervical cancer. Not enough is known about the 
natural history of LGSIL with certain HPV types to establish whether HPV 
typing would be useful in such situations.
As discussed earlier, a major concern is that women who have benign 
atypical or CIN 1 changes on cytology may have a more severe lesion on 
biopsy. Borst et al. (1991) investigated the possibility of performing HPV 
typing on the cytological specimens of women who have mildly atypical 
smears. In their small sample (n=51) HPV 16 positivity (by Southern blot) 
was a poor predictor of whether someone had histologic evidence of CIN. 
(Borst, Butterworth et al. 1991). In a sample of 133 women with abnormal 
smears of various grades referred for colposcopy in Britain, high levels of
HPV 16 had a positive predictive value for CIN 3 of 93 per cent. The 
sensitivity was only 59 per cent, however. Using high levels of HPV 16 or 
high levels of either HPV types 18 or 31 improved the sensitivity of the test 
for detecting women who had histological evidence of CIN 3. However, the 
positive predictive value fell due to a reduction in specificity. They conclude 
that HPV typing may be a helpful adjunct to cytology for women who have 
CIN 1. If high risk types are detected in this group of women, they should be 
referred for colposcopy. (Cuzick, Terry et al. 1994).
Summary
Human papillomavirus infection is presently considered to be causally 
related to cervical cancer. Several case-control studies have demonstrated a 
strong consistent relationship between HPV infection and cervical cancer. 
Risk of cervical cancer appears to increase with viral load and 
epidemiological evidence is consistent with molecular biological knowledge 
about HPV. Retrospective studies cannot establish the temporal nature of the 
relationship between HPV and cervical cancer and it is possible that HPV 
DNA is more readily detected or incorporated into neoplastic tissue. One 
study suggests that some HPV DNA detection methods may be more 
sensitive to the presence of HPV DNA in neoplastic tissue (Guerroro, Daniel 
et al. 1992). Finally, although there appears to be a very strong relationship 
between HPV infection and cervical cancer, the prevalence of HPV infection 
(even with high risk types) among healthy women may be reasonable. Not 
all women with cervical cancer have infections with high risk HPV types. 
HPV infection is neither a necessary nor sufficient cause of cervical cancer. 
Other factors may be important in the causation of cervical cancer. Also, 
although HPV infection may explain most of cervical cancer incidence (high 
attributable risk per cent) the absolute risk of cervical cancer associated with 
HPV types may be low. Prospective cohort studies will enable the temporal 
nature of HPV infection and cervical neoplasia to be established and will 
provide evidence regarding the risk of CIN associated with HPV infection.
The natural history of cervical cancer
Several methods have been used to determine the proportion of precursor 
lesions that progress and regress. These include longitudinal studies 
(summarised in Table 2.3) and modelling the disease using population rates 
of different stages of the disease. I consider each of these approaches in turn.
Longitudinal Studies
Longitudinal studies provide the most reliable data about the natural history 
of cervical cancer precursor lesions. Table 2.3 summarises studies that have 
examined the natural history of cervical precursor lesions. They are 
presented from most recent to earlier studies.
Comparison between the studies is difficult. Below I list some of the 
problems with the longitudinal studies listed in Table 2.3.
1. They use different criteria for entry into the study. For example, some 
studies use one abnormal smear to define disease status on study entry, 
others three consecutive abnormal smears and others biopsy-proven 
disease. These different criteria will affect progression and regression 
rates. If one abnormal smear is taken as a criterion for entry it is more 
likely that this smear is misclassified. It may be a higher or lower grade 
lesion on follow-up, and therefore progression and regression rates may 
be higher than if three abnormal smears or biopsy-proven disease is used. 
The studies that use several consecutively abnormal smears to define 
disease status are likely to report higher rates of persistent disease.
2. Different criteria are used to define disease progression or regression. 
Some studies use cytology and others histology. Like (1) these different 
criteria will affect the reported progression and regression rates.
3. There is some evidence that biopsy may occasionally completely remove 
the neoplastic tissue and interrupt the disease process (Koss, Stewart et al. 
1963). Therefore, if biopsy is used to define disease status at entry into the 
study, progression rates may be underestimated and regression rates 
overestimated.
4. There is no uniformity in the disease classification systems used in natural 
history studies. Most of the studies were conducted some time ago. It is
likely that reporting practices have changed and therefore the 
generalisability of the findings of these early studies is limited.
5. Most studies did not have a control group, so risk of progression and 
regression among those women with neoplastic disease could not be 
compared with a group of women who had no evidence of disease.
6. Few studies have followed women in a consistent manner. Even in 
studies with protocols for follow-up, women with less severe levels of 
disease were not followed as intensely as other women in the study. More 
frequent contact means that it is more likely that transient states of 
progression and regression may be detected which will affect the rates 
reported.
7. Most studies (particularly the earlier studies) do not account for time in 
the denominator of their calculations. They present the proportion of 
women with disease that has progressed or regressed over an average or 
range of follow-up periods. Recent studies have used lifetables which 
account for the differing periods of time in the study.
8. There is poor intra- and inter-test reliability for the classification of cervical 
cytological and histological specimens. Misclassification errors may affect 
rates of progression and regression.
9. The natural history of cervical cancer is likely to be different for women of 
different ages. Studies do not take account of the age distribution of their 
sample. Overall rates of progression and regression are reported, rather 
than age-specific rates.
These studies were often conducted under stringent research conditions.
They frequently involved experienced pathologists and gynaecologists.
Therefore, findings from these studies may not be directly transferable to
clinical practice where conditions and levels of experience are more variable.
T
ab
le
 2
.3
 T
he
 n
at
ur
al
 h
is
to
ry
 o
f c
er
vi
ca
l a
bn
or
m
al
iti
*s
1> vw »w Vw
!| II
©
S- n
I
8
l
i
&c05
Eo*
CO
cvi
5?
3$
<5
8
w
5
2
55
.E
1
2
.1
5.
© .2 o>
l 1? gs I s
* §  & s | §
•5 u i  u S i
- 5 Q. w
J U |  
© £  "2 ©  °  
'S 1  © © «5 S ® s i
© © g © o -c £ © o ^
c ° g f S o c
8 * 5  ä  s
^ c >> c ___P J) O J) qj ©
I  E 5  E s  Es  o S  o © o
5 }  5 J  5 i
© <p “ j 'S* ©
§ s i ° f
i i i i i ' i
°8 |f l l
© ©f ! ? . g  
» 5 E I - - D  
i f  §  l i S  8-C ©--O . © 3  3
8  §  1 2  e  S
I r l i s
9 > © co
I p i
f i dsi
£  2i E
§
w  ——
8 f
O -^  O ~  
V) y -  <J ( /)
_ D> .
£.2  ©  5? CL™iSco © £ ©
t i p i  « iiM  
£  8  “
© £
8 *  
* 1
©
i i
E
E
I
©
E
co
S
£
s
c©
©
E
©
ß
c/>
£
COf*
3
XL
V)
f f f !
.  ©
I  £ 
*  3
©
I
c0«3
1
2
c©
©
|S
(/)
£c
o
E
cor*
E
2
©
1
c0 £  « c
2
c
©
©
E
©.cH
1
© sz
E c o o 
.£ E 
g<o
o <o
O ™ 
~  V)
■o 2
S l  (/) £  
£©
If
8* oO) c 
^ 2  
S o 
5  2
M■S'©
Ts Q. 
V)
.3 gw E
.£ r*<0 TT-
E CM 
o w c ©
2 *  
8.2
T3 “<U © 
© £  
© o
§>■§
I s
*  .2 
<N ©
•is
COh-
©
% ©
c £  — c  
© o 
E E0
1 ^§ £
2  *
D  3m .t;w « 
© c o
f l
* £
$ 8C\J O
*  5
t i l l  
I f
i !
*1 
11 
S*
s
£  .c _ © •«
1 1 » !  
S 8 ? |  e £O © C —1
>  th» •“ »> © SZ
M il
* S « |
f|§*
© ©  ©
«  g -O  0 3r  m U m
- ®  ©
s i l l !
. I l l s »
i l l  i f
8 1  8 - 1  f
a. o ’■d o ' ©
n s
i t s ?
■5
>.1 
sz © ^  ■e o>o
I I ?
33
<0
.92
1
Ei—
oc
-Q
<0
0
1
B
COc
~o
Q)
3
.E•*—>c
o
CO
c\i
o
(0
I -
TJcCO
©
to
■0
(1)a
£v
$
S5CD
a
• ©
.E
co
E
§
£COo
o
CO
'«3
£
©
c0)
Eo
$
>scco
E
©
s
£ 'S
©
©©©
5
I
s ?
i l
s f
©
©
0
1
1
£
Q) W»
I I
n
i l
 2 « 2
i l l
'S 2
’r  ©
» §>
i i
w
w
©c«
TJc©
c
.S>
TJ
$
2
CO
JC*- o
8 . 3  
§■©
^  © 
o ©— 5w. ^© "O 
© C
o w 7  m c  x: E ■o fc /> °  ©
X ^  © 5
« 3  © ®
< 3  a s
i ? l
§S 8
£SJ£*
e  1 1  i l
€  ^ I  8 £
g  a
§ * S l £
11.1 -D 8 
£  ö  «  C  3
S I p3«i f  ©
f i l l !
» r * E| f  f l s
M i ­
l l  » I
| §  € R
E £
$ 3
*3 0
i!»  -*rr
i i
c  c
E 1  
uo m 
-m-
g £E tn 
in
$ 0
O O _ WIs  I I
f?
© © ©
•« a
i
Ü * 1
«  ™
c  .£
i l
*3© 2
O) O)
I I  
.2*2 
■o ©
2  o
Si
£ © ? !  
Q. £ 
«  «
1 .2 © © 
® ®
11 i l  11
p
2  0
C  C  
© ©
© © ©
© c  
.E c  
c  .2
0 Sß« .2
®-g
2  22 0
5 §x: of  «
2  °
i s11 £ £ 
CD O)
O £
o- ©
© Cc  .2
§ § 
I J 
33CO ©
o> o> 
© © 
i l
Vi
Ü
£ 8
g»£  £ o>
CL © 
«2 © 
0 I
I s
o 55 '» JÖ 
© ® 2  ©
— CM S  00
s s z  
CMQ 
m .4 
*0 o •. 0l 
<0 I
. _  o  z
o O  5 5 0
CM >  g  >
’- a .  . 0.
t«: I  cm i  _
$  o $ 0  $ 0
O vP O vP O  vp
v  S. 0N  V
I s  I s  I s
£©
® . s j
8- i  '* 1  -8 -S
.c £  3  ^  © o 
•e -s c! - 1 © o 
5 *  ®
£ 3  £  §> o- -o
!  3  fi 1 1 8 1m i l l s
a S i *
cd
o
O
o
©0c
1©
TJ©
JO
55m
co
a.3i
0
(o
£
i : - l
1 E 0
©
I I
s i
i  =  6T© T O
a s ?
0 8  £
i ^ i l l ! 
’ I I P '
OCO
©
©
%I
o
©
•I«
oc
©>©£
£©©>.
o
©
©
©
£©o
©
>
>
.E
o
$
§
i
10h-
©©©
£
©
£co
E
3
«
55
CM
cvi
©ra
5
! l  • - ■ §
© 5  I  S S
I n ! !
i f  | s f
©
£co
E
3
©
£cdCM
©©
$
0
1
£
I
©
£
§
E
CM
©
55
m
3
©©
$
co
18
£ ~
g 5 o
S. io
CL
£  1 
f  s
Q. o
O
w
>
©
i30
©x:
I-
•3©
iS
1
!
g 'S© £
0  3 0)
£ S .S  j  2  of l i l l l
a .  Q.  S 5  _ j  cl
©
©
a
© O)
a  f aCO T-
s’lo ® .
ro «  g  
© 5 2
 ^^  5 co_  r* “sr •—
J l f |4
■§ ® f ^ <  §-
©
S*S
11
11
a s
©
.£
©
130
5
I—
•3© ^  cn o
a  £
6  5
1!
2
£  x: &•5 £  «
J  $ 2:
© TJ 2
E  ® .£
1  I  i
cd £5 ~  Ui <0
0 S 0 
o  » n  .
S - & S  8
5 I I I
f s i f
S - O Z  g 5 
® © <  ©
p s i
f M
©
©
£  c
w c  © fc
| S  2  -  
© © i  i
£  co
5  ?E O
i  2
*i©
I
s .  8
©
£co
E
8
o>
©
©©©©©
T3
©
©
£
s.
TJ©x:
55
CD
©£co
E
0CO
O)▼"
o3
s
1
£
?
55
|8  
- 8 !  
z  a s
OÖ £ 
x  a  
■'S ^  m5 05 © 
C 2  TJ
® O ®
i t s
> r  W 
'  ■§ £ §  5 a
- ^ ®
o £  «
■o §3 E to
2
3w
©
(X
>
TJ 
©
u. 5 ^
© o  2
£ 0CL u_ x:
I l f
£  S  2  
d-S T3
T5
©
f iI S3
Ui
0
I
Ek_oc
JQ
CO
£
<D
O
**—o
fro
W
7 5k_
B
COc
■O
CD
£
§
C O
csi
0)
nß
I
W
'</)
(0c
«
TJ§
c
,2>
£
2
C/3
o
. c
3<
55
Tt-
CNJ
o
M
®
©
TJ
2CT
©
sz
,g>
JC
©
o
T3
CL E —
io  t j  ^  «j
B l ;  g
f |*  |
2§l|
I p lJ«-?!
t i l iSöö«
2  s , * , ®
Q. o  O £T
ÜL
=  CT© T"
© —; 
© ©
s *  ©
1 ss £ 
S l S ä
f  I f f
i  § 11
sm*
I:
2 * | t  2Q_ cj LL ' '
— (0 iT ' 8&
»IIII2  -5 , o  — 2n  jv i O Ol
hm  i f
g  ‘i s  2  ö S «  a  3 ?  
® ® w 2* w w x:! | i l |  .11
P P S  II
©
g £ ~
I f S
ro
« 5 - 5
1 - ,  
z  8
=  ct 
© T~
1 -s
o
N
oT“
5
x:
V
■o ct§s
"ir- O
o*
55
d
© o©
©
■a
©
2
ct
©
©
TJ
2CT
.c
o>
Z
©x:CT
© z
o ©
TJ o
8 T3
®CT
2
a .
®
2
55 Q.
od 5500
d 8
© 3
.£ W
©
E
o
.£
2
.£
©
E
o
.£©
o 2
o S
TJ ■2 -d
1? "O © ® 8
CT $  
O £
S -g >
55 ^
®
6 g
l gCT CT
cvi cvjv>l rr\ of CT
^  g j - g<N ™ ö> ©  ^©
CO CM . ©  T ,  S  x j
-  CD Q .  i ß  £  w
•5  TJ ■§ ~
w • -  ■£ o5 © o5ins«
4
E ö i i
«  ^  ©
c  °  © .© © > . > *
O J5 -?:
I | | l |
S84?l
i n s t
° 1  <0
| l | | l
Q- Q) — > © 
W 'O £  «  W
2  g  t ?  © 8>
0- E x: 5  cl
T3 T-
S g© %
V)
0
1
Ei—
o
c
nca
0)o
o
2 *
o
w
! c
2
B
<0
c
-O
0
3
C
o
CO
C\j
0 )
n
<o
I -
I
E oo ^
£ 8
E  ®
CO
o
-  E
5  CO
© £  ■O c5
g 2.CÜ — (D C?!© o
E ^
O Q
5 2
ö S ;
z  °--o
c  •*- © © o .c
I I I  i 2.1 
* . • 5
^  g c
1  0  ®•c .£ §
© S f
£ 0  o  
.2» 2 *3© CO £
§ £  o
■b | 5
«  £  5
.S  ©  O© 2 - -C
2  E *Q . O  ._
& | e=  F o 
< t j
w
'55
©
£
co>
'55
©-O
2CO
o£3<
© > *“ p
'55 ©  «  S
_ £ f s § £
S 8 ® 8 ©
§i=8il.82 > 2  * fE c  c 8 « «  iX:
S5 r i l l  
l l * | f 5CT 5 (2 H o ©
! | i
l i f l i L
2 >
g 0  
)« w
■ * ■ 8
©£co
E
o>
E
8
i• c
8 .
Q.3
I
8
C
£
=  W w 
2 f i £  
© E  o  
E
O) <©
°  lA *0
= 1
I
©
«
E
&
13
jC
55ID
CO
•is
c8
t
; e 1! e 2 . 
i l l  1
i'll «
I f f  !
11
|  5 2 s
« ' * ' © «
8
2
!
*
Cl
55
. £  o
© o
0
1
8  ©
w 5>-d
&?il
_   W
1 - S  s
1 1 1
H i
S 5 ^ g |
^  CO 00 CO 00 2
c  _
o  .© o  
£ © o
TJ
©£
aß0>
9
3. t ;
o
£8
o  ©
0 §
8  §  
.2 O 
©
1
$  O)  
| 8
« 3 *
I if J i l l
fell
S f l ?|i |; |
i !
* i o  8
i i a | -
I  ^ l - fIS H i
i l l - I f
« 2  g ?■?© © >• 5 0 > ' 55-0 °  c
f  S S  äI
S U S s J i
75
©
§ Ic  ©.C JC 
0 . 2  w, 
2 z  £■
8
© © ©
8  s. a £  3>- > s  0  C  ©0. jz >, © x:
N
8
> ST
<8
©
§•55
■ T5
0  C © © 
|.S S
$5 Q.
™ & 
f" -O
§■01 ©
1 8 =  ©
2  S
o ©
E c  © ©
CD 8
er © £  Cl
CM
•o (8
o ^  
c
o
j o ? .
Is
m "o
© ©
£  m
© 8 
£  «
.2 ®g 8fS © 
> 1  
§ 2
i  ©
S s.
§1
0
1
©
1c
i s.
O  CO 
M- CM
O O •
© ©
"Oc
©
0
8
©
©>,
c
©
©
1jQ
8n
5»
c
©
E
o
$
2
00co
V 5 ?  
«  ^  8  © © CO CO ro CO ©
© © ^  © o
CDCD^CD  ^w w (3 t- 03
H 5 8 S© © © © © o o © o ©
•JS ©
& * * 
© 0 0 ^ 0 ^
■c 0 0*0 0 0
"m '©'©©'©©
1  8 8 8 8 8
'  g- g . i  f i
Ä  CL i © CL
11
§ -  
2  jo 
© ©
j= >,.ts „
S o
© o
5 1 -
2 2 - 1
f t
K c -
S S I
■g.S C  
1 . 2  £  
® 2 ?
?  05 m *0 © O) 
C  »“  
© T3
8 c 
© £  
©Ü
Despite the above reservations, it is clear that CIN/dysplasia/SIL is a 
dynamic condition and that the probability of developing carcinoma in situ or 
worse increases with more severe levels of abnormality. In a recent review of 
the natural history of CIN based on the published literature, Ostor (1993) 
concluded that 57 per cent of CIN 1 lesions regress, 32 per cent persist, 11 per 
cent progress to CIN 3 and one per cent progress to invasive cancer. In 
contrast, he estimated that 43 per cent and 32 per cent of CIN 2 and 3 lesions 
regress respectively; five per cent and 12 per cent of CIN 2 and 3 lesions 
progress to invasive cervical cancer respectively. Ostor's approach is 
seriously flawed, however. To calculate these proportions he merely 
tabulated the proportion of cases with a particular diagnosis that experienced 
a particular endpoint. As well as the methodological differences between the 
studies in defining the various disease states and endpoints, his approach 
takes no account of the different follow-up periods in the different studies 
and for individuals within each study. As stated earlier, those followed for 
longer periods have a greater chance of experiencing a particular endpoint.
Progression also appears to be more likely when CIN lesions are associated 
with infection with HPV types 16 and 18. Several studies have found that 
CIN is more likely to progress if women are also infected by high risk types 
of HPV. (Campion, McCance et al. 1986; Kataja, Syrjanen et al. 1990; Murthy, 
Sehgal et al. 1990; Kataja, Syrjanen et al. 1992). Some consider lesion size 
might be important, hypothesising that women with larger CIN lesions may 
be more likely to develop cervical cancer than those with smaller lesions of 
the same severity. (Tidbury, Singer et al. 1992).
The new classification systems combine HPV and CIN 1. They also combine 
CIN 2 and CEN 3. Future studies of natural history will use these systems 
which have been developed to accommodate contemporary thinking about 
natural history. To what extent will this system of classification for cytology 
shape the findings and interpretation of future epidemiologic investigations?
Scientific writing on CIN assumes a natural history. Rates of progression, 
regression or persistence are discussed. Yet one does not know whether the 
area of the cervix which has LGSIL changes is the same area that would later 
develop a higher grade lesion. Should we conceive of CIN as a marker of risk 
rather than a precursor of cervical cancer? Is it important to make this 
distinction?
One further point should be emphasised. The natural history of cervical 
cancer became a subject of public debate following Professor Herb Green's 
study of the natural history of carcinoma in situ (Mclndoe, McLean et al.
1984). 4 This was first publicly exposed in 1987 (Coney and Bunkle 1987) and 
was later subject to a national enquiry (Committee of Inquiry into Allegations 
Concerning Treatment of Cervical Cancer at the National Women's Hospital 
and into Related Matters 1988). Review of the literature on the natural 
history of cervical cancer reveals that this unethical experiment was not an 
isolated incident, however. Several earlier studies have followed women 
with carcinoma in situ until they developed invasive cancer and even died. 
One study followed women with evidence of invasive cancer (Petersen and 
Wiklund 1959). There is much debate today about ethical endpoints for 
studies of the natural history of cervical cancer precursor lesions, but most 
would accept that invasive cancer is ethically an unacceptable endpoint.
CIN 3 is the most severe endpoint that is accepted.
Modelling the natural history of cervical cancer
Modelling the disease using observed rates of dysplasia, carcinoma in situ 
and invasive cervical cancer begins with the assumption that cervical cancer 
passes through a series of transition stages, which can be distinguished 
morphologically, before invasive disease develops.
The simplest way to model the natural history of cervical cancer is to use 
population incidence and prevalence figures. For example, Boyes et al. (1982) 
proposed that should all preclinical lesions progress, the ratio of the 
cumulative incidence of the preclinical cancer (dysplasia and carcinoma in 
situ) to the prevalence of preclinical cancer plus the cumulative incidence of 
cervical cancer should be one. To test this, incidence rates from the British 
Columbia cohort study were used. They examined the results of two birth 
cohorts of women. Boyes et al. (1982) demonstrated that the ratios were less 
than one for both dysplasia and carcinoma in situ at all ages. Regression was 
found to be more frequent in the younger age groups and for less severe 
degrees of dysplasia (Boyes, Morrison et al. 1982). The modal age for
4 This study is not included in Table 2.3 because it followed women who had been treated. 
All but 25 of the 948 women in the study received some form of treatment for histologically 
proven carcinoma in situ. 131 women had persisting cytological evidence of cervical 
neoplasia following treatment. 22 percent of these women developed invasive cancer. Using 
survival analysis the authors estimated that risk of developing invasive cancer if a woman 
has cytological evidence of neoplasia following treatment was 18% and 36% at ten and 
twenty years respectively.
carcinoma in situ in the British Columbia Cohort study was 25 to 29. This 
was 35 years earlier than the modal age for invasive carcinoma implying a 
long natural history. (The Walton Report 1976). These data have 
subsequently been used by numerous researchers to model the disease.
The ratio of the point prevalence to the incidence of the disease has been used 
to estimate the sojourn time (period during which the state is detectable by 
screening but not clinically apparent) of the preclinical states. Albert (1981) 
extended this formula by summing the age-specific prevalence and dividing 
it by the age-specific incidence of disease to determine the sojourn time using 
British Columbia data. Using this method, the mean duration of carcinoma 
in situ was 7.6 years. However, the mean sojourn time may not represent the 
experience of most women who develop carcinoma in situ. If the distribution 
of sojourn times is positively skewed, most women will have sojourn times 
shorter than the mean.
A number of mathematically-based computer models have been used to 
estimate the course of cervical cancer. Such models have informed cervical 
cancer screening policies. Prorok (1986) provides a comprehensive review of 
these models.
Several models have been used to simulate the natural history of cervical 
cancer. Models are restricted by their structure and assumptions about the 
disease process. The output of the model can be compared with real data to 
test the validity of the estimations and assumptions made in the model. By 
far the most common model is the Markov chain model in which the 
probability of an individual with a particular disease status moving into 
another disease status, over a specified period of time, is assigned a transition 
probability. These are constant regardless of previous disease status and 
duration in state, a limitation of the model.
For example, Barron et al. (1968) developed a Markovian model to describe 
transition probabilities. These probabilities were based on their earlier study 
with 557 women. (Barron and Richart 1968). These data were compared 
with cross-sectional data derived from Barbados, West Indies. (Barron and 
Richart 1970). They predicted that progression of carcinoma in situ to 
invasive disease was a function of time. They assumed that carcinoma in situ 
eventually progressed to cervical cancer. This is not consistent with recent 
evidence. The Barbados data were then used with the British Columbia data 
to derive estimates of disease duration. The upper time limit for progression
of carcinoma in situ was estimated to be ten years and the lower limit three 
years. (Barron, Cahill et al. 1978).
Coppleson et al. (1975) used the published results of a 1971 study by Bibbo et 
al. (1971) to develop a Markovian model. The model that best fitted the data 
had high rates of regression of dysplasia and carcinoma in situ, especially in 
the younger age group, and an increasing rate of conversion to carcinoma in 
situ to invasive cancer with increasing age. (Coppleson and Brown 1975).
Micro-simulation models have also been used to model natural history. 
Habbema et al. (1985) developed MISCAN, a computer simulation model 
designed to examine the cost-effectiveness of different screening situations.
In this model life histories of individual women are simulated generating a 
hypothetical cohort. The data were fitted to the Dutch pilot data and British 
Columbia data. Based on the Dutch data it was estimated that the mean 
duration of the preclinical phase of cervical cancer is between 14 and 19 years 
and that 45 to 65 per cent of preinvasive disease regresses. (Habbema, van 
Oortmarssen et al. 1985).
A probabilistic model using four disease states was constructed by Albert 
(1981) to examine the natural history of cervical cancer. The British Columbia 
data were once again used as the basis for the model. The rate of transition of 
carcinoma in situ to invasive cervical cancer was 3.7 per cent per year; 98.6 
per cent of carcinoma in situ lesions were estimated to progress to cervical 
cancer; and between 1.7 and 9.7 per cent of new cases of cervical cancer were 
estimated to be of the rapid onset variety. (Albert 1981).
Based on empirical data on Swedish population incidence and mortality rates 
of carcinoma in situ and cervical cancer Gustafsson et al. (1989) estimated the 
progression of carcinoma in situ to cancer by solving differential equations. 
They estimated that 12 per cent of all new cases of carcinoma in situ would 
progress to cervical cancer. The proportion of prevalent cases that progress 
was estimated to be 15 to 23 per cent. The mean duration of the in situ phase 
was estimated to be 13.3 years. (Gustafsson and Adami 1989).
By applying a similar method to that used by Gustafsson et al. (1989) to the 
British Columbia cohort study data, van Oortmarssen et al. (1991) found a 
good fit between model and data with the following assumptions: 84 and 40 
per cent regression rate for women less than 34 years of age and over 35 years
of age respectively and an average duration of carcinoma in situ of 11.8 years, 
(van Oortmarssen and Habbema 1991).
The assumptions upon which a model are based produce different estimates 
about the natural history of cervical cancer. Different modelling approaches, 
but the same data set (eg British Columbia Cohort study), have produced 
different estimates for the progression of preinvasive disease. Some models 
have many unknown parameters (eg the sensitivity of the Pap smear and the 
natural history of preinvasive disease). When many parameters are 
unknown, several different natural history scenarios may fit the population 
figures used to model the disease. As stated earlier the models begin with a 
premise that CIN/dysplasia and carcinoma in situ are preclinical states that 
precede cervical cancer. The models provide parameter estimates for the 
premise. Another feature of models is that they are based on populations 
rather than a sample of individual women followed longitudinally. In these 
studies the women with invasive cancer and preclinical disease are not the 
same. Finally, the proportion of women who experience preclinical phases 
that are shorter or longer than the preclinical phase depends on the 
distribution of transit times. Knowledge of the distribution of transit times is 
important for policy recommendations about appropriate screening intervals. 
Longer screening intervals mean that a greater proportion of women may 
develop a preclinical lesion which progresses to invasive cancer between 
screens.
Conclusion
The natural history of cervical cancer is uncertain. More severe levels of CIN 
appear to confer on women a higher risk of developing cervical cancer. Most 
women with CIN will not develop cervical cancer. Risk may be a function of 
age. Infection with particular HPV DNA types is also associated with a 
greater risk of cervical cancer and CIN. There is no way of identifying which 
individual women with CIN will develop cervical cancer in the future.
The relationship between CIN and cervical cancer has usually been conceived 
as a morphological continuum; cervical cancer is considered to pass through 
a series of stages from CIN 1 to invasive disease. Based on this model, 
treatment of CIN at any stage will interrupt the disease process.
Some have shifted their thinking regarding the natural history of cervical 
cancer. New perspectives have been incorporated into the Bethesda system
and the Commonwealth recommendations for the classification of cervical 
cytology. Within this model, treatment is recommended for HGSIL only.
The research conducted for this PhD was carried out when the CIN 
classification system was in use. This classification system provides a 
framework for the status of knowledge and thinking about cervical cancer at 
the time my research was conducted. Even at the time of writing it is the 
main system of classification for clinicians and researchers in Australia. 
Throughout the remainder of the thesis I therefore use the term CIN to 
describe precancerous lesions of the cervix.
The assessment and treatment of women who have abnormal Pap smears
In this section I outline usual gynaecological assessment and treatment 
practices for women who have abnormal Pap smears. I conclude with a 
discussion about clinical protocols and public health policies.
Assessment of women who have abnormal Pap smears
When an abnormality is detected the woman may be advised to have a repeat 
Pap smear within a defined period of time, or alternatively she may be 
referred for gynaecological assessment usually with colposcopy.
Colposcopy was introduced into Australia in the late 1950s (Chanen 1990). It 
is currently widely used for the assessment of women who have abnormal 
Pap smears. Prior to the introduction of colposcopy women were admitted to 
hospital and a cold-knife cone biopsy was performed. The cone biopsy was 
diagnostic, and usually therapeutic. The introduction of colposcopy has 
meant that it is now possible to assess on an outpatient basis women who 
have abnormal Pap smears.
Colposcopy magnifies the cervix so that abnormal areas are more readily 
visualised. Acetic acid is applied to the cervix to identify abnormal areas. It 
is generally recommended that biopsies be taken and a histological diagnosis 
is made before any treatment is performed. Otherwise a woman with 
invasive disease may be inadvertently treated with an ablative treatment and 
women who do not have significant disease may have unnecessary 
treatment.
Two recent Australian studies have shown that the assessment and treatment 
of women with abnormal Pap smears is inconsistent. In a study following 
women with a cytological report of CIN 2 or 3, it was found that most had 
colposcopy and treatment. According to a protocol defined by experts, less 
than one third of women who should have had treatment follow-up 
colposcopy had it. (Towler, Irwig et al. 1993). Women with mild squamous 
atypia or CIN 1 had more heterogeneous follow-up. Fifty-one per cent of 
women with CIN 1 for the first time had treatment. Nineteen per cent of 
women with mild squamous atypia had a colposcopy to further investigate 
the lesion and eight per cent had treatment. (Hunt, Irwig et al. 1994). Both 
studies relied on general practitioners to obtain information regarding 
whether a woman had a colposcopy, treatment and follow-up. General 
practitioners may not always have complete information on their patients' 
assessment and treatment. Nonetheless these studies illustrate that a 
significant proportion of women with CIN 2 and 3 may not have appropriate 
assessment and treatment and that there is no consistent approach to the 
assessment and treatment of women who have minor abnormalities.
This is not a uniquely Australian problem. A survey of 72 gynaecologists 
performing colposcopy in Britain revealed that there was an inconsistent 
approach to the referral, treatment and follow-up of women who have 
abnormal Pap smears (Woodman and Jordan 1989).
There is international consensus that women with CIN 3 should have further 
assessment with colposcopy. Most would recommend that women with CIN 
2 have further assessment. The appropriate follow-up for women with minor 
abnormalities such as mild atypia, HPV atypia only and CIN 1 is far more 
controversial.
The call for referral of all women who have minor abnormalities on Pap 
smear is fuelled by concerns over the accuracy of cervical cytology. Many 
cross-sectional analyses based in hospital clinics have shown that women 
with minor cytological abnormalities may have more significant disease on 
colposcopy or biopsy.
Between three and 37 per cent of women with smears showing atypia have 
evidence of CIN on histology. On careful examination it is found the 
proportion of cases with CIN 2 or 3 ranges from two to ten per cent, however. 
(Soutter, Wisdom et al. 1986; Walker, Dodgson et al. 1986; Jones, Creasman et 
al. 1987; Spitzer, Krumholz et al. 1987; Morrison, Erickson et al. 1988;
Kaminski, Sorosky et al. 1989; Kaminski, Stevens et al. 1989; Cecchini, Iossa et 
al. 1990; Busseniers and Sidawy 1991). On the basis of these findings many 
authors recommend that women with mild atypical smears should have a 
colposcopic assessment in the first instance. (Jones, Creasman et al. 1987; 
Spitzer, Krumholz et al. 1987; Morrison, Erickson et al. 1988; Kaminski, 
Stevens et al. 1989; Busseniers and Sidawy 1991). Women who have 
cytological atypia on two or more smears have a higher prevalence of CIN 2 
or 3 than women who have only one smear showing atypia. (Soutter,
Wisdom et al. 1986; Spitzer, Krumholz et al. 1987; Morrison, Erickson et al. 
1988; Kaminski, Stevens et al. 1989). Older women were found to have a 
lower level of CIN on histology (Kaminski, Sorosky et al. 1989; Kaminski, 
Stevens et al. 1989).
A hospital based study found that 13.6 per cent of women who had smears 
showing HPV atypia had histologic evidence of CIN. Only 4.1 per cent with 
histologically proven CIN had normal repeat cytology. 11.6 per cent were 
CEN 2 or 3 and 6.1 per cent had CIN 3. On the basis of these findings the 
authors recommended colposcopic assessment for all women who receive a 
cytology report showing HPV only. (Pagano, Chanen et al. 1987). Mitchell 
(1992) found only one per cent of women who had a cytology report showing 
HPV were found to have CIN 3 on biopsy; 9.6 per cent had evidence of CIN 2 
or 3. On the basis of these findings she concludes that women with HPV on 
cytology have a low risk of undiagnosed CIN 3 and that repeat cytology in 
six to 12 months is a reasonable alternative to immediate colposcopy. 
(Mitchell 1992).
Studies of women who have a cytology report indicating CIN 1 have 
reported rates of CIN 3 on histology of between 6.2 and 45 per cent. (Soutter, 
Wisdom et al. 1986; Maggi, Zannoni et al. 1989; Anderson, Flannelly et al. 
1992). Soutter et al. (1986) found that 5.9 per cent of women who had only 
one smear showing CIN 1 had CIN 3 on biopsy. On the basis of these studies 
the authors conclude that all women with CIN 1 should be referred for 
colposcopic assessment. One study found that 33 per cent of women with 
CIN 1 on cytology had CIN 2 or 3 on biopsy. Repeat cytology confirmed CIN 
1 or greater in 93 per cent of women histologic CIN 2 or 3. Eighty-three per 
cent of these women had a CIN 2 or 3 on repeat cytology. (Giles, Deery et al. 
1989). Similarly 26 per cent of women with CIN 1 referred to a British 
hospital had CIN 2 or 3 on biopsy (Campion, McCance et al. 1986).
A recent longitudinal study found that women with cytological evidence of 
CIN 1 or 2 under the age of 35 (who have no previous history of an 
abnormality) had a 30 per cent risk of developing CIN 3 or worse over a ten 
year period. Women older than 35 had a lower risk of developing CIN 3. 
Follow-up with regular Pap smears identified most women with progressive 
disease. (Kirby, Spiegelhalter et al. 1992).
Because of the wide variation in reporting practices in Australia it is difficult 
to extrapolate from these studies to clinical practice in Australia. With the 
shift towards more frequent reporting of minor abnormalities it is likely that 
the prevalence of high grade CIN in women who have reports of minor 
abnormalities will be lower than the studies reported above. Most of the 
studies are based in hospital clinics and hence may represent a biased sample 
of women with cytological reports of minor abnormalities. Women may 
have been referred because of symptoms or other risk factors for cervical 
cancer. Even if these women make up only a small proportion of the sample 
the findings are likely to be biased because the prevalence of disease in these 
women will be much higher. Another problem is that the studies are cross- 
sectional. Although they show that a reasonable proportion of women with 
minor cytological abnormalities may have a high grade lesion on histology, 
the significance of these lesions is unknown.
Of all women with HPV and CIN nearly six per cent of women screened at 
any time would be referred for colposcopy. If women with any evidence of 
CIN were referred almost three per cent of women would require 
colposcopy. (Commonwealth Department of Human Services and Health 
1994). A British study showed that a shift in guidelines from recommending 
follow-up for women with CIN 3 only to recommending follow-up for 
women with CIN 2 and women with persistent evidence of CIN 1 would 
result in half the workload of a cytology laboratory being devoted to the 
follow-up of abnormal smears. The authors felt that the increased laboratory 
workload would undermine the effectiveness of the screening program 
because resources would be transferred away from evaluating cytology 
specimens from women participating in the screening program. (Raffle, 
Alden et al. 1990).
The treatment of histologically confirmed cervical abnormalities
Cervical intraepithelial neoplasia can be treated with ablative or excisional 
methods. Ablative methods destroy the area of the cervix that shows CIN 
changes. Excisional treatments involve removing the affected area. An 
advantage of the excisional method is that the removed tissue can be 
examined and examined histologically to see whether the entire CIN lesion 
has been removed. However, because excisional methods remove more 
tissue than is destroyed by ablative methods, ablative methods are preferred 
by clinicians. It is thought they are less likely to result in infertility or 
pregnancy complications.
Ablative methods include cryotherapy, CO2 laser, cold coagulation and 
diathermy. Cryotherapy and laser are most commonly performed using local 
anaesthetic in gynaecologists' rooms. Excisional methods include cone 
biopsy with cold knife, laser cone biopsy and more recently large loop 
excision of the transformation zone (LLETZ). Both LLETZ and laser cone 
biopsy can be performed on an outpatient basis using local anaesthetic. Some 
maintain that the advantage of this approach is that a biopsy can be taken at 
initial consultation that is both diagnostic and therapeutic. However, about a 
quarter of the patients in one series had no evidence of CIN, indicating that 
this approach may mean that many women have excisional treatment with 
no indication. (Luesley 1990). Both of these methods may result in heat 
artefact in the specimen making interpretation difficult. A recent study 
showed that laser cone biopsy was an unsuitable treatment technique if a 
reliable histological specimen was necessary (Howell, Hammond et al. 1991). 
An advantage of LLETZ is that the cost of the equipment is much less than a 
CO2 laser. A concern with ablative methods is that women with invasive 
disease may be missed and inadequately treated. Occasionally hysterectomy 
is used to treat CIN.
It is recommended that women with suspicion of early invasive disease, 
cytological evidence of precursors of adenocarcinoma or an unsatisfactory 
colposcopy should have a cone biopsy. For all other women ablative 
treatment is sufficient. (Giles and Gafar 1991).
The reported success rates for various treatments appears to be similar but 
there have been few properly conducted comparative trials. Instead rates of 
success and failure are reported in series of patients exposed to one particular 
treatment. At one and five years following treatment of CIN with
cryotherapy, 95 and 92 per cent of women respectively showed no evidence 
of CIN (Gordon and Duncan 1991). After a single CO2 laser treatment, 5.6 to 
14 per cent of women have persistent abnormalities. (Puttmemans, van Belle 
et al. 1968; Caglar, Ayhan et al. 1985; Ali, Evans et al. 1986; Pearson et al.
1989; Paraskevaidis, Jandial et al. 1991). One study found that women had a 
one per cent risk of invasive disease six years after laser treatment for CIN 
(Pearson et al. 1989). Chanen et al. (1983) found that 2.7 per cent of women 
had residual cervical abnormalities in the first twelve months of follow-up 
after treatment with electrocoagulation diathermy; a further 0.8 per cent of 
women developed CIN after one year of follow-up. (Chanen and Rome 
1983).
Tabor et al. (1990) compared the rates of recurrent or persistent disease for 
women who had CIN treated with cold-knife cone biopsy and laser cone 
biopsy. Cold-knife cone biopsy was the treatment of choice early in the study 
period. Later the unit performed mainly laser cone biopsy. In three to 21 
months of follow-up, evidence of persistent or recurrent disease was found in 
eight and five per cent of women with cold-knife and laser cone biopsy 
respectively. (Tabor and Berget 1990).
One commonly held concern is that excisional procedures are more likely to 
result in more frequent short term and long term complications than ablative 
treatments. A randomised controlled trial compared the laser excisional cone 
with laser vaporisation in a group of patients suitable for ablative treatment. 
There were no differences in the rate of treatment failure and short term 
complications such as bleeding. (Partington, Turner et al. 1989). However, 
the study was based on small numbers and lacked statistical power.
Most studies examining treatment failures (evidence of recurrent or residual 
(persistent) disease following treatment) are methodologically flawed. 
Women are followed for varying periods of time. Many are lost to follow-up. 
Yet the results are presented as simple proportions and no consideration is 
given to the length of time a woman contributes to the denominator. Future 
studies should employ survival models to analyse treatment failures.
An Australian study found that women who had a history of histologically 
confirmed CIN were twenty times more likely to develop squamous cell 
carcinoma in the future than women who had negative smears. Women in 
the CIN cohort were twice as likely to develop CIN as women in the control
group. (Mitchell, Medleyand Carlin 1990). This study illustrates the need to 
follow carefully women who have CIN after they have had treatment.
Given the reported rates of residual and recurrent abnormalities after 
treatment careful follow-up after treatment is necessary. One study reported 
that 95 per cent of women who had residual abnormalities were found at the 
first post-treatment visit (three to four months following treatment). The 
remaining five per cent of women with residual disease were detected at the 
second post-treatment visit (six to eight months following treatment). Three 
and nine per cent of women with residual abnormalities detected by 
histology had negative cytology and colposcopy respectively. Cytology and 
colposcopy combined detected 98.5 per cent of all residual abnormalities 
detected by histology. On the basis of these findings the authors conclude 
that one follow-up visit with cytology and colposcopy following treatment is 
necessary, after which follow-up with cytology alone is appropriate. (Falcone 
and Ferenczy 1986).
In the last twenty years there has been a shift from recommending 
hysterectomy for the treatment of CIN towards more conservative 
treatments. The term 'conservative' is used in many ways. Anything other 
than hysterectomy is sometimes considered conservative. Sometimes 
conservative is anything other than hysterectomy or cold knife cone biopsy. 
Alternatively conservative may mean ablative treatments only. Goodwin et 
al. (1990) documented that there was a steady increase in the percentage of 
women having conservative treatments (anything other than hysterectomy) 
in New Mexico. The proportions of women having treatments other than 
hysterectomy for their abnormal Pap smears was 11.8 and 50.3 per cent in 
1969 and 1985 respectively. They state that this shift occurred in the absence 
of any controlled trials comparing the two treatments. They compare the 
adoption of more conservative treatments for CIN with breast cancer 
treatment. In the case of breast cancer, evidence from controlled trials 
comparing radical mastectomy and local treatments was not incorporated 
into clinical practice. (Goodwin, Hunt et al. 1990). A common reason cited 
for the change in the treatment of CIN is that conservative treatments do not 
prevent future pregnancy in women treated for CIN. For example Sagot et al. 
(1990)say:
The increasing number of very young women with low parity 
presenting with cervical intraepithelial neoplasia has led to the 
development of conservative treatments to provide reliable 
oncological results.
48
To my knowledge there has never been an analysis of changes in treatments 
used for CIN in Australia over the last two decades, partly because there 
would be no suitable population data base that could be used for such an 
analysis. However, it is likely that there has been a similar, if not larger, shift 
in Australia towards the use of more conservative treatments. This shift has 
almost certainly been accompanied by other changes in clinical practice. 
Women with minor abnormalities are being treated more actively than 
previously. In the past hysterectomy or even cone biopsy required 
hospitalisation. With the advent of outpatient procedures more women with 
minor abnormalities are treated. Women with cytological and histological 
evidence of HPV are also treated with ablative treatments. A recent study 
found women who had ablative treatment for histologically confirmed HPV 
had similar rates of CIN in the following two years as women who had no 
treatment (Ward and Thomas 1994). Indeed laser vaporisation may disperse 
viral DNA onto adjacent normal epithelium (Ferenczy, Bergeron et al. 1990).
Protocols for the assessment and treatment of women who have abnormal Pap smears
The Commonwealth Department of Human Services and Health has recently 
released guidelines outlining approaches to clinical care for women who 
have screen-detected abnormalities. (Commonwealth Department of Human 
Services and Health 1994). This is the first time in Australia there has been a 
consistent set of recommendations regarding an appropriate approach to the 
assessment and treatment of women with abnormal Pap smears. On the 
working party formulating the guidelines were gynaecological oncologists, 
an epidemiologist, a cytopathologist, a medical educator, a consumer 
representative and a general practitioner. Consultation with interested 
individuals and organisations was sought. (In addition to formulating 
guidelines, the working party also developed the new reporting system for 
cervical cytology discussed earlier in this chapter.)
These guidelines suggest that any woman who has HGSIL should be referred 
for assessment with cytology, colposcopy and colposcopically directed 
biopsy. Decisions regarding treatment should be determined on the basis of 
the colposcopic and histologic findings in consultation with individual 
women. Ablative treatment can be recommended if the cervix has been 
evaluated by a competent colposcopist, there is no evidence of invasive 
disease, the abnormal transformation zone is fully seen, and there are no cells
indicative of the precursors of adenocarcinoma. (Commonwealth 
Department of Human Services and Health 1994).
Recommendations for LGSIL were less clear-cut. For HPV infection alone it 
is recommended that if HPV only is confirmed at colposcopy then Pap 
smears should be repeated six-monthly until two consecutive smears are 
reported as normal. Then annual smears are recommended. When two 
annual smears are negative, cervical screening at two year intervals is 
recommended.
It is suggested that all women with CIN be referred for colposcopy. If CIN 1 
is confirmed with colposcopy and directed biopsy, two approaches to the 
care of the woman are proposed. The 'observational' option involves six- 
monthly follow-up with Pap smears until the lesion either regresses or 
progresses. Further colposcopy may also be recommended. If two 
consecutive smears are normal, annual smears are then recommended. 
Biennial smears are recommended after two normal annual smears. 
Alternatively a woman may elect to have treatment. (Commonwealth 
Department of Human Services and Health 1994).
After treatment, follow-up with colposcopy and cytology (using a cytobrush 
and spatula) should be carried out within two to six months. Follow-up with 
colposcopy or cytology within twelve months of treatment and annual 
cytology thereafter are also recommended.
The Australian recommendations contrast with overseas approaches. In 
Canada, only women with CIN 2 or 3 are referred for colposcopic 
assessment. For women with CIN 1 with or without HPV effects, six- 
monthly Pap smears for two years are recommended. If there is evidence of 
progression or the abnormalities are persistent over that two year period then 
referral for colposcopy is considered appropriate. (Miller, Anderson et al. 
1990). In Britain referral of women with CIN 2 and 3 for colposcopy is 
recommended. It is suggested that women with minor abnormalities (CIN 1 
or less) should have a repeat Pap smear in six months and if that is abnormal 
referral for colposcopy should occur. (Shafi and Luesley 1992).
Clearly there is no agreement on the appropriate approach to the assessment 
and treatment of women with minor abnormalities detected on Pap smears. 
Women with these abnormalities are at risk of developing invasive disease. 
Several overseas trials which compare different approaches to the
gynaecological care of women with minor cytological abnormalities are 
currently underway. These trials will provide some guidance in the future. 
However, it is unlikely that any approach will offer unambiguous benefits 
over another. Immediate referral might reduce one's risk of future cancer by 
a small amount. Yet, whether immediate referral is justified in the light of the 
consequent economic, personal and social costs borne by the women affected 
and society is a crucial question.
Studies of the economic and non-economic costs of abnormal Pap smears
In this section I review the literature in relation to the costs of abnormal Pap 
smears for society and for individual women.
Economic costs
Few studies have been undertaken on the cost-effectiveness of cervical 
screening in Australia. Most Australian studies have concentrated on the 
costs and effects of screening at particular intervals.
Between 1988 and 1990 the Cervical Cancer Screening Evaluation Committee 
(CCSEC) directed the Screening Co-ordination Unit at the Australian Institute 
of Health to undertake an evaluation of current cervical cancer screening 
practice and consider various policy options. (Australian Health Ministers' 
Advisory Council. Cervical Cancer Screening Evaluation Committee 1991). 
The CCSEC report explored the cost-effectiveness of cervical cancer screening 
in three ways: by comparing the cost-effectiveness of the current approach 
with an organised approach; estimating the cost-effectiveness and marginal 
cost-effectiveness of different screening intervals under an organised 
approach; and, estimating the cost-effectiveness and marginal cost- 
effectiveness of screening different age groups with varying participation 
rates. (Australian Health Ministers' Advisory Council. Cervical Cancer 
Screening Evaluation Committee 1991). Following this evaluation the 
National Policy on Screening for the Prevention of Cervical Cancer was 
developed. Biennial screening is now recommended. It is suggested that 
screening commence between 18 and 20 years of age and cease at age 70, 
provided that the past two Pap smears taken in the last five years have been 
normal (Commonwealth Department of Health, Housing and Community 
Services 1991).
The Knox microsimulation model was used to estimate life-years saved 
under various screening scenarios (Knox and Woodman 1988). The cost of 
screening was determined from the pilot project data. Data included the 
costs of recruitment and education, taking and reporting of Pap smears and 
the notification of results and counselling. The costs of follow-up, which 
included general practitioner and specialist visits, claims for pathology tests, 
and procedures performed, were taken as 85 per cent of the scheduled 
Medicare fee. This was the cost to government if women were admitted to 
hospital as private patients or attended a private outpatient service. There is 
no Medicare rebate for women admitted to public hospitals as public patients 
or women attending a public hospital outpatient service. In addition, the 
limitations of the simplified treatment regimen reduce the accuracy of this 
cost analysis. For example, it was assumed that of the women referred for 
colposcopy, 60 per cent had treatment. It was also assumed that the 
treatment was either laser conisation or diathermy and was undertaken 
under general anaesthetic as a day patient. The follow-up after treatment or 
initial colposcopy included one further specialist visit and one general 
practitioner visit. CCSEC estimated that cervical cancer screening activities 
cost $125 million per year. The follow-up of women who had abnormalities 
detected on screening comprised over half ($64.4 million) of the total costs of 
the cervical cancer screening. (Australian Health Ministers' Advisory 
Council. Cervical Cancer Screening Evaluation Committee 1991). This 
contrasts with overseas models which have concluded that the follow-up of 
abnormalities comprises only a small part of a total cost of a cervical cancer 
screening program. (Koopmanschap, Lubbe et al. 1990).
A Dutch study modelled the effect of screening intervals on the number of 
diagnostic and treatment procedures performed as a consequence of the 
detection of abnormal Pap smears. More frequent screening resulted in a 
higher incidence of diagnostic and treatment procedures because women 
with abnormalities that might otherwise regress were more likely to have 
their abnormality detected, diagnosed and treated, (van Ballegooijen, 
Koopmanschap et al. 1990). The study assumed that all women with CIN 3 
or worse were referred for colposcopic follow-up and 60 per cent of women 
with CIN 2 were referred. Current Australian practice is to refer women with 
any level of CIN. Often women with HPV or mild atypical changes are also 
referred. The rate of diagnostic and treatment procedures that result from 
more frequent screening in Australia are therefore likely to be much greater 
than estimated by the Dutch model.
The most comprehensive study of the costs of abnormal Pap smears in 
Australia was conducted by Bragget et al. (1993). They used the following 
data to model the costs of different approaches to the follow-up of women 
with abnormal Pap smears: screening participation rates from the Victorian 
Cytology Service and Medicare; unpublished data on rates of progression, 
regression and persistence of minor abnormalities from studies conducted by 
the New South Wales Family Planning Service; age-specific rates of detection 
of different levels of abnormal Pap smears from the Victorian Cytology 
Service; and other information collected by CCSEC as part of the national 
evaluation from 1988-90. A series of flow charts were constructed that 
simulated what might happen if a woman had a particular level of 
abnormality detected on her Pap smear. The different treatments on the flow 
charts were derived from the recommendations from the recently released 
report by the National Health and Medical Research Council Working Party 
(Commonwealth Department of Human Services and Health 1994). They 
compared the different approaches to the evaluation of women who have 
CIN 1. Several approaches were compared:
1. colposcopic assessment of all women with cytological evidence of CIN 1 
and ablative treatment if CIN 1 is confirmed histologically;
2. colposcopic assessment of all women with cytological evidence of CIN and 
continued follow-up with cytology if CIN 1 is confirmed histologically;
3. cytological follow-up of all women with CIN 1.
They estimated that the costs of options 1,2 and 3 in 1993 would be $136.7 
million, $130.2 million and $129.5 million, respectively. The cost of further 
assessment alone was $61.6 million, $55.2 million, $54.4 million for options 1, 
2 and 3, respectively. Thus, no matter what approach to the follow-up of 
women with CIN was adopted, the cost of follow-up of women with 
abnormal Pap smears comprised a substantial proportion of the total budget 
for a cervical screening program. Women younger than 35 accounted for 
twice the costs of further assessment than women older than 35. (Braggett, 
Lea et al. 1993). Costing was based on Medicare statistics even though a 
significant proportion of women may have treatment in the public sector. 
Assumptions regarding assessment and treatment practices were often based 
on information from experts (eg length of hospital stay, item numbers billed 
for particular procedures, occurrence of residual disease after treatment). 
These may be inaccurate. There is also no discussion of the validity of the
rates of progression and regression that are used for the cost simulation. The 
report provides a useful benchmark on the economic costs of the various 
protocols recommended by the working party.
Non-economic costs
Very different techniques are required to consider the personal costs to 
women of an abnormal Pap smear. The most comprehensive account of the 
costs to women of the diagnosis and subsequent assessment and treatment 
has been provided by Posner and Vessey (1988). I therefore provide a brief 
synopsis of this research. The research involved structured interviews with 
153 women interviewed on one to four occasions (131 were interviewed on 
two or three occasions) during the course of their colposcopic assessment and 
treatment of their abnormal Pap smear. The first interview was conducted 
immediately prior to the first visit for colposcopic assessment. The research 
was based in two hospitals in the United Kingdom that provided outpatient 
colposcopy services.
Most women found the colposcopic examination distressing. Often nurses 
were important sources of support during the examination process because 
they discussed personal matters. Many found the procedure painful or 
uncomfortable. Many women felt 'weaker' or 'delicate' following colposcopy 
or treatment. Minor outpatient procedures were often associated with 
distress. The authors suggested that this may be because outpatient 
treatment is regarded as a minor procedure, both by doctors and others, 
while inpatient treatment is considered a life event of some significance. 
Many women feared cancer and initially felt their abnormal Pap smear 
signified cancer. Cancer was described in metaphorical terms as unstoppable 
and as destructive of human body and spirit. As a consequence of their 
abnormal Pap smear some women felt alienated and out of control; others 
felt dirty. Sexual relations were frequently affected. As a consequence of 
their abnormality many women 'took stock of their lives' and considered 
their own mortality. The abnormal Pap smear frequently affected women's 
moral and personal integrity. (Posner and Vessey 1988).
Susan Quillam's book "Positive Smear" is a resource book for women who 
have abnormal Pap smears. In producing this book, Quillam interviewed 
women who had had abnormal Pap smear results. She found that women 
had a wide range of experiences. Some women felt powerless, were 
concerned about death, felt guilty and violated. Women reported that their
sexual relationships often suffered as a consequence of their abnormal Pap 
smear. (Quillam 1989).
Another study, which involved open-ended interviews with women who had 
been referred to a colposcopy service because of an abnormal smear, found 
that women most commonly described fear in relation to the following: 
cancer, loss of reproductive and sexual function, medical procedures and 
concern about 'bodily betrayal'. Bodily betrayal was described as the concern 
that they could no longer directly control their bodies and were no longer 
able to be directly controlled by them. (Beresford and Gervaize 1986).
Other studies have used various psychological instruments to examine the 
consequences of an abnormal Pap smear result for women. Women 
experience anxiety and distress as a consequence of an abnormal Pap smear 
(McDonald, Neuten et al. 1989; Lerman, Miller et al. 1991). Two studies have 
demonstrated that women are less anxious if provided with an informational 
brochure at the time they are informed of their abnormality (Wilkinson, Jones 
et al. 1990; Stewart, Lickrish et al. 1993). These studies have also 
demonstrated that women who had abnormal Pap smears feared cancer 
(Wilkinson, Jones et al. 1990; Stewart, Lickrish et al. 1993), experienced 
changes in their sexual relationships (Campion, Brown et al. 1988; Lerman, 
Miller et al. 1991) and sleep disturbances (Lerman, Miller et al. 1991). The 
studies examined women's experiences through a series of psychological 
instruments which organised their responses. For example, the widely 
quoted study by Campion et al. (1988) examined female sexual experience in 
terms of their interest in sex, frequency of intercourse, vaginal lubrication and 
sexual arousal, frequency of orgasm with intercourse and negative feeling 
towards intercourse. The final item was taken to signify feelings towards 
one's partner. The questionnaire was administered before and after 
treatment. The study compared the experiences of women in three 
categories: women who had CIN and CO2 laser treatment; women who were 
partners of men with HPV; and, women who were partners of men who had 
been seen at the STD clinic with non-specific urethritis. After treatment, 
women with CIN reported a reduction in sexual interest, vaginal lubrication, 
frequency of intercourse and frequency of orgasm with sexual intercourse. 
Women with CIN also experienced pain with intercourse and reported 
negative feelings towards sexual intercourse following treatment. (Campion, 
Brown et al. 1988). Even though the results demonstrate psychosexual 
sequelae for women with CIN, these may not be experienced as 'personal
costs' for the women themselves. Instead the researchers identify what the 
costs might be and document them.
Summary
Based on simulations of current practice and future practice, we know that 
the cost of assessment and treatment of women who have abnormal Pap 
smears is a significant component of the economic costs of Australia's cervical 
cancer screening program. More conservative approaches to CIN 1 might 
realise some cost savings over other policy options. As yet there has been no 
Australian research that has considered the costs of treatment based on 
knowledge of current treatment practices.
Previous studies have documented that many women experience significant 
psychosocial consequences as a result of their abnormal Pap smear. The 
study by Posner and Vessey (1988) is the only study that provides an indepth 
account of women's experience. To my knowledge there has not been a 
published study of the experiences of Australian women who have an 
abnormal Pap smear. However, a study based in Sydney is examining the 
psychological consequences of screening for cervical cancer.
Conclusion
Cervical screening exemplifies some of the difficulties encountered in 
population-based screening programs. I have shown that there are many 
scientific uncertainties about abnormal Pap smears. Although cervical 
screening is an effective way to reduce cervical cancer incidence and 
mortality, the Pap smear itself is subject to error. Significant lesions may be 
missed and abnormalities may be under- or over-reported. The importance 
of some minor abnormalities is unknown. The significance of an individual 
having a particular abnormality cannot be determined. The economic and 
personal costs of current clinical practice and abnormal Pap smears may be 
substantial.
Abnormal Pap smears present dilemmas to clinicians, women and public 
health practitioners. The risk of an individual developing cancer must be 
weighed against the consequences to the individual and society of referring 
and investigating further every woman who has an abnormality. How are 
we currently managing the uncertainty of individual women receiving an 
abnormal Pap smear result?
Chapter Three
Age-specific patterns of Pap smear and colposcopy use
This chapter provides a population account of current clinical practice 
regarding abnormal Pap smears. Based on data from the ACT, current 
patterns of Pap smear and colposcopy use are described and the cumulative 
population effects of current patterns of referral for colposcopy simulated.
Background
Much of the research in this thesis relies on Medicare statistics. Some of the 
findings are adjusted for the proportion of women in various age groups who 
have not had a hysterectomy. Before presenting the research findings of the 
chapter, therefore, a brief outline is given of how the Medicare estimates and 
the estimates of the proportion of women who have had hysterectomy were 
derived.
Medicare estimates
Medicare, introduced in 1984, is Australia's national health insurance scheme. 
Private sector outpatient and inpatient medical services are provided on a fee 
for service basis. Medicare gives rebates for the services either directly to the 
medical practitioner or via a partial reimbursement to the patient. Item 
numbers describe the different services. For example, item number 35614 is 
the item number used for colposcopy. Scheduled fees, adjusted through 
periodic inquiries, are set for each item number. In most instances, the level 
of Medicare rebate is 75 per cent of the scheduled fee for inpatient services 
and 85 per cent of the scheduled fee for outpatient services. Medical 
practitioners can charge any amount for their services and patients using the 
service pay the difference between the Medicare rebate and the fee charged 
by their doctor. For example, the Australian Medical Association (AMA) 
recommends a higher set of fees than the scheduled fees determined for 
rebate purposes.
Samples derived from Medicare statistics are used in this chapter and in 
Part C of the thesis. The Medicare Estimates and Statistics Section of the 
Commonwealth Department of Human Services and Health (DHSH) 
extracted the Medicare statistics used here. To ease data extraction, most 
data were derived from a ten per cent sample of Medicare enrollees. In 1993, 
97.8 per cent of the Australian population and 99.1 per cent of the ACT 
population were enrolled in Medicare. Due to strict privacy provisions, 
Medicare data are only released in aggregated form. Cells with fewer than 
six episodes are not released and there is no access to unit record data.
Medicare data are used to calculate the total number of services, the 
proportion of women undergoing various procedures, and the ratio of 
women who claim for some procedures compared with women claiming for 
other services. To calculate the standard errors of these estimates, which are 
based on the ten per cent Medicare file, the formulas in Appendix A were 
used. When the average cost of various services is calculated (used in Part C) 
the standard error was calculated by DHSH because of lack of access to the 
individual data.
The denominators used in the calculation of the proportions and to estimate 
the size of the sample and populations, were the Medicare enrollees in the 
relevant age group for the relevant financial year. The number of women in 
each age group who were enrolled in Medicare are published in the Annual 
Reports of the Health Insurance Commission. In this chapter, the figures 
published in the 1989-90 Annual Report, which pertain to Medicare enrollees 
as at June 30 1989, are used (Health Insurance Commission 1990).
Hysterectomy estimates
Adjustment for the proportion of women who have had a hysterectomy 
should be made when calculating the rates of Pap smear and colposcopy 
usage. Cervical cancer screening is unnecessary for women who have had a 
hysterectomy unless the hysterectomy was done because of cervical 
neoplasia, or its precursors, or the hysterectomy was subtotal (the cervix was 
not removed). (Commonwealth Department of Health, Housing and 
Community Services 1991). Most women who have a hysterectomy therefore 
are not at risk of having a colposcopy or Pap smear. Hence the denominator 
for Pap smear and colposcopy rates should not include women who have 
had a hysterectomy. If hysterectomy rates increase, colposcopy rates will fall
if the total population of women is used, since fewer women will be at risk of 
colposcopy.
The Australian National Health Survey conducted in June 1989 was used to 
estimate the proportion of women in different age groups who had had a 
hysterectomy1. The Medicare statistics presented in this chapter and in 
Part C of the thesis pertain predominantly to 1989/90. Because the National 
Health Survey was conducted over a similar time frame the numerators and 
denominators used to estimate the age-specific rates were derived from 
women from similar birth cohorts.
Table 3.1 Age-specific proportions of women who have had a hysterectomy (%)
ACT/NSW A ustralia
Age group Proportion (%) * 95% confidence** 
intervals (%)
Proportion (%) * 95% confidence** 
intervals (%)
18-24 1.1 0.4, 1.9 0.9 0.5, 1.3
25-34 4.1 3.6, 5.6 4.0 3.4, 4.6
35-44 12.8 11.1, 14.5 12.6 11.5, 13.4
45-54 24.6 22.1,27.1 24.8 23.1, 26.5
55-64 24.0 22.1,25.9 24.1 22.4, 25.8
* Estimates from the National Health Survey June 30 1989 unpublished data
** The standard errors for these estimates were calculated using the method described in Appendix C 
pages 48-9, Australian Bureau of Statistics 1991,1989-90 National Health Survey Summary of Results, 
AGPS (Canberra).
The age-specific proportions of women who had undergone a hysterectomy 
are similar across New South Wales, the ACT and Australia. Nearly one 
quarter of women between the ages of 45 and 64, who were interviewed for 
the National Health Survey, had had a hysterectomy. For the remainder of 
the thesis Australian proportions are used because the NSW/ACT estimates 
are based on small sample sizes and lack precision. Some of the data 
presented in this chapter include women between 15 and 18 and women 
between 65 and 74. For women between the ages of 15 and 24 and 55 and 74
1 The National Health Survey, conducted between October 1989 and September 1990, 
collected data from 22,000 households and 57,000 persons (about one in 300 of the 
population). The survey was conducted by trained interviewers. The questionnaire was 
completed by 96.1 per cent of people eligible for the National Health Survey. The women's 
health questionnaire was a mail survey given to all female respondents between 18 and 64.
In the women’s health questionnaire women were asked whether they had had a 
hysterectomy. Only women between 18 and 64 were asked to respond to the women's health 
questionnaire. Ninety-seven per cent of women participating in the National Health Survey 
completed the women's health questionnaire.
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the proportion of women who had undergone a hysterectomy between the 
ages of 18 and 24 and 55 and 64 respectively have been used.
Age-specific rates of Pap smear and colposcopy use
Age-specific Pap smear frequencies
Four pathology laboratories process the cervical cytology of ACT women.
One laboratory is funded through the public hospital grant and does not 
receive a Medicare rebate. The public laboratory collects statistics on the 
number of women having smears in each age group. The other three 
laboratories operate in the private sector and their services are rebated 
through Medicare. Using the ten per cent patient file the number of ACT 
women claiming through Medicare for a Pap smear has been estimated. The 
Medicare estimates are added to the public laboratory totals2 to give the 
number of women having Pap smears in each age group.
Although both Medicare and the one public sector laboratory total can 
provide figures on total numbers of women having a Pap smear, rather than 
just total numbers of Pap smears taken, it is possible that a woman may have 
had more than one Pap smear which were processed by both a public and 
private laboratory. In such instances, women would be counted twice in the 
numerator of Pap smear frequencies resulting in an overestimate of Pap 
smear frequency. However, the public laboratory only processes 15 per cent 
of the smears taken in the ACT and therefore it is unlikely that double 
counting will seriously bias the results.
There is another possible source of bias from the use of public laboratory 
data. The public laboratory may process cytology from some women outside 
the ACT. Including these women in the estimation of Pap smear frequency 
will also overestimate the frequency of Pap smear use.
Table 3.2 shows the age-specific rates of Pap smear use for ACT women in 
the financial year 1989/90. Forty-four per cent of ACT women had a Pap 
smear in 1989/90. The highest frequency of Pap smear use was in the 25 to
2 The public laboratory provided data by calendar year whereas the Medicare data were 
given by financial year. The public totals for 1989 and 1990 were therefore added and 
divided by two to calculate the number of Pap smears by age group for the financial year 
1989/90.
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44 year age groups where over 50 per cent of women had a Pap smear in 
1989/90. These Pap smear data relate to a time period over which the ACT 
Pap smear campaign3 was operating, hence these frequencies may be slightly 
higher than might ordinarily be expected. It is currently recommended that 
women begin screening between the ages of 18 and 20 and cease screening at 
age of 70, provided the two previous smears have been normal 
(Commonwealth Department of Health Housing and Community Services 
1991). Therefore the younger and older age groups may not be homogeneous 
in terms of the frequency of participation. Inclusion of women between 15 
and 19 and 70 and 74 may underestimate frequency of use for women 
between the ages of 20 to 24 and 65 to 69.
Table 3.2 Annual age-specific Pap smear frequencies adjusted for hysterectomy 
(%) (1989/90)
Age group Estimated frequency of 
wom en having sm ears  
(%)
95% confidence interval 
(%)
15-24 33 .0 3 1 .1 ,3 4 .8
25-34 54.1 52.2, 56.1
35-44 52.7 50.6, 54.8
45-54 43 .9 39.9, 45.8
55-64 33 .5 30.0, 37 .0
65 and older 23.2 1 9 .1 ,2 7 .2
Total 43 .9 42.9, 44.9
Table 3.3 shows the age-specific frequency of Pap smear use in different 
states. Unfortunately the age groups are not directly comparable; the studies 
were conducted over different time periods the age-specific frequencies 
shown relate therefore to different cohorts of women. In addition, different 
methods of adjusting for hysterectomy were used.
ACT women however, appear to have a slightly higher frequency of Pap 
smear use than other states. The differences in screening frequency in the 
ACT and other states may be related to the higher socio-economic status of 
ACT women. Women in the higher socio-economic classes have higher 
screening participation rates than women in the lower socio-economic classes
3 The ACT Pap smear campaign was funded as part of a nationwide program to prevent 
cancer of the cervix. The campaign, which operated from June 1989 to September 1990, 
carried out promotional, educational and clinical services.
(Armstrong, Rouse et al. 1986). Like previous studies, participation in 
cervical screening in the ACT decreases in the older age groups.
Table 3.3 Recent Australian reports of annual age-specific frequencies of Pap smear 
use adjusted for hysterectomy
A g e  g ro u p W A  (S tra to n , H olm an  
e t  a l. 1 9 9 3 ) .
V ictoria  (M itchell a n d  
H ig g in s  1 9 9 3 ) .
N S W  (S h e l le y , Irwig 
e t  al. 1 9 9 0 ) .
Year o f stu d y 1992 1992 1987/88
2 0 -2 9 43% 3 8 % 2 8 %
3 0 -3 9 44% 4 6 % 35%
4 0 -4 9 39% 4 6 % 3 4 %
5 0 -5 9 29% 3 7 % 25%
6 0 -6 9 13% 2 0 % 13%
Age-specific frequencies of colposcopy use
All colposcopy services in the ACT are provided in the private sector. The 
ten per cent Medicare sample is used therefore to calculate the annual age- 
specific frequencies of women having colposcopy.
Table 3.4 Annual age-specific frequencies for colposcopy adjusted for hysterectomy 
(1989/90)
A g e  g ro u p F r e q u e n c y  (%) 9 5 %  c o n f id e n c e  in terv a ls
1 5 -2 4 2 .5 1 1 .9 2 , 3 .0 8
2 5 -3 4 2 .9 4 2 .3 2 ,  3 .6 2
3 5 -4 4 2 .5 9 1 .9 5 , 3 .2 2
4 5 -5 4 2 .6 6 1 .7 7 , 3 .5 5
5 5 -6 4 0 .8 6 0 .2 1 ,  1 .5 1
> 6 5 0 .7 6 0 .0 0 ,  1 .5 6
T otal 2 .4 6 2 .3 8 ,  2 .5 5
Nearly one in forty ACT women had a colposcopy in 1989/90. Between age 
15 and 54 similar frequencies of colposcopy use were found, with the 
frequency falling after age 55. The age-specific frequencies of colposcopy and 
Pap smear utilisation had a similar pattern in 1989/90. There have been no 
previous age-specific frequencies of colposcopy reported in Australia, thus it 
is impossible to compare how these results contrast with other states.
The colposcopy rates have been adjusted for women who have had a 
hysterectomy. It is possible that a small number of these women had vaginal 
colposcopy. This means that the annual age-specific colposcopy frequencies 
may be slightly inflated. This may affect the estimates for the older age 
groups because the prevalence of hysterectomy increases with age.
Age-specific patterns of follow-up
To examine patterns of follow-up two ratios for each age group have been 
estimated:
• smears taken to number of women having smears
• women having smears to women who have colposcopy
The first ratio is devised by estimating the number of smears taken in the 
ACT in the financial year 1989/90 and dividing this by the number of women 
who have a Pap smear. It is an estimation of the average number of smears 
taken per woman. Many of these repeat smears will be because of 
abnormalities or inadequate or inconclusive smear reports. Others will be 
repeated because of persistent symptoms such as bleeding or discharge. The 
second ratio provides information on relationships between gynaecological 
follow-up and Pap smear utilisation for each age group.
Table 3.5 Age-specific ratios for repeat smears and colposcopy
Age group Smears taken: 
women having 
smears*
Women having 
smears: women 
having colposcopy
95% confidence 
intervals
15-24 1.18:1 13.2: 1 13.0, 13.4
25-34 1.18:1 18.2: 1 17.9, 18.5
35-44 1.16:1 20.4: 1 20.0, 20.7
45-54 1.32:1 16.1: 1 15.6, 16.6
55-64 1.09:1 39.0:1 35.4, 42.6
>65 1.09:1 30.1: 1 25.4, 36.1
Total 1.19:1 17.8: 1 17.7, 17.9
* It is not possible to calculate confidence intervals for these ratios for the reasons outlined in 
Appendix A.
The higher the ratio of smears taken to women having smears, the greater the 
proportion of women in that age group who have had more than one smear 
in 1989/90. Interestingly, the 45 to 54 year old age group of women had the 
highest ratio of smears taken to women screened; for every woman screened 
in this age group 1.3 smears were taken. Overall, there were nearly 20 per 
cent more smears taken than women screened during the financial year 
1989/90. In Victoria, in 1992, eight per cent more smears were taken than 
women screened. (Mitchell and Higgins 1993).
On average, eighteen women had Pap smears for every one woman having 
colposcopy. For the age group 45 to 54 there also appeared to be more 
intensive colposcopy follow-up; 16 women had Pap smears to every one 
woman who had colposcopy. The highest ratios of smears taken to women 
having smears and the lowest ratios of women having Pap smears to women 
having colposcopy are found in women less than 55 years of age. It is 
possible that women over 55 who have Pap smears have participated in 
regular screening and thus may be a group with a low prevalence of 
abnormalities. Alternatively, clinicians may respond differently to Pap 
smears indicating abnormalities or reported as inadequate for women of 
different ages. It is possible that practitioners and patients have different 
interpretations of the significance of abnormalities for women of different 
ages.
Current and predicted trends in colposcopy use
In this section current cross-sectional incidence rates for colposcopy are 
computed and the cumulative risk simulated of ever having colposcopy if 
current rates of colposcopy follow-up continue.
Methods
The number of women claiming for colposcopy between January 1 1989 and 
April 30 1990 was obtained from the ten per cent Medicare file4. Women who 
had claimed for colposcopy in the previous two years were excluded. 
Therefore women included in this sample were assumed to be women 
claiming for a new episode of colposcopy. This number was multiplied by
4 These data were collected over a sixteen month period so that I could directly compare the 
assessment and treatment practices of gynaecologists in the ACT and Australia with the 
practices of the gynaecologists operating in the clinic in which the study outlined in Part C 
was based.
7.5 (equalling — xlO) to provide an estimate of the number of women
claiming for colposcopy in a twelve month period because data were 
obtained from ten per cent of the population and collected over a 16 month 
period.
Because all colposcopy services are undertaken in the private sector in the 
ACT, Medicare statistics can be used to estimate age-specific incidence rates 
for colposcopy. After estimating the number of women in each age group 
claiming colposcopy the incidence rates and cumulative risk of colposcopy 
were calculated using a lifetable approach. This is detailed below.
The terms used in the lifetable are:
No. of colposcopies for women aged between x and x + n 
Mid - year population of women between the ages x and x + n '
nCx = no. of women who have never previously had a colposcopy who have
a colposcopy between ages x and x + n,
lx = no. of women who have not had a colposcopy by age x,
lx + n = no. of women who have not had a colposcopy by age x + n,
nmx = rate of colposcopy among women at risk of having their first colposcopy.
12
nCx is derived from the Medicare data.
Therefore,
nMx nCx , 
^Wx
where nWx is given by the number of women enrolled in Medicare on June 30
1989 between ages x and x + n.
However, nMx does not equate to nmx 5 from a conventional lifetable. 
Women who have previously had colposcopy are included in the 
denominator. Therefore, one cannot use the conventional method that 
converts rates to probabilities to derive lx.
5 In a conventional lifetable nmx refers to the rate of an event, usually death, between ages 
x and x+n. Death removes people from population counts, however nWx includes all
lx can be derived with knowledge of nMx, however. The method assumes 
that women were exposed to the same incidence of colposcopy in the past as 
they are now. To calculate lx I use the method described below, which is the 
same as the method described by Dickinson and Hill 1988.
The proportion of women who have had a colposcopy between ages x and x + n 
is
lx + lx+n nrx = — -T-—2l0
Where lo = no. of women who have not had colposcopy at exact age 0, 
or who have not had colposcopy at the beginning of the simulation 
Therefore nmx (the rate of colposcopy among those women at risk of having 
a first colposcopy) is 
nCxnmx = --------——
nWx.nl x
(ie nLx = no. of women years at risk of first colposcopy = nWx.nPx)
And,
nmx
i nCx x
nMx
nPx
= nM x.( 2.10
lx + lx+n )
We know that
nmx nCx lx - lx lx - lx + n
n^X n .lx  + n + 7 -^. nCx ^  (lx + n + lx)
Therefore the above two equations can be equated
nM x. ( 2.10 v
lx + lx+n'
lx - lx + n 
^  (lx + n 4- lx)
women whether or not they have had a previous colposcopy. Therefore nWx will include 
women who are not at risk of first colposcopy.
Therefore,
\  l x - l x  + nnM x.10 = --------------n
and,
n . nMx . lO = lx - lx + n 
hence,
lx + n = lx - n . nMx . lO
The hypothetical cohort starts at exact age 15 with 1000 women. 
These rates have been used to derive 125, 130,135,145, 155 and 175.
If one assumes that women who have had a hysterectomy are no longer at 
risk of colposcopy6, the denominator for colposcopy rates should be adjusted 
to include only women who have not had a hysterectomy between ages x and 
x+n. To adjust for hysterectomy, nWx has been multiplied by the proportion 
of women between ages x and x+n who have not had a hysterectomy, before 
adjustment for colposcopy is made. The cumulative risk of colposcopy is also 
shown after adjustment for hysterectomy has been made.
From lx nmx (the incidence of first colposcopy with denominator adjusted to 
remove women who have previously undergone colposcopy) can be derived.
nmx
nCx
nLx
l x - l x  + n
n . lx + n + n2 . nCx
l x - l x  + n 
^  (lx + n + lx)
Findings
Table 3.6 shows the lifetable probabilities for colposcopy by ages 25,35,45, 55 
and 75 with and without adjustment for hysterectomy. Whether or not an 
adjustment for hysterectomy is made, if current cross-sectional rates of 
colposcopy continued, and current screening participation rates were 
maintained, most women would have had at least one colposcopy by age 75. 
In contrast, the lifetime risk of cervical cancer in a Western-style country in 
the absence of a cervical cancer screening program is only 1.6 per cent.
(IARC Working Party on the Evaluation of Cervical Cancer Screening
6 It is possible that some women who have had hysterectomy may have a vaginal 
colposcopy.
Programmes 1986). Thus there is mismatch between the risk of cervical 
cancer and the risk of further investigation with colposcopy.
Table 3.6 Lifetable of colposcopy with and without adjustment for hysterectomy
No adjustment for hysterectomy Adjusted for hysterectomy
Age (x - x+n) nMx* lx Cumulative
per cent
nMx lx Cumulative 
per cent
15 14.6 1000 0.0 14.6 1000 0.0
25 17.6 885 11.5 18.3 852 14.8
35 14.8 710 29.0 17.0 669 33.1
45 13.3 565 43.5 17.7 502 49.8
55 3.5 431 56.9 4.6 336 67.4
75 362 63.8 249 75.9
* no. of colposcopies per 1000 women-years
The annual incidence rates for colposcopy in the ACT are shown in Figure 
3.1. These were calculated using the lifetable method described earlier.
Figure 3.1 Annual age-specific incidence rates for colposcopy (ACT) calculated from 
simulation
Adjusted for hysterectomy 
No adjustment for hysterectomy
* 40 -
15-24 25-34 35-44 45-54
Age group
55-74
68
Incidence rates are similar if between the ages of 25 to 54. After adjustment 
for hysterectomy the highest incidence rates of colposcopy are in the 45 to 54 
year old age group where a rate of 39.6 per 1000 women years was found.
Table 3.7 shows the incidence rates of colposcopy without adjustment for 
hysterectomy and the incidence rates for cervical cancer in New South Wales 
and the ACT in 1989. Again a mismatch is obvious. The incidence rate for 
colposcopy is many times the incidence of cervical cancer. The overall ratio 
of annual colposcopy incidence rates to the annual incidence rates for 
carcinoma of the cervix is 122:1. The ratios of colposcopy incidence to 
incidence of cervical cancer are 1096:1,185:1,124:1,138:1 and 36:1 for the age 
groups 15 to 24,25 to 34, 35 to 44,45 to 54 and 55 to 74 respectively.
Table 3.7 Simulated annual incidence rates for colposcopy and cervical cancer per 
100,000 women years*
Age groups Colposcopy (1989-90) NSW** (1989)
15-24 1534 1.4
25-34 2202 11.9
35-44 2279 18.4
45-54 2674 19.3
55-74 877 24.5
Total 2042 16.8
* Neither of the figures is adjusted for hysterectomy
* *1989 incidence figures for cancer of the cervix for NSW 1989 from the NSW Cancer Registry. 
Unpublished data.
The International Agency for Research on Cancer published estimated 
incidence rates of squamous cell cervical cancer for women in a Western-style 
country without screening. These were 5,15, 25 and 45 per 100,000 women- 
years for women in the 20 to 24, 25 to 29,30 to 34 and 35 to 69 years, 
respectively. (LARC Working Party on the Evaluation of Cervical Cancer 
Screening Programmes 1986). Let us assume that precursor lesions take an 
average of ten years to develop. That is, those in the 20 to 24 year old age 
group would have an incidence of cervical cancer of 25 per 100,000 women- 
years in ten years' time, if they were not participating in a cervical cancer 
screening program. In a cohort of 100,000 women, 1534 would have a 
colposcopy annually (without adjustment for hysterectomy) at the ages 20 to 
24; 25 would develop cervical cancer in ten years' time. That is, 98 per cent of 
the women who have colposcopy would not develop cervical cancer in ten
years time. The same results are obtained if one uses the IARC incidence 
rates ten years hence for the age groups 25 to 34, 35 to 44 and 45 to 54; 98 per 
cent of women in these age groups who have colposcopy now would not 
develop cervical cancer in ten years time.
Conclusion
It has been shown here that if current patterns of referral for abnormal Pap 
smears continue most women will have a colposcopy during their lifetimes, 
although very few women would ever develop cervical cancer. The ratio of 
incidence of colposcopy to incidence of cervical cancer is many times greater 
in the youngest age group.
There are some limitations to the lifetable approach to deriving cumulative 
risk of colposcopy and age-specific annual incidence rates for colposcopy. 
These are:
• The numerator may include women who had a colposcopy more than two 
years ago. Inclusion of these women will inflate estimates of incidence 
because women who have had a previous abnormality are at greater risk 
of another abnormality than other women (Mitchell, Medley et al. 1990).
• The method assumes that women were previously exposed to current 
rates of colposcopy. Instead women were probably not referred for 
colposcopy as commonly in the past. In fact the use of colposcopy has 
only expanded in the last fifteen years. This assumption will also inflate 
the incidence estimates.
• This simulation includes all women. If a woman does not participate in 
screening she is not at risk of colposcopy. If it were possible to adjust the 
denominator to include only women who participate in screening7 the 
cumulative risk estimates for these women would be greater at the ages 
shown.
• Some women in the ACT may have had a colposcopy in a public sector 
service in NSW. These women would not appear in the Medicare 
estimates. Omission of these women will underestimate colposcopy rates.
7 The only way to do this would be to construct a computer simulation model. For example, 
a microsimulation model could be used. This is beyond the scope of this thesis.
However, if one assumes that nMx is inflated by 50 per cent the cumulative 
risk of colposcopy at age 75 would be 38 and 34 per cent, with and without 
adjustment for hysterectomy, respectively. A clear mismatch between risk of 
colposcopy and risk of cervical cancer is still evident.
Discussion
There is a disparity between risk of cervical cancer and use of cervical cancer 
screening and colposcopy services and the mismatch is greatest for younger 
women.
The highest frequencies of Pap smear and colposcopy service usage were 
found among women under age 55. Although women younger than 35 have 
much lower rates of cervical cancer than women over 35 years of age, their 
patterns of follow-up were similar to those of women aged between 35 and 
54, and their rates of follow-up were higher than women over 55, even 
though they have a lower incidence of cervical cancer than older women.
About one in forty women between 15 and 54 had a colposcopy in 1989/90 
whereas less than one per cent of women between 55 and 74 had a 
colposcopy. These differences in colposcopy use by age may be explained by 
differential rates of referral for colposcopy after Pap smear, different length 
of follow-up (it is possible that younger women are followed more 
intensively, increasing the prevalence estimate), and higher frequency of Pap 
smear use in the younger age groups.
Women in the 15 to 54 year old age group appear to have more intensive 
follow-up. More Pap smears are taken for each woman screened and they 
are more likely to have colposcopy. The differences may be explained by 
different ranges of abnormalities across the age groups. Additionally, 
clinicians may respond differently to abnormalities for women of various 
ages. It is possible that the older age groups include women who are 
previously well screened and hence have a lower risk of abnormalities than 
other women. Without clinical data it is impossible to disentangle the 
reasons for the age differences in follow-up. However, in 1992, only two per 
cent of smears reported in Victoria showed evidence of CIN and only 1.7 per 
cent of smear reports recommended referral to a gynaecologist. (Mitchell and 
Higgins 1993). It is likely that many of the women having colposcopy have 
minor abnormalities of unclear significance.
The age-specific incidence of colposcopy, constructed from the lifetable 
simulation, follows a similar pattern to the prevalence of colposcopy.
Women over 55 have a much lower incidence of colposcopy. The high 
referral rate of women younger than 55 partly explains the high incidence of 
colposcopy in these age groups. They also participate in screening more 
frequently. The implications of current practices are significant. If current 
cross-sectional rates of colposcopy continue it is estimated that 76 per cent of 
eligible women will have colposcopy by age 75.
It is impossible to compare the practices in the ACT with other states or 
territories because no comparable data are available. It is possible that the 
ACT has a more active referral pattern than elsewhere. The higher 
proportion of women participating in screening in the ACT compared with 
other states will also increase colposcopy rates.
As a screening test, Pap smears must differentiate between those women who 
are likely to develop cervical cancer and those who are unlikely to do so. This 
study suggests that if current referral practices for colposcopy continue most 
women will be defined at some time as likely to develop cervical cancer. 
Women who would not develop cervical cancer but nevertheless have further 
investigation could be thought of as having 'pseudodisease'. These women 
could also be considered to be false positives. Although the screening tests 
may identify women with an abnormality, current practices do not 
distinguish between those likely to develop cervical cancer and those who are 
not.
The mismatch between risk of cervical cancer and risk of referral 
demonstrated may be a consequence of the different perspectives of public 
health practitioners and clinicians.
For the epidemiologist risk describes categories of people, not individuals. 
Risk summarises the experiences of an aggregate of people who share a 
particular characteristic, for example, class or age. Each individual in that 
category either does or does not develop the disease studied over a specified 
period of time. The experiences of different sets of people (their risks) are 
compared. In epidemiological terms, risk of a particular disease resides 
within that collection of people, not within an individual.
Although cervical cancer screening is conceived at a population level it is 
instituted in clinical practice where clinicians see individuals. Thus 
population-derived risks must be translated to individuals. The aggregate's 
risk becomes the individual's. Direct translation is seldom possible, however. 
An individual may share characteristics of several categories or have 
characteristics not previously described. Also, the conditions under which 
risk was computed, may not correspond to the clinical situation.
From interviews with physicians practising in Canada, Beresford (1991) 
identified many sources of uncertainty. Scientific knowledge was often 
incomplete. Frequently scientific research had not clearly described the 
particular clinical problems. Clinicians sometimes found their own 
knowledge was insufficient. Abstract data from scientific studies were 
difficult to apply to individual situations. They were required to take the 
general to the specific. Clinicians' experiences with uncertainty had 
consequences for their practice. They performed diagnostic tests to assure 
their patients and themselves, for fear of litigation and to achieve diagnostic 
certainty.
Clinicians may fear litigation if they do not refer a woman with an abnormal 
Pap smear for colposcopy. An Australian study found most doctors were 
very aware of the threat of litigation and this appeared to contribute 
increased levels of servicing. It meant they were more likely to order tests 
and procedures, take time to explain risks, spend time keeping records, and 
suggest preventive consultations. (Commonwealth Department of Flealth 
1993).
Clinicians are concerned about the consequences of making a mistake. 
Gifford (1986) interviewed surgeons who saw women who had benign breast 
disease, a risk factor for breast cancer. These surgeons interpreted the 
women's risk of breast cancer as their own risk of making a mistake. This 
encouraged them to perform investigations and procedures in order to 
reduce their own uncertainty.
Clinicians who do not avail themselves of a test when they are unsure of a 
diagnosis are going against the grain of usual clinical practice. Gathering 
information enables them to assuage their uncertainty a little. It also means 
they have used all possible technologies to achieve the most accurate 
diagnosis. Such practices might be understood as acting in the best interests
of the patient. They are moving towards the best description of the patient's 
problem so that they can then offer the best possibility of cure.
However, in the case of cervical cancer screening, the clinical aim for 
diagnostic certainty results in many more women being investigated for the 
precursors of cervical cancer than would ever develop cervical cancer. 
Investigating a large number of women may increase the sensitivity of the 
screening program but the trade-off is a substantial reduction in program 
specificity. Colposcopy will become the norm, the Pap smear will be an 
inefficient screening test, and the goal of the cervical cancer population-based 
screening program — to achieve a cost-effective reduction in cervical cancer 
incidence and mortality — will not be met. The high rates of investigation 
with colposcopy will also cost the community financially and women will 
incur significant personal and financial costs.
In this chapter, the public health significance of current practices relating to 
abnormal Pap smears have been identified. I have shown that if current 
patterns of referral do not change many more women will be investigated for 
an abnormal Pap smear than will ever develop cervical cancer. Let us now 
turn to exploring current practice from the perspective of women who have 
had abnormal Pap smears.
Part B
Women’s accounts
Chapter Four
Methods
This chapter describes the methods of the qualitative study undertaken to 
explore women's accounts of cervical abnormalities. The study design, 
context and processes of the research and analysis are also outlined.
To my knowledge there has been no published research in Australia which 
addresses women's experiences of cervical abnormalities. Consequently 
there has been limited capacity to consider women's experiences in policy 
and clinical practice even though cervical abnormalities are common.
This is an exploratory study with broad aims to capture the range of women's 
experiences. The intention was to describe the consequences of abnormal 
Pap smears for women who receive the diagnosis; to explore how women 
understood their abnormality and its consequences; and to document their 
experiences of clinical services.
Characteristics of abnormal Pap smears
This section reviews particular features of abnormal Pap smears which may 
influence how women feel about their abnormality and their clinical care.
Secondary prevention through screening and treatment of precursor lesions 
is an important element of modem public health practice. Risk factors for 
disease, defined in terms of a collective experience, are modified at an 
individual level to prevent disease. There is no way of knowing for sure 
whether the individual would get the disease. The drug and dietary 
management of high serum cholesterol illustrates this situation. In 
epidemiological terms CIN is not a risk factor. It is considered a precursor of 
cervical cancer, and therefore, as part of a disease process that sometimes 
results in cervical cancer. HPV, on the other hand, is generally thought of as 
a risk factor, that is, HPV confers women with a higher risk of developing 
cervical cancer in the future. In current thinking HGSIL might be conceived 
as a precursor and LGSIL could be thought of as a risk factor. No matter the
precise definition, both HPV and CIN signify a future risk of cervical cancer. 
The public health paradigm asserts that modification of individual risk 
reduces the epidemiological risk of disease and the incidence of disease is 
decreased. Within this paradigm, women who are unlikely to get cervical 
cancer receive treatment by the health care system because it is impossible to 
discern who will develop cancer and who will not at a given level of cervical 
abnormality, and there is no other means of eliminating these abnormalities. 
But how do individual women who are diagnosed as having a cervical 
abnormality experience risk?
Gifford (1986) found that both clinicians and women thought of risk as a 
'specific property of an individual'. Benign breast disease, which had been 
associated with future risk of breast cancer in epidemiological studies, came 
to define individual women as 'at risk'. This risk became something that 
could be diagnosed, managed and treated. Cervical abnormalities share 
many similarities with benign breast disease; both conditions are biologically 
defined states that are associated with future cancer and both are specific to 
women.
Within Western medicine, diseases are understood to be 'abnormalities in the 
structure and function of body organ and systems' and illnesses are 
'experiences of disvalued states of being and in social function' (Eisenberg 
1977). Clinicians deal with disease and patients experience illness. Presence 
of disease does not necessarily imply illness nor illness disease. (Eisenberg 
1977).
Most conditions produce symptoms or signs of which a person with the 
condition is aware. In the typical clinical model an individual recognises 
their symptoms as deviating from implicit normative standards. The 
decision to seek a professional opinion usually involves discussion and 
advice from members of one's social networks. (Eisenberg 1980). In the 
clinical encounter individuals tell of their symptoms, and doctors interpret 
them and seek out signs. Doctors make sense of individual illness within a 
biomedical framework and construct a diagnosis and treatment plan (Good 
and Delvecchio Good 1980).
However, abnormal Pap smears differ from the usual work of clinical 
medicine. Diagnosis relies completely on a test. Asymptomatic women are 
given a diagnosis which, in medical terms, denotes a pathophysiological 
process. Symptoms are not part of the diagnostic process. Treatment is
technological. The diagnosis is constituted almost independently of women's 
own experience. The cervix, an invisible part of women's genitalia, is 
diagnosed and operated upon. Women cannot see what is happening. They 
have no yardstick, no thermometer, no symptom or sign, with which to 
recognise or monitor their cervical abnormality. They have no basis on 
which to dispute their doctor's diagnosis.
The risk factors for cervical cancer and its precursors, described in 
epidemiological studies, may also shape women's experiences. For example, 
sexual behaviour has long been identified as a risk factor for cervical cancer. 
Discourses concerning cervical cancer and its precursors may construct 
particular meanings for cervical abnormalities.
Study design
As this research was exploratory the most appropriate study design is 
qualitative since this enables an intricate investigation of women's 
experiences. Detailed individual interviews were therefore conducted with 
women who had cervical abnormalities.
The research was conducted in two phases. In 1990/91 pilot interviews with 
ten women were performed. After preliminary analysis and feedback from 
women involved in the pilot interviews, 19 more interviews were conducted 
during 1991 and 1992. The study was approved by the Ethics Committee of 
the Australian National University.
Recruitment of women
Women who had an abnormal Pap smear, and who had had gynaecological 
assessment and treatment, were eligible for the study. Most of the women 
responded to a pamphlet or poster describing the study, placed in the 
gynaecologists' rooms. Additionally, three women were recruited through 
the ACT Women's Health Service (all of these participated in the pilot study)
Women volunteered for the study. Although one gynaecologist asked 
women if they wanted to participate, the others refused to ask women 
directly fearing that women might feel compelled to participate.
Interview procedures
An interview schedule, in the form of a theme list, was used to guide the 
interviews. Interviews lasted between 45 minutes and two and a half hours 
and were tape-recorded and transcribed. Each woman signed a consent form 
indicating they had agreed to the interview and that they were free to decline 
to answer specific questions or to withdraw at any stage. Personal identifiers 
were kept separate from the data.
Interviews were flexible and allowed women to explore their own issues and 
ask questions. I was identified as a medical practitioner, as someone who 
had expert knowledge of disease and illness. So, just as I gathered 
information from women about their experiences, they gathered information 
from me about their cervical abnormality. My practice followed that of Ann 
Oakley, who was often asked about her own experiences of motherhood or 
for advice when she was studying women's experiences of motherhood 
(Oakley 1981). I therefore responded to questions and provided advice when 
asked. After the interview I often gave women written material. Several 
women rang after the interview for advice about their ongoing 
gynaecological care.
The first interview schedule included the themes: diagnosis, treatment, 
effects of treatment and decisions about treatment as well as questions about 
cancer and precancer, the effects of this condition on women's relationships 
and sexuality and how this diagnosis affected their own and other people's 
perceptions of the woman's health. These themes reflected my experiences as 
a medical practitioner and as a user of health services. There were no 
predetermined questions, rather, the schedule served to remind me of the 
issues I wanted to explore.
After the ten pilot interviews, a preliminary analysis was performed on the 
interview transcripts and the memos recorded after each of the interviews. 
Recurring themes were identified. A discussion group with the women from 
the pilot project was also organised. Through preliminary analysis of the 
pilot interviews and discussions with women a second more focussed 
interview schedule was developed (see Appendix B). This interview 
schedule was used for the remaining 19 interviews. In the second round of 
interviews the following issues were focused on: experiences with their 
health care providers; understandings and explanations of their abnormal
Pap smear; perceptions of their cervix; perceptions of control; and feelings 
about how this experience had changed their lives.
Following the interview socio-demographic data were collected using a 
precoded questionnaire. Most interviews were conducted in women's 
homes. A few women were interviewed in an office at the National Centre 
for Epidemiology and Population Health at the Australian National 
University.
Characteristics of sample
Women saw one of six gynaecologists. There was only one female 
gynaecologist who was seen by two women in the study. Four of the 
gynaecologists worked from the same clinical premises and shared the same 
receptionist staff. All women in the study were still seeing their 
gynaecologist for follow-up at the time of interview.
Tables 4.1 to 4.4 provide details of the sample of women interviewed. The 
median age was 34 years. About half the women in the sample were enrolled 
in or had completed a tertiary qualification. Most women were living in 
married or defacto relationships. Canberra's population has higher education 
status than elsewhere in Australia and this is reflected in the sample. Most 
women were bom in English-speaking countries; all women spoke English at 
home.
When reporting direct quotes a pseudonym is used for each woman. A brief 
description of each woman is provided with her pseudonym in Appendix C. 
When reporting the quotes in the text I use upper case for my questions. The 
women's responses are in lower case and are single-spaced and indented.
Table 4.1 Age of sample
Age group Frequency
Table 4.2 Education of sample
Educational status Frequency
Some secondary school 6
Completed secondary school* 10
Trades or apprenticeship 0
Certificate or diploma 3
Bachelors degree or higher 10
* Five women in this category were enrolled in a bachelors degree at the time of interview 
Table 4.3 Marital status of sample
Marital status Frequency
Single 4
Married or defacto 24
Divorced or widowed 1
Table 4.4 Country of birth of sample
Country of birth Frequency
Australia 24
United Kingdom 2
France 1
New Zealand 1
Malaysia* 1
* Her parents are Australian.
Judging the research findings
In order to produce an accurate representation of women's accounts, the 
research instrument must be flexible so that it can incorporate new and 
emerging themes. The researcher must be sensitive to the ways particular 
research questions obscure some constructions and highlight others. After 
ten interviews, reflections and input from some of the women interviewed 
facilitated the refinement of the interview schedule so that it focussed on 
exploring more fully the developing themes.
To ascertain how accurately the women's experiences had been reported, a 
summary of results was sent to the women interviewed and they were 
invited to comment. Several women contacted me by phone and described
80
their pleasure at reading about themselves and other women like them. One 
woman commented that she felt her GP had been extremely good at 
providing her with information. Another wanted to publish the research in a 
magazine with which she was involved. Another wrote explaining that her 
partner had been most supportive and understanding. I organised a meeting 
with participants to discuss the research findings. At this meeting women 
commented on the document they had received.
I regret not getting my highlighter pen out - there were so many 
points I agreed with at the time and now. ...I identified strongly 
with the stigma. I really struggled with my conscience on that one. 
(Amanda)
I think the common thread that runs through this is the fact that 
the information is not available and of course then you have fear 
and then you have other problems associated with it. But it was 
very informative, it was a very informative document about 
yourself and about others too because you're not alone are you? 
(Jenny)
I suppose I read this and I thought yes, yes, yes but I felt more 
stronger about it than the way it was put and that made me 
wonder whether feelings I had were stronger than what other 
people felt or whether it was just the way you'd written it. (Amy)
Amy's comment prompted me to reflect on the difficulty of representing all 
women's experiences in one document. In summarising the whole, I had 
understated Amy's experience. Lather (1991) calls this 'shattering the 
individual narrative' (Lather 1991).
Most comments from women related to the descriptive, rather than the 
interpretative, research findings. This is probably because they did not have 
the time or opportunity to immerse themselves in the text as I had done. 
Many women described the 'click of recognition' that Lather maintains is 
essential to establishing the validity of a study (Lather 1991).
Lather (1991) argues that a study is worthwhile if the findings are useful for 
the people studied and other relevant stakeholders. The group who met to 
discuss the findings spoke about how, at the time of diagnosis, they had 
wanted better information and someone to talk to who shared their own 
experience. This group decided to set up a support group so they could help 
other women who were faced with the diagnosis of an abnormal Pap smear. 
Despite initial enthusiasm the support group has not continued. Findings of 
the study have also been reported to gynaecologists who said they found it
interesting and that it had given them a different perspective on their 
practice.
As the research was based in Canberra, the socio-economic status of the 
sample was less varied than if the study was based in another Australian city. 
Most women were of Anglo-Saxon descent. There were no Aboriginal 
women or women from non-English speaking backgrounds. The project only 
included volunteers who were being followed by private gynaecologists. 
These women may supply a different account from women who did not 
volunteer for the study or who were followed up elsewhere.
All the women interviewed had seen a gynaecologist because of a cervical 
abnormality. These women are more likely to have accepted professional 
ways of understanding and interpreting this experience than women who 
did not attend a gynaecologist. Interviews with women who did not seek 
gynaecological advice for their cervical abnormality may have revealed 
alternative meanings for cervical abnormalities.
Data analysis
The text of the interviews constituted the data for the analysis. All 29 (pilot 
and subsequent) interviews were analysed. A coding framework to organise 
data into categories was developed. The coding framework was constructed 
from the aims of the research, the interview schedule and emerging themes. 
The framework has three topic headings: explanations and understandings, 
interactions with health services and relationships with others. Within these 
topics there are up to ten more categories and in some cases there are 
subcategories within the categories. Each interview was also coded for 
socio-demographic data (age, marital status, education) and clinical data 
(diagnosis, treatment, time since treatment).
The text of the interviews were entered into the computer software program 
NUDIST (Non-numerical Unstructured Data Indexing, Searching and 
Theorising) (Richards, Richards et al. 1992). This involved entering the text of 
the interviews into the NUDIST program. The segments of text that 
corresponded to various categories in the coding framework were coded.
Tesch (1990) maintains that qualitative research can be divided into four 
groups. This research is concerned with two of these groups: the discovery of
regularities and the comprehension of meaning in text or action1. These 
groups have overlapping features. The aim of the analysis was both to 
describe and interpret women's accounts, so the analysis concentrated on 
considering the meanings of particular themes and exploring how these 
might relate to other ideas. For example, under the category of precancer the 
meanings of precancer for women were examined. Under the category of 
general practitioners the common themes women mentioned when 
discussing the role of their general practitioners were examined.
As the analysis is based on small numbers of women, and this study is 
concerned with the meanings and themes, it is inappropriate to present my 
findings in terms of the number of women who experienced a particular 
event or spoke about particular concepts in similar ways. Therefore, when 
discussing the research findings terms such as some, most, several and a few, 
are used to provide an indication of the rough frequency of a particular 
interpretation or theme.
To code the categories under the first heading of the coding framework 
'explanations and understandings' models were used, developed within 
interpretative medical anthropology, as the basis of the coding scheme.
Explanatory models
The explanatory model framework offers a method of investigating how 
women make sense of their abnormality. It is a means of organising the data 
and facilitating interpretation. The framework enables some interpretations 
of the data and prevents others.
Some medical anthropologists conceive the health system as comprised of 
professional, popular and folk sectors (Kleinman 1980). In Western society, 
clinical medicine constitutes the professional sector. The popular sector 
includes family, social and community networks. In Western culture, the folk 
sector includes healers such as herbalists and naturopaths. (Kleinman 1980). 
Most episodes of self-identified illness are managed in the popular sector. In 
deciding to consult a doctor or folk healer an individual may consult with 
their own social networks and evaluate their symptoms against implicit 
normative standards (Eisenberg and Kleinman 1980).
1 These two groups include many research perspectives such as grounded theory, 
phenomenology and hermeneutics. It is not within the scope of this thesis to describe the 
features of these different perspectives.
Explanatory models, formulated by medical anthropologists, provide a 
framework for exploring how health professionals and lay people make sense 
of a particular illness episode and evaluate approaches to treatment and 
healing (Kleinman, Eisenberg et al. 1978; Kleinman 1980).
Explanatory models are notions about an episode of illness
employed by those engaged in the clinical process (Kleinman
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Kleinman (1988) argues that all systems of healing are to some extent 
concerned with questions about the disorder such as: cause, onset, what is 
wrong, future course, sources of improvements and exacerbations, and 
approaches to treatment. Thus explanatory models are considered to consist 
of five elements — aetiology, pathophysiology, onset of symptoms, course of 
an illness, and treatment. (Kleinman, Eisenberg et al. 1978; Kleinman 1980). 
Specific features of the explanatory models are emphasised in particular 
illness episodes, by different participants in the clinical process (the sick 
person, the professional and the folk healer), and in particular cultures 
(Kleinman 1980). I use all the features of the explanatory model, except onset 
of symptoms, as a coding scheme under the major topic heading, 
understandings and explanations. The categories of aetiology and 
pathophysiology have subcategories which were formulated from themes 
arising within the category (for example 'stress' under the aetiology 
category). I do not consider explanatory models to be entities in themselves, 
rather I used them as a tool which enabled me to gain insight into the ways 
women made sense of their abnormal Pap smear and the meanings it held for 
them.
The way individuals come to understand and explain particular illness 
experiences is shaped by the personal meanings they bring to an episode of 
illness from their own life experiences. Particular illness episodes also shift 
those systems of meaning. Illnesses thus become incorporated into and 
shape individual identities and life trajectories. (Kleinman 1988). Illness 
experiences are also culturally shaped. Thus, members of a particular social 
group may hold particular meanings for symptoms or illnesses. (Kleinman 
1988). For example, in Iran heart distress described a syndrome that had a 
series of related meanings about Iranian women's sexuality and the 
oppression they experience in their everyday lives. Heart distress was a 
culturally specific idiom, a collective representation of an illness, which 
described something about the stresses and conflicts of the lives of Iranian 
women. (Good 1977). Illnesses such as cancer have a range of meanings in
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different cultures. In Western culture, cancer is used metaphorically to 
describe uncontrollable growth (Sontag 1977). In contrast, the Navajo 
describe cancer as a 'sore that does not heal'; cancer represents decay 
(Csordas 1989). Social groups, such as those defined by class, gender and 
race, may also share particular meanings. These culturally shared 
interpretations of symptoms and illnesses enable communication between 
individuals who share the same culture or social group. For example,
'tension headaches' have particular meanings in Western culture. Individual 
interpretations of what another says when they describe a symptom or 
syndrome, such as tension headache, are also shaped by their ongoing 
relationship. Within that relationship particular meanings for the symptoms 
and illness are constructed. (Kleinman 1988).
The professional, popular and folk sectors have particular cultural models of 
sickness. In Western society the professional sector is predominantly 
concerned with disease. Disease is a concept used to describe biological 
dysfunction or the way doctors understand the experiences of individuals 
who consult them. The doctor reconstitutes an individual's illness complaint 
as disease, which describes an alteration in that individual's biological 
functioning. Professional explanatory models are therefore mostly concerned 
with disease as a universal biological entity. (Kleinman 1988). For example, 
Blumhagen (1980) found that the professional and popular interpretation of 
hypertension differed. The professional interpretation was high blood 
pressure and the popular understanding was excessive tension or anxiety. 
(Blumhagen 1980). The contrasting professional and popular meanings for 
high blood pressure offer quite different alternatives for managing the 
condition.
Although the professional, popular and folk sectors are usually considered as 
separate, they feed into and shape each other. For example, an English study 
found that both general practitioners and their patients drew on scientific 
and folk accounts of colds and fevers. The germ theory of disease did not 
conflict with the folk model of 'feed a cold, starve a fever'. Instead, folk and 
professional models were mutually reinforcing. (Helman 1978).
Explanatory models are dynamic. The models vary over time so that an 
illness experience can be incorporated into an individual's changing life 
circumstances. Particular explanations and meanings are reworked, 
elaborated or expunged as a consequence of social interactions (including 
interactions with physicians) and life experiences. In this way explanatory
models are grounded in individuals' lives. (Hunt, Jordan et al. 1989).
Cultural representations of illness are also historically contingent. Farmer 
(1990) reported on the representations of AIDS (SIDA) in a Haitian village.
He found that at the beginning of the epidemic, before anyone in the village 
had suffered from SIDA, it was not a frequent topic of conversation. At that 
time SIDA was a disease of city people, men who slept with other men, and 
was characterised by diarrhoea. There was no collective representation of 
SIDA. When three villagers became affected, the cultural model of SIDA 
shifted. SIDA became incorporated into previous interpretative frameworks 
for illnesses. SIDA was associated with divine punishment, North American 
imperialism, the corruption of the country's leaders and the ongoing 
suffering of Haitian people. The cultural model was related to the political 
events in Haiti at that time. (Farmer 1990).
My interviews were conducted at a particular point in the course of women's 
clinical care. Women's reflections revealed some of the fluidity of their 
explanations. No doubt a series of interviews over the period of their 
abnormality and treatment would have enabled further insight into how 
women's explanatory models were extended and modified over time.
Summary
I have described the purpose of this investigation, the context of the inquiry, 
the process of the research, the sample of women and the applicability of the 
research findings. The results of the analysis are reported in the following 
three chapters.
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Chapter Five
What is a cervical abnormality?
The following two chapters explore the meanings of cervical abnormalities 
for women. The central argument of this chapter is that this diagnosis shifted 
women's conception of their risk of cervical cancer so that their risk came to 
reside within their body. This embodied risk meant they were in an ongoing 
liminal state of neither health nor illness. Rather, they were in a state of 
potential ill health. I conclude the chapter with a discussion of how cervical 
abnormalities reshape women's perceptions of their cervix, reproductive 
systems and self-definitions.
Women constructed their meanings for cervical abnormalities from their past 
experiences (both within and outside the health system), popular medical 
culture and scientific medicine. First, I explore how women understood the 
terms HPV (or wart virus) and precancer. I show how women's 
interpretations of these terms drew on their previous beliefs about the 
meanings of warts, viruses and cancer.
Interpreting medical terminology
Wart virus infection
Wart virus manifests in a variety of ways (see Chapter Two). Treatment of 
HPV is difficult. Ablative treatments such as laser or diathermy and anti 
viral ointments or creams such as idoxuridine are commonly used. The 
natural history of wart virus infection is one of regression and recurrence 
both with and without treatment. HPV presents diagnostic and treatment 
difficulties.
Previous beliefs about warts and viruses influenced how women interpreted 
the diagnosis of wart virus infection. This diagnosis was understood in the 
context of their more general understandings of viruses, warts and similar 
infections. For example, from previous experience with the medical system
they knew viruses were rarely treated and usually went away. Treatment 
did not make sense in the context of their general understanding of warts and 
viruses.
Wart virus infection was linked to growths commonly found on one's hands. 
Their doctors' explanations about the different strains infecting the hands and 
genitals were often discounted. Viruses were expected to circulate in the 
bloodstream and spread throughout the body — similar to the common cold.
A wart to me is something you get growing on your hand... and 
everybody wants to get rid of them. And a virus is something that 
spreads...I had this vision of having 50,000 warts down there. 
(Ruth)
Given this perception local ablative therapy was hard to understand.
...if it is all wart virus that the whole thing stems from, how do 
you treat warts with laser? I only had the virus from what I 
understand. If you've got a virus in your bloodstream, how can 
you treat it with laser? (Adrienne)
For some women, recurrent or persistent wart virus infection after ablative 
treatment could be understood because they believed that ablative treatment 
could not address the infectivity of the virus. Virus implied that the 
condition did not only reside in the genitalia. Several women suggested that 
treatment was unnecessary as viruses went away without medical 
intervention. Often women drew parallels, and occasionally equated wart 
virus infection with genital herpes or cold sores.
Information about wart viruses contradicted previous beliefs. Women's 
understanding reflected sophisticated reasoning within the biomedical 
paradigm. Yet, women’s understandings were often dissonant with 
contemporary medical practice. Recent policy is more congruent with 
women's models for wart virus infection. The recently released report: 
"Guidelines for the Management of Women with Screen Detected 
Abnormalities" states:
It must be stressed that the human papilloma virus cannot be 
eradicated by current methods of treatment. (Commonwealth 
Department of Human Services and Health 1994). pl8
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Precancer
Women had not heard the term precancer before they had their cervical 
abnormality. When they first heard it, many thought precancer was the same 
as cancer which was equivalent to death.
I didn't know anything about precancer, soon as it was linked to 
cancer I thought I'd had it. (Valerie)
I really did think I was going to die, because I had never heard 
about it before and then when I went to this doctor that first gave 
me the Pap smear, it was told to me that it was CIN 3, the last 
stage of cancer. (Rosemary)
Rosemary, and a few other women, still believed they had had cancer at the 
time I interviewed them.
Women's interpretation of precancer was drawn from their understanding of 
cancer.
As soon as you hear the word cancer, you think the worst. It's a 
word you dread. You just don't want to hear. (Carmel)
One mere mention of the word cancer is enough to really frighten 
you. (Heather)
The word cancer was imbued with frightening connotations. Women 
described how mentioning cancer caused a healthy man to die quickly and 
made rational people become irrational. People withdrew from cancer's 
victim and cancer meant a slow and painful death. The word cancer created 
fear.
Sontag (1977) maintains that diseases such as cancer, which are poorly 
understood and have no effective treatment, are often 'awash with 
significance'. The diseases themselves become metaphors. Cancer, which is 
viewed as the modem day epidemic, represents 'our culture's insult to the 
natural order'. (Sontag 1977).
Cancer was sometimes perceived as equivalent to death.
There's a part of me that has this real pessimistic outlook on cancer 
which is cancer is death. And no matter how much I see people 
around me and read a lot about people who actually fight their 
cancers, I was scared. (Leslie)
I thought "oh my god I've got cancer I'm going to die". (Phillipa)
A death from cancer was long and painful.
Cancer makes me think of suffering. I had a few friends that died 
of cancer. It just makes you think of the horrible chemotherapy
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treatment and horrible death. Their wasting away and it's just 
really painful. Sort of grey coloured skin. (Lorraine)
If I'm going to die young I want to go straight away and not go 
slowly.. .1 just want to go at once. (Ruth)
Military metaphors similar to those by Sontag (1977) were used to describe 
cancer. Cancer was cast as the smart and deceptive enemy and the body as 
its vulnerable and sometimes defenceless prey. Cancer constantly 
threatened. Stress, smoking or anything unhealthy made one more 
vulnerable to a cancer 'strike'. Youth and health protected one against cancer. 
Young people with cancer were more perplexing, revealing the inadequacy 
of their body's defences against cancer — the mighty and skilled attacker.
Cancer invades one's body and robs you of your body and your life.
I think I would much rather think I'd died a 'natural' death of old 
age rather than feeling...it's an invasion...the feeling is that cancer 
invades you as opposed to a natural deterioration of the body. 
(Jenny)
Cancer is a foreign force, taking over territory that it does not own. Cancer 
was cast as an attack upon the body. However, one could 'fight' or 'battle' 
cancer.
I'm not scared of cancer any more. I think once you battle it, I 
think that's it, once you're over it you try and prevent it with 
things like Pap smears. (Rosemary)
A few women spoke of cancer as 'in the family'. There were cancer families. 
In this situation cancer symbolically spread beyond the boundaries of 
individual corporeality to other bodies within one's family.
Women spoke of cancer as difficult to control. They could not prevent nor 
recognise cancer.
If it was a heart attack problem you could think of it as the heart 
not doing its job properly or that the valve is blocked - it's more 
tangible, whereas cancer seems to be a very insidious disease that 
just creeps around and you can't control it or see where it is. It's 
hard to describe but you can't come to grips with it as easily as 
something where you can see what it's doing or what it's not doing 
and why. I think it's just the insidiousness of it. (Anna)
Cancer was perceived in punitive terms. For several women, it signified the 
general unhealthiness of modem society.
...there seems to be a higher incidence with our lifestyle at a more 
hectic pace, more highly processed foods and chemicals and 
things, whether that's bringing it about, I don't know...(Phillipa)
I think it is a fact of life at the moment, in our world, in our society, 
we live with it all the time, and the fear of it. (Jenny)
In summary, cancer was considered an enemy, striking when one is most 
vulnerable, spreading and taking over the body, resulting in a painful, 
prolonged death. The meanings cancer had for women shaped their 
descriptions of the nature of precancer, and their reactions to their cervical 
abnormality.
By the time of interview most women distinguished precancer and cancer. 
Cancer provided the conceptual framework for making sense of the term 
precancer and women reworked the meaning of precancer within this 
framework.
Many women distinguished precancer from cancer.
The receptionist was the one that allayed my fears in relation to 
cancer. And then he [the doctor] said to me, look it's not cancer, 
it's precancerous cells, that made a big difference as well, to know 
that it wasn't cancer. And then his confirmation that it is all gone 
and that basically we are just dealing with wart virus now rather 
than with precancerous cells. (Sharon)
For Sharon wart virus was not precancer. Other women referred to wart 
virus as a precancer. Because of the ominous meanings cancer holds in our 
culture women were often reassured by differentiating cancer and precancer.
For most women precancer was a condition that could develop into cancer if 
they did not have treatment.
I took it to mean that if the condition was untreated it would 
proceed to cancer. That is why I had no hesitation having 
treatment. (Maeve)
For Ruth precancer inevitably resulted in cancer.
...I guess precancer is something, when you think of cancer you 
think of it being incurable. So with me when somebody says 
precancer, you think oh its going to turn into cancer and that is 
going to be it. You don't think of it as a stage that can be stopped. 
(Ruth)
Ruth describes precancer as a condition that will turn into cancer despite 
intervention. Precancer, like cancer, is incurable. Ruth's description of 
precancer is indistinguishable from cancer.
Get it [the treatment] done quickly. I know it was precancerous, it 
can stay a couple of years but I wanted to get rid of it.
WHAT WERE YOU THINKING ABOUT?
That it would multiply and when I went back in next week, or in 
two weeks, it was going to be all over me. Nobody could put that 
out of my mind. I was convinced I was infected. I felt incomplete, 
unhealthy. I felt my whole body was unhealthy. I had this growth 
and felt really unhealthy about the whole thing. I just wanted to 
get rid of it. (Ruth)
Precancer was going to spread in the same way as cancer. Precancer, like 
cancer, was separate from her and spread throughout her body. While 
precancer was present she felt unhealthy. Precancer defined her in a new 
state of ill heath.
Precancer was cancer, as well as not cancer, as well as a precursor to cancer in 
women's descriptions of cervical abnormalities. Sometimes these definitions 
occurred simultaneously. Precancer was interpreted in relation to cancer, in 
terms of what it is not or what it might become; it did not have intrinsic 
meaning in itself. Therefore, precancer is an ambiguous state, for lay women 
as it is in medical discourse.
Healthy or ill?
Women tried to make sense of their cervical abnormality in terms of the 
conventional definitions of health and illness. The lack of symptoms and 
their newly defined state of risk was understood as neither a state of health 
nor illness, rather it was a liminal state of potential ill health.
Lack o f sym ptom s
...if you've got a wound on your arm you can see what is 
happening to it, if you've got a pain, well at least you've got a pain, 
but you just don't have anything, nothing at all, which is very 
confusing. (Anna)
Perplexity, such as that expressed by Anna, over the lack of symptoms was a 
recurrent theme.
Women with cervical abnormalities rarely suffered symptoms. However, 
symptoms are central to modern definitions of illness. Illness is constituted 
from symptoms.
REMEMBER BACK TO WHEN YOU FIRST HAD AN 
ABNORMAL PAP SMEAR. WHAT DID THAT FEEL LIKE?
It was horrific. Actually my life wasn't good and it wasn't bad but 
I was coping. As soon as I found out the results I just went 
downhill, I couldn't cope any more. I became ill. Even though 
physically I felt well. I was going to the gym etc., I just all of a 
sudden thought, I'm sick and made a physical illness for myself.
...As soon as I was told the results I was ill. All of a sudden. Then 
it became interlinked with depression. I automatically became 
different. All I wanted to do was stay in bed and I just felt 
lethargic and I thought I had cancer. If you've got cancer, you 
don't do anything because you're sick. (Lorraine)
Despite being asymptomatic at the time of diagnosis Lorraine developed 
symptoms with the diagnosis. Lorraine describes how the diagnosis of the 
cervical abnormality move her from a state of health to illness. 
Transformation to this state of ill health rests on the diagnosis of the 
abnormality and the presence of symptoms. Furthermore, because she is sick 
she has a different relationship with the world — she no longer does 
anything.
Not all women responded in this way. Judith did not consider her cervical 
abnormality as an illness.
I thought this was something like when I had warts on my fingers; 
the doctor froze them or burnt them off or something. I saw it in 
relation to that - something that was there that had to be taken off - 
I didn't really think of it as an illness or sickness or anything 
severe. (Judith)
Her cervical abnormality was perceived to be a physical entity. However, it 
was not an illness, she does not suffer any symptoms that would define her 
as ill.
Sarah did not experience any physical manifestations of the diagnosis, but 
she was emotionally affected by it.
I wasn't even sick, that's the problem, like it's not being sick, I 
didn't feel sick, I know I didn't look sick. So it was really on an 
emotional basis. Sure there was the physical stuff you had to fix 
up, but it was the emotional stuff you attach to abnormal smears 
which could lead to cancer, which could lead to death. So that 
stuff was worrying me, but not physically. (Sarah)
Sarah used sickness to refer to physical not emotional experiences. Yet Sarah 
'suffered' emotionally because of her abnormality. The abnormality signified 
her mortality. She was neither sick nor well. No term adequately described 
her experience.
The lack of symptoms meant the condition could pass unnoticed.
My sister in law had it just before or around the time I did. She 
ended up having a full hysterectomy. But she was bleeding all the 
time so...I didn't have any of that. I didn't even know. I mean I 
wouldn't have known there was anything wrong with me. That's 
the scary part. Like you don't have a pain and say, "oh I am sick I 
have to go to the doctor and have it checked". Only through these 
tests. And then I heard, it was on the radio or something that they 
couldn't pick it up in all cases, that the lab could overlook it, or the 
human eye. That is scary. In my case now that I've had it twice, 
the bad cells, if they don't check carefully enough now...(Carmel)
Carmel recounts her usual experience of sickness. She recognises symptoms 
and the doctor diagnoses and legitimises her as sick. In this instance, she 
does not recognise herself as sick because she has no symptoms. Also, even 
the doctor and tests may 'miss' the diagnosis. The fear is related to the cancer 
that could result from such an error.
Symptoms and signs mark the individual in a way that identifies them as ill. 
They and others respond to them as ill. Without such symptoms women are 
not ill, unless they developed symptoms like Lorraine. They were not 
healthy either, however. They were in an ill-defined liminal state of neither 
health nor illness.
The physical nature of cervical abnormalities
Abnormal cells, precancer, wart virus and CIN referred to conditions from 
which women suffered. They were not abstract, depersonalised, 
disembodied risk factors for women with cervical abnormalities.
WHEN YOU HEARD THE WORD PRECANCER DID THAT 
BRING UP ANYTHING FOR YOU?
It is a bit like knowing that I had something, a condition that could 
lead to cancer if I didn't monitor it or be vigilant about it. It was 
just a feeling like having something wrong with my body that I 
had to keep checking on or that I had to ask other people, like 
doctors, to check up for me. (Brenda)
Clearly precancer is a condition that is part of Brenda's body. As in medical 
discourses, her risk of cervical cancer is a physical entity. Even after
treatment her risk is still considered to be something wrong'. Her risk still 
resides within her body. She is a state of potential cancer that is a disease in 
itself.
In contrast, Maeve and Phillipa spoke of their cervical abnormality as a 
physical entity that had been removed.
I'm sure that I'm fixed now but that doesn't mean it can't return in 
the future. Whatever was there has been fixed up and I don't have 
any worries at all. (Maeve)
I feel quite open and happy about it now, it's not perturbing me, I 
mean it's not going to send me grey for the next 30 years. All the 
cervix is cleared and the abnormal cells have gone so that's the 
main thing. (Phillipa)
However, the cervical abnormality itself needs to be fixed. Their bodies have 
a future risk of disease. With the abnormality gone Maeve and Phillipa have 
no concerns. Like Brenda, their cervical abnormality is not a part of a healthy 
body; however, unlike Brenda, removing 'it' returns her to a healthy state.
Women spoke of getting, fixing and being cleared of their cervical 
abnormality.
it's only three or four months that I have actually been clear of it. 
(Leslie)
Cervical abnormalities had physical boundaries. Ineffective treatment failed 
to remove the entire abnormality. Several women wondered, on their follow­
up visits, whether all of 'it' had been completely removed.
I'll probably worry until I go back in September - did he get 
everything? (Mary)
Cervical abnormalities were definitive physical entities that encapsulated 
women's risk of malignant disease — they were not abstract risk factors that 
exist separate from an individual. For most women, they were conditions 
and disease in themselves. Treatment reshaped women's perceptions of their 
cervical abnormality. For some women treatment returned them to a healthy 
state since their abnormality had been removed. For others, for example 
Brenda, even treatment of their cervical abnormality did not remove their 
embodied risk.
Experiencing risk
[prior to her abnormal Pap smear]...I never considered that I'd be 
at risk at all. (Louise)
This condition signified women's vulnerability to cervical cancer and death. 
Women became aware of their 'risk' of cervical cancer and death. Some 
women experienced a new found state of vulnerability in terms of their own 
health. In epidemiological and clinical terms, this is not a new risk, but the 
diagnosis of the cervical abnormality brought this risk into women's 
consciousness.
I think I am going to get it eventually, [when she goes for Pap 
smears] ...I am just waiting for him to say "it's not looking good, 
you are in for it"...I have always gone for regular checkups and 
not thought a lot about them. ...I can't look at it the same way 
now, I can't have a smear done and be relaxed. ...They say "well 
you're being watched a lot more than anybody else so your 
chances of getting it bad are not as high". But it is just me. I think 
it is because I know that it can happen and it makes me a lot more 
aware. (Ruth)
Ruth speaks of her risk as a certainty; she believes she is going to get 'it'. Her 
cervical abnormality altered her awareness of her risk. Her risk of cervical 
cancer has a different quality from before she had her abnormal Pap smear. 
She is now constantly aware of her risk. The risk is now part of her. In this 
quote Ruth speaks of risk of cancer and death.
I was concerned about the implications of being on the pill for 
somebody who had a risk ...who had a history of abnormal 
smears. (Amy)
They [the doctors] didn't really tell you anything that you could do 
to change your risks. (Veronica)
Amy and Veronica possess their risk of cervical cancer. It is not a risk factor 
that is objective and describes groups of women like them. Instead, they are 
now defined by and live their risk of cervical cancer.
Some women described risk in relative terms.
I don't feel I am a different person now. I have had this problem 
and it has been fixed, or not fixed, but I am back in the same boat 
as everyone else and I don't feel like I am more likely to have 
problems than they are. (Anna)
Treatment has returned her to the same risk state as everyone else. Her 
likelihood of risk is described in relation to others. In assuming the same 
'risk state' as everyone else her risk is no longer a problem.
Many women said they had not considered themselves to be at risk of 
cervical cancer prior to their abnormal Pap smear. Prior to the diagnosis of 
their abnormal Pap smear they felt at no risk of cervical cancer.
...he [her gynaecologist] told me that once you had treatment, 
particularly laser treatment, your chances of abnormal cells goes 
back to zero. (Leslie)
Leslie implies that the time before her abnormal smear she was at no risk of a 
cervical abnormality. After treatment she returns to this state of no risk. In 
epidemiological terms she would be considered to be at risk, both before and 
after treatment, of cervical cancer or an abnormal Pap smear. She does not 
experience this risk, however.
Because of their cervical abnormality, women now experienced a sense of 
their own risk of cervical cancer. For many women their cervical abnormality 
symbolised their vulnerability to cancer and its consequences. Women 
frequently became more aware' of cancer generally.
because it is all cancer related, I check my skin, moles and things 
like that and get straight to the doctor if I thought there was 
something wrong. I think it has made me a lot more aware of 
cancer generally. (Ruth)
But on the other hand it is a reality to me now that I might get 
cancer there. And it has made me think more about cancer in 
other areas, like breast cancer. So it's made me think more of 
cancer related to females. (Ruth)
Not only is her cervix a site of potential disease but her whole body, 
especially parts of her anatomy that are defined as uniquely female, are 
potentially diseased. Mary's response to this newly defined awareness of her 
own susceptibility to cancer was to suggest removal of any parts of her that 
were 'unnecessary' and liable to cause her problems.
I think the bits that I don't need, they may as well have and just 
leave me with the bits I need. Before, I probably would be scared 
stiff if they took my appendix out. Now they can whip them out 
and as long as they say, "you don't need it", they can have them. 
Because the tiniest bit can go wrong, and if that's not there well 
you can't have a problem with it. I'd be quite happy to go in and 
say "well I've still got my tonsils and I've still got this, rip them all 
out and I can go and I never have to come back again". (Mary)
In light of the vulnerability women experienced, several reflected on the 
quality of their own life and death.
Life is important...you realise how important life is to you, and 
you want to live, you don't want to die. You want x amount of
years ahead of you and you are not going to waste them. You are 
going to enjoy every second of those, in whichever way, shape or 
form it takes, you are going to enjoy it. So it's very positive. I felt I 
came out of it, out of that particular period, feeling very positive 
about myself. (Jenny)
It's certainly changed the way I think, I don't worry about six 
months' time now. (Mary)
Carmel reflected on her own mortality.
DO YOU THINK IT HAS MADE YOU THINK ANY 
DIFFERENTLY ABOUT YOUR LIFE?
Yes it has. It made me think that you are not invincible, that you 
can, anything can happen to you. Like there was a little boy killed 
across the road here. That sort of thing really frightens me and it is 
out of your control in a lot of cases. Someone can come with a gun 
and blow you away. Like in the shopping centre in Sydney or this 
little boy at the bus stop. (Carmel)
Carmel reflects on the nature of the human condition (she uses 'you' rather 
than T). Her experience is compared with indiscriminate killing. She 
realises that she, like everyone else, is susceptible to death. All of us will die. 
Frequently this is out of our control. One does not have control over one's 
bodily processes or one's own death.
In summary, a cervical abnormality had a physical reality for these women. 
Their risk of future cancer and death became part of them. They felt and 
experienced their risk. The diagnosis shifted or developed their awareness of 
their risk of cervical cancer, so that it came to reside within their bodies. This 
awareness of their risk resulted in many women experiencing a sense of 
vulnerability. Their sense of their own bodily integrity changed. They now 
experienced their cervix, and sometimes other parts of their physical body, as 
potential sites of cancer — as dangerous.
The cervix: the site of the abnormality
Meanings for the cervix
The cervix was defined in terms of its reproductive capacity and 
reproduction constituted the essence of femininity. Some women spoke of 
how their cervical abnormality, and the medical treatment of it, affected their 
femininity and sexuality.
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...because your cervix is such an integral part of your being, your 
sexuality...I think it's a bigger emotional deal than if it was another 
part of you. (Leslie)
For many women a cervix gone awry affected femininity — a distinguishing 
organ of womanhood was out of order.
[In relation to how she felt when she found out she had a cervical 
abnormality]...I think the fact that it is [that] part of your anatomy, 
you feel your femininity is affected...Not so much the 
precancerous cells, it goes through your head, but on top of that 
what is wrong with me, I'm not so much a woman any more. 
(Heather)
Heather links a healthy cervix with womanliness. Her disordered cervix 
made her less of a woman.
Yet medical treatment involved 'management' of the cervix as if it were 
separate from the rest of oneself. Some women explained how organ-specific 
management of their cervices conflicted with their perception of their cervix 
as interconnected with the rest of their body and central to their femininity 
and sexuality.
I remember at one point...that I felt really dislocated from my 
cervix, that it was something nasty that I did not want to deal with.
Like I wish I could get rid of it. So instead of feeling good about 
myself and my body I began to feel really bad about it. (Leslie)
Only women have cervices. A cervix is a feature of womanhood. A cervix is 
often defined as the 'neck of the womb' — as integral to women's 
reproduction. Medical treatment generally attempts 'cervix conserving' 
treatment in women of reproductive age. Once a woman feels she has 
'completed child bearing' (or her clinician judges her to be so) or is 
menopausal, hysterectomy is a more readily acceptable option. In the realm 
of medical practices cervices are reproductive organs only and reproductive 
organs are of no use when a woman is not 'reproducing' (Fisher 1986). Rubin 
(1984) maintains that genitals are generally construed as the most inferior 
part of one's body. (Rubin 1984). In a New Zealand study, McDonald 
(1993), found that women did not think of their cervix separately from other 
reproductive parts. Some women did not use the term cervix. Therefore, for 
some women this abnormality may have defined their cervix for the first 
time. So, what did it mean to women to have a part of their body which was 
constructed within medical discourses to be reproductive and might be more 
generally considered to be an inferior part of the body?
To explore further the meaning of the cervix I asked women how they would 
feel if treatment had involved removal of their cervix. Women considered 
three factors when assessing the impact of the removal of their cervix. First, 
the cervix was less readily perceived by women than other parts of the body. 
Some women spoke of how they did not experience sensations such as pain 
from it. Also, the cervix is less readily touched than other parts of the body. 
Second, they were concerned about loss of fertility due to removal of the 
cervix. And, finally, they spoke about its relevance to their sexuality and 
femininity.
Removal of the cervix was often contrasted with removal of the breast. 
Breasts are visible, part of women's image of who they are, and therefore a 
mastectomy was perceived as more disruptive to one's self definition.
I don't think it would worry me as much as having a breast 
removed through breast cancer, because you can't see it, so you don't 
feel. You can take the whole lot it wouldn't worry me. I wouldn't 
have any problems psychologically because I can't see and you 
don't think about it. Whereas if they were taking your breast, you 
see it everyday and it would stick in your mind. (Mary)
The cervix, as an invisible part of Mary's body, is less important in Mary's 
construction of her body than other, visible parts of her.
The cervix was often thought of in terms of its role in female reproduction. 
Some of the women who had completed their families or were menopausal, 
were unconcerned by the possible removal of their cervix.
I've stopped having my periods - I haven't had periods for a year, 
so all that...is not working now. I'm not going to conceive. I'm a 
fairly practical person, I don't think that [removal of the cervix] 
would have been an emotional upset. (Judith)
Because menstruation had ceased, heralding the end of her reproductive life, 
removal of Judith's cervix is less of a problem. The cervix is mostly defined 
in terms of its reproductive function.
Some women thought they would be upset because they would be unable to 
have children.
It [removal of the cervix] would be really scary. It would be a 
surgical procedure to start with - and there would be the infertility. 
Losing your femaleness. (Anna)
Losing one's cervix prevented having children. Fertility was linked to 
femaleness. Infertility would make her less female. Reproduction was an 
integral part of femaleness. Again, the theme of the cervix as an essential
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organ of womanhood because it is defined, particularly in medical 
discourses, as reproductive, arises.
A few women who said they did not intend to have any more children still 
did not want to lose their fertility.
I don't think it would make me feel any differently about myself if 
they did take my cervix out, or they did a hysterectomy... it's just 
that I wouldn't be able to have any more children, I don't want that 
possibility being taken away from me. (Amanda)
Amanda thinks of her decision to have more children as something she 
possesses. It is something she has control over. Removal of her cervix means 
that she loses that control.
Reactions to removal of one's cervix in terms of its effect on one's fertility 
constructs a view of the cervix as a reproductive organ. Its function, and 
therefore its definition, is in terms of its role in reproduction. Reproduction is 
part of one's femininity. Judith illustrates this when she describes her cervix 
and uterus as not 'working' once her periods stopped. This construction of 
the cervix is consistent with the medical definition of cervices as reproductive 
organs and useless in women who are not having children.
The impact of the cervix being denoted as a reproductive organ was assessed 
in different ways. Some women accepted or rejected its removal only in 
terms of their capacity to have children. Other women believed that removal 
of their cervix would affect their femininity which they linked with their 
capacity to reproduce. Both these judgements about the effect of removal of 
the cervix are related. Both groups of women, like gynaecology, construct 
cervices as reproductive organs.
In contrast, a couple of women thought of their cervix as like any other part 
of their body. For Ruth, her cervix was not considered 'special' but was 
important like any other part of her body. She wanted to maintain her body 
as complete.
WHAT ABOUT AN OPERATION FOR HAVING YOUR CERVIX 
REMOVED?
...I would feel, not that I am not whole as a woman any more, but 
just that I'm not complete any more. As if they took my arm away.
I would feel the same way, that something is missing. (Ruth)
Gladys was not concerned about removal of her cervix at all.
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Your tonsils are part of you but they're ripped out constantly. 
They're not part of the reproductive system of your body so people 
just accept it. I've still got mine. Why because another part of your 
body has broken down should it be any different than any other 
section that needs repair and removal? It makes no difference to 
me. None whatsoever.
Neither Gladys nor Ruth consider their cervix to be special because it is 
reproductive. Gladys and Ruth have different responses to the removal of 
any body part, however. Ruth thinks about herself in holistic terms; Gladys 
uses mechanical metaphors to describe herself. Such views of the cervix were 
the exception.
Several women spoke about how their cervical abnormality was further 
evidence for the disordered nature of women's reproductive systems.
[Talking about the responses of other people she told of her 
abnormal Pap smear responses]. My mother was the only one 
who seemed to be worried about it. My girlfriends all seem to 
have some problems with their reproductive systems. One of 
them had a hysterectomy; another one is having problems with her 
periods. Everybody seems to have something wrong down there. 
(Sally)
Many women considered reproductive disorders, such as cervical 
abnormalities, to be part of women's lot in life.
[After telling her sister and her close friends]. They understood, I 
s'pose it's just part of being female, you sort of find these things... 
(Mary)
Reproduction, which defines women, is disordered by nature. Like Sally, 
many women spoke of how their cervical abnormality was indicative of 
women's reproductive disorders. In some situations reproductive disorder 
was conceived as one's 'natural' state. Reproductive disorders, such as 
cervical abnormalities, both threatened one's femininity and caused one to 
redefine it.
Several women were stigmatised because the condition affected a part of 
their genitalia and the cervix signified their reproductive capacity.
DO YOU THINK YOU WOULD HAVE FELT DIFFERENTLY IF IT 
DIDN'T INVOLVE YOUR GENITALIA?
I wouldn't have felt anywhere near this vile. It is to do with the 
fact that it is sexually transmitted and it has to do with unclean 
aspects if you like. ...If I had a melanoma removed, which is
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exactly the same thing supposedly, I could have told everyone that 
I was having a melanoma taken off. (Amy)
For Amy the condition is stigmatised because of its sexually transmitted 
origins and because it deals with her 'unclean aspects'. (The stigma of 
cervical abnormalities as sexually transmitted is developed in Chapter Six.)
A melanoma is not related to sexual transmission and is not a condition that 
involves female genitals. Consequently she does not tell others of her 
abnormality, but she would tell them if she had a melanoma.
Amy carries the stigmatisation of those aspects that define woman, her
reproduction and genitalia, to a logical conclusion.
There's also the feeling that I think is really deeply ingrained in a 
woman's psyche, the sense that basically you're unclean.
For Amy, woman is unclean and woman is stigmatised.
Through women's discussion of abnormal smears a view of the cervix as 
reproductive and woman as reproductive emerged. This construction of the 
cervix and of woman is drawn from the medical assessment and treatment of 
cervical abnormalities as well as from other lay and medical discourses. The 
definitions of the cervix and of women as reproductive shaped women's 
experience. A disordered cervix impacted on their femininity, and resulted 
in stigmatisation for some women.
The physical nature of the cervix
Medicine, the privileged knower of bodies, has greatest access to visual 
interpretations of the cervix. Doctors have visual access (via the speculum) to 
a part of the body not normally accessed by anyone, except in unusual 
circumstances, through the medium of touch.
Colposcopy involves magnification of the cervix so that abnormal cells are 
seen. Cytology and histology entail microscopic examination of the cells of 
the cervix. Colposcopy and microscopic techniques extend the view beyond 
the naked eye, dissecting the surfaces of the cervix to render the cells that 
constitute the cervix visible. Microscopic is understood in terms of the 
absence of visual access by the naked eye, rather than an absence of texture 
for example.
I haven't seen my cervix but I think it's like a dome, pointing 
downwards, with a hole on top of it. I think I remember that from 
the plastic model at the Pap smear clinic, or maybe from drawings
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inside the tampon packet. If I had warts, it would probably have 
blistery things on it. With CEM it would look normal because they 
said you couldn't see anything. (Adrienne)
Adrienne describes her cervix in terms of how she visually imagines it. She is 
uncertain of her translation, uncertain of the accuracy of her description in 
relation to a real cervix — a cervix which is visually constructed. Also, her 
cervix is depicted by a model of a cervix as like all others.
Women tended to 'know' those parts of their body they could see.
If you've got a skin cancer you can love it. It's like a baby or a 
child, if they fall over you rub its knee to make it better. If it's 
getting worse you can see it. You can't see this. (Lorraine)
Brenda uses her visual interpretation of her cervix, obtained through 
medicine, to 'know' her cervix.
I've seen my cervix on photographs [taken at colposcopy], I've also 
seen my cervix in smear testing, and I've felt it lots of times now.
It's a bit odd but I feel like I've made friends with it now because I 
realise, especially after seeing it in the mirror, that it is part of my 
body that needs to be cared for, so I've actually gone out of my 
way to find it and feel it with my hand so I know it's there.
Despite knowing her cervix through the medium of touch as well as sight, 
'seeing' was the key way Brenda came to recognise her cervix as part of her. 
In fact, it is the medically acquired visual knowledge which enables Brenda 
to 'know' her cervix as part of her.
Many women wanted to see their cervix during colposcopy. Seeing her 
cervix on a video monitor during the colposcopy reshaped Louise's visual 
knowledge of her cervix.
Having the monitor helped a lot, because you could see it all. It 
was just a mass of discoloured cells, you could see it wasn't green 
and gangrenous. ...Before I visualised it as horror, absolute 
horror. I imagined it as a big black mass of growth...
In Louise's situation visual (and therefore medical) access to her cervix, was 
important in forming a more positive image of her cervix. Many women felt 
that seeing their cervix, or a video of the procedure, would enable a better 
understanding of their cervical abnormality.
Others did not want to see their cervix. Some felt it would be worse if they 
did. They would 'really' know how 'bad' their cervical abnormality was.
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I put a lot of trust in the sense that I couldn't see it. I suppose if I 
could see it, it would be a lot worse, because I would be looking at 
it. Because it was there and I couldn't see it I probably did not 
think it was as bad. (Ruth)
Many women found pictures, diagrams and video representations useful. In 
fact, many women commented that if they could see their own cervix during 
colposcopy it would enable them to understand their problem better. 
However, although medically assisted visual access to their cervix enabled 
women better understanding of their cervical abnormality, such knowledge 
will always be inferior to medical knowledge — whose gaze is finer and 
more accurate because it is microscopic. Also, medical knowledge of the 
cervix holds visual knowing as privileged. Within medical practices and 
discourses about abnormal smears women's ways of knowing their cervix is 
inferior. There is no space for definitions of the cervix developed through 
sensations other than sight. However, Brenda appropriates medically 
accessed visual knowledge of her cervix, along with her own knowledge 
acquired through touch, to construct her own cervix.
Discussion
I have shown that the diagnosis of a cervical abnormality resulted in women 
redefining who they were. Their understanding of who they were shifted as 
a consequence of the abnormality. In doing this, they drew on their current 
diagnosis of a cervical abnormality and previous beliefs about the nature 
wart virus, cancer and female reproductive systems.
Women now considered themselves to be at ongoing risk of cervical cancer 
and death. This risk was not an abstract risk that existed separately from 
them. Instead the risk inhabited their bodies. The risk was corporeal. For 
the epidemiologist, risk is an abstract notion that exists outside of the 
individual. In contrast to the epidemiologist, individual women experience 
the risk, used by the epidemiologist to characterise a category of people, as 
part of themselves. The risk meant that they were neither healthy nor ill. The 
lack of symptoms further blurred the definition of health and illness. Women 
moved into a socially ill-defined state of possible future ill health.
The findings relating to risk that are reported in this chapter, are similar to 
those described by Gifford (1986) who performed indepth interviews with 
women who had benign breast disease. She found that women with benign
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breast disease who attended outpatient hospital clinics, came to 'live' their 
risk of breast cancer. Like women in this study, this risk was ambiguous and 
meant they were neither healthy nor ill. (Gifford 1986).
Women's newly experienced appreciation of their risk of cancer caused some 
women to reflect on their mortality. Women came to have a different 
awareness of their own vulnerability.
Redefinition of femininity also occurred. Broom (1989) described how 
'women are sick, and sickness is feminine' (Broom 1989). pl31. This 
diagnosis meant that women now experienced their cervix as a site of 
possible derangement. Most women considered reproduction to be defining 
of women. Cervical abnormalities both characterised femininity, since female 
reproductive systems are constitutionally disordered, and endangered it.
As shown in Chapter Three many women will have further investigation 
because of an abnormal Pap smear. Women who receive such a diagnosis 
might come to experience their risk of cervical cancer in the way I have 
described. If this occurred most women would come to perceive their cervix 
as potentially disordered even though few women would develop cervical 
cancer if they had never had a Pap smear.
If I had conducted interviews with women prior to their diagnosis of an 
abnormal Pap smear, I could have documented how women's perception of 
their risk was shaped by their diagnosis and treatment. However, women in 
this study reported, retrospectively, that their appreciation of their risk had 
changed since their diagnosis of a cervical abnormality.
In summary, I have shown that cervical abnormalities result in women 
experiencing their own risk of cervical cancer and death. The diagnosis also 
caused some women to reshape their notions of their femininity. In the 
following chapter, I examine how women sought to manage their physical 
experience of their own risk of cervical cancer.
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Chapter Six
Managing risk
WHAT DOES PRECANCER MEAN TO YOU?
The fact that if I don't look after myself there is every possibility, a 
very high possibility, of me contracting cancer, through basically 
not looking after yourself. (Gladys)
Cervical abnormalities, such as precancer, symbolise Gladys' risk of cervical 
cancer and her responsibility for managing her experienced state of risk. If 
she developed cancer it would be through her own mismanagement.
This chapter describes how the women sought to manage their recently 
developed and experienced, state of risk. Control was a crucial concept. 
Therefore, before turning to the ways they sought to handle their embodied 
risk of cervical cancer, I discuss how the women employed the concept of 
control. Then, I discuss how they managed their state of risk by subjecting 
themselves to their own and medicine's regular surveillance and by 
identifying ways of modifying their risk through lifestyle changes. Through 
their explanations for their cervical abnormality this experience became 
woven into their lives and became part of their life trajectory.
The concept of control
Control was mentioned in relation to treatment decisions, procedures 
performed and one's risk of cervical cancer.
Women used control to describe actions they could take to modify their risk 
of cervical cancer.
I really believe that stress is going to cause a lot of cancer. If I don't 
learn to control my stress it's probably what I'll end up getting, or a 
heart attack ...worry myself stupid. Then I'll eat and put on 
weight and my cholesterol will soar. (Phillipa)
Phillipa uses control to reduce her stress. She is both the subject, the 
individual exercising control, and the object, the site of the stress that calls for 
the control she exercises.
The women spoke of exerting control on the disease process or their risk of 
cervical cancer. Sometimes they spoke of lacking the control to cure or avoid 
contracting their abnormality.
[after Anna was told of her abnormal Pap smear] I couldn't achieve 
much that weekend. I was like a zombie. Not really knowing 
what is happening ...what is happening to your body, something 
that you have no control over. You can't see anything, you can't 
feel anything. (Anna)
Anna does not have control over her body. Her body behaves almost 
independently of her. For some women, the absence of any action they could 
take to reduce their risk or foster recovery meant they did not have control.
Heart attack in our society means cut down on your cholesterol, 
you can do something about it. Precancerous cells, the whole idea 
of cancer is much more uncontrollable, much more wriggly. 
(Leslie)
Leslie speaks of precancer as cancer, which is a disorder that is difficult to 
control. At another point in the interview she seems to talk about doctors 
preventing her from having control over the abnormality.
We put so much faith in doctors because I was motivated by fear, I 
don't think I had a lot of choice until I overcame that. I was angry 
with myself at the time that I did go ahead and have these 
treatments because I knew it wasn't dealing with it the way I 
wanted to deal with it. I knew that giving up control and saying 
OK just zap me wasn't the answer for me. In an emotional sense, 
in a physical sense.
...people believe wholeheartedly that all they have to do is close 
their eyes and have this magic performed on them and it is going 
to be all right. It means that you don't take control of the issue 
yourself, it means that you are happy to give over responsibility to 
the doctor. (Leslie)
By having medical treatment Leslie 'gives up' her control over 'it' and she 
does not 'take control' of the 'issue'. 'It' and 'issue' appear to refer to her 
cervical abnormality. Later, Leslie chose to have herbal treatment, following 
which her CIN 3 was no longer present. The success of this treatment meant 
that Leslie shifted from not having control to having control.
I think that now I can do something about it, I think that now I 
have much more control, ...I still feel I have definitely got the 
potential [to develop an abnormality] but I also know that if I 
choose I can do something about it. (Leslie)
Leslie now appears to be speaking of actions she can take which enable her to 
have control over her risks of developing a further abnormality.
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Like Leslie, several other women also felt they did not have control over 
medical treatment.
I felt totally out of control. That's why I wanted to try herbal 
medicine and homoeopathy because I was in control. ...It was 
like: spread your legs, laser treatment, and that's it. No control, no 
control whatsoever. (Lorraine)
Some women however suggested that only doctors had the capacity to 
exercise control over women's abnormality and future chances of cancer.
It's under control now. There is a possibility it will come back but 
it doesn't worry me. If it does they will treat it again the same way 
as they did. (Adrienne)
On several occasions the women expressed a desire for more information 
about how they could alter their lives so that they had more control over their 
risk of a further abnormality. They spoke of this information exchange as 
doctors 'giving' them control.
If they'd just give you more control. Even if it's just crap, telling 
you to eat a couple of lentils everyday. You'd think well at least I 
am doing something for myself. (Lorraine)
The doctor never gave me any indication as to whether there was 
something I could do to have any control over getting it or not 
getting it. (Sharon)
Medical information enabled Heather to feel in control over decisions about 
treatment.
I certainly felt under control. Dr X sort of gave me all the 
information and the decision was up to me. (Heather)
In contrast, although Anna sees the benefits of better medical information, 
such information does not mean she feels in control.
...Perhaps if I had more information about it - you wouldn't feel 
any more in control but at least you'd understand why you had it. 
(Anna)
Anna is referring to feeling in control over her risk of cervical cancer rather 
than treatment for an abnormal smear. She wants information to address the 
question of why she developed her cervical cancer.
Often exercising control was contingent upon circumstance. Amy describes 
how she can exercise control only sometimes.
It makes you acutely aware of the way you live your life, the 
things that you perceive that you have, that you are in control of -
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like how much you eat, and how you can reduce your risks. 
(Amy)
I didn't feel I was in a capacity to make judgements about 
treatment. I couldn't see a problem, had no indication other than 
what the doctors told me about what was going on, and I thought - 
well, you make decisions, you're the qualified one. Over things 
that I did have control of, like what contraception I used, I felt 
pissed off about that ...in the way that he made judgements about 
that. (Amy)
Amy perceives herself as 'having' control over taking the pill and what she 
eats; she does not have control over decisions about her treatment. Amy, like 
Leslie, only speaks of possessing control over something if she perceives 
herself as having a capacity to act. Thus, Amy speaks of having control over 
whether she takes the pill. She does not consider herself to have control over 
treatment. In contrast, Leslie perceives herself to have control over treatment. 
Her decision to have herbal treatment is construed as exercising choice.
For Amy, 'handing over' control did not preclude 'feeling' in control.
I felt in control in as much as I was totally happy handing over 
control, [in relation to decisions about medical treatment].
Allowing her doctors to make decisions about her treatment meant that she 
felt in control.
Information enabled some women to shift into states of feeling in control 
regarding treatment. In relation to medical treatment and follow-up the 
women felt differently about their states of control. Many found that 
treatment and their own actions could change their perception of their 
control over their risk of cervical cancer.
Surveying risky cervices
Managing one's risk of cervical cancer involved participating in medical 
surveillance. The women's descriptions of follow-up used visual and 
disciplinary metaphors of surveillance. Both women and medicine surveyed 
women's cervices.
Surveillance enabled transformation of the women's perception of their risk.
Even though the laser treatment's no big deal, I'll always be 
running into doctors' surgeries and getting checked. That worries 
me a bit. But I can't see that I'll ever develop cancer because I'm so
no
vigilant now and if I develop any sort of cancer it will be 
something else. (Brenda)
Brenda's perception of reduced risk rests upon regular surveillance.
However, the vigilance she describes is contingent upon her recognising her 
risk. Although Brenda perceives the dimension of her risk to be lower, her 
awareness of her risk is now different from what it was prior to her abnormal 
smear.
An analogy is relevant to emphasise the point further. Suppose someone is 
burgled. After such an event, the person increases security to prevent a 
recurrence. They then consider they may have less risk of a repeat burglary 
because such security measures reduce their risk. However, the event itself 
has brought to consciousness the risk of burglary. The person becomes 
aware of their risk of burglary. The dimension of the risk may be thought of 
both objectively and subjectively as changed but the quality of the risk is 
different; it is now part of the person's experience.
Heather describes how her awareness of her risk reduces her chances of 
cervical cancer.
I know it is something that I need to keep an eye on but no more 
than everybody should be doing. Certainly I don't see it as 
something that is going to hang over my head for the rest of my 
life. ...Because 1 am more aware of what can happen and how 
easily it can be treated I think I probably have less chance [of 
cervical cancer]. (Heather)
The women are now aware of their risk even though the risk may be 
perceived as less than prior to the abnormality. The cervix is now always a 
potentially diseased organ. The risk now has a reality and a presence.
The terms used to describe the follow-up of a cervical abnormality suggest a 
surveillance of individuals by an institutional authority — medicine. 
Individual bodies are inspected, checked, watched and looked upon by this 
institution, and are transformed from an ambiguous state of ill health to an 
ongoing state of potential ill health.
The women's perception of being at low risk of either recurrence or cancer 
rested on two, sometimes separate, premises. First, the notion that treatment 
was effective, and, second, the effectiveness of surveillance.
I feel that having had the laser treatment, I don't suppose it's a 
guarantee it won't happen again, but I'll just keep an eye on it, it's 
not worrying me. (Maeve)
When I went back and had the inspection he said everything 
looked fine. I do realise that it could come back again but at the 
moment I feel it's been treated, it's all gone, and I don't have to 
worry about it for six months. If I ever have it again, I think I'll feel 
OK about it. I'll just go and have the treatment again. (Judith)
It's under control now. There is a possibility it will come back but 
it doesn't worry me. If it does, they'll treat it again the same way 
as they did. I've always had Pap smears, probably not religiously, 
but from now on I'll make sure I have them every year - if I get 
over this. (Adrienne)
So far I have used several quotes that draw on visual metaphors to describe 
follow-up after a cervical abnormality. Maeve and Heather mention that they 
need to 'keep an eye on it' and Ruth mentions being 'watched'. Maeve and 
Heather are the 'lookers' and medicine 'looks' in Ruth's case. Both medicine 
and women survey cervices to prevent cancer.
I find the fact that they really keep a close eye on you very 
reassuring because you are actually under closer scrutiny than a 
woman who has not had that sort of treatment and so for a year 
and a half you have really got them pouring down and looking at 
you and nothing can go wrong while that is happening, 
presumably, so that is really quite reassuring. (Veronica)
Veronica is 'observed' meticulously by medicine, is the object of the medical 
gaze, which prevents anything going 'wrong'.
Other metaphors used to describe this surveillance were disciplinary.
I don't feel under threat any more, because I know whatever 
happens to me I am well checked. If there is any threat of anything 
coming up it will be found fairly quickly. I don't know how 
accurate Pap smears are, all I know is that when I have had them 
something has been found, but whether there is something that 
happens and it doesn't always get it I don't know. But I've been 
lucky so far and it hasn't been allowed to develop into anything 
serious. (Louise)
Cancer no longer 'threatens'. (The military metaphors employed to describe 
cancer have been discussed earlier.) Now one is checked and the condition is 
not allowed to develop. Again, the condition, which is cast as separate from 
Louise, is the object of this medical surveillance. Louise too is the object of 
the surveillance — 'I am well checked'. Judith, above, spoke of her follow-up
visit as an 'inspection'. She too is the object of the medical gaze, which 
decides whether or not her cervix is diseased.
Effective surveillance rests on care and frequency. The more frequently Pap 
smears are done, the less risk. All women spoke of how they would have 
Pap smears regularly because of this experience. Several women thought 
they would have Pap smears more often than recommended to reduce their 
risk further.
...even though I get Pap smears once a year, I will probably be 
more inclined to have them twice a year, even though the doctors 
told me that it is not necessary. The laser clinic doctor and my GP 
told me that it is not really necessary to do that. But, I probably 
will get a Pap smear more often. Maybe every eight months or 
something like that. But I feel the Pap smears are going to be 
important to keep tabs on it. (Sally)
Again, managing one's risk involves greater medical supervision.
In fact, participating in medical surveillance was cast as morally correct 
behaviour.
HOW LONG SINCE YOUR OTHER PAP SMEAR BEFORE YOU 
HAD THIS ONE?
I can't remember off hand I think it was a couple of years. Before 
that, I used to be very slack because I didn't really like having 
them - no-one does. The doctor would practically take me by 
surprise: right you're having it. But now I will be very good. 
(Peggy)
'Good' meant having Paps. Abiding by medical guidelines was morally 
correct, as well as necessary, to manage one's risk. This position rests on two 
assumptions. First, that medicine is an appropriate source regarding norms 
of correct behaviour in relation to one's health.; and, secondly, that an 
individual is responsible for their own health. It is argued that the notion of 
individual responsibility for one's own health is part of contemporary 
Western culture, because modern-day diseases affect individuals alone rather 
than the collective suffering of the past (for example, through the plagues) 
(Herzlich and Pierret 1987). This notion of individual responsibility arises 
again when I discuss how women 'explained' their cervical abnormality.
Through participating in the surveillance women manage their risk of 
cervical cancer. They construe the surveillance as exercising control over 
their risk of cervical cancer. The form of surveillance described by the 
women is similar to the disciplinary power Michel Foucault described in
prisons, armies, schools and hospitals (Foucault 1979). Both women and 
medicine contribute to the surveillance of their cervix. And their cervix 
becomes an organ of potential disorder and danger that requires occasional 
adjustment.
Why me, why now?
[after Leslie had a cervical abnormality that recurred despite two 
treatments] it wasn't like something that I could say I am just not 
going to deal with it. If I left it [her cervical abnormality] I was in 
for trouble, probably serious trouble. So I decided I was going to 
do something different about it and I was going to deal with it. 
...My friend was going to see a herbalist and she said why don't 
you go and see her. I was in the middle of my degree and I 
postponed that. I just started approaching life differently. 
...stopped taking some drugs, stopped smoking cigarettes. I 
started eating better, I started meditating twice a day, doing yoga,
Tai Chi every morning. ...really combining things together and not 
living on adrenalin. ...I guess I knew it was something that I had 
to do regardless of the abnormal cells.
Because I started studying again I have really let things slide. Just 
before you arrived I was seeing a friend of mine who helped me 
through ...I haven't seen the herbalist for a long time and I actually 
should be having more treatments. Once I am doing my academic 
work I become focussed and it is really bad because I just let these 
things slide...I have not gone far enough in working myself out, 
doing these things, I have let things slide and I would not be 
surprised if I get it again...it is just like a warning sign - I am not 
looking after you, I will come back and get you. (Leslie)
After two recurrences of her abnormality, following diathermy and laser 
treatment, Leslie's cervical abnormality becomes significant. It becomes a 
symbol of her need to take control of her life. If she does not take control 
then she faces the consequences of cervical cancer and death. She makes 
dramatic changes to her life. Her cervical abnormality disappeared after her 
herbal treatment. However, the abnormality remains a symbol of her belief 
that she can control her own health. She is responsible for her own health. 
At the time of interview, Leslie believed that she had let her lifestyle 'slide'. 
Because of this she perceived herself to be vulnerable, as likely to have 
another cervical abnormality. Her risk of cervical cancer is cast as a being, 
she speaks of it as T, that is observing her and ready to 'get' her should she 
become irresponsible about her own health.
In this section I discuss how women sought to make sense of this 
abnormality. Some women, like Leslie and Gladys (quoted at the beginning
of the chapter), conceived their abnormality as signifying their need to take 
control of their own health. These women invoked explanations that firmly 
located this abnormality in the life narratives. The abnormality became part 
of their lives and shaped them as individuals who were in control of their life 
circumstances. In doing so, these women identified ways they could change 
their lives. Their narratives about their cervical abnormality became linked 
to their narratives about control. Other women saw this as a minor event. 
Their ways of understanding their abnormality did not offer them such 
capacity for life changes and tended not to be linked to narratives about 
control.
Explanations were invoked retrospectively because the women had no 
knowledge of their abnormality prior to its diagnosis. Their explanations 
were multifactorial and complex and drew on both scientific medicine and 
popular medical culture. To explore how the women made sense of their 
abnormality I used the approaches of interpretative medical anthropology 
outlined in Chapter Four. I am interested both in the structure of the 
women's accounts and in the meanings they ascribe to the development of 
their abnormality.
The women's explanations can be condensed under seven overlapping 
headings: stress, lifestyle factors, personal experiences, outside influences, 
sexual transmission, individual susceptibility, and luck or fate. Most women 
used explanations from several categories.
Stress
Some women considered their abnormality using narratives of stress. The 
notion of stress was used in a variety of ways. Most commonly, stress 
connected unpleasant experiences or events in a woman's life with her 
cervical abnormality.
I think it is probably significant that I got this, at this time, in fact 
even a friend had suggested this to me, because I was married and 
it was a very, very bad marriage and it was just very, very stressful 
for me and I think that is why it happened then. (Brenda)
For Brenda, her stress narrative enables her to make sense of why she 
developed a cervical abnormality at this time in her life. The stress idiom 
located women's abnormality in their life context. Women used stress to link 
their inner and outer worlds and connected events that otherwise seem 
unrelated.
Stress was a polysemic concept. Stress was an action, an entity, and a state of 
being. That is, stress acted upon the body, stress described a situation or an 
event, and stress was something that one experienced or felt (sometimes 
described as an illness or personality state). Often stress had multiple 
meanings in the one interchange.
Well I explained it to myself that I was under a lot of stress [stress 
as action]. And that it was probably just a reaction to stress and 
yeah that's where I kick myself now, I think I wish I trusted my 
own body. And my own intuition don't get it fixed up, just go 
along and maybe I smoke, so I thought maybe cut down on 
smoking, look at my diet a little bit more and take away some of 
the stresses [stress as entity]. And don't just take them away but 
reduce them. I had moved house and all those things were 
stressing me out [stress as state of being] but they were going to 
and you know they had peaked. And they were going to go back 
down anyway. So that naturally I tend to think the body would 
have just calmed itself down and healed in the way it needed to 
heal. (Sarah)
In this quote stress has many meanings. Stress acts on Sarah so that she 
becomes sick. Stress is also an entity. Moving house is an example of stress 
as entity. Stress as an entity could also reside within an individual. That is, 
an individual could have or take away stress. Sarah herself is 'stressed out'. 
Stress describes how she feels and experiences herself. The notion of stress 
enables her to link her abnormality with other life experiences. Stressful 
events or experiences cause her to experience a state of being stressed. In 
fact, this stressful state of being requires healing itself. It is not a healthy 
state. Through the concept of stress Sarah's cervical abnormality becomes 
part of her life story.
This unhealthy state of being 'stressed' meant one was more vulnerable to 
diseases such as cancer or diseases that signified one's risk of cancer (cervical 
abnormalities).
...there's also the idea that cancer strikes at times of stress. That 
worries me a bit - that if I am run down, then I might face this 
condition repeatedly. (Brenda)
Events and experiences are defined retrospectively as stressful because 
women have no symptoms of their abnormality prior to the diagnosis. The 
concept of stress was used to make sense of the abnormality if women 
identified the time preceding the diagnosis as 'stressful'. Brenda attributed 
her first abnormality to stress. When her abnormality recurred the stress 
explanation was not consistent with her experience.
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I can't fathom why it happened again in May last year because I 
certainly hadn't experienced the same stress levels as I had the first 
time. (Brenda)
For Brenda, stress was only a credible reason for her abnormality if external 
events or experience were identified as stressful.
Phillipa did not remember feeling stressed, but particular events in her life 
were identified as stressful. She associated her abnormality with stress.
It was later on the lady was telling me about a study relating to 
stress that she'd done on a course [a discussion with a nurse in the 
clinic] I pieced together the last eight months ...You think you're 
not stressed, but when you're working full time and you've got 
four kids and you're travelling lOOks a day and you've got them on 
you're own...Peter [her husband] was over here [Canberra] and I 
was in X [a country town]. I'd leave home at ten to eight in the 
morning and get home at 5, 6, 7 whatever, and had all the kids on 
my own... And for six months that's what I did and then I 
resigned and I stewed about that - what am I going to do 
unemployed, that's all I can do, I don't have any skills - and you go 
through all that trauma and then there's selling our house and then 
two moves in a month... Moves are horrendous. Apparently on 
the stress list moves are up near the top... (Phillipa)
Stress described Carmel's nature.
...I am a stressed out sort of person. Although I try not to be, I try 
to be calm most of the time and I try not to let things worry me, 
but yes I do get stressed. (Carmel)
Stress narratives enabled women to feel in control of their own risk of 
cervical cancer. This was done in two ways: by changing exposure to 
stressful events and, secondly, by modifying one's response to those events 
so that they did not feel 'stressed'.
I have to go for a walk. At least that gets stresses out. That's the 
way I relieve my stress. (Carmel)
I think, don't get too stressed about things, that is something that I 
have changed. I am determined not to get too bothered about 
things because, I think, in the long run it doesn't help my body. 
(Ruth)
Carmel and Ruth speak of modifying their own experience of feeling 
stressed. Ruth relates how her state of being stressed affects her body. Her 
body is conceived as separate from her. Her state of being stressed acts on 
her body. Earlier Sarah spoke of reducing or taking away stresses. When 
Leslie developed a second cervical abnormality, she changed aspects of her 
life. She deferred her university course, had counselling with a friend and
took up Tai Chi. Thus, through their stress narratives these women located 
their cervical abnormality in their own lives and identified ways in which 
they could control their risk of cervical cancer.
Some women who used the stress explanation experienced the treatment as 
inappropriate. The treatment failed to address the underlying problem.
Leslie describes the dissonance between her stress explanation and medical 
treatment.
I am not saying that it is a total physical manifestation of an 
emotional crisis but I think there was some connection and maybe 
that is why I found the treatment I was getting was wrong because 
it was isolating that and saying OK here is your cervix, here is the 
problem, zap it off, it wasn't saying what is wrong with the total 
person (Leslie).
In Leslie's case, a fragmented part of the unwell body is treated and the cause 
of her condition is left unaddressed. Treatment failed to address the root of 
her problem. Narratives of stress integrated the women's abnormalities into 
their everyday lives. Medical treatment dealt only with a small part of their 
body as if it was separate from the rest of their body and life. Earlier Leslie 
described how submitting to medical treatment meant she 'gave up control' 
to medicine. Her herbal treatment, on the other hand, together with other 
life changes that she makes, moves her perception from 'giving up' to 'having' 
control over her risk of cervical cancer.
Stress is a culturally specific concept. Popular usage of the concept occurred 
in Western societies following the second world war (Pollock 1988). The 
notion of stress, however, is not unique to lay explanations of disease and 
illness. It is part of both modern popular culture and biomedicine. While its 
origins are in the natural sciences — first recognised in physics and later 
biology through animal laboratory experiments — it now has wide 
acceptance in the medical and social science literature. Selye (1956) first 
described stress, a term he coined from the physical sciences, to explain the 
physiological responses of animals to stimulation. Social science explored the 
concept of stress further. Life event scales, such as the schedule of recent 
experience used in epidemiological research (Rahe 1974), are examples of 
social science's application of the stress concept. Events and changes in the 
subject's life are given a numerical value. Adding the scores provides an 
index of 'stress' in the subject’s life. At a population level high scores have 
been linked with the onset of disease and illness. In this application, stress is 
constructed as something that is universal and that exists separately from an
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individual. The meanings that individuals attribute to events are ignored. In 
social science literature, events and experiences cause an individual to 
develop disease because they become emotionally aroused. An individual's 
response to stress is dependent on their intrapsychic ability to deal with 
external stressors.
Stress is integral to the biomedical concept of psychosomatic diseases.
Irritable bowel syndrome is an example (Drossman, Powell et al. 1977). The 
relapsing course of chronic diseases such as diabetes have been linked to 
stress (Stein and Charles 1971). Several authors suggest that biomedicine and 
empiricist social science locate the pathology in the individual (Young 1980; 
Pollock 1988). In doing so, responsibility for the illness is shifted to the 
individual or their environment, away from biomedicine (Helman 1985). 
Young (1980) maintains that stress discourses reinforce and legitimise the 
social order. The pathos of society is objectified and located within the 
individual (Young 1980). Pollock (1988) maintains that stress discourses 
position responsibility simultaneously within an individual and society.
Stress discourses encapsulate beliefs about the deleterious effects of modem 
society on individual health.
Narratives of stress tend to be invoked, both by physician and patients, in the 
context of diseases that are characterised by ambiguity in biomedical 
understanding and treatment. Responsibility for this illness, both for its 
cause and treatment, is shifted away from medicine. Although cervical 
abnormalities are characterised by ambiguity, treatment strategies for 
abnormalities are well established. Several studies have examined the 
relationship between life stressors, an individual's coping style, and the 
progression of CIN (Goodkin, Antoni et al. 1988; Antoni and Goodkin 1989; 
Goodkin, Antoni et al. 1993). In these studies the stressors are conceived as 
events, entities that exist outside the individual, devoid of the meanings an 
individual may attribute them. Individuals' coping styles moderate the effect 
of these stressors on their biology.
Some physicians agreed with (or did not dispute) the women's assessment of 
their cervical abnormality as stress related. However, medical consultations 
regarding cervical abnormalities did not usually include questions about 
stress or advice about reducing it. Consultations for conditions which are 
accepted as psychosomatic, illnesses with less clear medical treatments, 
routinely include inquiries about stress.
The women were aware of the popular literature on stress, mentioning stress 
scales and life events. Popularisation of social science research was taken as 
further evidence for the use of stress as a way of understanding their 
abnormality. Exposure to the popular literature enabled this view.
However, women used the concept of stress in a different way from both 
social science and clinical medicine.
Doctors use stress to describe an individual's response to external stressors 
that have universal meaning defined by medical and social science 
discourses. When clinicians employ the concept of stress the individual is the 
pathological unit. The context in which stress manifests in individuals is 
ignored. In contrast, the women in this study group used stress to 
problematise their own life circumstances. Their stress narratives were 
linked to narratives of control. This diagnosis signified their lack of control 
over their own health. By deploying the stress idiom the arbitrariness of their 
cervical abnormality was reduced. Instead, their cervical abnormality 
become part of their narrative about who they were. They were constituted 
as having control over their own life circumstances.
Lifestyle factors
Another popular explanation related the women's cervical abnormalities to 
aspects of their lifestyle such as diet, smoking, exercise and medications, 
particularly the oral contraceptive pill. Like stress, these ways of 
understanding their abnormality firmly positioned this event in the context 
of women's everyday lives.
Diet was commonly mentioned.
You wonder sometimes whether you've got it because of 
something to do with your diet. There could be all sorts of 
complications, all sorts of things that come into it. (Valerie)
Several women associated their abnormality with the oral contraceptive pill. 
Although these explanations were developed from scientific research, 
clinicians tended to reject the pill as a possible source of women’s cervical 
abnormalities. Amy believed that the oral contraceptive pill was related to 
her cervical abnormality.
...he went on with all this stuff about how there was no firm 
evidence to suggest a relationship between the contraceptive pill 
and ovarian cancer - and I said that the incidence of ovarian cancer 
is a lot less than the incidence of cervical cancer. Because I've had
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two abnormal smears I was quite concerned about the risk of 
cervical cancer. He just said he really didn't think there was any 
risk and I just thought it's all very well it's not your cervix and it's 
not your life. Anyway, in some ways out of the pressure I felt 
from him - he gave me a script for the pill and he said "if you feel 
like it take it", and I thought "what drug company are you working 
for?" So I ended up going on the pill and I wasn't really happy 
about it, but in some ways it was the convenience of it and not 
having to worry about ovulating. ...I had thrush for three months 
and stomach pains and everything else. In all the books I read, it 
said the contraceptive pill can be associated...it will make the 
Candida worse, and that was the excuse to give it the flick. (Amy)
For Amy, the pill remained an important means of making sense of her 
abnormality, despite her doctor's refutation of the pill's relationship to her 
abnormality. Another scientific theory about the pill's association to Candida 
eventually provided impetus for her to discontinue it. Several women 
discontinued the pill as a consequence of their cervical abnormality. Only 
one woman, Julie, accepted her doctor's rejection of the pill's association with 
her abnormality.
Maeve linked her cervical abnormality to a change in her medication. Her 
doctor disagrees with her.
I blamed medication to myself ...When I changed over, I can't 
remember the name of the stuff I changed to, but what I was 
taking became quite expensive and the doctor said that he could 
give me a substitute that is not quite so expensive. So I changed to 
that. I always felt that was the reason and he said it wasn't that; he 
didn't explain it or wipe my worry away. I really thought that it 
was the change [in medication] that caused this cell change, but he 
said it wasn't. (Maeve)
Maeve's thoughts about the relationship between her medication change and 
her abnormality persists, notwithstanding her doctor's disagreement with 
her.
Some of the women changed aspects of their lives in light of their cervical 
abnormality. In a similar way to the stress, thinking of the abnormality in 
terms of lifestyle grounded the abnormality in the women's daily existence 
and enabled them to make changes in their life that would prevent 
recurrence, assist healing and maintain their general health. Narratives about 
lifestyle factors construed women as having control over their own health.
Environmental influences
A few women connected their abnormality with the unhealthiness of modem 
society.
...my sister [who also had a cervical abnormality] was very 
unhealthy. She was underweight, did not look after herself and 
did not eat regularly. That has got to have something to do with it.
She is more likely to get it than me. I remember when I got it I was 
thinking ..."I am fairly robust. I think I am fairly healthy, so why 
did I get it?" I thought people like my sister are more likely to get 
it than me. Whenever I see programs on television about people 
that live near power stations and dumps I always think they are 
more likely to get cancer than other people. I am very aware of 
this with where we live, with pollution and I'm more conscious 
about spraying aerosols. I think it is all connected. Before I had it,
I looked at myself and thought I looked fairly healthy, I don't think 
I am going to get it. (Ruth)
This quote demonstrates how Ruth's model for understanding cervical 
abnormalities shifted after she had a cervical abnormality. Initially she 
believed that only 'unhealthy' people developed abnormalities. In this model 
individuals are in control of their own health. When she develops an 
abnormality, her experience is not reconcilable with her previous 
construction. The model is reworked. Now she believes that cervical 
abnormalities, and other cancers, are a consequence of various environmental 
factors. In recent years these environmental factors have become part of both 
scientific and popular models of illness. Her cervical abnormality signifies 
the dangerous nature of contemporary society.
Life events
A  few women related their abnormal smear to past experiences such as a 
rape, abortion and an episode of depression and self-hatred. Each of these 
explanations had different implications.
Well it brought up all the horrible memories of 1983 because I had 
an abortion then. I thought - "does this mean I can't have children 
now?" ...I'm getting paid back for what I did then. (Anna)
For Anna the abnormal smear was a 'punishment' for her abortion. The 
notion of disease as a punishment for one's sins is still a common theme in 
contemporary Western culture (Herzlich and Pierret 1987). In Anna's case, 
although the abortion contextualises her cervical abnormality in her life
narrative, she is personally responsible, and her model does not offer her any 
way of changing her risk.
Mary related her cervical abnormality to a rape some years earlier. She 
connected both unfavourable events. In both instances she was a victim. She 
had no responsibility for her cervical abnormality.
Lorraine related her abnormal Pap smear to a period in her life which she 
described as 'self-destructive'. At the time she was depressed and she 
separated from her husband.
I was on self-destruct. Therefore I probably wished it upon myself.
I think I probably created it for myself. I was just so bad. I am 
sure that I will never ever get it again.
At the time of interview her life was much better.
...emotionally I feel so good that nothing can get me now.
Lorraine's narrative is similar to the stress narratives described earlier. In this 
model she is responsible for her own health. Her cervical abnormality is a 
symbol of her 'self-destructive' phase. She is clearly in control of her life. She 
construes herself as being able to destroy herself.
Although all these women related their cervical abnormality to episodes or 
events in their life, each narrative constructs a different relationship between 
the woman and her life world. For Anna, her cervical abnormality is a 
retribution for past sins; Mary is constructed as having little control over her 
life; and, Lorraine as responsible and in control of her own health.
Sexual transmission
Explanations involving the sexually transmitted nature of the condition were 
drawn from scientific research. This was the dominant cultural model of 
cervical abnormalities and cervical cancer. Most women talked about the 
sexually transmitted nature of cervical abnormalities. The rarity of cervical 
cancer among nuns was commonly mentioned. The misquoted studies on 
nuns and cervical cancer were widely accepted as true. This cultural model 
imbued cervical abnormalities with significance. Few women accepted 
sexual transmission as an explanation of their abnormality. Instead, they 
reworked their previous model and developed ways of making sense of their 
abnormality that was consonant with their own life circumstances and world 
view.
123
The following section begins with a discussion of the cultural meanings of 
cervical abnormalities. It is followed by a description of how the women 
modified the dominant popular and scientific explanatory models for cervical 
abnormalities. Later, I discuss how the prevailing cultural representation of 
cervical abnormalities as sexually transmitted affected women.
Cultural models for cervical abnormalities
I read something that said it [wart virus infection] is typified by 
these great warts and that it is passed on by sexual intercourse. I 
thought how can it be? I've been really fastidious. I’ve only had 
one partner. I've followed all the rules.
...papilloma virus, I thought, how did I get that? I've been with 
one partner for nearly 20 years. When I went to the gynaecologist 
he asked me when I started having sexual relations. I said I was 
very good I was about 18... (Phillipa)
For Phillipa the acceptable form of female sexual expression is heterosexual 
monogamy. Phillipa describes how the most highly valued form of female 
sexuality involves sex at an appropriate age and level of commitment. Rules 
imply a generally agreed rather than an individual standard. Many of the 
women referred to sex too young or with too many partners. Implicit in 
these statements is a normative standard. Norms of female sexual behaviour 
were defined according to how often women had coitus and with whom. In 
addition, rules imply a code originating outside of oneself. Phillipa refers to 
cultural norms. The norms are constructed from scientific and moral 
discourses on cervical abnormalities and other discourses on female 
sexuality, and are perceived as almost naturally occurring. Obeying 
culturally accepted 'rules' prevents disease.
The women I interviewed, like Phillipa, referred to acceptable and 
unacceptable forms of female sexual practice. Central to this reflection is the 
assumption, common in Western culture, that disease is a punishment for 
one's sins. Transgression of sexual norms entails punishment in the form of 
disease or illness. Sometimes acceptable behaviours or norms were 
expressed explicitly but they were often unstated or implicit.
As far as I know I'm hygienic. Except for the abortion there is 
nothing else I thought that could have been behind it. You 
associate these things with people who sleep around a lot - dirty 
habits. I didn't think it would happen to me. (Anna)
'You' implies everyone thinks of cervical abnormalities as sexually 
transmitted; that only women who have many sexual partners are likely to
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have a sexually transmitted disease; and, that such behaviour is stigmatised 
— ’dirty'.
Sexual transmission as an explanation
...this girlfriend [who had a cervical abnormality] ...I said "was 
she promiscuous?" That was my first reaction. She said no, she 
had just had a boyfriend for a couple of years. I know the doctor 
said that normally it was with promiscuity that you got this sort of 
thing, but then he said you know nuns have had it, little old ladies 
or whatever. I tend to go along with that; but at first it's the 
embarrassment. (Valerie)
Valerie describes how her initial reaction to a friend having a cervical 
abnormality is to question her sexual practices. When she develops a cervical 
abnormality, she uses evidence from her doctor that nuns and 'little old 
ladies' also develop cervical abnormalities. This is taken as indicating that 
sexual practices are not always relevant. Valerie's initial way of thinking 
about cervical abnormalities was refashioned when she was diagnosed as 
having a cervical abnormality.
In most instances, the construction of cervical abnormalities as sexually 
transmitted did not provide an acceptable framework for women to make 
sense of their abnormality. In contrast, Woodward (1993) found the 
diagnosis of chronic fatigue syndrome provided sufferers with a coherent 
framework within which to make sense of their experience of their illness.
The diagnosis of chronic fatigue syndrome enabled them to define the 
meanings of their illness and arrested deterioration in some cases.
(Woodward 1993). The experience of people who have chronic fatigue 
syndrome and women who have cervical abnormalities is very different, 
however. Those with chronic fatigue syndrome experience symptoms that 
are concerning and baffling. The diagnosis provides an illness category to 
describe and synthesise their experience. However, women who have 
cervical abnormality are asymptomatic. The diagnosis is made almost 
irrespective of their experience. The cultural framework provided by the 
diagnosis of a cervical abnormality defines an individual as having sinned 
and results in stigma.
Some women spoke of how they initially believed that their abnormality was 
sexually transmitted but then rejected the explanation and its implications. 
Doctors' opinions were mentioned as justification for this change. Women 
were eager to accept medical statements about evidence that the wart virus
was not sexually transmitted in all cases. Doctors were particularly 
important in reshaping the sexual transmission hypothesis.
I went to family planning, they explained that it was wart virus.
So, then my first thought was, "you caught it off someone". 
Sexually transmitted yeah. And they sort of explained to me that 
not necessarily, 'cos I've only had two sexual partners. Then when 
I went to Dr X [her gynaecologist] and he explained that it could 
be in your body since you were bom. And just sort of come out... 
(Penny)
Frequently, the women spoke of how they believed they were bom with the 
wart vims or they acquired it non-sexually. They did not bear personal 
responsibility if they did not acquire the condition sexually. Some women, 
like Penny, who acknowledged the sexual transmission hypothesis and 
reframed it, spoke of the moral implications of such an explanation.
The women used the sexual transmission hypothesis to reflect on their own, 
their partners' and other people's sexual behaviour and, in so doing, invoked 
or rejected sexual transmission in their instance. For example, Valerie felt she 
caught wart virus because her husband had an affair some years ago.
I have this deep down feeling that maybe women wouldn't get 
these things if men were faithful. ...so I am one hundred percent 
convinced that and there's never been anything said about this in 
the papers or whatever ...well I know three or four women who 
started getting vaginal infections when their husbands started 
playing up.
Reflecting on her own experience, Valerie concluded that conditions affecting 
female genitalia signified men’s disruption of the moral order. Similarly, 
Brenda thinks she caught her condition from her ex-husband whose first wife 
also had a cervical abnormality. In light of her experience Brenda concludes 
that men cause many women's health problems.
WHAT HAS BEEN THE EFFECT OF THIS EXPERIENCE ON THE 
REST OF YOUR LIFE?
Well, I feel, and this may be an unfounded way to think or feel, I 
feel that women are particularly susceptible to illness and that 
male and female health are intrinsically linked. I know some 
babies are bom with wart virus but I guess that makes a lie about 
what I am saying. But to me it reinforces the opinion that we must 
actually protect ourselves and I guess that's the affect it has had on 
me and I perceive men as being the cause of many problems, 
physically, and I'm sure a lot of people think that's unfair... We 
always seem to be having to protect ourselves. That's how I feel - 
that I actually have to be more careful of myself - more careful 
than I ever have. (Brenda)
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Brenda casts women as liable to develop illness because of men's 
transgressions. For Brenda, the female body bears the marks of men's 
disruption of the moral order and it is women's responsibility to protect 
themselves from men. In Brenda's narrative women are cast as victims, but 
they are also conceived as personally responsible and able to protect 
themselves. Judith held her husband responsible for her abnormality. She 
believes that if she has her warts treated and they return later then she would 
'prove' that her husband had infected her.
The doctor told me that there was a good chance (80 per cent) that 
I had it from John, and because nuns got it so it definitely wasn't a 
100 per cent chance, but because of that I was reluctant to have sex.
...I just thought that if I had them already, and if I got them from 
him, there would be a chance that I would get more. I'm going in 
and having them off, and then if they came back later then maybe 
that would be proof that they came from him. (Judith)
The women who resorted to the sexual transmission theory and suggested 
that their partner infected them were not held responsible for having their 
cervical abnormality. Instead, they were the victim of their partner's offence. 
Only a couple of women concluded that they were responsible for acquiring 
their condition sexually.
A few women, who thought their condition was linked to their own or their 
partner's previous sexual practices, avoided sex with their partners.
It affected the whole thing [any form of sexual expression] but 
sexual intercourse was probably the hardest because I felt it was 
like it was going to be stirring up the cervix. I didn't feel sexual for 
months - I just didn't give a damn about it. (Amy)
Rosemary, who thought she was going to die of cervical cancer, feared sex 
because it could result in a recurrence of her abnormality.
Me and my fiance just recently broke up because I just don't [want 
a sexual relationship]. It is something that I don't miss, having sex 
.. .now because it frightens me.
Amy and Rosemary related their abnormality to sex. The abnormality also 
signified their own vulnerability to cancer and death. Sex was now 
considered dangerous. Their cervical abnormality symbolised the dangers of 
sex.
Many of the women described themselves as less sexual after treatment.
They avoided sex because they felt invaded, sensitive, it was painful, or they 
wanted to prevent a recurrence. Women who avoided sex often felt guilty
because their partners' needs were not satisfied. Gladys maintained 'you 
should not change your sexual practices' (despite her feeling dirty) because 
'you shouldn't buck the system'. She considered the system to be a generally 
agreed upon, perhaps even naturally occurring code which requires a woman 
to be sexual in accordance with male sexual needs.
Heather had a lot of pain with sex. She linked the pain to her vulval and 
cervical wart virus infection. She had recently married and has had pain 
with sex from very early in her current relationship. As a consequence she 
avoids sex.
...it does tend to knock your self confidence around and you think:
I'm not much good for this and I can't do that - so you knock 
yourself unnecessarily because it doesn't make you any less a 
lovable person. But you feel a less useful person.
Part of her role as a wife is to have sex with her husband. She is unable to 
fulfil this role and is therefore less useful. Heather prevents recurrence and 
avoids pain by refraining from sex yet this action contravenes other codes of 
female sexual behaviour which require a wife to be sexually available to her 
husband.
The women experienced conflicts between two discourses. Popular and 
scientific discourses about cervical abnormality implicated women's sexual 
practices in its genesis. Women were cast as responsible for their own health. 
They were required to protect themselves from sexually transmitted diseases 
like their cervical abnormality. On the other hand, women were required to 
be sexual for men. For some women, both sex and no sex were perceived as 
problematic. Often, nothing was sanctioned. Female sexuality was aberrant. 
There was no unequivocally appropriate form of female sexual behaviour. 
Discourses about cervical abnormalities construct a view of female sexual 
behaviour as abnormal and dangerous, yet sexual norms derived from other 
discourses about female sexuality often require a woman to be sexual for 
men.
In summary, although most of the women spoke of sexual transmission as 
being related to cervical abnormality, most did not accept sexual 
transmission as a way of understanding their cervical abnormality. A few 
women suggested that the condition might be sexually transmitted but held 
their current or previous partners responsible for infecting them. Only a 
couple of women considered their own sexual behaviour to be associated 
with their abnormality. Some women who thought their abnormality may
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have been related to sexual transmission changed their sexual practices. This 
enabled them take charge of their risk of cervical cancer.
Stigma
As a consequence of the principal popular and scientific explanatory models 
of cervical abnormalities, and the meanings they created, women experienced 
stigma.
The way I explain it is it [the abnormal smear] seemed to confirm 
at a very deep-seated level, the fact that I was very bad and that if I 
hadn't been bad then I wouldn't have been punished. No matter 
how much you go through that...it sort of filters up to the surface.
It's a combination of, you know "only sluts get this", or "if you 
hadn't had so many partners...who gave it to you, you don't even 
know who you got it off - and you know, if you'd been good this 
wouldn't have happened to you. (Amy)
By linking the presence of disease with punishment, Amy construes that her 
condition retrospectively defines one's sexual behaviour as outside of a moral 
order. Sexual immorality is stigmatised. When describing her transgression 
of this moral order, Amy uses 'you' instead of T, which distances her both 
from the sexual behaviour and the moral code, as though the code is imposed 
from outside. Women frequently used 'you' as a personal pronoun instead of 
T, and as a consequence distance themselves from their own experience.
'You' also generalises their experience. Any woman in their position would 
feel the same because this condition is stigmatised.
[Discussion of an eye problem proceeds this comment]. At least 
when your eye's deteriorating or degenerating you're still a clean 
woman. That just happened. But there's just this horrible dirtiness 
feeling you get at the GP, that sexually transmitted cervical cancer 
is dirty. Do you know what I mean? It is like they put their gloves 
on. It is awful. ...you feel dirty. You feel like you have done 
something naughty. (Lorraine)
Lorraine refers to feeling dirty because of the disease and to feeling 'naughty' 
because of her implied sexual behaviour. In contrast, the eye problem is 
clean and the person is not responsible ('It just happened').
I asked women how having a cervical abnormality might compare with 
herpes or gonorrhoea. Women's responses to this question gave further 
insight into what stigmatises the disease and/or associated sexual 
behavioural risk factors. For example, do women who do not invoke the 
sexual transmission hypothesis avoid feeling stigmatised? In the case of
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AIDS, some people with AIDS are portrayed as 'innocent victims’ (such as 
Holly, a haemophiliac who died of AIDS). In contrast, others, who are by 
implication drug users or homosexuals, are guilty and responsible. (Lupton 
1992). In this situation, one's behaviour (rather than the disease alone) 
stigmatises.
Phillipa, who felted 'tainted' because of the sexually transmitted nature of 
HPV infection, thought having gonorrhoea or herpes would be better than a 
cervical abnormality because they are treatable.
The deciding factor is that there is no cure for papilloma virus, 
whereas from what I understand for gonorrhoea, I don't know 
herpes much, there are cures. ...Perhaps I wouldn't feel so bad if I 
knew there was a cure or a magic pill you could pop, or a needle 
or whatever, that could wipe this from your body. I think I could 
cope with gonorrhoea and syphilis, you think you've got this 
terrible thing, but when you look at it and take a course of 
whatever you have to take, and then you're fine and it's totally 
forgotten. (Phillipa)
For Phillipa, without a physical manifestation of the sexually transmitted 
disease, there is no stigma. At another point in the interview Phillipa 
described how she did not feel tainted after treatment because she had been 
cured of the abnormality. However, she was concerned by the propensity of 
HPV to recur.
Sharon freely discussed partners who, in retrospect, she thought might have 
given her wart virus infection. She readily contemplated sexual 
transmission. However, she was delighted to hear that it was not always 
sexually transmitted because it did not carry the same stigma.
It was nice to know that it isn't (always) sexually transmitted in 
that it sort of doesn't have the stigma that VD or even herpes 
seems to have.
She considered that her abnormality was likely to have been a result of sexual 
transmission. She also understood that sexually transmitted diseases (STDs) 
carried stigma. She did not refer to feeling stigmatised herself, because this 
condition was not 'always' sexually transmitted, although it was likely to 
have been so in her case. Although she linked sexual transmission with 
stigma, she did not believe that the community considered HPV or CIN to be 
sexually transmitted and therefore these conditions did not carry stigma for 
her. Her cervical abnormality had neither the status of an STD, nor the 
stigma attached to it.
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Sharon and Phillipa associate the presence of a sexually transmitted condition 
with stigma. However, they interpret it differently. Phillipa believes that 
cervical abnormalities carry community-wide stigma. Sharon, in contrast, 
believes that her condition is not generally considered to be an STD. As a 
consequence Sharon talks about her abnormality readily while Phillipa is 
secretive about hers.
Brenda spoke freely about the relationship between her sexual behaviour and 
her cervical abnormality. She linked her abnormality to her ex-husband 
whose first wife had the same problem.
I'm beyond the idea of being tainted. It's a specific idea that we're 
given, I won't apply it to myself or to anyone else for that matter. 
(Brenda)
Although Brenda accepts the sexual transmission as a possible explanation 
for abnormality she rejects the cultural meanings of such an explanation. In 
doing so, she avoids feeling stigmatised. Brenda demonstrates discursive 
resistance to the dominant cultural meanings for cervical abnormalities. She 
was the only woman who tried to redefine the cultural meanings of sexually 
transmitted diseases. All other women worked within the cultural 
framework for STDs. They might have considered that their cervical 
abnormality was not sexually transmitted. However, the notion that STDs 
were stigmatised was never reframed.
Kleinman says this of cultural meanings:
Cultural meanings mark the sick person, stamping him or her with 
significance often unwanted and neither easily warded off nor 
coped with. The mark may be either stigma or social death. 
(Kleinman 1988). p26
He suggests that the effect these meanings have for an individual depends on 
their 'place in the local cultural system'. Some people may be able to rework 
or resist the cultural meanings. For many women, the stigma associated with 
having a cervical abnormality meant they felt differently about themselves 
and were often reluctant to tell others about their abnormality.
Individual susceptibility
A few women thought they had an inherent susceptibility, constitutional or 
acquired, to developing a cervical abnormality.
Adrienne believed her abnormality resulted because she was more 
susceptible due to another illness.
I thought it was because I'd got chronic fatigue syndrome. The 
doctor said when that starts, you're liable to pick up anything 
because you have no immunity.
I think I was convinced that I wasn't going to live. I just thought 
this is it. Because I had come down with everything else it was just 
a matter of time before something was going to come and get me.
In Adrienne's account she is conceived as susceptible and unable to prevent 
cancer.
Several women thought they had a tendency towards warts, illustrated by a 
history of warts on their hands. This belief persisted despite their doctors' 
disagreement.
I thought back to my early twenties and I did have a couple of 
warts on my thumb and somewhere else on my hand. It is 
possible that it's one and the same. The doctor says it's not, that it's 
a different strain. I can't help thinking that if you're susceptible to 
that sort of thing, it could be in you and you wouldn't even know 
about it - even if it is a different strain. I know a couple of people, 
and any time they get a nasty cold in the head they get a cold sore.
I've never had one in my life, and I don't expect to, but some 
people have something there and they can't get rid of it, and it 
keeps coming back. (Valerie)
Except when used in combination with other concepts such as stress and 
lifestyle factors, explanations from this category did not offer actions that 
women could take to change the course of their abnormality.
Bad luck or fate
Some women felt there was no specific explanation for their having had an 
abnormality. It was just fate or bad luck.
Having an abnormal Pap smear is nothing. You don't feel that 
anything you are doing is causing the problem. (Julie)
The feature that appeared to typify the experience of most of the women who 
had no specific explanation for their cervical abnormality was the low profile
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their abnormality took in their lives. For example, Julie considered her 
cervical abnormality to be fairly minor in comparison to her inflammatory 
bowel disease, which was causing her ongoing problems. These women did 
not perceive their condition to be life-threatening and did not experience the 
same degree of vulnerability as many other women in the study. They were 
confident that future Pap smears would detect any further abnormalities and 
that gynaecological treatment was effective.
...it was just one of those things that happened. When you look at 
the statistics on how many women come out with this sort of 
thing or breast cancer I think it was pretty lucky it wasn't anything 
more serious...
At this stage it is not life threatening and so you do have to be 
realistic about it and just understand what it is.
WHAT IS THE MOST IMPORTANT ISSUE THAT HAS COME 
OUT OF THIS EXPERIENCE FOR YOU?
In general, I am well open to anything, we are not an island, we 
are susceptible to anything, to be able to understand that we are 
only human and that these things are around in our society and 
what lies ahead for people. The medicine that we have available is 
there to help us and that we need to trust it. (Louise)
Louise construes her cervical abnormality as denoting the nature of the 
human condition. Individuals are susceptible to any disease or illness and 
one cannot protect oneself from such conditions. Prior to her abnormality 
Louise did not consider herself at risk of cervical cancer because she had only 
had one sexual partner in her life. Prior to her abnormal Pap smear, then, 
Louise linked sexual activity with cervical cancer. When she developed a 
cervical abnormality, however, and her experience was not consistent with 
her previous model, she shifted to thinking in terms of fate. Although 
Louise's quote illustrates that she has a new appreciation of her own 
vulnerability (she speaks of being susceptible), she viewed medicine as 
capable of managing her abnormality. She trusts her doctors and seems able 
to live with the uncertainty of her newly defined risk.
Another characteristic of women in this group is that they rarely spoke of 
control. On the two occasions they mentioned control, it referred to 
knowledge about treatment and experience of the examination. They never 
spoke of control in relation to the disease, their risk of cancer, or their own 
health.
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Summary
In this section I have shown that the women's explanations for their 
abnormality were embedded within networks of personal and cultural 
meanings.
For many of the women the abnormality signified how they could — and 
should — have control over their risk of cervical cancer. Narratives about 
stress and lifestyle factors enabled them to make these changes in their lives. 
They became active participants in managing their risk. For these women, 
their cervical abnormality became part of their life narrative. They were 
women who could shape and have control over their worlds.
In constructing these explanations the women drew on popular medical 
culture and scientific medicine. However, they only appropriated those 
aspects of scientific research that were consonant with their own world view.
Many of these women experienced medical treatment as not enabling them to 
have control over their own health. Some spoke of medicine as taking control 
away from them. Furthermore, medical treatment involved their diseased 
cervix only. In contrast, the women's explanations were firmly rooted in 
their own life circumstances. Their cervical abnormality had become part of 
who they were. It had a reality and presence beyond the gynaecology clinic. 
Medical management of their abnormality was curative and technological. It 
failed to deal with the complex meanings the abnormalities had assumed 
within individual women's lives.
Some women did not seek an explanation for their abnormality. Their 
abnormality was just bad luck, fate, or was because they were susceptible. 
These women did not speak in terms of control over their own health. One 
feature of this group of women is that they perceived their abnormality to be 
minor. It was not a major health problem. Rather, it was something that 
could be easily managed, and although they were aware of their risk of 
cervical cancer as discussed in Chapter Five, this risk was easily managed by 
medicine. Medical surveillance and treatment did not conflict with the way 
they conceived their abnormality.
It is possible that because the condition was perceived as minor it did not 
throw up the question: "why me, why now?". It is unclear why some women 
came to see this as a significant health problem and developed complex ways 
of making sense of their abnormality, while others conceived the problem as
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minor. Impressions of severity did not appear to relate to the degree of 
abnormality. Women like Leslie and Gladys (pl07 and p ll4  respectively) 
had ongoing abnormalities even after treatment. Leslie and Gladys therefore 
experienced this as a chronic problem that required incorporation into their 
own life narratives. The women's perception of the severity of their 
abnormality was shaped, in part, by their interactions with health 
professionals. This is discussed in the next chapter. But, their perceptions of 
the severity of their abnormality was also shaped by their past life 
experiences, including various illnesses. Without developing a more 
complex account of each woman's life it is not possible to explore why the 
women came to view the severity of their abnormality differently.
Although I have presented these two groups as distinct — those women who 
seek explanations for their abnormality and those who do not — the groups 
overlapped. A few women discussed how there was no explanation for their 
abnormality, that it was just bad luck, and at another point in the interview 
suggested that their abnormality might be linked to aspects of their life.
Discussion
There are two major arguments in this chapter. First, in order to manage 
their newly-appreciated awareness of their proneness to cervical cancer, the 
women felt they must participate in continuing medical surveillance. This 
surveillance defined them as always likely to suffer cervical cancer or some 
such abnormality even after treatment. Second, the women sought to make 
sense of this abnormality and incorporated it into their life narratives.
Not only did the women come to experience their risk of cervical cancer, but 
within gynaecological practice this risk was only managed by medicine.
They had been unable to identify their risk (this required the Pap smear) and 
they were unable to monitor or treat it. At the same time their risk was their 
responsibility. To manage it, they needed to subject themselves to medical 
surveillance and treatment. The women's narratives about stress and lifestyle 
factors might therefore be thought of as forms of resistance to the medical 
discourses about cervical abnormalities, which cast them as powerless and at 
the same time responsible.
The women constructed their explanations for their abnormality in ways that 
made sense to them. In doing so, they accepted and reworked evidence from 
scientific medicine and popular culture that were congruent with their own
lives. For some women, their abnormalities became firmly grounded in their 
everyday life and became part of their own identity. Yet their gynaecologists 
approached their cervical abnormality in isolation. Gynaecological care 
decontextualised the women's abnormalities as though they were not part of 
women's identities or their lives.
It appears that gynaecological practice has no space for ways of 
understanding cervical abnormalities that are not consistent with the current 
clinical approach to such abnormalities. It may be that, in the clinic setting, 
conversation and actions enable particular accounts of cervical abnormalities 
and prevent others. In the case of surgery, Fox (1993) argues that surgeons 
use the ward round as a strategy to manipulate conversation so that it 
upholds their position as healers. Patients' versions of what is happening to 
them could not be heard within the structure of the ward round. (Fox 1993).
How do encounters between gynaecologists and women who have abnormal 
Pap smears operate so that women's accounts are marginalised? The next 
chapter examines the women's experiences of the health care system. Not 
only were the women's accounts silent in the clinical setting, but many 
women felt they were not fully informed of the reasons for their clinician's 
approach to their abnormality.
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Chapter Seven
Interactions with the health system
Interactions with health care professionals shaped this experience for the 
women in this study. In this chapter I discuss the importance to women of 
information, health promotion and policy material, and interactions with 
doctors.
Information needs
The women in this study group obtained information about their condition 
from many sources. Books, pamphlets, the media and the health care system 
were all important sources of information. Within the health care system, 
women consulted their own popular health networks as well as nurses, GPs 
and gynaecologists. Women felt that the most helpful information addressed 
their fears about the malignant and deathly potential of the abnormality, and 
dispelled concerns about its sexually transmitted nature (see Chapter Six). 
Individual women required different amounts of information at differing 
levels of detail.
Many women found the information they were received was difficult to 
understand.
With your doctor, you're sitting in their office and they're telling 
you things but you're not absorbing them. It doesn't seem to make 
a lot of sense to you. You go out and you think, "what did they say 
about that ?" I can't even remember because you are feeling so 
nervous and wondering what is going to happen. The 
gynaecologist was good but he was talking on a technical level and 
you can't get basic information out of them. (Anna)
Instead, Anna sought the information from books. In contrast, Gladys found 
books too difficult and she, like several other women in the study, felt that 
she might misconstrue the detail given in books.
I feel that if something bothered me sufficiently, I would give 
somebody a pain in the arse and I would get on the phone and 
find out exactly, rather than reading books that are possibly over
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my head and misconstrue what I am reading anyhow. Better to 
find somebody that will explain in language exactly what is going 
on. (Gladys)
These women used different sources to obtain 'basic' information.
Anna raises another issue — not only can information be too hard to 
understand but the nature of the clinical consultation makes it difficult for 
some women to take in all the information they are given. Frequently, 
women described 'not hearing' what their doctor said.
I think you block it out when people talk to you about it. I know I 
did. Like when the doctor talks to you about it and they say "it's 
all right you'll get over it, ...you must be feeling this" but they 
don't really know what you're feeling. So I thought, "how would 
you know", so I didn't even listen sometimes. (Rosemary)
Like Rosemary, several women described this process of 'not hearing' in 
relation to information that did not address their own needs. She feels the 
gynaecologist does not understand her experience.
GPs and gynaecologists provided different kinds of information.
He [her gynaecologist] talked more about the wart virus. She [GP] 
talked more about the stages - trying to reassure me that it was at 
this stage, and if it is untreated it moves on to another stage, but it 
wasn't at that stage. So she was more in counselling mode, he was 
more in clinical mode explaining where he was taking the biopsies 
from, the shape of the affected area, and that he was putting the 
stuff on it to see the cells change. (Veronica)
Some women thought their GPs provided good, more basic and 
understandable information. Other women felt gynaecologists had better 
information as GPs were not experts about cervical abnormalities. However, 
often doctors' receptionists were the source of the most needed information.
Some women found the best information within their own social networks. 
For Sharon, a colleague in the health area was the source of useful 
information about the prevention of a recurrence of her cervical abnormality.
I was talking to Ruby [a friend who works in the health sector] 
about it and she was saying that recent literature indicates that the 
wart virus has a lot to do with pressure and stress ...so that if you 
are under stress and under pressure and are run down, you don't 
eat properly and you don't exercise, then you are more likely to get 
it, because your system's run down; so there is no natural defence 
to the virus. ...it made me feel good. I could actually make some 
improvements. .. .I'm thinking positively because I have a new job 
and I will be working less hours. In terms of dieting, exercising
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and stress, I'm feel more positively about the fact that in the future 
I'll have more control and be more easily able to make lifestyle 
changes.
Sharon wanted to know what she could do about her abnormality. Her 
friend addressed this need. Sometimes friends also provided the most useful 
information regarding the experience of treatment and symptoms after 
treatment.
The nurses in the study spoke of the ease with which they related to technical 
biomedical information and their familiarity with the language used to 
describe their condition. They shared a knowledge base with their health 
care providers. The women used the information that was most congruent 
with their ways of understanding their abnormality and their life 
circumstances.
A central theme used by women when discussing information they found 
useful related to the rationale for treatment and the precautions 
recommended following treatment. Women expressed frustration when they 
could not make sense of the treatment and instructions they were given by 
their medical practitioners.
I didn't like the first gynaecologist I saw. He did a Pap smear and I 
rang back and they said the results weren't back and to ring back 
in a couple of days, which I did. Having phoned back they said it 
has come up as an abnormal Pap smear, come in and get a 
prescription. I got in there and I asked if I could see him - and they 
said he was too busy ...I couldn't see him. I said "well how am I 
meant to know what's wrong?". And in the end the receptionist 
just said over the counter that I had thrush. Unless you actually 
tell someone what they've got and what they're taking the 
prescription for, it makes no sense. The other thing that I picked 
up was chlamydia, either through my husband or through a 
previous relationship. The thing that hit the hardest was when the 
first Pap smear came back and the receptionist just said it was 
abnormal. What does that mean? I didn't know what to do about 
that. But chlamydia, a friend of mine had had it and her mum is a 
nurse so I wasn't worried about that. I saw my GP and he was 
really good he gave me antibiotics and said to make sure my 
husband took them too. And everything was fine. That was the 
real thing that hit me at first, that made me really worried, I 
thought what is it, and then once I knew it was that I thought OK 
that it is fine and I don't need to panic. (Bronwyn)
Bronwyn describes two situations. In the first situation her gynaecologist 
does not tell her anything about her abnormality and just suggests she take
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the medication he prescribes. In the second situation contact with a friend 
who has a similar problem enables her to understand the antibiotics her GP 
prescribes. She is happy to take the prescribed medical treatment as long as 
it makes sense to her. For Bronwyn, worry or panic is a product of her lack of 
knowledge and understanding of conditions which affect her. The doctor 
also fails to address the meaning of 'abnormal'. Similarly, Adrienne describes 
frustration at the lack of information about why she should not pursue 
certain activities.
They didn't give me much information at all. Even as to what they 
were going to do. I just went in and they do the colposcopy - I 
knew what that was because I'd had one - and then he told me he 
was also going to do a biopsy. ...between the time of the biopsy 
and laser treatment there was no contact then except the phone call 
to make the appointment for laser treatment. I didn't know what 
to expect... they don't tell you you're going to bleed or have a 
discharge afterwards. They give you a little sheet of paper and it 
says "do not swim, do not bathe, do not wear tampons etc..." but 
they don't tell you why you can't do these things. (Adrienne)
Most women sought to make sense of the treatment suggested by their 
gynaecologists. Only a few women were satisfied with reassurances that 
merely told them not to worry. The few women who were satisfied with 
such reassurances were the least concerned by their abnormality and its 
medical treatment. They spoke of how they preferred not to 'know too much' 
and spoke of 'trusting' their doctor.
I'm a bit of an ostrich - I'd rather not know. I know he’ll say to me 
if it is wrong "quick we have got to do something", or if I come 
back earlier for treatment. I just trust him. (Carmel)
Carmel 'worried' that she may construct the condition as serious if she was 
given too much information. Earlier Gladys expressed a similar concern 
about written material.
The women wanted information in a variety of formats. Some emphasised 
the need for clear diagrams so that they could conceptualise the information. 
Others, for example Sharon, wanted detail about the disease process but not 
about the anatomical nature or location of her abnormality.
I wanted to know all about the wart virus. But I mean he was 
drawing pictures of the cervix and where it was in terms of some 
canal thing and that meant nothing to me except that it was easy to 
get at and it was less likely to be scary and it was a very small area 
and those sorts of things. But you know it didn't make you feel
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better or worse knowing where it was and this is what it looks like 
or any of that. (Sharon)
A few women described doctors who expressed their uncertainty in relation 
to their own lack of knowledge and long term outcome of their condition as 
honest. This honesty enabled women to trust their medical practitioner.
When uncertainty was not expressed, and the condition recurred, women 
were upset that they had been led to believe their condition was definitely 
curable.
Similarly, several women found there were discrepancies between the 
cytology and histology results and interpreted these as signifying a 
worsening of their condition.
I would say I'm scared to go back in September because it changed 
so quickly, when I went the first time it was CIN 2, by the time I 
got back for the biopsy it had gone to CIN 3. But it seemed like a 
matter of a couple of weeks. By the time I go back in September it 
may be back again. (Valerie)
However, Amy who initially had a Pap smear with only wart virus changes, 
later had one that demonstrated CIN 2. Her gynaecologist described to her 
the uncertainty that is part of pathological diagnoses.
I knew that I had CIN 2. When I spoke to Dr X, I found that the 
definition is based on visual interpretation by the pathologist ...so 
you could have variations across pathologists in terms of how they 
define, whether they say its CIN 1, 2 or whatever else. It's not like 
running it through a machine that gives out a magnetic signal etc. 
(Amy)
With a clear explanation, Amy understood the imprecision of pathology 
reports.
Previous research demonstrates that medical practitioners often do not 
communicate the limits of medical knowledge and the dimensions of medical 
uncertainty (Fox 1975; Bloor 1976). All the women who experienced a 
recurrence of their abnormality or discrepancies in the pathological tests were 
surprised. Without information about the inherent uncertainty of medical 
information and procedures, women have no knowledge base from which to 
interpret the recurrence or apparent progression of their condition.
Relationships with medical practitioners
Trust was of crucial importance in the women's relationships with their 
doctors. Practitioners who spent time, answered questions and enabled 
women to make their own decisions were commended.
Trust or faith was mentioned in relation to medical science and doctors. 
Women who did not want 'too much' information (because they feared they 
would misinterpret it and construe the condition more seriously) spoke of 
trusting their doctors. These women trusted their doctors to give them 
'enough' information and to make the 'right' decisions for them. Some 
women who did want more information also developed trusting 
relationships with their doctors. However, trust always referred to women's 
impression that their doctor was cognisant of their personal needs. Distrust, 
on the other hand, related to fear that one is only one of masses of women.
I have a basic distrust in doctors because I always have this feeling 
that you're only one of millions and you can be missed. (Ruth)
Often, trust developed over a long period of time. For example, Maeve had 
'faith' in her first gynaecologist but was unsure of the second.
I went to Dr X for a number of years. He saw me through my 
baby's childhood and I went to him every year for a Pap smear and 
I got used to him. Then when this one came [a new gynaecologist] 
he was a bit younger and I thought new to the job and I was a bit 
concerned about having somebody new so that when this came up 
[the abnormal Pap smear result] I wondered whether it was 
accurate. (Maeve)
Those women who did not trust their doctor were liable to question their 
clinical competency and the information they gave. Amanda trusted her GP 
to make appropriate decisions, but she did not find him helpful in answering 
questions about her abnormality.
However, a couple of women said they trusted all doctors, trusting both their 
medical knowledge and professionalism.
I generally have a fairly good faith in doctors. I imagine they sit 
there, the professionals, and they know what they are doing. 
(Judith)
The parameters for establishing trust varied among the women interviewed. 
For example, Maeve trusted an older gynaecologist whom she had known for 
many years and Judith trusted the institution of medicine itself.
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The women commended health care practitioners who were readily available 
to give them information and answer their questions. Nurses in the specialist 
clinics and a few GPs were mentioned in this regard. Gynaecologists were 
often criticised because they did not respond to questions even within the 
consultation.
It's quite hilarious really - you've got this thing over your knees 
and this doctor has got, have you ever seen that little thing that 
you put on top of the TV or something and it has got this nose 
which hangs down over the fence, well that is what the doctor 
looked like. He is talking to me while I was up like that [in the 
colposcopy chair], and it is not conducive to thinking of what 
you're meant to ask. ...He is looking at you as soon as you get out 
of the chair, he starts writing his notes, you get dressed, and he 
opens the door for you. There's really no discussion at all - you 
virtually just do as you're told. I have no hesitation to ask my own 
doctor, but this guy... his personality is pleasant enough - it's just 
that he seems in a hurry. (Adrienne)
Consultations with the gynaecologists were often perceived as rushed and 
lacking a structure that would enable women to ask questions.
Inclusion in the decision-making process was important for many women.
Fortunately I have a very good relationship with our GP and he 
asked me who I wanted to be referred to and I was consulted at all 
points: do I want to or not, do I understand what it means, do I 
realise what the next step could be, what if I don't? He was very 
good he allowed me to choose the gynaecologist I wanted to see 
and I researched my options prior to going to see him so I knew 
from the research what I wanted and fortunately it was what he 
advised anyway. (Jenny)
Despite demonstrating how she was involved in decision making, Jenny casts 
herself in the position of the powerless. She constructs her doctor as 
'allowing' her to take part in the decision making. In her account the doctor 
is the person with power to give away.
Compare Jenny's experience with Gladys'.
I went to the health clinic to discuss the options of having laser 
treatment, and their response was I would take their advice. So 
again you're left high and dry, unsatisfied. (Gladys)
In contrast to Jenny, Gladys perceived herself as actively seeking the advice 
of medical practitioners regarding her treatment options so that she could 
make a decision. The practitioners she spoke with did not facilitate her 
taking such an active role, indicating that she should be a passive recipient of
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medical advice; that decisions should be made/or her, not by her. 
Consequently, Gladys is dissatisfied because she wanted to be part of the 
decision-making process.
Several women described their experience of gynaecological treatment with 
factory metaphors.
You are just a number. I like Dr X, but I really feel like you go in 
there and he's very pleasant, and up you get and it's just another 
fanny here and off you go. He probably hasn't time for that sort of 
neurosis and you're there and you want to get it over and done 
with. (Phillipa)
I would like it not to be a production line, in a slot, and that's as 
much time as your given. You're not allowed to deviate. I would 
have liked to discuss other things peripheral to it but that were 
important to me but you just feel this is your time and you 
shouldn't deviate. (Anna)
According to these women's accounts, each woman is treated the same and 
there is a schedule, a timetable, that guides the consultation. Asking 
questions disrupts the schedule.
In contrast, Julie felt 'involved' because her gynaecologist canvassed her 
opinions about the treatment.
I didn't feel that I had to have it [the laser treatment], I just 
understood it was necessary. Seeing a woman doctor it was a bit 
nicer. And then after that, when I went back for a follow-up Pap 
smear, she asked my opinion of how I experienced the treatment.
She gave me a couple of tablets beforehand and I felt really 
knocked out. She asked me how that was and whether I thought 
that was necessary. So I felt really involved not like a piece of 
meat on the table. (Julie)
Julie is not an unidentifiable slab of meat that is operated upon, but a person 
who is part of the clinical procedure.
The most important quality for health care professionals was a capacity to 
engage with women, individually addressing each woman's needs. This 
quality was necessary for trust to develop and for women who wanted to be 
involved in decisions about their treatment. Often women perceived 
gynaecologists as detached. Detached practitioners cannot engage with 
women personally. The emotional distance sustained the 'factory-like' 
environment of gynaecological practice.
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Gauging severity
Women often used their practitioners' responses to gauge the significance of 
their condition. Some women maintained that the information given at the 
time of initial diagnosis was often inadequate and were often critical of what 
they perceived to be 'information gatekeeping' by their medical practitioners. 
Because they thought their doctors were not telling all, their doctors' 
behaviour assumed greater significance in the shaping of the women's 
impression of the severity of their abnormality, since they could not know 
enough from what the doctors said.
Most women were notified of their abnormal result by their GP, by phone or 
letter. This is in stark contrast to women's usual experience of the health 
system where communication with GPs outside the consultation is rare. Such 
written or telephone communication with their GP signified a serious 
condition. A few women felt their GP was panicking and construed this as 
signifying a serious problem. Similarly, prompt specialist referral also 
signified a grave condition.
Seriousness frequently equated with cancer and imminent death.
It was April 1991 when I had a routine Pap smear. I hadn’t had 
one for two years. Usually I have them every year or so. I went 
into my GP for a routine Pap smear and I didn't think about it 
much until the surgery phoned me in the afternoon after I came 
home from work and they told me to come and see the doctor 
straight away. I knew it had to be serious because the doctor 
didn't ring me at home. I've been going to him for ten years, and 
my children go to him, I immediately thought the worst. Two of 
my friends had died of cancer six weeks before this, of breast 
cancer. My grandfather died of cancer too. (Amanda)
Her doctor's out-of-the-ordinary behaviour was the source of Amanda's 
concern about severity.
Similarly, doctors' emotional responses were yardsticks for judging severity.
So, I finally had that test [serum cholesterol] and they told me it 
would take ten days or whatever to get the result. I thought "what 
I'll do is I'll ring up the doctor when both the results were in and 
then I won't have to disturb the doctor twice". It was probably 
about six weeks since I'd had the Pap smear when I actually found 
out the results. When I phoned up, the receptionist said to me,
"Oh, thank God you've phoned. We've been trying to ring you for 
weeks and weeks" - and there was all this panic in her voice. And 
I said, ’What?" I was practically hysterical and then she put me
through to the doctor and said, "My God, we've been trying to get 
in touch with you for weeks and weeks. Where have you been?
We haven't been able to contact you and we have tried and tried".
There was all this air of panic and I said, "What's happening?".
And she said, "You've got a bad test". And because it had all of 
this sort of air of panic, because they hadn't been able to reach me,
I just went into instant panic myself. (Veronica)
The urgency with which it was treated by her doctor and her receptionist 
caused Veronica to feel concerned.
On the other hand, a few women concluded that because their doctor did not 
appear overly concerned that the abnormality was not serious.
I received my notification about having an abnormal Pap smear in 
the mail. It was not long after my daughter was born. ...the 
doctor just sent my prescription in the post with an accompanying 
letter. That was my first introduction to abnormal smears. Having 
great faith in my doctor, a gynaecologist, I figured that if he 
thought there was no reason to have a heart attack, all must be 
well. (Gladys)
Gladys trusted her doctor to respond appropriately and was willing to follow 
the doctor's instructions regarding treatment. However, other women felt 
that their doctors might not communicate the full extent of their problem.
Initially I got the feeling that they were blase about it, Family 
Planning and Dr X, and I thought either it is very serious and they 
are not telling me or a lot of people get it and they don't think 
anything of it. In which case I started to think if it was serious are 
we going to miss it? (Ruth)
Ruth interprets her doctor's response. The possibility of her problem being 
serious can only be entertained — given her doctor's response — if her doctor 
does not tell her the full details of her condition.
Several women were told initially that they had a normal smear and were 
subsequently rung up (or in one instance told via their spouse who visited 
the doctor for another reason) to be told that their smear was abnormal.
These women were angry with their GPs or receptionists who had initially 
informed them incorrectly.
Referral to a specialist also signified a serious condition. Several women 
spoke of an earlier abnormal Pap smear result casually. Until their Pap 
smear result caused their GP to suggest referral, their condition was 
considered minor. Several women thought their complaint to be serious 
because of the haste with which they were referred to a gynaecologist.
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He [her GP] said "there's nothing to worry about but you must see 
a specialist straight away". I opted to see my gynaecologist, Dr X, 
but he couldn't see me until February and my GP said "oh no that 
is much too long to wait. I suggest you see someone who sees you 
before that". That's why I saw Dr Y. That made me panic too, 
because I thought: "oh gosh, it's nothing to worry about but I can't 
wait to see my own specialist". I had to see someone a lot sooner.
So that made me panic too. They are saying, "oh it's nothing to 
worry about but you must see someone straight away". (Lorraine)
The urgency of referral was not consistent with a minor complaint.
The need for treatment signified the importance of the condition for Leslie.
I think to start with the result is only, you only have a slightly 
abnormal result and my doctor was so confident that it was very 
normal to have this, it is fine. I wasn't upset about it. I was quite 
.. .1 didn't like it but I wasn't uptight about it.
YOU HAD SUBSEQUENT ABNORMAL RESULTS?
Yes, my first result was sent to a gynaecologist and he diagnosed 
CIN 1 and he said we can leave it for a while and I think three 
months later it was CIN 2 and he suggested I have treatment and 
after that, I think it was at that point that I started to feel anxious 
about the whole situation. Because before then I thought it would 
just go away and when I got to the point of actually having 
treatment it started getting really ...oh no this is my body, what 
are you going to do to it. (Leslie)
Initially, Leslie's result was perceived by her doctor to be a normal 
occurrence. When treatment was suggested, her abnormality became 
significant, crossing the boundary constructed between normal and 
abnormal.
In contrast, Judith was not perturbed by her abnormality because she 
considered it to be routine.
I wasn't too worried about it. I don’t know why...I just saw it as 
something that had happened, it was routine, and it was going to 
be fixed up. (Judith)
Both the commonness and amenability of her abnormality suggested to 
Judith that her abnormality was not serious.
Many of the women described how they initially believed that cervical 
abnormalities were uncommon because they had not heard of anyone else 
who had had one.
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Actually I found out later that my sister had had that (an abnormal 
smear) but I didn’t know that before. And various people since 
that have had abnormal smears. (Julie)
Like Julie, most women did not know anyone who had an abnormality prior 
to having one themselves. After they received the diagnosis they found 
other women who had experienced similar problems.
It’s like once you have a baby you see women who have had a 
baby. Actually another friend of mine had to go and have laser 
treatment for a similar thing ...plus this little girl she was having 
it and her mother was having it. So within a short period of time 
there were four people who had a similar thing. (Phillipa)
The apparent infrequency of the problem may partly be explained by 
Phillipa's explanation — that is, one does not become aware that women are 
telling you of their cervical abnormality until you have experienced an 
abnormality yourself. The precise nature of their problem may remain 
unclear until after you have experienced a cervical abnormality. It is possible 
that the apparent infrequency also relates to women feeling reluctant to 
speak of their abnormality because it is stigmatised.
...with this cervical stuff there's this insinuation that you got it 
from promiscuity, that, I think, keeps a lot of women quiet about 
it. (Brenda)
DID YOU TELL ANYBODY ABOUT IT?
No, not a soul. I'm tainted. I'm not going to tell anybody I've got 
this bloody wart virus. I didn’t tell anybody. I told people that I 
had an abnormal smear and funny sort of precancer cells... 
(Phillipa)
Initially, many of the women thought that because cervical abnormalities 
were uncommon they were severe.
Some authors maintain that the linkage between uncommonness and severity 
in relation to disease is peculiar to modem experiences of sickness. 
Previously, diseases affected the collective and were, therefore, common. 
Severe diseases, such as the plague, involved collective suffering. Now 
severe diseases, like cancer, affect the individual and are uncommon. (Planz 
and Keupp 1977; Herzlich and Pierret 1987). However, a couple of women 
did not link uncommonness and severity.
Sharon, who was initially concerned about the hastiness of her GP's referral 
to a gynaecologist, was reassured when told that her situation was not
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urgent. Her gynaecologist's assertion that if she were pregnant her treatment 
could be delayed was also reassuring.
...the first meeting with the gyno and he again said it was no big 
deal and said for example, if you were pregnant we would leave 
the treatment until after you had the kid. And that made me think 
that is great, that is nine months, and that slowed down my 
concern, because the way the GP had been treating me I thought 
"shit I was destroyed". (Sharon)
Interpreting health promotion and policy messages
Like practitioners' responses, health promotion messages and policy 
guidelines shaped the women's understanding of their abnormality. Two 
distinct interpretations of health promotion and policy were evident: strict 
participation in screening according to the intervals outlined in policy 
prevented cancer of the cervix, and an abnormal smear indicated cancer.
A few women spoke of how the time since their last normal Pap smear 
shaped their perception of the seriousness of their condition.
I wasn't worried about cervical cancer. I thought having regular 
Pap smears I was fairly safe. I thought if there is a change it would 
be very slight. (Julie)
In Julie's view, having regular Pap smears indicates that her problem is 
minor. However, Sharon is concerned because she considers the interval 
between her Pap smears to be too long.
It was nearly two and a half years since my last Pap, which just 
floored me. So having learnt that I felt even worse, I thought "oh 
God two and a half years what could have developed?". (Sharon)
Sharon and Julie, like many women in the study, understood the 
recommended screening interval to be indicative of the underlying course of 
the condition. At the time of the study the recommended interval for 
screening was changing from one to two years. Decisions based on effective 
population screening were translated at the individual level to bring meaning 
to the diagnosis.
Lorraine conceived that her risk changed because she did not have a Pap 
smear at the recommended interval.
I always have a Pap smear every June but that year for some 
reason or another because I had little kids or whatever, I left it 
until November. I was in a panic because the media is telling you 
to have a Pap smear once a year, once a year. For those four or five
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months I was panicking because I had not had one in June. ...The 
media keeps telling you all the time to have it done, no-one is safe, 
whether you're Asian, Italian or a nun. If you have sexual 
relations with men, then you must have a Pap smear every year. 
Therefore I started to panic when I had not done it yearly. 
(Lorraine)
From the media messages she construed that she was at risk of cervical 
cancer. When she did not have her Pap smear at the recommended interval 
her perception of her risk shifted. She became anxious about her new state of 
risk. Lorraine uses the health promotion messages she was exposed to to 
construct her perception of her own risk. In epidemiological terms,
Lorraine's risk of cervical cancer is only increased minutely by having the 
smear at a two-yearly rather than yearly intervals, yet Lorraine experiences a 
dramatic change in her risk state.
Policy guidelines were used as sources of information about the nature of 
cervical cancer. The women thought of policy as reflecting the underlying 
'truth' about their abnormality. Given the notion that policy decisions were 
based on truth, they were used by women to discern the significance of their 
own abnormality.
Within the conceptual framework that policy reflects the nature of the 
cervical cancer, changing screening intervals requires a conceptual shift in 
thinking about the course of cervical cancer. Women frequently expressed 
concern about the policy change from a one- to two-year interval, fearing that 
the longer interval would mean that their abnormalities would be 
significantly worse before they were detected.
Most health promotional material is aimed at recruiting women to participate 
in cervical cancer screening at a defined interval. Health promotion 
messages do not address the detection of abnormalities on a Pap smear.
Many women had not heard of abnormalities picked up by screening and 
concluded that any abnormality must be cancer.
.. .you either get an all clear or you have got cancer. (Ruth)
I don't think I realised that you can have abnormal cells but it 
doesn't mean you have cancer. I think, I automatically thought if 
you had abnormal cells that it was the beginning of cancer. That is 
why when they told me that it didn't mean that, it was reassuring. 
(Peggy)
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The failure of health promotion material and health care practitioners to 
address the process via which cervical screening prevents cancer of the cervix 
meant that many women thought cervical abnormalities were cancer.
Primary health care practitioners and health promotional material must 
address the way cervical screening prevents cervical cancer. At the time of 
doing a Pap smear practitioners could discuss with their patients the purpose 
of the test and explain the significance of any abnormality that might be 
detected.
Gynaecological examination and treatment
I spent four months in a private gynaecology clinic whose major service was 
laser treatment of gynaecological abnormalities. My task during this period 
was to record data from the clinical records for Part C of this thesis.
However, during this time I observed the arrangements in the clinic, women 
entering, waiting for their consultation with their gynaecologist and leaving 
the clinic. (I did not observe the clinical consultations.) I draw on my own 
observations and women's accounts to describe the clinic experience.
The role of woman as patient
Eisenberg (1980) maintains that "patienthood is a psychosocial not a 
biological state". Only by consulting a physician can a person become a 
patient. On entering the clinic or hospital a woman became a patient. 
Entering this role meant that women now had to behave in particular ways. 
If they could avoid it, women did not sit next to each other or enter into any 
conversation unless initiated by the clinic staff.
However, women who come to the clinic embody a multitude of other 
capacities. For example, women are household managers, professionals, 
academics, bush-walkers, but in the clinic setting the role of patient prevails. 
Unlike most other identities in women's lives, however, this role is a 
temporary one and is relevant only to the clinic.
...look so many people say I hate going into hospital but if you've 
got to go, you've got to go. And if you have to go I accept it, and 
righteo I'm a nurse one minute and a patient the next. You play 
the role of patient. (Gloria)
For Gloria the transformation from nurse (the role she assumes prior to 
entering the hospital, even though she has not practised in a professional
capacity for some years) to patient is even more dramatic because the role of 
nurse and patient are not compatible in the one encounter.
The patient role requires that a woman be quiet both in the waiting room and 
within the clinical consultation.
I was very determined with this laser treatment not to make a 
sound and I didn't. (Phillipa)
When another woman is heard crying out during treatment this is perceived 
as embarrassing.
I must have gone to the toilet about three times because I was 
really nervous, and to make matters worse one lady was before 
me, I could hear her crying out, she let out this really muffled 
scream, and I thought that was that - and I cringed down like this.
Poor lady. It was embarrassing. (Phillipa)
Occasionally one could hear a woman cry out when she was having 
treatment. Such reactions were ignored. These women were stigmatised by 
her reaction, much like someone who is disabled. No one looks for fear they 
will be construed as staring.
The waiting room was not the forum for women to air personal concerns. I 
observed, on a few occasions, women speaking of 'personal' matters loudly. 
For example, one woman spoke loudly to the clinics’ reception staff about 
different sexually transmitted diseases she had contracted. The clinic staff 
tried to quieten her and the women waiting tried to ignore her. When she left 
her behaviour was commented on by the clinic staff and by women waiting, 
at the invitation of the staff. She was dressed shabbily and the staff 
suggested that she had a psychiatric illness. Her behaviour was quite clearly 
outside the code of behaviour that a patient should assume.
Exposing oneself
For their colposcopic examination and treatment women must remove their 
underclothes so that their genitals can be examined by the gynaecologist. 
Women described this process of undressing as 'exposing' oneself. As Gloria 
says:
I was embarrassed [with the examination]...the other day, there's 
still a sort of getting up and exposing yourself. You know I get 
undressed and put a towel around me and get up on that lovely 
couch, it almost looks like a dentist's chair to me. And I get up and 
put a towel around me, you know until the last minute, and its
stupid because I see my patients doing it. [Gloria is a nurse] You 
are just the same as they are.
Removal of her underpants does not just expose her genitals as a part of her 
anatomy, as rolling up a shirt sleeve 'exposes' an arm. It exposes all of Gloria 
to the medical gaze. Embarrassment is a consequence of 'exposure'. A towel 
postpones exposure for a while. This exposure and its consequent 
embarrassment is typical of women who have gynaecological examinations. 
Gloria realises she is just like any other patient.
Exposure embarrasses, stigmatises and reduces one's dignity. Rosemary 
avoided having Pap smears for these reasons.
WHAT HAD BEEN STOPPING YOU HAVE A PAP SMEAR 
BEFORE?
I think it's the stigma attached to it really. ...I was embarrassed, I 
was embarrassed having a baby, so I am very embarrassed about 
things like that...
The chair in the clinic, which many of the women described in vivid terms, 
symbolises the position of woman as a patient.
CAN YOU DESCRIBE WHAT THE LASER TREATMENT WAS 
LIKE?
It was in Dr X's office. And it’s, oh there's this terrible chair and it 
makes you feel so embarrassed. (Rosemary)
The specialist is confronted with the woman's genitalia, with almost no view 
of any other part of the woman's body. The woman, on the other hand, is 
unable to see her own genitalia. She too has only a partial view of herself.
Within the context of a sexual relationship, exposing one's genitals to a man 
was acceptable.
I suppose it's just the way you know. You don't mind being 
exposed to your partner but when it comes to a doctor, someone 
else putting instruments inside you, you know it's a different 
thing. (Penny)
In our culture the 'exposure' of female genitalia to a man is only sanctioned in 
a relationship that is acknowledged as sexual. The gynaecological encounter 
is not a sexual relationship. Exposure of genitalia outside of a sexual 
relationship was undignified.
The thing that gets difficult after a while - you get sick and tired of 
going to sit in a chair with yet another fellow, and it's not the
world's most comfortable or demure position. There aren't many 
female gynaecologists. (Bronwyn)
I don't know, probably because I'm a bit old fashioned, I'm of that 
generation. I haven't been sexually active with anybody except for 
my husband. You feel undignified, exposing yourself to a man, 
and he is sitting down, and you're right up in a chair. I know it's 
nothing, and he sees everybody all day, but you just feel a little bit 
undignified. (Judith)
Many women spoke of a preference for female gynaecologists. A few women 
felt more comfortable with older rather than younger men. Perhaps these 
women felt that female and older male gynaecologists were less likely to 
regard their genitals sexually.
Lorraine claims that her cervix shifts from a sexual organ to a non-sexual 
organ within the gynaecological encounter. In order that she 'trust' her 
gynaecologist she must perceive him to regard her cervix as non-sexual.
I've trusted these people or they haven't revolted me. They're not 
looking at me with dirty eyes or pornographic eyes - they're 
looking at my cervix as a cervix and not as a sexual part. 
(Lorraine)
However, the definition of the genitalia or cervix as non-sexual only has 
meaning in reference to what it is not. A non-sexual organ does not have its 
own essence. As such the medical definition of the genitalia as non-sexual is 
a precarious one.
The shift in meaning of the cervix, as part of the genitalia, from sexual to non- 
sexual was more readily made by women who have had children.
After three or four kids nothing they could do really worries you.
You have that many things shoved up inside you and...you don't 
care any more. (Mary)
I think I block off. I'm just used to it you know - being a woman 
and having given birth twice. I think I block off actually and think 
they're just looking at another part of my body. (Lorraine)
For these women the exposure of genitals outside a sexual relationship was 
not as unusual an event. They were more used to experiencing their cervix 
and genitalia as non-sexual.
Emerson (1970) describes how the medical definition of the female genitalia, 
within a vaginal examination, as non-sexual is sustained by certain 
behaviours and activities such as draping and the detachment of the
gynaecologist. She suggests that other meanings become manifest during the 
gynaecological encounter and that a careful balancing act takes place that 
enables the examination to proceed.
Unlike women patients, gynaecologists (of whom most are men) have the 
immense experience of medical situations where female genitalia are 
regarded as non-sexual.
Sustaining the two separate realities of 'up there' and 'down there'
Procedures such as draping and the angle of the gynaecological chair means 
that women cannot view their own genitalia and the gynaecologist cannot 
view the upper part of women's bodies easily. Women are physically 
separated into two parts — up there' and 'down there'.
In the context of the gynaecological examination two separate realities 
coexisted, referred to here as 'up there' and 'down there'.
Last time I was having laser this nurse/receptionist came in and 
she said "well what have you been doing in your holidays?" Well 
you're sort of up like this, and I went "Oh, I've been to the beach 
lately". And then I felt embarrassed because the gynaecologist had 
an observer in, which I agreed to on the day, but I was a bit pissed 
off about it. I knew I could say no, but I thought no ...so he had 
another gynaecologist with him as an observer. He was talking 
about me and what was wrong with my cervix, and this woman 
was chatting, and I said "excuse me do you mind if I listen to what 
they [the gynaecologist and his observer] are saying", and she just 
went away. I felt in a really odd situation because on the one hand 
I've got these two men talking about me and my genitals and my 
cervix and then I've got this woman at my head asking me what it 
is like at the beach. I thought "I can’t stand this..." I didn't want to 
penalise her because I suppose she was trying to relax me by 
talking about the beach but I had these two men talking about 
what my labia looked like and all this and I actually want to talk to 
them, or at least get in on their conversation, not because I think 
it's more important talking to them but because they were 
discussing me and my body and up the other end ...I just felt 
completely again, that complete disassociation. (Brenda)
The nurse 'chats' to Brenda and the doctors talk about her pelvis. Brenda 
experiences herself as separated into two parts. Brenda wants to be part of 
the 'down there' conversation. Instead the nurse distracts her from 'down 
there'. The two separate realities of 'up there' and 'down there' facilitate the 
split between body and mind and contribute to women's experience of their 
pelvis as an object of the medical gaze.
Unlike Brenda most women found this separation comforting.
HOW DID THE NURSE MAKE YOU FEEL BETTER?
She'd keep your mind on other things. She talks about your baby 
and work and school or whatever it was. She talked to you about 
anything. Plus you wouldn't try and think about what was going 
on and when it hurt she'd talk about something else and you'd get 
your mind off it. Trying to keep you away from it and it felt much 
better because you weren't just sitting there just with the doctor 
and you feel like he's talking to you and you have to talk back and 
you think gosh you know how embarrassing and he's trying to talk 
to me and I wish he'd leave me alone. (Rosemary)
By talking to the nurse 'up there' Rosemary is removed from the examination 
of her genitals. They are objectified and separate from Rosemary. However, 
she is unable to converse with the doctor. She experiences dissociation. He is 
'down there' and in order to talk to him her genitals must be part of her. 
Rosemary feels a need for sustaining these two separate realities.
Several women reported difficulty talking to doctors while they operated on 
their genitals.
HOW DID YOU FEEL DURING TREATMENT?
Rather strange. You feel stupid sitting there - the way you are 
sitting is not the most elegant - and this gynaecologist is talking to 
you from between your legs, trying to carry out a normal 
conversation. I didn't really feel like being intellectual in that 
position. The nurses were really good, trying to distract you from 
what he was doing. (Anna)
Topics of conversation 'up there' only occasionally referred to 'down there'. 
Almost no conversation was possible between the woman 'up there' and the 
doctor 'down there'.
Both Anna and Rosemary use 'you' rather than T to describe their own 
experience. In contrast, Brenda, who asserted a right to listen, used T. 'You' 
removes the woman from the experience. Not only are the genitals 
objectified and separated from the self, but the experience of the 
gynaecological examination and treatment is also separate from T.
On two occasions the nurses did not chat to the women 'up there'. In these 
circumstances both women experienced themselves as objects of the nurse's 
gaze.
The most embarrassing thing was that the Sister was walking 
around and having a look all the time and you feel really up for
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inspection. I know that she was looking to see that everything was 
in place and that's part of her job - I realise all that - but I'd rather 
not know that she was doing it. (Maeve)
...I felt like asking her what was she looking at. If she'd been 
handing him a glass of water or whatever, I could have coped with 
that, but there she was... I couldn't see any rhyme or reason to 
what she was doing. I guess I felt more comfortable at the GP's: 
there was just him. (Winnie)
The nurse's participation is necessary to create the reality of 'up there'. 
Instead, in Maeve and Winnie's experience, women were merely objects of 
both the nurse's and the doctor's gaze. The nurse's gaze is not considered to 
have a specific medical purpose. An important question might be, what 
purpose did the construction of these two realities serve?
Metaphors of attack
Some women described the gynaecological examination using metaphors of 
attack. On two occasions the examination was spoken of in rape-like terms.
I think about women who have been raped. I sort of think that it 
must be the same as the way they feel. Only [they feel] one 
hundred times worse. You know, being vulnerable like that. 
(Penny)
Women were exposed, unsafe and liable to attack. When a woman is having 
a colposcopy she is unclothed with her feet in stirrups and is no longer able 
to defend herself against attack.
My gynaecologist in Melbourne said it was like a big microscope 
— they have a really good look inside and I thought, yes that's OK, 
but not knowing what to expect. It was more unpleasant than 
some of the examinations that I have had before but it was just 
again, it is the unknown and you are not sure what is happening. I 
mean it is never pleasant sitting anywhere with your legs in 
stirrups. That on its own is very daunting because you feel so 
vulnerable. (Louise)
The examination and treatment were described in terms such as violation and 
invasion.
HOW DID YOU FEEL WHILE YOU WERE HAVING 
TREATMENT?
It's not a comfortable position to be in. It never is, to be up in 
stirrups. It's quite an invasive thing to have done. (Jenny)
He was really good but I just felt really violated. There was this 
burning sensation that I could feel, and I was bleeding and they
were dabbing away, and you feel really open. It felt like - well I 
was pretty slack anyway after four children, but I felt like Grand 
Central Station. (Phillipa)
Ruth considers the experience in terms of a foreign attack and feels 
uncomfortable within a sexual encounter following the gynaecological 
encounter.
...any sort of foreplay or anything I just wasn't interested. I think 
it was for both of us really. It was just feeling that something alien 
had gone inside and done this treatment, it is just off-putting. 
(Ruth)
As for cancer, the women used military metaphors to describe their 
experience of the gynaecological examination. However, unlike cancer, 
women could not battle or fight the invasion of a gynaecological 
examination.
Other effects of examination and treatment
Some women described feeling pain or discomfort during and after 
colposcopic examination or treatment. Many experienced bleeding or 
discharge following treatment.
Pain and discomfort
A few women experienced pain with the biopsy, local anaesthetic or laser
treatment. Jenny experienced pain both during and after her laser treatment.
[speaking of the pain of laser treatment] it’s an insidious type of 
pain, it's something that builds, you could say, it's a sharp searing 
pain. It suddenly becomes uncomfortable and it becomes more 
and more uncomfortable but it's the whole area and it became 
unbearable. I can't say it was truly sharp pain, it was just 
unbearable. It was like someone was putting pressure for a 
continuous amount of time...
I think the first eight hours the only place I could sit was in a bath 
of hot water with my legs hanging over the side. That was the 
only position I was comfortable in. When I saw Dr X he said I 
should have phoned him, he would have given me something 
stronger, but I didn't, I thought it would pass. I was not prepared 
for it because I did not expect it to be painful. I expected it to be 
uncomfortable because I was told I could not go to work the next 
day. (Jenny)
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A few women experienced discomfort following treatment or biopsy. They 
described feeling 'sensitive' rather than experiencing pain. Ruth describes 
her experience following colposcopy and biopsy.
I was glad it was in the doctor's surgery and not in the hospital. It 
was a lot more relaxing because the room is more pleasant. ...I 
remember getting into the car afterwards and feeling very, very 
sore and tender. But, in fact, I wasn't really sore, it was just my 
whole body had got into a high pitch, hypersensitive.
Ruth raises another interesting issue — the importance of the physical 
surroundings. She compares the doctor's surgery to the hospital. It is 
possible that if her examination and treatment had occurred in the hospital 
rather than the gynaecologist's rooms she would have experienced greater 
discomfort. Following treatment Ruth did not experience pain either.
I didn't have any pain then either. I had discomfort for a couple of 
hours but not really sore. He said to me "you might have a lot of 
pain or a lot of discharge, come back". I was waiting for that, I 
thought I was going to get that, ...I was slightly tense waiting for 
this real soreness, but it did not happen, I got through it fairly 
easily.
Ruth was expecting pain. What she experienced did not compare with what 
she expected. Several women described how they had been told to expect 
pain and discomfort and their experience of pain was much less of a problem 
than they had anticipated. Others, like Jenny, were not expecting pain or 
discomfort following treatment, and when they did experience it, they were 
concerned that there was something wrong. In contrast, Judith, who 
described her pain as 'slight' understood her pain to be a consequence of 
cutting.
Well, I realised that the laser treatment was like an operation and 
they had cut something off. I just thought it was from that because 
if you cut yourself you get pain. (Judith)
Knowledge that one might feel pain and having a way of making sense of the 
pain seemed to modify how an individual experienced pain. (It is possible 
that the women who did not experience much pain remembered their 
doctor's descriptions of the pain they might experience, because it was not 
consistent with their experience.)
Several women complained of the smell of burning.
The smell was vile. It was very uncomfortable. You could feel the 
burn - you know like a steam burn if you put your arm over a 
kettle, it bums, that's what it felt like, only inside your body where
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it wasn't deadened. The needle is gross enough and it hurt like 
hell. I felt really faint and I thought, oh no, I'm going to throw up. 
(Phillipa)
As a consequence of the pain and smell, a couple of women felt that they 
would prefer a general anaesthetic.
The women's experiences of pain, before and after treatment, varied. It is 
possible that the cervix was not always adequately anaesthetised. However, 
other factors are likely to have shaped the women's experience of their pain 
and discomfort. For example, information about the possibility that they 
might experience pain or discomfort and an explanation for what this could 
signify, would provide women with a conceptual framework for 
understanding their experience. Most women who experienced pain or 
discomfort were afraid they were suffering a complication of treatment.
Bleeding and discharge
Most women experienced some bleeding or discharge following treatment 
and for many women it was quite heavy. Several women attended GPs, the 
emergency department or their gynaecologists because of bleeding or 
discharge.
Two factors appeared to be important in the women's interpretation of the 
significance of their bleeding and discharge. First, some women, such as 
Maeve, did not expect to have heavy bleeding or discharge. They were 
concerned that their discharge or bleeding signified a problem. They had no 
conceptual framework for understanding the significance of their symptoms. 
Second, the meanings attributed to the bleeding and discharge were drawn 
from past life experiences and cultural understandings. These meanings 
shaped how the women interpreted their bleeding or discharge.
I started bleeding really heavily. I can't remember what they 
thought [she was admitted to hospital] but they did something and 
then it stopped. But I didn't even expect that. It didn't bleed at 
first so I thought I must be different from everybody else. Then it 
did.
HOW DID YOU FEEL WHEN THAT HAPPENED?
I felt pretty sick. I didn't know what was happening. I was really 
frightened. (Rosemary)
Although I had a sheet saying what could happen afterwards, I 
was a bit unprepared for the fluid that came away afterwards. It 
was a bit more than I was expecting from the notes. It lasted
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longer than I thought too. They told me that because I wasn't 
having periods any more, that it was quite likely to be very light - 
but there was quite a bit of fluid. (Maeve)
Maeve did not know when she should consult her gynaecologist. Although 
she had been told to contact him or his receptionist staff should she have 
heavy bleeding or discharge, difficulty arose in interpreting what they meant 
by 'heavy'. Other women expressed similar concerns about translating 
clinical instructions to their experience.
Gloria, a nurse, experienced heavy bleeding following treatment. She had 
difficulty deciding whether she should go to hospital.
[Describing when she began bleeding about ten days after her cone 
biopsy] I went shopping, I went to the hairdresser and I had dark 
jeans on. My car was close so I bolted to the car and came home 
and I had these huge big clots. ...I thought gosh you can't contact 
doctors on weekends. Two or three hours after [she got home] I 
did. Dr X was going away for the weekend, I thought he was 
pretty blase about it... he says "take yourself to hospital". Righteo 
I'm a nurse, at what stage of the problem do I go up to the 
hospital? If I was a nurse visiting someone in this situation I 
would get the GP there and then do something - take the patient to 
hospital... But I thought "righteo when do I go? How long do you 
expect this for?"
Despite knowing how she would respond if she saw someone else with the 
problem, Gloria could not discern whether the bleeding was significant in her 
case. Her interpretation of the significance of the bleeding was shaped by her 
nursing experience.
...at the back of my mind I remembered being a young nurse. I 
can remember the threatened miscarriages coming in and these 
poor girls coming in and they'd bleed and bleed and bleed and 
they were passing these clots. I was a young nurse and you 
wonder if they have any blood left. I associated it with that time. 
(Gloria)
Gloria had seen young women lose a lot of blood from miscarriages. She had 
given them blood transfusions and cared for them. These women's 
experiences were reference points for hers.
Adrienne had an infection following the biopsy.
I had an infection after the biopsy - which apparently is very 
common. I didn't know that. You're told not to have a bath, 
you're not to this that or the other - and I followed all the rules and 
ended up with this infection. You begin to worry that what you 
are doing is not clean. (Adrienne)
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Brenda had a way of interpreting her bleeding following treatment.
The second time I was annoyed because it took me a month or so 
to stop bleeding. In fact I rang Dr X and told him it had gone on 
too long. But, he told me not to worry. I went to see him anyway - 
I almost insisted on having an appointment. I resent people saying 
don't worry because this is the only body I've got to live with and 
if I lose it - everyone will say don't worry. .. .1 don't take no for an 
answer very much any more. ...I was worried about not healing 
and becoming infected because I thought if it's still bleeding it 
hasn't healed. It wasn't heavy - it was just bleeding. (Brenda)
Assurances from her gynaecologist did not change her interpretation that she 
had not healed. After a follow-up colposcopy she was reassured, however.
Those women who expected some bleeding or discharge seemed less 
concerned when they did experience these symptoms. As for pain or 
discomfort, the women needed a way of interpreting their bleeding or 
discharge. Most women did not expect to experience bleeding or discharge. 
When they did, they were concerned that it was symptomatic of a 
complication of their treatment. Some did have complications that required 
further treatment.
It is important that the possible effects of treatments be discussed with each 
woman. As discussed previously, with respect to treatment gynaecologists 
need to work with the women who see them towards a shared understanding 
of the possible effects of treatment. An information sheet for patients with 
advice on what to expect and what steps to take may be useful. However, the 
relevance of each piece of advice should be discussed with each woman, and 
a shared model of notions like heavy bleeding (such as how many pads are 
soaked over a specified period of time ) developed.
Recommendations made by women
The women's recommendations concentrated on information. Adequate 
information was perceived as crucial to women taking part in and making 
informed decisions about their treatment.
I am quite capable of deciding what I need to do as long as you are 
given the information in terms you understand as well. Not like 
reading a medical text. (Anna)
The women wanted more detailed information in a comprehensible format. 
They suggested a variety of forms that this information should take. Firstly, 
the GP or gynaecologist should provide more detailed information within the
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consultation. Women wanted more time with their practitioners, enabling 
the provision of more detailed information and an opportunity to ask 
questions about issues that concern them.
The women also suggested counselling and information services about 
abnormal smears. Again, they raised the key issues of time, detailed 
information and opportunities for asking questions.
Finally, some women wanted access to visual information about their 
abnormality. Several women felt that seeing their cervix at the time of the 
procedure would be useful.
...like when you have an ultrasound done and they've got the TV 
screen and you can actually see it, if they could do the same thing 
when they do a colposcopy you'd feel a lot better because you 
could see what they're talking about and probably understand it a 
lot better. ...they just say that's what it is and you have to take 
their word for it. (Mary)
Many women thought a video or pictures providing information about the 
abnormality and the procedures would be very useful.
I certainly would have liked to have a picture of it [her cervix]. 
Even if it didn't have what was going on, just a photograph would 
have been very, very good. (Valerie)
The final recommendation related to cost. Many women found the cost of 
gynaecological care prohibitive.
Apart from that I would also like to see it on Medicare so that we 
don’t have to pay for it as well. Laser treatment is quite expensive.
It cost hundreds of dollars for one visit. The people who need it 
most simply can't afford it. (Anna)
Gynaecological care is rebated on Medicare. Women pay the difference 
between the Medicare rebate and the specialist fees which is often a 
substantial difference. However, on most visits more than one item number 
was accrued. This can result in sizeable out-of-pocket payment for women. 
This issue is addressed in Chapter Nine.
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Discussion
In this chapter I have shown that health professionals, particularly GPs and 
gynaecologists, shaped this experience for women. The information doctors 
gave, the way they behaved and whether they spent time answering 
questions and listening to each individual woman were of crucial importance 
for women.
The arguments developed in this chapter flow from Chapter Six. I have 
shown that the women responded to information that was congruent with 
their own lives. Women were not passive recipients of medical information, 
rather they used it selectively and actively to make sense of their 
abnormality.
Most women wanted to understand the rationale for various treatments and 
instructions about what they should or should not do after treatment. They 
needed knowledge about possible after-effects and how to interpret them. 
Doctors were important sources of such information. Yet many of the 
women were dissatisfied because they were not given enough information to 
understand their gynaecological care. Just as the doctor should listen to 
women's account of their abnormality, doctors must supply their account. 
Such information is crucial. It enables women to develop a conceptual 
framework for understanding their treatment and its after-effects. This 
information is also important for women who want to be involved in 
decisions about their gynaecological care.
Women used health promotion messages to interpret their cervical 
abnormality. Consequently they frequently assumed that an abnormality 
must be cancer. Health promotion messages must do more than simply 
recruit women into the screening program. Details on how screening 
prevents cervical cancer should also become part of health promotion 
campaigns. That is, health promotional messages should address the 
mechanism of prevention. When health care practitioners perform a Pap 
smear test they could also explain the reasons for the test. With such 
information from both health promotion material and health care 
practitioners women who have an abnormality would be better equipped to 
interpret its significance.
The gynaecological examination requires more attention to individual 
women as well. There is no single formula for doing a sensitive
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gynaecological exam. Rather, each woman has different needs. For example, 
some women did not want a nurse present. Women should be invited to 
decide whether they find the presence of a nurse helpful. Some women 
wanted to see their cervix on a monitor. Provision of such a facility would 
contribute to those women's understanding of their gynaecological care.
The last two chapters have demonstrated the critical importance of the 
professional relationship for women who have cervical abnormalities. I have 
shown that the significance of this abnormality is in large part shaped 
information from health professionals, mainly doctors. For most women, 
their abnormality had a presence beyond the GP surgery or the gynaecology 
clinic. The abnormality signified their ongoing risk of cervical cancer — a 
risk which became integrated into their life story. In the clinic the 
gynaecologist's way of understanding cervical abnormalities was dominant. 
The clinicians approached the women's risk as though it had no salience 
beyond the clinic. It was risk that simply required their intervention, but 
doctors often failed to communicate clearly their approach and treatment. 
Two separative narratives about each woman's abnormality occurred 
concurrently — the women's and their doctor's. These narratives were often 
in conflict and neither person's account was communicated to the other. It is 
crucial that clinicians and women hear each other's accounts of the woman's 
cervical abnormality. Then they can work towards a way of approaching her 
abnormality that is cognisant of both perspectives. Such an approach would 
enable the women to make decisions about their gynaecological care and 
have a better understanding of the treatment and its effects. By listening to 
women's accounts, doctors could be more attentive to each woman's needs 
and life circumstances thus possibly reducing the emotional burden of the 
diagnosis.
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Part C
A clinic’s accounts
Chapter Eight
Method and sample characteristics
By describing the methods of data collection and the characteristics of the 
sample used for Part C of the thesis, this chapter sets the scene for the 
following two chapters, which examine the financial costs of the 
gynaecological follow-up of women who have abnormal Pap smears and the 
socio-demographic and clinical predictors of non-attendance.
This chapter consists of five parts: the methods of data collection; a 
description of the colposcopy clinic sample used for the study; a discussion of 
the concordance between cytology, colposcopy and histology; comparisons 
between the clinic sample and ACT and Australian Medicare samples to 
assess the generality of the findings of this study; and, a description of how I 
derived the cost estimates.
Background
In Australia, general practitioners usually refer women who have abnormal 
Pap smears to a gynaecologist. A woman is seen first as an outpatient. The 
gynaecologist then recommends assessment or treatment of a woman with an 
abnormal Pap smear as an outpatient or inpatient. In an outpatient service it 
is possible to follow each patient's gynaecological care, from the first 
outpatient visit through all further outpatient and inpatient services. For this, 
and for other reasons outlined below, the current study was located in an 
outpatient gynaecological service.
At the time this study was carried out, it was impossible to obtain an ACT 
population-based sample of women with abnormal Pap smears as there was 
no centralised system for following women with abnormalities. This was 
another reason for carrying out the study in an outpatient service.
A clinic sample has the advantage that the status of each woman's follow-up 
is known, providing answers to questions such as: did women complete 
treatment or not attend? did women move? and so on. Adjustments for the
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Status of follow-up can then be made in the cost analysis. It must be stated, 
however, that the treatment practices of one clinic sample are likely to differ 
from some colposcopy services elsewhere. For example, public hospital 
clinics are funded through the states and services are not rebated through 
Medicare and therefore may have different treatment practices and costs 
from outpatient services located in the private sector. However, there are no 
public clinics for colposcopy in Canberra.
A case note audit of an ACT private outpatient colposcopy service was used 
to estimate the financial costs to government and to women clients, of the 
gynaecological assessment and treatment of abnormal Pap smears. The 
financial cost estimates for different levels of presenting smear are compared, 
and the relative contributions to total cost of treatment of women who have 
different levels of abnormality are estimated.
Methodology
Sixteen gynaecologists practise in the ACT, only six of whom provide a 
regular colposcopy and laser service. The remaining gynaecologists only 
occasionally see women who have abnormal Pap smears. Four 
gynaecologists in the ACT work from the Canberra Laser Clinic (CLC), a 
private clinic dedicated to the treatment of women who have abnormal Pap 
smears. A CO2 laser on the premises is the main method of treatment. The 
CLC was negotiated as the site of this study because most of the 
gynaecologists who perform colposcopy and laser treatment in the ACT 
practice from this clinic. They have a consistent method of record keeping 
and data collection.
The study was approved by the Australian University Ethics Committee. I 
recorded the data from the case notes.
Sam ple selection
I conducted a case note audit of the records of all women presenting to the 
CLC for their first consultation with abnormal cervical cytology (but no 
evidence of invasion) between 1 January 1989 and 30 April 1990. Women 
were only included in this sample if the abnormal Pap smear was the 
principal reason for their referral, as indicated in the doctor's letter. In order 
to follow the entire management of each woman's abnormal smear, only 
women who had never, as far as I could ascertain, had a previous
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consultation with a gynaecologist for an abnormal Pap smear were included. 
A relatively wide case definition of abnormal Pap smears was used because 
the aim of the study was to describe current clinical practices as they relate to 
the range of abnormalities seen.
Data collection
I entered the data into a computer software program designed specifically for 
this research. Three sources of data were used to compile this audit: a case 
record completed by the gynaecologist at the initial consultation, case notes, 
and account details recorded on the clinic's computer-based accounting 
system. The clinic has a case record designed so that each gynaecologist asks 
each woman attending the clinic about their previous abnormalities, Pap 
smear frequency, marital status, parity, present contraceptive use, and 
private health insurance status1.
The following information was recorded: case number, date of birth, previous 
Pap smear history and frequency, marital status, parity, private health 
insurance status, date of referral, source of referral, date and category of 
presenting smear, details of all tests, treatments and items associated with 
each clinic visit, and details of all hospital inpatient tests and treatments. 
Medicare item numbers were recorded from each visit and were then used to 
cost women's gynaecological treatment. Personal identifiers were recorded 
for those women whose test results were incomplete so that I could follow 
the results up with the laboratory. The data file did not have any personal 
indentifiers. The clinic coded information such as marital status, previous 
Pap smear history and frequency of Pap smears on a standard form. I used 
their coding system to code these variables.
Information on each woman's clinic visits and inpatient treatment was 
recorded until 16 August 1991 when the accounting data were down-loaded 
onto my computing system for this project. Thus, women who were first 
seen on January 1 1989 and 30 April 1990 had their notes audited for two 
years and seven and a half months and one year and three and a half months, 
respectively.
1 Private health insurance status describes whether or not women have private health 
insurance. In Australia, there are different levels of private health insurance cover. There 
were no details in the notes on the level of cover women had.
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Coding categories for cytology and histology were as follows: 
normal, 
inconclusive, 
inflammatory, 
mild atypia,
HPV;
atypia + HPV;
CIN 1;
CIN 1 + HPV;
CIN 1-2 only;
CIN 1-2 + HPV;
CIN 2 only;
CIN 2 + HPV;
CIN 2-3 only;
CIN 2-3 + HPV;
CIN 3 only;
CIN 3 + HPV; 
microinvasive cancer; 
invasive cancer; 
other; and, 
not recorded.
The results of colposcopy, further cytology and histology were obtained from 
the notes and pathology reports. When more than one abnormality was 
present, the highest grade of abnormality was recorded. If the report 
indicated possible evidence of abnormality, the result was coded as if the 
abnormality were confirmed (eg possible CEN 1 is coded as CIN 1).
I coded the level of the women's presenting cytology (reason for referral) 
from the GP referral letters and the Pap smear reports accompanying the 
letters. Where possible, each woman’s presenting smear result was confirmed 
with the laboratory to which it was sent. Only one woman in this sample 
was referred with 'an abnormal smear', the level of which was impossible to
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discern from the letter or notes. Nor was it possible to trace her smear 
through the laboratories.
Description of sample (n=502)
In the following section I describe the socio-demographic and clinical 
characteristics of this sample. Because the clinical records were not always 
complete, most of the variables have up to ten per cent missing values. The 
percentages for each category of a variable were calculated using the number 
in the sample for which the category of the variable was known.
Socio-demographic characteristics
Table 8.1 shows the socio-demographic characteristics of the CLC sample. 
Approximately 70 per cent of women in this sample were under 35 years of 
age.
Table 8.1 Socio-demographic characteristics of CLC sample
V a ria b le No. o f w o m e n P e rce n t (% )
Age (n=502)
< 2 5 173 3 4 .5
25  to  3 4 182 3 6 .3
> 3 5 147 2 9 .3
Health insurance status (n=446)
N o p riv a te  hea lth  in su ra n ce 2 13 4 7 .8
P riva te  he a lth  in su ra n ce 233 5 2 .2
M arital status (n=453)
M a rrie d  o r de fa c to 3 3 0 7 2 .8
D ivo rce d , se p a ra te d  o r w id o w e d 25 5 .5
S ing le 98 2 1 .6
Parity (n=476)
N u llip a ro u s 2 3 4 4 9 .2
P a rous 242 5 0 .8
Age was strongly associated with marital, parity and health insurance status. 
Compared with women over 35 years of age, women under 35 were less 
likely to have children (x2 = 146.7, df=2, p=0.00001); be married or defacto, or 
divorced, widowed or separated (x2 = 68.3, df =4, p<0.00001); or have private 
health insurance (x2 = 28.0, df=2, p<0.0001). Only 16 per cent of women
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under age 25 had children, while 85 per cent of women who were 35 and 
over had children. Sixty per cent of women under 25 were married or 
defacto whereas 82 per cent of women over 35 were married or defacto. Most 
women over 35 years of age had private health insurance (69 per cent) while 
this was true of only 38 per cent of women under 25. The high proportion of 
women in this sample in younger age groups may explain the relatively 
small proportion of women who are divorced, separated or widowed, and 
the finding that nearly 50 per cent of women in this sample did not have any 
children.
Self-reported Pap smear history and frequency
Table 8.2 shows the distribution of the sample with regard to self-reported 
Pap smear history and frequency. Most women (76 per cent) reported having 
Pap smears at least biennially and so are at relatively low risk of cervical 
cancer. However, in previous studies of self-reported Pap smear history, 
women were found to over report the frequency of their smears (Bowman, 
Redman et al. 1991). Although this sample did not include women who had 
previously seen a gynaecologist for an abnormal Pap smear, 38 per cent of 
women reported having had a previous abnormality (Table 8.2). That is, 38 
per cent of the sample had had a prior Pap smear abnormality that had not 
resulted in their referral to a gynaecologist for further assessment. Of the 
women who had had a previous abnormality, 90 per cent (158 women) 
reported having CIN 1 or less. Only three women reported having previous 
abnormalities of CIN 2 or 3, and 14 women (eight per cent) did not know the 
grade of their previous abnormality.
Table 8.2 Self-reported Pap smear history and frequency
V ariab le No. of w o m e n P e rc e n t  (% )
Self-reported previous Pap sm ear history  
(n=464)
N orm al o r n o  p re v io u s  s m e a r s 2 8 9 6 2 .3
A bnorm al 175 3 7 .7
Self-reported Pap sm ear frequency (n=448)
At le a s t  b ien n ia l 3 4 2 7 6 .3
L e s s  o ften  th a n  b ien n ia l 106 2 3 .7
Cytology, colposcopy and histology
Below I outline the frequency of categories of presenting smear and the 
distribution of the results of colposcopy and histology obtained on the 
women's first visit (initial colposcopy and initial histology). The concordance 
between cytology, colposcopy and histology in this sample is detailed later in 
the chapter.
Table 8.3 Frequency of presenting smear, initial cytology and initial histology
Variable No. of wom en Percent (%)
Presenting sm ear (n=501)
Inflam m atory, atypia or HPV 227 45.3
Inconclusive 3 0.6
CIN 1 +/- HPV 73 14.6
CIN 2 +/- HPV 142 28.3
CIN 3 +/- HPV 56 11.2
Initial co lposcopy (n=497)*
Normal or inflam m atory 98 19.7
A typia & /or HPV 82 16.5
CIN 1 +/- HPV 161 32.4
CIN 2 +/- HPV 113 22.7
CIN 3 +/- HPV 39 7.8
M icroinvasive 1 0.2
O ther colposcopic changes 3 0.6
Initial histology (n=498)
Not perform ed 70 14.1
Normal or inflam m atory 40 8.0
Inconclusive 3 0.6
Atypia 8Jor HPV 68 13.6
CIN 1 +/- HPV 138 27.7
CIN 2 +/- HPV 99 19.9
CIN 3 +/- HPV 76 15.3
M icroinvasive cancer 1 0.2
Invasive cancer 1 0.2
Other 2 0.4
Many women in this study had only minor (CIN 1 or less) abnormalities. 
Approximately 46 per cent had smears that did not demonstrate CIN (ie they 
showed atypia, HPV, inflammation, or were inconclusive). Thirty-eight per
172
cent of initial colposcopies did not demonstrate any evidence of CIN whereas 
only 26 per cent of women who had biopsies did not have evidence of CIN 
on biopsy. However, of the 70 women who did not have biopsies taken at 
the first visit, 65 had colposcopies that were normal or had no changes of CIN 
(inflammation, atypia or HPV). Two women who did not have biopsies were 
pregnant at their first visit and although the colposcopy demonstrated CIN 2 
in both cases, follow-up biopsies after pregnancy showed HPV only.
Three women had evidence of microinvasion or invasion on histology. All of 
these women had CIN 3 on presenting smear.
Follow-up status and days in study
When the audit of each woman's notes was complete her follow-up status 
was classified into one of the five following categories:
1. discharged during the study period
2. still attending (on 16 August 1991)
3. moved or changed gynaecologist (five women were referred to Sydney for 
further assessment and treatment)
4. did not attend in the time specified by the gynaecologist
5. unknown.
For the last category, I could not discern from the case notes whether the 
women were discharged, had moved, or did not attend. Women were 
classified as not attending if they did not attend in the time period specified 
by the gynaecologist (eg six months) provided the specified period elapsed 
before 16 August 1991. The women whose next appointment was due after 
this date were classified as still attending, since there was no further clinical 
information after that date. This decision may have overstated the number 
still attending. The time period during which I recorded data is the number 
of days between each woman's first visit and her last clinic visit. I have called 
this 'days in study'. (Women attending only once are recorded as having one 
day in the study.)
Follow-up status is important both for the cost analysis and analysis of non- 
attendance presented in the following two chapters. Only women in the 
discharged group completed treatment. Women in the non-attending group
do not incur any further costs for this episode. Therefore, only women in the 
discharged and did not attend groups can be used to calculate the cost of this 
episode of treatment. In the case of the analysis of the predictors of non- 
attendance, women in any other follow-up status category, other than the did 
not attend group, were no longer at risk of non-attendance after their last 
clinic visit. The details of how the the follow-up status codes were used in 
the different analyses of cost and non-attendance are detailed in the relevant 
chapters. They are mentioned here to draw attention to the significance of 
the variable 'follow-up status'.
Table 8.4 shows the various follow-up status groups and the distributions of 
their length of time in the study.
Table 8.4 Follow-up status and days in study (n=502)
Follow-up sta tu s No. of w om en F requency  (%) M edian (d ays  
in study)
25th  percentile , 
75th  p ercentile  
(d a y s  in study)
D isch arged 2 7 3 5 4 .4 2 9 7 1 4 1 ,4 4 2
Still attending 51 10 .2 4 5 3 3 6 9 , 5 8 0
M oved or c h a n g ed
g y n a e c o lo g is ts 3 4 6 .8 99 13, 17 3
Did not attend 102 2 0 .3 125 4 1 ,2 2 9
U nknow n 4 2 8 .4 3 0 7 123, 4 1 4
The length of time in the study varied with the women's follow-up status 
(Medians test, x2=97, df=4, p<0.0001, Table 8.4). The women still attending 
or who had an unknown follow-up status were in the study for the longest 
periods of time. Those who did not attend or who moved or changed 
gynaecologist had the fewest days in the study.
The level of the women's presenting smear did not vary significantly between 
the follow-up status groups (x2=5.7, df=4, p=0.22). Similarly, the women's 
initial histology did not vary significantly between the groups (x2=4.6, df=4, 
p=0.33).
Twenty per cent of the women in this sample did not attend a clinic 
appointment recommended by their gynaecologist. Inadequate follow-up 
may place women at greater risk of cervical cancer. In Chapter Ten I explore 
which factors are associated with women's non-attendance.
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Concordance between cytology, colposcopy and histology
1 assessed the relationship between the three assessment modalities — 
cytology, colposcopy and histology — by computing the degree of 
agreement between each of these measures and the predictive value of 
cytology and colposcopy. When a woman is referred she has her cytology 
result. In most cases at the initial visit a colposcopy is performed. Target 
punch biopsies are taken from the abnormal staining areas of the cervix, seen 
by the colposcopist, and then examined microscopically to yield a histological 
diagnosis.
The negative predictive value is the likelihood that an individual with a 
negative screening test does not have disease and the positive predictive 
value is the likelihood that an individual with a positive screening test does 
have the disease. For the purposes of the following analysis, disease was 
defined as CIN 2 or 3. CIN 1 or less was considered to be a negative result.
The histological diagnosis was taken to be the gold standard for defining the 
presence or absence of disease. I therefore computed the negative predictive 
value of Pap smears and colposcopy demonstrating CEM 1 or less and the 
positive predictive value of Pap smears and colposcopies demonstrating CIN
2 or 3.
To assess the relationship between cytology and colposcopy I define 
colposcopy as the gold standard. In this situation the negative predictive 
value of Pap smears demonstrating CIN 1 or less, and the positive predictive 
value of Pap smears demonstrating CIN 2 or 3 were calculated.
For the following analysis I have combined all presenting smears that were 
normal, inflammatory, inconclusive, atypia and HPV to form one category 
called 'No CIN'.
To measure the degree of agreement between the three investigative 
modalities (cytology, colposcopy and histology) I have used a weighted 
kappa. The weighted kappa takes into account the amount of disagreement 
between the different tests, whereas an ordinary kappa only measures the 
degree of perfect agreement between the different measures and hence is 
more suited to the analysis of nominal rather than ordinal variables. (Altman 
1991).
The results from this analysis should be viewed with caution. Many women 
in this sample reported having had previous smears demonstrating an
abnormality; women who have had two smears demonstrating minor 
abnormalities are more likely to have major abnormalities than those who 
have never previously had an abnormality. In this study pathologists or 
gynaecologists were aware of the results of other tests. Therefore the 
correlation between the different assessment modalities is likely to be biased. 
There are also problems with defining any test as the gold standard. 
Colposcopy may give a false negative report if the lesion is located high in 
the endocervical canal. And, histology may be falsely negative if target 
punch biopsies miss the affected area.
Presenting smear and colposcopy (Table 8.5)
Table 8.5 demonstrates the relationship between presenting smear and initial 
colposcopy.
Table 8.5 Concordance between cytology and colposcopy (n=492)
Initial colposcopy
No CIN CIN 1 CIN 2 CIN 3
Presenting
smear No CIN 126 75 27 1 229
number 
% of row 55% 32.8% 11.8% 0.4% 100%
CIN 1 16 37 15 3 71
22.5% 52.1% 21.1% 4.2% 100%
CIN 2 32 43 58 6 139
23.0% 30.9% 41.7% 4.3% 100%
CIN 3 6 5 13 29 53
11.3% 9.4% 24.5% 54.7% 100%
For the purposes of this analysis disease is defined as CIN 2 or 3 on 
colposcopy.
The negative predictive value of cytology showing no CIN and CIN 1 was 88 
per cent and 75 per cent respectively. Excluding women who had had 
previous abnormalities, the negative predictive value of smears showing no 
CIN increases to 94 per cent. Excluding women who report previous 
abnormalities does not increase the negative predictive value of smears 
showing CIN 1.
Of the 109 women who had no history of prior abnormalities, and without 
CIN on Pap smear, none had CIN 3 on colposcopy. One woman out of 43
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women with CIN 1 on Pap smear and no previous abnormalities, had 
evidence of CIN 3 on colposcopy.
The positive predictive value of smears showing CIN 2 and CIN 3 was 46 per 
cent and 79 per cent respectively.
Women with CIN 1 or less on presenting smear comprised 61 per cent of the 
total sample. They constitute 30 per cent of those who had CIN 2 or 3 on 
colposcopy, and ten per cent of those who had CIN 3 on colposcopy.
The weighted kappa for colposcopy and presenting cytology was 0.41. This 
represents only moderate agreement between the two measures. (Altman 
1991).
Presenting smear and histology (Table 8.6)
Disease is defined as CIN 2 or 3 on histology. If no biopsy was performed the 
initial colposcopy result was used.
The negative predictive values for smears with no CIN and CIN 1 were 83 
per cent and 63 per cent respectively.
Table 8.6 Concordance between histology and cytology (n=490)
Initial histology
No CIN CIN 1 CIN 2 CIN 3
Presenting
smear No CIN 122 66 32 7 227
number (% 
of row) 53.7% 29.1% 14.1% 3.1% 100%
CIN 1 19 26 16 11 72
26.4% 36.1% 22.2% 15.3% 100%
CIN 2 28 40 47 24 139
20.1% 28.8% 33.8% 17.3% 100%
CIN 3 6 7 5 34 52
11.5% 13.5% 9.6% 65.4% 100%
The positive predictive value of smears showing CIN 2 was only 51 per cent. 
In contrast the positive predictive value of smears showing CIN 3 was 75 per
The weighted kappa for the relationship between presenting smear and 
histology was only 0.37 which is rated as only fair agreement.
Initial colposcopy and initial histology (Table 8.7)
To calculate the predictive values for this comparison, disease was defined as 
CIN 2 or 3 on histology.
Table 8.7 Concordance between histology and colposcopy (n=420)
Initial histology
No CIN CIN 1 CIN 2 CIN 3
Initial
colposcopy No CIN 53 36 16 8 113
number (% 
of row) 46.9% 31.9% 14.2% 7.1% 100%
CIN 1 41 65 40 13 159
25.8% 40.9% 25.2% 8.2% 100%
CIN 2 13 34 38 26 111
11.7% 30.6% 34.2% 23.4% 100%
CIN 3 3 2 4 28 37
8.1% 5.4% 10.8% 75.7% 100%
Seventy-nine per cent and 67 per cent were the negative predictive values of 
colposcopies with No CIN and CIN 1 respectively. Again, if those women 
with no CIN on colposcopy had had biopsies the above results may have 
increased. CIN 2 had a positive predictive value of 58 per cent and CIN 3 
had a predictive value of 86 per cent.
The weighted kappa between colposcopy and histology was 0.35 which is 
classified as fair agreement. The concordance between colposcopy and 
histology may have improved if those women with normal colposcopies had 
had biopsies.
Conclusion
In Chapter Two I discussed published studies on the reliability of cytology, 
colposcopy and histology. I established that the intra- and inter-test 
reliability of these tests is low. I have now shown that in this sample the 
inter-test reliability is also low.
Despite clinicians having the benefit of the results of other tests the 
agreement between the three tests was poor. This may be due, in part, to the 
lack of consistent reporting criteria for the different laboratories. The 
introduction of a consistent set of guidelines for reporting cervical 
abnormalities may improve the agreement between the assessment
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modalities (Commonwealth Department of Human Services and Health 
1994).
A significant proportion of women with CIN 1 or less on presenting Pap 
smears were found to have CIN 2 or 3 on colposcopy and histology because 
of the poor agreement between the tests and the high prevalence of disease in 
this study population. Because many of the women had had previous 
abnormalities the prevalence of major abnormalities in this sample may be 
higher than women with CIN 1 or less in the population. However, there 
were no cases of invasive cancer or microinvasive cancer in women who had 
Pap smears with CIN 2 or less.
The poor inter-test reliability has implications for women who have 
abnormal Pap smears, as well as for clinicians and public health practitioners. 
During my time collecting data, the gynaecologists working at the CLC 
frequently told me of women presenting with Pap smears showing only 
minor changes, but who on colposcopy or biopsy were found to have high- 
grade lesions. The gynaecologists were concerned that if they did not 
investigate all women with minor lesions, then some women with high grade 
lesions would not be treated and might develop cervical cancer. They 
accepted a low criterion of positivity in order to detect all women with high 
grade lesions.
The results reported in this section show that there is some basis for their 
concerns. However, to investigate every woman who has minor changes of 
CIN 1 or less would result in many orders of magnitude more women having 
colposcopy, biopsy and treatment than would ever develop cervical cancer. 
Although the program sensitivity may be high its specificity would be low. 
Such a situation concerns the public health practitioner.
For individual women, knowledge of the positive or negative predictive 
value may be a useful guide in making decisions about their own 
gynaecological care. If they had a minor grade lesion the negative predictive 
value tells them how likely they are to have a major lesion on histology or 
colposcopy. Based on this knowledge they could make a decision about 
whether or not to have a colposcopy.
These results cannot be considered representative of women who have CIN 1 
or less on Pap smear in the general population; rather, they represent the 
experience of one colposcopy service. Further studies are needed to explore 
the relationship between cytology, colposcopy and histology in the clinical
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setting. An ACT centralised cytology service that collects details of the 
gynaecological assessment of women who have abnormal Pap smears is 
ideally suited to explore this further.
Assessing the generalisability of the findings
In order to assess the relevance of the findings of this study to other clinical 
situations the age distributions and assessment and treatment practices of the 
CLC sample are compared with ACT and Australian Medicare samples.
ACT and Australian Medicare samples (Table 8.8)
The Medicare Estimates and Statistics Section of the Commonwealth 
Department of Human Services and Health (DHSH) extracted two samples of 
women who claimed on Medicare for a colposcopy2 over the period 1 
January 1989 to 30 April 1990 (the same time period for which women were 
eligible for the CLC study) who had not claimed for colposcopy in the 
previous two years. One sample was of women with an ACT postcode, the 
other was of all Australian women. The two-year criterion was used so that 
only women commencing treatment were included in the samples. However, 
it is likely that the Medicare samples include some women who had had a 
cervical abnormality more than two years previously. In contrast, my sample 
only includes women who, as far as I can ascertain, have never previously 
been referred to a gynaecologist for the assessment and treatment of a 
cervical abnormality.
To convert the sample numbers to a population estimate, the number of 
women in the Medicare samples was multiplied by ten. Table 8.8 shows the 
total estimated number of women in the ACT and Australia billed for 
colposcopy during the time period of the study, who had not claimed in the 
two previous years.
2 1 used the item number 35614 (formerly 6415) which is defined as: "examination of the 
lower female genital tract by a Hinselmann-type colposcope" (pl79, Medicare Benefits 
Schedule Book, AGPS, Canberra, 1993). Benefits for this item are limited to the following 
circumstances: "(1) where a patient has had an abnormal cervical smear; (2) where there is a 
history of maternal ingestion of oestrogen by the patient's mother during her pregnancy; or 
(3) where the patient has been referred by another medical practitioner because of suspicious 
signs of genital cancer.
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Table 8.8 Total Number ('000) of Medicare patients claiming for colposcopy (item
35614)
Estimated number* Standard error** 95% Confidence 
Interval
ACT 1.88 0.12 1 .64-2 .12
Australia 64.8 0.71 63.4 - 66.2
* The estimates of the population totals were obtained by multiplying the number of women in each 
sample by ten as the Medicare samples were obtained from the ten percent sample of Medicare 
enrollees.
** See Appendix A for details of how the standard errors were calculated.
Sampling fraction
The sample of 502 women included in this study make up 27 per cent of the 
estimated total number of women claiming for the first time during the study 
period. The total estimated number of ACT women billed for colposcopy 
during the study period was used as a denominator for this calculation 
(Table 8.8). The estimate of 27 per cent is a lot lower than expected because, 
as stated earlier, only six gynaecologists regularly practise colposcopy and 
laser in Canberra and only four of these work from the CLC. However, the 
ACT estimate is likely to be a biased estimate of the population from which 
the CLC sample was derived, for the following reasons:
1. The ACT sample includes women who claimed for colposcopy more than 
two years earlier, and therefore may have had a previous abnormality, 
whereas the clinic sample excludes women who have previously been 
investigated for an abnormal Pap smear by a gynaecologist;
2. The ACT sample includes women who claim for colposcopy because of 
another genital tract abnormality (for example, vulval warts), whereas the 
CLC sample only includes women who have been referred with an 
abnormal Pap smear;
3. The ACT sample only covers women who have a colposcopy and who are 
resident in the ACT, whereas the CLC sample includes women from 
outside Canberra. (As the postcode of women in the sample was not 
collected I do not know the proportion of women who attended the CLC 
from outside the ACT.) There is no way of estimating the population of 
women who would come to the ACT for treatment if they had an 
abnormal Pap smear. Some ACT women seek investigation interstate and 
some women from interstate seek investigation in the ACT.
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Reasons 1 and 2 are likely to result in an overestimation of the true 
denominator and therefore reduce the estimate of the proportion of the total 
population represented by the CLC sample. The inclusion of ACT women 
who seek investigation interstate in the denominator of the sampling fraction, 
underestimates the proportion the CLC sample represents of women having 
colposcopy in the ACT. Interstate women seeking investigation in the ACT 
are not included in the ACT total estimate, resulting in an overestimate of the 
proportion represented by the CLC sample. Nonetheless it is evident that 
this clinic sees a reasonably large proportion of women who are referred for 
the investigation of an abnormal Pap smear in the ACT.
Age distribution (Figure 8.1)
Figure 8.1 Age distribution of CLC and Medicare samples
■  CLC (n=502)
□  ACT (n= 188)
□  Aust (n = 6483)
45-5425-34 35-44
S. Age group
The CLC sample was slightly younger than the ACT and Australian 
Medicare samples. Thirty-four per cent of the women in the clinic sample 
were under 25 years of age, while in both the ACT and Australian Medicare 
samples only 26 per cent were under 25. The CLC sample had a smaller 
proportion of women in the age group 45 to 54 and over 55 than both the 
ACT and Australian populations. The ACT has a greater proportion of 
people in the younger age groups than elsewhere in Australia, which might 
explain the age differences between the CLC and the Australian Medicare
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samples. The age differences between the clinic and ACT sample are less 
easily explained. However, the age differences are modest and are unlikely 
to produce large biases in the cost estimates.
Distribution of abnormalities
It has not been possible to compare the distribution of cytological 
abnormalities seen at this clinic with an ACT sample because there was no 
cervical cytology register operating in the ACT at the time of the study.
There are no published Australian data on the distribution and frequency of 
women with different abnormalities referred for gynaecological assessment. 
Because there is a larger proportion of younger women in the CLC sample, 
and younger women have a higher prevalence of minor abnormalities, it is 
likely that the CLC sample has a higher proportion of women with minor 
abnormalities than the Medicare samples.
Assessment and treatment practices
It is not possible to compare the assessment and treatment practices of this 
clinic with other services without conducting a case note audit on other 
services. There has been no published research in Australia examining 
gynaecological practice in relation to abnormal Pap smears. I have therefore 
again relied on the Medicare data to make my comparisons, despite several 
limitations. Although the Medicare file contains individual rather than 
aggregate data, I did not have direct access to Medicare data and it was 
impossible for me therefore to trace the experience of individual women or to 
know the follow-up status of women in the Medicare samples. Instead, the 
Health Insurance Commission provided me with aggregate totals. Many of 
the differences in assessment and treatment practices may be explained by 
differences in the prevalence of women with minor abnormalities and major 
abnormalities at the different services. Medicare data do not contain 
information about diagnosis.
Comparisons have been limited to claims for colposcopy, biopsy and laser 
treatment since other treatment methods such as diathermy, cone biopsy and 
hysterectomy require that women be admitted as inpatients to hospital.
Large loop excision of the transformation zone (LLETZ) can also be 
performed as an outpatient procedure. Its use was infrequent in Australia 
until after 1992 (after this study was conducted). Inpatient services are only 
rebated on Medicare if a woman is admitted as private patient.
183
Consequently, although I have details for inpatient procedures for the clinic 
sample, I do not have comparable data for the ACT and Australian Medicare 
samples.
Figure 8.2 shows the obvious differences in the numbers of colposcopies 
claimed by the three different samples. A large proportion of the ACT and 
Australian samples had only one colposcopy (43 per cent and 55 per cent 
respectively). In contrast, only 14 per cent of the clinic sample were billed 
only once for colposcopy. The clinic sample has higher proportions of 
women having two, three and four or more colposcopies than the ACT and 
Australian Medicare samples. The new Commonwealth protocol 
recommends that women referred for the assessment and treatment of CIN 
should have a colposcopy to assess the lesion, plus a biopsy, and that after 
treatment they should have at least one follow-up colposcopy 
(Commonwealth Department of Human Services and Health 1994). The 
differences in colposcopy claims may be a reflection of inadequate 
assessment and treatment elsewhere in Australia and at other services in the 
ACT.
Figure 8.2 Proportion of women billed for colposcopies
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A much greater proportion of women in the clinic sample were billed for 
laser treatment (item number 35539) (Figure 8.3). Only a small proportion of 
women in each sample claimed for laser to one or more anatomical sites (item 
35542) or for laser to condylomata (item 35545).
Figure 8.3 Proportion of women billed for biopsy, diathermy and laser treatment
CLC (n=502) 
ACT (n=188) 
Aust (n=6483)
35608 35539 35542 35545
Item numbers claimed at least once
No data on the number of women in the ACT sample who claimed for item number 35542 were 
available because of the small numbers and the need to protect privacy.
The item numbers are described as follows:
35608 - CERVIX, cauterisation (other than by chemical means), ionisation, diathermy or biopsy of, with 
or without dilatation of the cervix
35539 - COLPOSCOPICALLY DIRECTED C02 LASER THERAPY for previously confirmed 
intraepithelial neoplastic changes of the cervix, vagina, vulva, urethra and anal canal, including any 
associated biopsies - one anatomical site
35542 - COLPOSCOPICALLY DIRECTED C02 LASER THERAPY for previously confirmed 
intraepithelial neoplastic changes of the cervix, vagina, vulva, urethra and anal canal, including any 
associated biopsies - two or more anatomical sites
35545 - COLPOSCOPICALLY DIRECTED C02 LASER THERAPY for condylomata, unsuccessfully 
treated by other methods
Not all gynaecologists have a colposcope and CO2 laser in their rooms. 
Because CLC has a CO2 laser, a much higher proportion of women in this 
sample will have laser treatment than women in the ACT and Australian 
population samples. It is likely that many of the women in the other samples 
had inpatient treatment for abnormal Pap smears. The differences in the
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proportion of women in the clinic sample claiming for one or more 
colposcopies may also mean that this colposcopy clinic offers more intensive 
assessment and treatment than services elsewhere. For both these findings 
mean that the applicability of the research findings of the CLC sample 
elsewhere may be limited. The differences in outpatient versus inpatient 
treatment is likely to result in a lower estimate of financial costs to 
government than would ap ply to a total population, while the more 
intensive assessment and treatment may overestimate the population costs.
Methods of costing
In the CLC sample, the cost of each woman's assessment and treatment was 
costed for the duration she was in the study. All outpatient and inpatient 
episodes were costed because the aim of the study was to cost current 
gynaecological care as it relates to women who have abnormal Pap smears.
Two costs were calculated — costs to government (Appendix E), and costs to 
women (Appendix F). These costs were calculated for the financial year in 
which they occurred, as well as for 1991/92, the latest financial year for 
which costs from the Health Insurance Commission were provided3.
The financial costs to women and government only included the direct costs 
of medical care. Indirect costs such as loss of work time, child care and 
transport expenses were not included.
Most of the cost estimates used in this study are based on the charges (the 
price paid for a service) to government and to women. Finkler (1982) argues 
that charges are often poor proxies for the economic cost because the 'real' 
cost of a good or service may be different from its charge. However, while 
Medicare benefits do not represent the cost to the service provider they are 
the economic cost to government and women. Because this study is not 
estimating the cost to society, but rather the separate costs to government and 
women, charges are a legitimate measure of the cost of a service.
3 No discounting of costs was performed since the costs were incurred over such a short time 
period. Most health economic studies use discounting on the premise that people have a 
time preference for costs. That is, they would rather delay costs. Discounting enables 
present costs to be given greater weight than future costs.
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The remainder of this chapter outlines how I calculate the costs under the 
headings of outpatient treatment, public hospital inpatient treatment and 
private hospital treatment.
Outpatient treatment
All visits to the CLC were outpatient visits. Medicare item numbers detailed 
in the patients' accounting records were used to determine the costs to 
government and to women for outpatient care. Rather than calculating the 
costs of treatment using the costs charged by the clinic, I have used a 
Medicare sample of ten per cent of Australians4 enrolled in Medicare to 
calculate the costs. I did this for two reasons: using Medicare cost estimates 
improves the transferability of the cost findings of this study to other 
situations, and because it was difficult to obtain charges from the clinic.
Multiple items were billed at most visits. When multiple therapeutic services 
are performed (as was often the case for example, colposcopy and biopsy) 
then the scheduled fee is reduced and the Medicare rebate is 85 per cent of 
the reduced scheduled fee5. Items for consultation and local anaesthetic were 
not subject to the multiple operation formula.
Because most outpatient visits result in accounts with more than one item 
number, I determined the costs of treatment by using the item combinations 
for each visit as the units of costing. However, many combinations were not 
found frequently (less than 20 in the ten per cent Medicare sample). In this 
situation costs were calculated using charging bands. There are three 
charging bands (a to c). Charging bands are relevant for items subject to the 
multiple operation formula described in footnote 5. When items are rebated 
at 100 per cent of the scheduled fee they are on band a; when rebated at 50 
per cent they are on band b; and at 25 per cent they are on band c.
4 An Australian rather than an ACT sample was used because the ACT sample would have 
been too small. Many item combinations would not occur with sufficient frequency to yield 
reliable estimates.
5 For therapeutic procedures there is a multiple operation formula which states that: 'The 
fees for two or more operations, other than amputations, performed on a patient on one 
occasion are calculated by the following rules -100% for the item with the greatest scheduled 
fee plus 50% for the item with the next greatest scheduled fee plus 25% for each other item.' 
The rule goes on to state that if two items have the same scheduled fee, one of the items will 
be treated as greater. (Section 8.5, p82, Medicare Benefits Schedule Book, AGPS, Canberra, 
1992)
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The average cost to government and to women for all item combinations 
charged by the clinic was calculated using a ten per cent sample of female 
Medicare enrollees for the financial years 1988/89,1989/90,1990/91 and 
1991/92. The costs of cytology and histology were also calculated in this 
way. As the costs were based on a ten per cent sample of Medicare enrollees, 
they are subject to sampling variation (except in the case of pathology 
services where cost was calculated using the total population). The Medical 
Estimates and Statistics Section of the Department of Human Services and 
Health (DHSH) examined the distribution of costs to government and 
women and calculated the mean, median and variance for each item and item 
combination. Below I describe the methods for calculating costs and give a 
brief description of the DHSH analysis. Due to privacy restrictions of the 
DHSH, I was unable to examine the distribution of costs personally. 
Descriptions of the items billed and used for costing are in Appendix D.
Cost to government
The government pays the Medicare rebate for a particular item or item 
combination in an outpatient setting. Therefore, the average cost incurred by 
government is given by formula 8.1:
Formula 8.1
Average cost to government = total benefits paid (Medicare rebate) total number of services
Tables E.l to E.4 in Appendix E detail the costs to government of outpatient 
services for financial years 1988/89 through 1991/92.
The average and median costs to government are almost identical for the 
item mix table (E.l), abatement table (E.2) and consultation table (E.4). The 
median is always between 97 per cent and 102 per cent of the mean. The 
distributions tended to modal with very few outliers. This is because the 
rebate is set by government. The interquartile range was zero in most cases 
and was never more than seven per cent of the average cost to government. 
Therefore, although costs to government were not normally distributed, the 
average cost to government appears to be representative of the costs to 
government in all instances. This is because the only source of variation in 
these costs comes from changes in the scheduled fee. The standard errors are
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included in Appendix E, Tables E.l, E.2, E.4 and E.6. These are extremely 
small relative to the mean.
Cost to women
Women pay the difference between the fees charged by gynaecologists and 
the Medicare rebate. Therefore, the average cost paid by women is given by 
formula 8.2.
Formula 8.2
Average cost to women total amount charged - total benefits paid total number of services
Tables F.l to F.4 in Appendix F detail the costs to women of outpatient 
services for the financial years 1988/89 through 1991/92.
For the item mix Table F.l and the abatement Table F.2 the median ranges 
from between 61 per cent to 129 per cent of the average cost to women. The 
distributions of cost tended to be positively skewed. That is, there is a greater 
range of cost above the median than below. The standard errors of costs to 
women, based on the ten per cent Medicare sample, were much greater than 
the standard errors for the costs to government. The use of the mean to 
calculate costs to women may overestimate costs incurred. For the 
consultation items the cost to women resembled more closely a normal 
distribution (Table F.3). In addition, the mean and the median were almost 
identical and the standard errors were low.
Inpatient services
There were 86 hospital inpatient services provided to women attending this 
clinic — 78 women were admitted to hospital, and eight women had two 
hospital admissions. I did not have access to the hospital case notes of any of 
these women, which made it more difficult to cost inpatient treatment than 
outpatient.
Cost to government for inpatient public hospital services
Most of the admissions (69) were to a public hospital (Table 8.9). Six women 
were admitted on two occasions. The four women in the 'other' category on 
Table 8.9 include one who had a secondary haemorrhage, another who had a 
hymenectomy, and two for whom the type of treatment was unclear.
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Table 8.9 Public hospital treatment
Type of Service No. of services
Laser 1
Diathermy 34
Cone biopsy 20
Vaginal hysterectomy 1
Total abdominal hysterectomy 9
Other 4
Total 69
I could not discern from clinic records whether the women admitted to public 
hospitals were private or public patients. I have therefore costed each 
woman's inpatient public hospital treatment as if she were a public patient. 
Private patients are charged by medical practitioners for the services 
provided in hospital and are eligible for a Medicare rebate. Costing all 
patients admitted to public hospitals as public patients may underestimate 
the cost to women and overestimate the cost to government. Women 
admitted as private patients may have out-of-pocket expenses.
Public hospitals are managed by the relevant State and Territory 
governments and are subsidised by Medicare grants from the 
Commonwealth. However, despite the different sources of financing for 
public hospital care, care such as outpatient treatment, for example, still 
involves a cost to one government or another. There is no cost to women for 
inpatient public hospital services.
To estimate the cost to government for inpatient public hospital treatment I 
multiplied the diagnostic related groups (DRG) cost per bed-day for the 
relevant procedure by the length of hospital stay (in days) for that procedure.
The DRG costs per bed-day were calculated for laser, diathermy, cone biopsy 
and vaginal and abdominal hysterectomy. These costs were determined for 
the financial years 1989/90 through 1991/92 for the relevant diagnostic 
related groups 6 using the casemix data at Woden Valley Hospital (WVH).
6 Diagnostic Related Groups (DRGs) are used to describe the casemix of hospitals for 
resource allocation purposes. Therefore, each DRG includes patients who are similar both in 
terms of their resource intensity and clinical features. I used the Australian National 
Diagnostic Related Groups as a means of classification. It contains 23 major diagnostic 
categories. Within each category, DRGs are defined as medical or surgical. A patient is 
considered as surgical if they have an operating room procedure during their hospital stay. 
(Australian National Diagnosis Related Groups, Definitions Manual, Version 1; 1992, Health 
Information Systems (Australia)).
The costs included WVH and Royal Canberra Hospital, the two major public 
hospitals operating in Canberra at the time of the expenditure study. There 
are no DRG cost data prior to 1989. I therefore used 1989/90 costs for 88/89. 
The DRG costs relate to the costs incurred by the hospital in the delivery of 
services both to public and private patients. Hence the DRG estimates 
provide some measure of the cost to government both for private and public 
patients. (The DRG estimates do not take into account the revenue that 
public hospitals receive from private health insurance companies for private 
patients.) The DRG codes used are detailed in Appendix D, Table D.2.
To estimate the length of stay for the procedures performed in public 
hospitals, the ACT hospital separation data were used. These data are coded 
according to the International Classifications for Disease 9-CM procedure 
classification (World Health Organization 1992). The procedural ICD-9 
codes were used to examine the length of stay for various procedures. When 
no procedural code existed or if it was not relevant, the ICD-9 disease codes 
were used. The ICD-9 codes used are shown in Appendix D, Table D.3.
All records of inpatient stay, for the relevant ICD-9-CM and ICD-9 disease 
codes and during the time period of the CLC study (1 January 1989 to 16 
August 1991), were extracted from the ACT hospital separation data base.
This data base includes any patient admitted to one of Canberra's three 
public hospitals as a private or public patient. The average length of stay for 
each of the relevant codes was calculated. Women admitted as day patients 
were assigned a length of stay of one day. The cost of each procedure was 
calculated by multiplying the average length of stay (ICD-9 or ICD-9-CM 
code) by the average cost per bed-day (DRG code).
Each DRG code includes a variety of procedures or diagnoses. The ICD-9 or 
ICD-9-CM codes are more specific for particular episodes of inpatient stay. 
Cost estimates are not routinely made for specific ICD-9 or ICD-9-CM codes. 
Use of the ICD-9 and ICD-9-CM codes to estimate length of stay and the DRG 
per diem costs enables a more precise estimate of the cost of public hospital 
inpatient treatment than the DRG episode cost.
Hence the cost to government for an inpatient episode is given by formula 
8.3.
Formula 8.3
Cost to government = mean DRG cost /  day x mean LOS for procedure
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Private hospital
Fifteen women had treatment at John James Hospital (JJH), the only 
exclusively private hospital in Canberra. Table 8.10 shows the distribution of 
cases.
Table 8.10 Private hospital treatment
Type of Service No- of Services
Diathermy 6
Cone biopsy 9
Total abdominal hysterectomy 2
Total__________________________________________17_
Three components of treatment were used to calculate costs: cost of medical 
services, theatre costs and accommodation costs.
When women are admitted to private hospitals, the only costs government 
incurs are for inpatient services. The government does not contribute to the 
theatre or accommodation costs in a private hospital.
Because individual doctors, rather than the private hospital, issued bills to 
patients, the private hospital inpatient treatment was costed through the ten 
per cent Medicare sample. All records of women who claimed for the item 
numbers describing diathermy (35646), cone biopsy (35618) and total 
abdominal hysterectomy (TAH) (35653) as inpatients during the financial 
years 1988/89,1989/90,1990/91,1991/92 were extracted from the ten per 
cent Medicare file. The relevant item number above and all other items 
referring to services provided on the same date were used to calculate the 
costs to government and women. This method ensured that items covering 
anaesthetic and pathology services were included in the cost calculations.
The cost to government is the Medicare benefit for inpatient services. The 
Medicare benefit falls to 75 per cent of the Medicare scheduled fee for private 
inpatient services. The costs to government of private hospital inpatient 
services were calculated using Formula 8.1.
Because the average cost is computed from a wide range of items the costs 
tended to be more variable outpatient costs to government, and 
approximated a normal distribution; the interquartile range was between 19 
and 35 per cent of the mean. The median was between 90 per cent and 101
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per cent of the mean. Table E.6 in Appendix E shows the average costs and 
standard errors of the surgical procedures.
Private health insurance covers women for the difference in cost between the 
Medicare benefit and the Medicare scheduled fee. All women admitted to 
the private hospital had private health insurance. Therefore the cost to 
women for medical services in a private hospital is given by Formula 8.4 
below.
Formula 8.4
Average cost to women total amount charged - total scheduled fee total number of services
Although the costs to women of private inpatient services were distributed 
more normally than outpatient services, they still tended to be positively 
skewed. The median was between 73 per cent and 87 per cent of the mean. 
Table F.5 in Appendix F details the costs and standard errors of private 
inpatient treatment for women.
Government does not pay anything towards the theatre costs of private 
hospital treatment. Therefore, only the cost to women is outlined below.
The cost paid by women for theatre expenses was calculated by subtracting 
the private health insurance rebate from the costs charged by the private 
hospital.
John James Hospital supplied their schedule of theatre fees, and the dates of 
any changes in theatre fees, for the financial years 1988/89 through 1991/92 
for diathermy, cone biopsy and TAH.
Medibank Private made available the schedule of benefits paid to women 
who claimed for the theatre expenses for specific procedures. They also 
provided the dates of any changes in benefits for theatre procedures. 
(Medibank Private is one of the four major private health insurance 
companies in the ACT, (Private Health Insurance Administration Council 
1992).) The other three major insurance companies operating in Canberra 
would not provide their benefits schedule.
During the time of the study, the private health insurance rebate from 
Medibank Private always covered the theatre costs for the relevant
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procedures at JJH; therefore women did not incur any costs for theatre 
charges.
Government does not pay anything for the accommodation costs of patients 
admitted to private hospitals.
The cost to women for accommodation expenses is given by Formula 8.5:
Formula 8.5
Cost to woman = n x  (charge /  bed day - private health insurance rebate /  bed day) 
where n = no. of bed days
Women were assumed to be in a shared ward for the purposes of the costs of 
accommodation.
ACT Hospital Separation Data were used to calculate the number of bed days 
for each procedure. Unfortunately, JJH was not part of this data collection 
during the study period. Again, ICD-9-CM codes were used to identify 
women who underwent the same procedures as the women who were 
admitted to JJH. All women who underwent the relevant procedures during 
the time period of the study (1/1/89 through 16/8/91) were extracted from 
the ACT Hospital separation data base. Only women who were admitted as 
private patients to the public hospitals in the ACT were used for this bed-day 
calculation. Women admitted as day patients were assigned a value of one 
for the number of bed-days. The median number of bed-days is used as the 
indicator of length of stay because the distribution of bed-day stays is 
positively skewed.
During most of the study period the private health insurance bed-day rebate 
covered the private hospital charges, resulting in no accommodation costs for 
women. Details of the costs paid by women for accommodation expenses in 
private hospitals during the time period of the study are to be found in 
Appendix F, Table F.6.
Costing each woman 's treatment
Using the methods described in this section, the tables of financial costs to 
government and women outlined in Appendices E and F were generated.
Each woman's gynaecological treatment was costed using these tables.
According to the date of women's inpatient and outpatient treatment the
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costs of treatment to government and to women were calculated using the 
relevant tables. When the date of hospital treatment was not known it was 
estimated to be the midpoint between the clinic visit before and the clinic 
visit after hospital treatment.
Perusal of the tables for costs to government and women shown in 
Appendices E and F, reveals that cost of services increased during the time 
period of the study.
Summary
In this chapter I have described the methods of data collection employed 
during this study as well as the sample characteristics. I have also compared 
the CLC sample with ACT and Australian samples obtained through 
Medicare. The CLC sample has a greater proportion of younger women and 
shows more frequent investigation and treatment than the ACT or national 
Medicare samples. The CLC sample is also likely to be biased towards more 
frequent outpatient rather than inpatient services. Also, this study is 
predominantly located in a private outpatient service. A different allocation 
of costs to government and women would occur had this study been 
performed in a public hospital outpatient service. Such differences limit the 
transferability of the cost estimates derived in this study to other clinical 
situations. Nonetheless, this is the first study in Australia to calculate costs 
based on real rather than hypothetical data, and to assess the cost of 
treatment on the basis of women's presenting Pap smear results.
I have shown that the concordance between cytology, colposcopy and 
histology was poor. I suggest that the poor inter-test reliability has different 
implications for women with abnormal Pap smears, for clinicians and public 
health practitioners. I return to these implications in Chapter Eleven.
The following two chapters report the analyses of costs and describe the 
patterns of attendance for follow-up in the CLC sample.
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Chapter Nine
The financial costs of abnormal Pap smears
In this chapter I examine the cost to government and women for the 
gynaecological care of women who have abnormal Pap smears. I compare 
the cost of care on the basis of presenting smear, compute the potential 
savings of new Commonwealth policy recommendations for the care of 
women who have abnormal Pap smears, and examine what factors predict 
cost in this sample. Both current and alternative approaches are examined.
Two measures of cost are used. First, cost was calculated on the basis of the 
financial year in which the service was provided. For the remainder of the 
thesis I refer to these costs as 'current costs'. Second, cost was calculated 
using the financial year 1991/92 (the latest financial year for which the 
relevant Medicare data were available). These are referred to as 'constant 
costs'. The second calculation of cost gives a better approximation of the 
present costs of treatment. I refer to the cost of women's entire episode of 
care, from their first to last clinic visit, as the 'episode cost'. In this chapter, 
presenting smear is divided into four categories: No CIN, CIN 1, CIN 2, and 
CIN 3.
Cost to government of current approaches
In this section I compare the costs of care borne by government according to 
the category of presenting smear (No CIN, CIN 1, CIN 2, CIN 3).
Geometric mean cost to government and presenting smear
Because the costs to government in this sample of 502 women were positively 
skewed, the average cost is not an appropriate measure to compare costs for 
the different categories of presenting smear. The average cost is influenced 
by the individual cost estimates. Therefore, the geometric mean cost is used. 
This gives less weight to the large estimates. The natural logarithm of cost to 
government approximates a normal distribution. The entire episode cost is
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compared for the different levels of abnormality. Cost estimates over the 
time periods three, six and 12 months are also compared for different levels 
of abnormality.
Women were included in the analysis of each time period if they were in the 
not-attending or discharged category (permitting the costing for their entire 
treatment episode), or if they were in another follow-up group and attended 
for the relevant time period (for example, 183 days for the six month 
category). In theory, if women in the other follow-up status codes (still 
attending, moved, or changed gynaecologists and unknown) were excluded 
from the analysis, biased estimates of costs would be obtained. For example, 
women in the 'still attending' category may have had more intensive 
treatment, or may have had recurrences or persistence of abnormalities, 
explaining why they had more 'days in study' than any other group (see 
Table 8.4 pl74). If these women were dropped from the analysis, costs to 
government may be underestimated.
Tables 9.1 and 9.2 detail the geometric mean current and constant costs for 
different levels of presenting smear.
Table 9.1 Geometric mean current costs to government by level of presenting 
smear
No CIN CIN 1 CIN 2 CIN 3 All O ne way 
ANOVA
0 - 3 m onths
(n=481)
Geometric m ean 272.35 320.41 367.31 55336 32809 p< 0.0001
(95% Cl) (24E93,29357) (28525,36000) (337.14,400.21) (47223 640.28) (309.95 347.23)
0 - 6  m onths
(n=459)
Geometric m ean 330.83 412.61 45318 64878 40351 p< 0.0001
(95% Cl) (300.76,36391) (362.02,42027) (41834,490.93) (557.52 750.17) (380.77,427.61)
0 - 1 2  m onths
(n=432)
Geometric m ean 390.52 481.11 54348 77650 477.47 p< 0.0001
(95% Cl) (355.70,42880) (419.26,55208) (50290 587.34) (66322 90923) (450.52 50598)
0 -  last visit
(n=374)
Geometric m ean 404.03 497.70 571.00 76832 48634 p< 0.0001
(95% Cl) (36507,447.20 (43092 58237) (527.05 61869) (6231Q 947.38) (45641,51827)
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Table 9.2 Geometric mean constant costs to government by level of presenting 
smear
No CIN CIN 1 CIN 2 CIN 3 All O ne way 
ANOVA
0 - 3  months
(n=481)
Geometric m ean 29557 34540 40327 634.54 35699 p< 0.0001
(95% Cl) (26553,32575) (30585 389.98) (367.45 44261) (53534,75212) (337.92 381.42)
0 - 6  m onths
(n=459)
Geometric m ean 357.77 447.33 49631 740.48 44Q89 p< 0.0001
(95% Cl) (324.18,394.85) (389.51,51373) (454.95 541.42) (52647,87524) (414.51,46695)
0 - 1 2  m onths
(n=432)
Geometric m ean 420.99 520.19 594.90 889.36 52019 p< 0.0001
(95% Cl) (38222,46368) (449.80,601.60) (54615 64601) (74642 1059.66) (489.31,55370)
0 - last visit
(n=374)
Geometric m ean 43533 540.29 621.29 861.35 527.95 p<0001
(95% Cl) (30280,484.69) (46095 63327) (569.16 677.83) (690.90,107384) (49374,564.53)
Cost increases with the level of abnormality. The significance of these 
differences was tested using a one-way analysis of variance. This was highly 
significant for both constant and current costs, for all time periods. The 
means for each group were compared using the least significance differences 
test in SPSS (SPSS-X Inc 1988). A five per cent significance level was used. 
This test showed that the costs to government for CIN 1, CIN 2, and CIN 3 
were statistically significantly different from No CIN for both constant and 
current costs, for all time periods. The costs to government for the No CIN, 
CIN 1, and CIN 2 groups were also statistically different from the CIN 3 
group over all time periods and for both current and constant costs. That is, 
the cost to government for the gynaecological care of women in the No CIN 
group was less expensive than for women with CIN. And, the cost to 
government of the CIN 3 group was greater than CIN 2 or less. The CIN 1 
and 2 groups were not statistically different in terms of costs to government.
It is the magnitude of the differences between the groups that is important for 
policy, however. The cost of treating CIN 3 is much greater than any of the 
other abnormalities at each time interval.
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The majority of costs occur in the first three months when women are likely 
to have both an assessment and treatment visit.
If the discharged and not-attending groups only are used to calculate costs, 
then the geometric mean cost is underestimated when compared with the 
geometric mean cost calculated when women who attended (from the other 
follow-up status groups) for the relevant time period are also included. For 
No CIN, CIN 1 and CIN 2 the magnitude of this underestimation is small. 
However, for CIN 3 this bias is much greater, particularly at longer time 
intervals. At 12 months (using constant costs), if the discharged and not- 
attending groups only are used, the geometric mean cost to government for 
CIN 3 is $791.13 (95% confidence intervals 649.43, 964.20), which is less than 
the estimated $889.36 (95% confidence intervals 742.71,1064.86) using all 
women who attended for 12 months as well as women in the discharged and 
not-attending groups.
One explanation for the tendency to underestimate costs for CIN 3 when 
using not-attenders and discharged categories alone is that 21 per cent of 
women with CIN 3 were in the 'still attending' category, and these women 
are likely to incur larger costs because they were followed for a longer period 
of time. Between six and 12 per cent of women with No CIN, CIN 1 and CIN 
2 were in the 'still attending' follow-up category. Over three quarters of 
women in the No CIN, CIN 1 and CIN 2 groups on presenting smear were in 
the 'did not attend' and 'discharged groups'; however, only 55 per cent of 
women who had CIN 3 on presenting smear were in these groups.
Twelve-month costs and episode costs are similar for all categories of 
presenting smear. Episode costs are likely to be underestimated by this 
technique because only women in the did not attend and discharged 
categories were included in the estimation of the geometric mean episode 
cost. Only these women could be assumed to cost no more to government for 
this episode of care. This underestimation is likely to be more evident for 
CEN 3 for the reasons stated earlier. Indeed, both current and constant 
geometric mean episode costs are less than the geometric mean twelve-month 
costs for CIN 3.
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Median cost to government and presenting smear
One way to adjust for the likely biases resulting from estimates based on 
women at different stages of follow-up is to use survival analysis. Survival 
analysis enables the calculation of median cost of treatment which has been 
adjusted for censoring. Figure 9.1 illustrates how the calculation of median 
cost was made.
Figure 9.1 Illustration of procedure used to calculate median cost
q. Censor marks
3
Upper 95% confidence interval 
for survival probability
Median cost = $290 
(95% Cl $260-$360)
Lower 95% confidence 
interval for survival 
probability .
Cost ($)
In this section the median cost of treatment is estimated using the Kaplan- 
Meir curve. Cost is on the X axis instead of time. Cost, like time, is a 
continuous variable that consistently increases (i.e. is monotonic) and hence 
can be used in the same manner as time. For the purposes of this analysis, 
women who are discharged and who do not attend are 'failures' in the 
traditional survival sense. The Y axis is the cumulative survival probability 
and in this instance is the cumulative probability of continuing treatment. 
This 'failure' occurs at the cost of this episode of treatment because cost, 
rather than time, is on the X axis. All other cases were censored, but 
contribute to the calculation of cost until they were censored. Because 
survival analysis allows for censoring, an unbiased estimate of median cost is 
obtained. This analysis was performed in EGRET (Statistics and 
Epidemiology Research Corporation 1990).
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The median cost is the cost at the point at which 50 per cent of women have 
completed follow-up. In the illustration, 45 per cent of women had 
completed at a cost of $260 (i.e., only 55 per cent had not completed 
treatment). At $290, 55 per cent had completed follow-up (i.e., 55 per cent 
had not completed follow-up). The median cost is defined as $290 because 
the line crosses the 50 per cent mark at this cost. EGRET estimates 95 per cent 
confidence intervals around the different survival probabilities (i.e. around 
points on the Y axis). To calculate the 95 per cent confidence intervals around 
the median cost estimates, the confidence intervals for the survival 
probabilities were used. This is shown in Figure 9.1. In the illustration, the 
upper and lower confidence intervals of the survival probability (probability 
of not completing follow-up) are approximately 0.65 and 0.35. Then, the cost 
at which the survival probability is equal to, or crosses this survival 
probability, is identified from the graph. These costs are $360 and $260. This 
method enables an approximation of 95 per cent confidence interval around 
the cost estimate to be made. Figure 9.1 also has censor marks which 
illustrate the observations of the follow-up status groups moved or changed 
gynaecologists, still attending and unknown. The costs for women in these 
groups contribute to the calculation of cost, at different survival probabilities, 
up until their last visit, when their observations are censored.
Table 9.3 Median cost to government by level of presenting smear ($)
N o CIN 
(n = 230)
CIN 1 
(n=73)
CIN 2  
(n = 142)
CIN 3  
(n=56)
Total
(n=502)
Current cost
M edian 511.77 488.50 601.66 1036.44 540.70
(95%  Cl) (470.36, 537.35) 464.57,548.30) (54070,67348) (751.84,1781.83) (537.36 601.66)
Constant cost
M edian 541.05 529.28 64220 137273 580.69
(95%  Cl) (504.85,56227) (504.85,58069) (58069,71395) (86680,2146.22) (56227,640.25)
Table 9.3 shows the median costs to government for each category of 
presenting smear. Similar median costs are obtained for No CIN and CIN 1. 
The median cost of treatment is greater for CIN 2 than lower levels of 
abnormality. However, the median cost of treatment of CIN 3 is much 
greater than for any of the other groups and might reflect the increased 
chance of hospitalisation and prolonged follow-up in this group.
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Proportion of the cost of total care to government and presenting smear
In this section I show the contribution of each abnormality to the total costs of 
gynaecological care for the sample at three, six and 12 months and for the 
entire treatment episode. In these calculations, women in the discharged and 
not attending categories are included for all time periods and women in other 
categories are included if they attended for the relevant time period. Only 
women in the discharged and did not attend categories are used to calculate 
episode costs. (These are the same inclusion criteria as those used for the 
calculation of the geometric mean cost to government.)
At all time periods the No CIN and CIN 1 categories combined constitute 
more than 50 per cent of the costs of treatment to government for this sample. 
Therefore, a substantial proportion of the costs to government come from 
minor abnormalities. This is because more women were referred with CIN 1 
or less than CIN 2 or CIN 3. Recent policy regarding the gynaecological care 
of women with screen-detected abnormalities proposes more conservative 
treatment for these minor abnormalities (Commonwealth Department of 
Human Services and Health 1994).
Figure 9.2 Proportion of total constant costs to government at three months
H No CIN 
CD CIN 1
□  CIN 2
□  CIN 3
3 M onths (n=481)
34 .5%
38 .4%
12.9%
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Figure 9.3 Proportion of total constant costs to government at six months
B No CIN 6 Months (n-459)
ID CIN 1
□  CIN 2
□  CIN 3
18.4%
k 37,1 %
30.1%
14.5%
Figure 9.4 Proportion of total constant costs to government at 12 months
B No CIN
□  CIN 1
□  CIN 2
□  CIN 3
30.7%
12 Months (n=432)
18.0%
36.1%
15.5%
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Figure 9.5 Proportion of the total constant costs to government for entire episode
B NoCIN
m ciNi
□  CIN 2
□  CIN 3
30 .2%
Entire episode (n=374)
39 .7%
16.2%
Cost to women of current approaches
The costs to women of gynaecological care according to the severity of their 
presenting smear are described in this section.
Arithmetic mean cost to women
The estimated costs to women approximate a normal distribution, hence the 
arithmetic mean costs are compared for each category of presenting smear. 
Current costs are shown in Table 9.4 and constant costs are shown in Table 
9.5.
In Chapter Eight I discussed the distribution of costs to women that were 
calculated using the ten per cent Medicare file. (The relevant data are in 
Tables F.l, F.2, F.3 and F.5 in Appendix F.) I discussed how these costs to 
women tend to be positively skewed and there were large variances in the 
estimates of the mean. Cost estimates for each woman in the clinic sample 
were obtained, in part, from the ten per cent Medicare file cost estimates. 
Therefore, the cost estimates for each woman's treatment are subject to error. 
To describe this error I include, for each category of presenting smear, the 
mean variance of the individual cost to women estimates. This gives an 
indication of the variability of individual cost to women estimates. I have
204
called this the mean intra-individual variance1. These were not included in 
the cost to government because the variance in the estimates of the individual 
cost to government estimates was very small.
Tables 9.4 and 9.5 show the mean costs to women at three, six, 12 months and 
total costs using both current and constant costs respectively.
Women were included in the relevant time period calculation if they 
attended for that time period or were in the discharged or not attending 
category. Only women in the discharged and not-attending category were 
used to calculated the mean episode costs of treatment for each category of 
presenting smear. Similar results are obtained when only the discharged and 
not attending categories are used to calculate average costs over all the time 
periods.
One-way analysis of variance showed statistically significant differences in 
the costs to women between the groups for all time periods and for both 
current and constant costs. However, using the least significant differences 
test described earlier, only the CIN 2 and No CEN group are statistically 
significantly different, at the five per cent level, for all time periods. At three 
months, all CIN groups have statistically significant different costs compared 
with the No CIN group.
1 The variance of each woman's cost estimate was calculated by summing the variance of all 
the components of the cost estimates. For example, the cost at one clinic visit might consist 
of a consultation fee as well as cost of colposcopy. The variance in the estimate for 
consultation would be added to the variance for the cost in colposcopy and would constitute 
the variance in cost for this visit. This variance would be added to the variance in cost for all 
other visits and inpatient procedures (if relevant). In this way the total variance in cost is 
obtained for each woman's treatment. The variances can be summed because it is known 
that the variance of a sum is equal to the sum of the variances, assuming that the components 
are independent.
An average variance for each category of presenting smear is produced by the adding 
variance of each woman's cost estimate and dividing by the number of women in the 
category.
When estimates with large variance are combined, a popular way of addressing the problem 
of their variances is to weight each observation by the inverse of its variance. It is not 
appropriate to use this procedure in this situation, however. To do this would result in a 
bias towards those cases with lower costs because they have the smallest variances.
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Table 9.4 Average current costs to women by level of presenting smear ($)
N o  CIN CIN 1 CIN 2 CIN 3 T ota l O n e  w a y  
A N O V A
0 - 3 m onths
(n = 4 8 1 )  
A v e r a g e  c o s t 89.83 102.74 10 5 0 9 10 2 7 4 97.84 p = 0.006
(9 5 %  C l) (84.16,9548) $ 4 .9 8 , 110.59) (1 0 0 1 9 ,1 1 2 0 0 ) (89.85 11563) (94.23101.44)
M ean
intraindividual 6 0 7 831 8 5 7 9.14 7.46
variance
0 - 6 m onths
(n = 4 5 9 )  
A v e r a g e  c o s t 109.82 124.76 131.18 1 2 0 4 6 119.41 p = 0 0 0 7
(9 5 %  C l) (102.74,11589) (114.79,134.73) (1 2 3 5 5  13578) (1 0 5 9 5  13397) (114.95 12387)
M ean
intraindividual 621 8 6 6 9.41 1058 7.99
variance
0 - 1 2  m onths
(n = 4 3 2 )  
A v e r a g e  c o s t 130.30 141.75 151.85 4 5 4 5 139.91 p = Q 0 0 9
(95%  C l) (121.33,139.60) (1 3 0 4 0 ,1 5 3 0 9 ) (1 4 3 6 5  160.04) (127.91,16399) (134.53 14530)
M ean
intraindividual 673 9.06 9.69 1277 855
variance
0 - last visit
(n = 3 7 4 )  
A v e r a g e  c o s t 1 3546 150.87 167.19 151.74 14536 p = 0.001
(95%  C l) (124.83,14504) (1 3 5 5 5  16519) (1 5 5 9 3  17545) (1 2 8 3 0  177.17) (141.60 15512)
M ean
intraindividual 6 8 5 9.73 1027 1331 881
variance
There is less variation in cost to women by level of presenting smear than 
variation in costs to government. In fact, CIN 2 costs more to women, on 
average, than CIN 3 for all time periods (although these differences were not 
statistically significant in the multiple comparisons test). This is probably 
because women with CIN 3 were more likely to have inpatient treatment. 
Most of these women were admitted to a public hospital which did not entail 
out-of-pocket expenses to them. Therefore, some women with CIN 3 would 
have paid less for their treatment than women who had outpatient treatment. 
Most of the costs are in the first three months of treatment. This analysis 
shows that women had significant out-of-pocket expenses.
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Table 9.5 Average constant costs to women by level of presenting smear ($)
NbQN QN1 ON2 QN3 Total Onev\ay 
ANOVA
0 - 3  m o n th s
(n=481) 
Average cost 109.77 12310 13336 127.89 12097 p = 0.002
(95% 0 ) (102.54,117.01) (11597,13323) (12547,14125) (11081,194.98) (11327,12597)
M e a n
in tra in d iv id u a l 12.99 1281 1327 1279 1280
va ria n ce
0 - 6  m o n th s
(n=459) 
Average cost 131.72 150.70 16265 147.92 14532 p = 0.001
(95% 0 ) (122.78,140.66) (13342 16299) (15263 17264) (13005 169.78) (139.60 151.04)
M e a n
in tra in d iv id u a l 1329 14.65 1293 17.15 1382
va ria n ce
0 - 1 2  m o n th s
(n=432) 
Average cost 15367 169.35 18510 17553 167.53 p = 0.001
(95% 0 ) (14288,164.46) (15549,18322) (174.23 19593) (15253,19354) (160.84,174.21)
M e a n
in tra in d iv id u a l 14.58 1531 1251 1898 14.56
va ria n ce
0 - last v is it
(n=374) 
Average cost 15384 179.73 20204 184.76 17359 p =0.002
(95% 0 ) (14313 171.50) (16242 197.04) (187.95 21312) (154.60 214.93) (16335 184.82)
M e a n
in tra in d iv id u a l 14.49 1661 1372 1898 14.97
va ria n ce
There is considerable intra-individual variation in the cost estimates 
particularly for the constant costs to women estimates.
Median cost to women
The median costs to women were calculated using survival analysis in the 
same way as discussed for costs to government.
The median costs to women are similar for the categories No CIN and CIN 1. 
CIN 2 appears to cost women more than CIN 1 or less. CIN 3 is slightly more 
expensive again. However, the magnitude of the differences between the 
costs of the various presenting smear categories is much less for women than
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for government. This is probably because unless women are admitted to a 
private hospital they have no out-of-pocket expenses for hospital treatment. 
However, because most women had no out-of-pocket expenses for their 
hospital treatment, differences in costs to them for each category of 
presenting smear were less evident.
Table 9.6 Median cost to women by level of presenting smear ($)
No O N  
(n=230)
am
(*=*3)
Q N 2
(n=142)
Q N 3
(*=56)
Total
(*=502))
Current costs
M ed ian 151.02 15 2 0 9 17610 184.86 164.52
(9 5 %  C l) (149.78,16721) (1 3 6 6 0 ,1 7 3 9 5 ) (17679,194.87) (164.52 25265) (1 5 6 1 6  174.72)
Constant costs
M ed ian 180.84 180.84 2 0 7 2 5 2 2 6 4 9 19697
(9 5 %  C l) (173.67,200.06) (180.84,19697) (2 0 0 .0 6 2 3 2 1 0 ) (207.26 321.79) (189.27,200.08)
Proportion of the cost to women and presenting smear
In this section I calculate the costs to women on the basis of their presenting 
smear. Total costs are the estimated costs paid by all women in this sample. 
At each time period the total costs paid by women in each category of 
presenting smear were computed and was divided by the total costs paid by 
women for that time period to give the proportion of total costs for that time 
period. These results are presented in Figures 9.5, 9.6,9.7 and 9.8 and are 
based on constant costs.
The inclusion and exclusion criteria are the same as those used when 
calculating the average costs paid by women for each time period.
Costs paid by women with CIN 1 or less on presenting smear constituted 
over 55 per cent of the total costs paid by women for each time period. Over 
40 per cent of the total costs paid at each time period were from women with 
no evidence of CIN on presenting smear. Clearly, minor abnormalities 
comprise much of the costs paid by women. The new Commowealth 
protocols attempt to rationalise the clinical care of women who have minor 
abnormalities. Below, I outline the projected savings in these costs if the new 
approaches were implemented in this clinic.
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Figure 9.6 Proportion of total constant costs to women at three months
3 Months (n=481)
B NoCIN 
ID CIN 1
□  CIN 2
□  CIN 3
11.2%
41.3%
32.1%
15.4%
Figure 9.7 Proportion of total constant costs to women at six months
H NoCIN
□  CIN 1
□  CIN 2
□  CIN 3
32.7%
6 Months (n=459)
11.3%
40.9%
15.1%
Figure 9.8 Proportion of total constant costs to women at 12 months
B NoCIN
□  CIN 1
□  CIN 2
□  CIN 3
32.2%
12 Months (n=432)
11.2%
41.4%
15.2%
Figure 9.9 Proportion of total constant costs to women for entire episode
H NoCIN
m ciN 1
□  CIN 2
□  CIN 3
32.7%
Entire episode (n=374)
9 .4%
15.7%
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Comparing the costs to government of current and alternative approaches
In this section I estimate the proportion of the costs to government (due to the 
current approach of the clinic) that would be saved if the new 
Commonwealth policy (Commonwealth Department of Human Services and 
Health 1994) produced by the NHMRC Working Party for the Management 
of Women with Screen Detected Abnormalities, were instituted in this clinic. 
Constant costs are used for this analysis.
The new Commonwealth policy was summarised in Chapter Two. In the 
policy two clinical protocols for CIN 1 were proposed. These different 
protocols were referred to as "active" and "observational". The observational 
approach entails the assessment of all women who have CIN 1 with 
colposcopy and, if appropriate, biopsy. According to this approach, if a high- 
grade lesion (CIN 2 or greater) is demonstrated then treatment is undertaken. 
If assessment confirms a diagnosis of CIN 1, then it is recommended that 
women have Pap smears at six-monthly intervals until regression occurs. In 
contrast, the active approach entails the treatment of all women who have 
CIN confirmed on histology. Women with a diagnosis of HPV are 
recommended to have follow-up Pap smears rather than gynaecological 
assessment and treatment in the first instance.
I estimate the proportion of constant costs — resulting from the current 
approach of this clinic — that would be saved if these different approaches, 
active and observational, were introduced. In both cases it is assumed the 
newly recommended approach to HPV is also adopted. Table 9.7 details the 
assumptions used to construct the constant costs of the active and 
observational approach.
Table 9.7 Assumptions used to compare the costs of current and alternative 
approaches
C u rren t a p p r o a c h A c tiv e  a p p r o a c h O b se r v a tio n a l a p p r o a c h
W h o  is re ferred  for  
c o lp o s c o p y  a n d  b io p sy ?
All w o m e n  in th e  C LC  
s a m p le
All w o m e n  w ith CIN 1 or  
g r e a te r  or w o m e n  w h o  
h a v e  h a d  p r e v io u s  
a b n o r m a lit ie s
All w o m e n  w ith CIN 1 or 
g r e a te r  or w o m e n  w h o  
h a v e  h a d  p r e v io u s  
a b n o r m a lit ie s
W h o  is d is c h a r g e d  
fo llo w in g  c o lp o s c o p y  
a n d  b io p sy ?
All w o m e n  in th e  C LC  
s a m p le
All w o m e n  w ith n o  
e v id e n c e  of CIN on  
b io p s y
All w o m e n  with n o  
e v id e n c e  of CIN 2  or  
g r e a te r  on  b io p sy
W h o  is  tr e a te d  fo llo w in g  
c o lp o s c o p y  a n d  b io p sy ?
All w o m e n  in th e  C LC  
s a m p le
All w o m e n  w ith CIN o n  
b io p s y
All w o m e n  w ith CIN 2  or 
3  o n  b io p sy
First, I describe the potential savings of the active' approach over the current 
approach of the clinic. It is assumed that women with No CEN and no past 
history of abnormalities are not referred to the clinic. Therefore the cost of 
their treatment is saved. I have assumed that all women who have a 
persistent abnormality, whatever the level of severity, are still referred for a 
gynaecological assessment. Only those with histological evidence of CIN 
have treatment. It is assumed that women without evidence of CIN are 
discharged and have their follow-up Pap smears with their general 
practitioners or other primary health care providers. They do not incur 
further costs for their gynaecological care once they are discharged.
Second, I describe the potential savings of the observational approach over 
the current approach. Like the active approach, it is assumed that women 
with no previous abnormalities and no CIN are not referred to the clinic. In 
this model, only women with CIN 2 or greater on histology have further 
treatment. For both the active and observational approach women with CIN 
2 or CIN 3 are still referred for gynaecological assessment.
The assumptions do not entirely correspond with the policy 
recommendations. However, the models are useful approximations of the 
active and observational approaches outlined in the recent Commonwealth 
policy. In each case the results are presented as the proportion of the costs of 
the current approach that is saved for each of the time intervals.
Table 9.8 Costs to government saved from alternative approaches
S a v in g s  of active  
approach  com p ared  with 
current approach  (%)
S a v in g s  of ob servation al 
approach  com p ared  with 
current approach(% )
3  m onths (n = 4 8 1 ) 4 0 .0 51.1
6  m onths (n = 459) 4 0 .8 5 3 .3
12 m onths (n = 432) 4 0 .7 5 2 .3
Entire e p iso d e  (n=374) 4 3 .4 5 5 .5
About 40 per cent of the cost of the entire episode of clinical treatment could 
be saved in this clinic if the active approach was adopted. These savings are 
a result of a more conservative approach to the care of women who have no 
evidence of CIN. The observational approach would bring a further ten per 
cent savings on top of the active approach. The potential savings are slightly 
greater when episode costs, rather than costs of the time intervals three, six 
and 12 months, are used. These differences reflect the fact that the estimated
episode costs only include women who were discharged or non-attenders.
As discussed earlier, women with a presenting smear of CIN 3 are more 
likely to be in the still-attending category. These women are likely to cost 
more to government. Their exclusion means that the total costs to 
government are underestimated and the potential savings of the new 
approaches overestimated.
These costs savings cannot be generalised to the population. As this 
modelling was done using the clinic data it only includes women who had 
been referred for colposcopy. Currently, some women with minor 
abnormalities may not be referred for colposcopy. There is no cost to 
government for the gynaecological care of these women currently, or under 
the active or observational options. The potential savings of the active and 
observational approaches could be estimated if the proportion of women 
who are currently referred with minor abnormalities such as atypia, HPV and 
CIN 1 was known. As there is no population data-base for cytology in the 
ACT it was not possible to estimate these referral rates.
Nonetheless, it appears that both the active and observational approaches, 
coupled with other recommendations regarding HPV, would produce 
substantial savings if introduced in this clinic. The potential savings of these 
strategies Australia-wide depends on the profile of abnormalities in the 
population that are referred to gynaecologists. Unfortunately, no estimate of 
the range and prevalence of the different grades of cytological abnormalities 
referred to gynaecologists in Australia is available. A high proportion of 
women referred to this clinic had CEN 1 or less. Another clinic with a less 
active approach to the management of minor abnormalities would result in 
fewer savings for women.
Under the active and observational approaches, some women who would not 
have treatment might need it in the future because their lesion progresses. If 
their lesions progressed to CIN 3 this may entail a greater expense to 
government. The marginal cost-effectiveness of the observational approach 
over the active approach depends on the probability of progression of minor 
lesions, particularly CEN 1. As discussed in Chapter Two, the studies on the 
natural history of minor lesions are poor. However, in Chapter Three I 
showed that many more women will be referred for colposcopy than would 
ever develop cervical cancer. Most women who are currently referred are 
unlikely to develop CIN 3. Therefore, most of the cost savings from a more
conservative approach to the gynaecological care of women who have smears 
showing CIN 1 or less, would be long term.
Earlier in the chapter I discussed the geometric mean and median costs to 
government of different levels of presenting smear. Assuming that the 
relationships between the costs of care remained the same, if even half the 
women with CIN 1 or less subsequently developed CIN 3 (which is much 
higher than would be expected from natural history studies), long-term 
savings from the active and observational approaches over the current 
approaches would still occur. Progression and regression rates for CIN 1 
based on recently adopted reporting criteria (Commonwealth Department of 
Human Services and Health 1994) are needed before the cost-effectiveness of 
these two approaches can be evaluated further.
The new approaches to gynaecological care of women with abnormal Pap 
smears are likely to produce substantial cost savings in the short term. Much 
of the savings will result from the more judicious referral of women whose 
Pap smears show abnormalities with no evidence of CIN. However, the 
long-term impact of these new approaches depends on the natural history of 
minor abnormalities.
Comparing the costs to women of current and alternative approaches
In this section the costs savings for women of the new Commonwealth policy 
are outlined. The approaches are the same as those outlined in the previous 
section and are summarised in Table 9.7. Again, constant costs were used for 
this analysis.
The potential savings realised by government and women with the 
institution of the new Commonwealth policy recommendations have quite 
different meanings. Government can be considered a single entity. Thus 
new clinical protocols change the amount that government, as a single entity, 
pays. While new clinical protocols will decrease the total amount paid by 
women as a whole, the overall result achieved by the policies will have 
different impacts on different women. Some women will pay the same, some 
will pay less and others will have no out-of-pocket expenses.
In Table 9.9 the proportion of the savings of the costs of the current approach 
are shown for the active and observational approaches.
214
About 40 per cent of the costs to women of the current approach would be 
saved if the active approach were implemented. The cost savings are greater 
at the longer time periods. This is because I assumed that all women who 
had a previous abnormality were still referred. These women would receive 
a colposcopic assessment visit. In the case of the active approach, if their 
colposcopy was normal or there was no histological evidence of CIN these 
women were then discharged. This means they still incur a cost for their 
initial consultation which happens in the first three months.
Table 9.9 Cost savings to women under alternative approaches
S a v in g s  of active  
approach  com p ared  with 
current approach  (%)
S a v in g s  of observational 
approach  com p ared  with 
current approach  (%)
3  m onths (n = 481) 3 8 .8 5 2 .2
6  m onths (n = 459) 3 9 .2 5 3 .9
12 m onths (n = 432) 4 1 .0 5 6 .7
Entire e p is o d e  (n = 374) 42.1 5 7 .8
Over 50 per cent of the costs to women of the current approach would be 
saved if the observational approach were implemented in this clinic. Again, 
the proportion saved is greater as the time period increases. This is because 
women with CIN and recurrent minor abnormalities are still assessed but 
only receive treatment if CIN 2 or greater is confirmed on biopsy. Like costs 
to government, these savings cannot be generalised to the population because 
they are based on women who have already been referred for colposcopy.
In sum, these are short-term savings. The savings in cost to women in the 
long term are contingent upon knowledge of the natural history of these 
minor lesions.
Substantial short-term savings in costs to women would be realised if either 
the observational or active approach were instituted in this clinic. However, 
this relates to the finding that over half of the costs paid by women in this 
sample are from women with CIN 1 or less. At a clinic with a lower 
proportion of women with minor abnormalities the cost savings to women of 
these new approaches would be less.
Predicting the cost to government
Throughout the chapter I have compared costs on the basis of the presenting 
smear. Government policy is formulated in the same way. That is, clinical 
protocols are based on pathological tests. However, the differences in cost to 
government for each level of presenting smear may be confounded by other 
factors, such as insurance status or a woman's age. The comparative costs I 
have shown depend on the distribution of possible confounders such as age 
and health insurance status.
In this section I therefore explore which factors predict costs to government 
in the Canberra Laser Clinic, using multiple linear regression. This enables 
the examination of the association between cost and presenting smear while 
controlling for possible confounders.
Methods
Costs for 1991/92 financial year were used for this analysis. That is, constant 
costs were used for the entire episode. The natural logarithm of cost was 
used as the outcome measure to achieve a constant variance of the residuals 
(homoscedasticity). Therefore, the antilog of the beta coefficient provides an 
estimate of the multiplicative effect on cost of moving from the baseline 
category of an explanatory variable to another category, while holding the 
other explanatory variables constant.
The normality of residuals assumption, which was tested by graphical 
means, was met by these models.
Only women in the 'did not attend category' or 'discharged category', who 
had no missing values on any of the explanatory variables, were included in 
this analysis (n= 328). Women who did not attend were included on the 
assumption that they would not consume any more resources for this 
treatment episode. (They may, of course, consume more resources in the 
future.) Similar results were obtained when the analysis was restricted to 
women who were discharged. A five per cent significance level was used.
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Results
Table 9.10 shows the frequency of variables used in this analysis. Two 
variables that have not been previously described were constructed for this 
analysis. The first variable describes whether or not there was evidence of 
HPV on the presenting smear (+ /- CIN). The second describes whether there 
was cytologic, colposcopic or histologic evidence of persistent abnormalities 
following treatment at any of the visits following treatment.
Table 9.10 Frequencies of variables used in the multivariate analyses of costs to 
government and women
Variable No. of women Percentage (%)*
Presenting sm ear (1 unknown)
No CIN 178 47.5
CIN 1 58 15.5
CIN 2 107 28.5
CIN 3 31 8.3
Age
<25 129 34.4
25-34 136 36.3
>35 110 29.3
Health insurance status (46 unknown)
No private health insurance 159 48.3
Private health insurance 170 51.7
M arital status (67 unknow n)
Ever married 229 74.4
Single 79 25.6
Parity (9 unknow n)
Nulliparous 177 49.7
Parous 179 50.3
H PV  on presenting sm ear (1 unknow n)
No HPV 157 42.0
HPV 217 58.0
Persistence of abnorm alities
No persistent abnormalities 351 93.6
Minor abnormalities < CIN 10 2.7
CIN following treatment 14 3.7
* Cases with missing values on the variable were not included in the calculation of frequency per cent.
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Age and insurance status were entered into the initial model because they 
may confound the relationship between presenting smear and cost. 
Presenting smear was then entered into the model. This significantly 
improved the fit of the model (F (3,322)= 12.78, p < 0.0001). This model 
details of which are given in Table 9.11 below — explained 12.8 per cent of 
the variation in costs.
Table 9.11 Cost to government and age, presenting smear and health insurance 
status
V ariable eß 95%  Cl P va lu e
A ge
< 2 5 1 .0
2 5 - 3 4 0.91 0 .7 8 , 1 .08 0 .2 9
> 3 5 0 .8 4 0 .7 1 , 1 .00 0 .0 5
Health  insurance status
N o private health  in su ran ce 1 .0
Private health in su ran ce 0 .9 5 0 .8 2 , 1 .08 0.41
Presenting sm ear
N o CIN 1.0
CIN 1 1.21 0 .9 9 , 1 .47 0 .0 6
CIN 2 1.41 1 .2 0 , 1 .6 5 < 0 .0 0 0 1
CIN 3 2 .0 5 1 .5 8 , 2 .6 7 < 0 .0 0 0 1
R2=0.128
F(6,322)=7.94, p <0.0001
In this model (Table 9.11) the cost of gynaecological care increases with the 
more severe levels of abnormality. After controlling for age and health 
insurance status, women with CIN 1 to CIN 3 cost government more than 
women with No CIN. This is statistically significant, at the five per cent 
level, for CIN 2 and 3. Women with CIN 3 cost approximately twice as much 
to government as women with no evidence of CIN. The relationship between 
diagnosis and cost is likely to be mediated by in-hospital treatment and 
through more clinic visits. More serious abnormalities may result in hospital 
admission and more costly inpatient procedures. Similarly, more serious 
abnormalities may result in more clinic visits. The increasing costs of 
treatment with level of abnormality may be related to the finding that women 
with more severe abnormalities are more likely to be admitted to hospital 
(x2 =14.92, df=3, p=0.002). However, although there appears to be an
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association between the severity of the presenting smear and hospitalisation, 
the strength of this association is weak (phi=0.203, p=0.002). Also, women 
with higher levels of abnormalities appear to have more clinic visits (medians 
test, x2 =15.64, df=3, p=0.0013).
Cost decreased with age. Women older than 35 cost 16 per cent less to 
government than women under 25.
An interaction between age and presenting smear was incorporated into the 
model to examine whether presenting smear is an effect modifier of age. The 
addition of this variable addresses the question: is the effect of age different 
for the different categories of presenting smear? Ten women had persistent 
minor abnormalities such as atypia or CIN following ablative or excisional 
treatment. Fourteen women had persistent evidence of CIN after treatment.
A variable describing persistence of abnormalities was also added to the 
model. Adding the variables describing the age/presenting smear 
interaction and persistence of abnormalities significantly improved the fit of 
the model (F (8, 314)=3.73, p=0.003). Table 9.12 details this model.
Women who have persistent abnormalities with evidence of CIN cost the 
government approximately 60 per cent more than women with no persistent 
abnormalities after treatment.
For CIN 1 or less, women over age 35 cost government less than women 
under 25. When there is no evidence of CIN, women older than 35 cost 
government 63 per cent of the cost of treating women younger than 25 with 
no evidence of CIN. However, in the case of CIN 3, women over 35 cost the 
government 2.43 times more than women younger than 25.
In contrast, the costs of treating women in the 25 to 34 year old age group did 
not vary significantly from women under 25 for all levels of abnormality.
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Table 9.12 Final model for predicting costs to government
Variable eß 95% Cl P value
Age
<25 1.0
25 - 34 0.83 0.65, 1.05 0.13
>35 0.63 0.49, 0.80 0.0002
Health  insurance status
No private health insurance 1.0
Private health insurance 0.95 0.83, 1.08 0.43
P resenting sm ear
NoCIN 1.0
CIN 1 0.97 0.71, 1.33 0.86
CIN2 1.05 0.81, 1.37 0.68
CIN 3 1.38 0.83, 2.31 0.22
A ge/P resenting  sm ear interactions
Age 25-34 X CIN 1 1.14 0.73, 1.77 0.57
Age 25-34 X CIN 2 1.27 0.87, 1.85 0.21
Age 25-34 X CIN 3 1.25 0.68, 2.31 0.48
Age > 35 X CIN 1 1.73 1.05, 2.85 0.03
Age > 35 x CIN 2 1.74 1.20, 2.53 0.004
Age > 35 x CIN 3 3.86 1.74, 8.56 0.001
P ersistence of abnorm alities
No recurrence 1.0
No CIN 1.35 0.92, 1.99 0.12
Evidence of CIN 1.58 1.14, 2.20 0.006
R2=0.226
F =5.77, df=16,312, p < 0.0001
On the other hand, for minor levels of abnormality, women younger than 25 
cost government more than women older than 35. Further exploration of the 
data revealed more intensive outpatient follow-up of younger women with 
minor abnormalities. The Mann-Whitney test was used to compare the 
number of visits for women less than 25 and women 35 or older. Younger 
women had significantly more visits than women older than 35 (n=239, z=- 
2.37, 2 tailed p=0.018). However, after stratifying by category of presenting 
smear, it was found that there was only a statistically significant difference in 
the number of visits between women younger than 25 and women 35 or older 
if the presenting smear did not show any evidence of CIN (M-W test, n=116,
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z=-3.09, 2 tailed p=0.0021). For presenting smears showing CIN 1 or greater 
there was not a statistically significant difference (at the five per cent level) in 
the number of visits between younger and older women.
Marital status and parity did not predict costs to government and were not 
confounders of other variables.
Conclusion
This multivariate analysis has demonstrated that there are associations 
between costs to government and presenting smear, age and persistence of 
abnormalities following treatment.
There are two problems with the analysis. First, only women in the 
discharged and not-attending categories were included, since it is not 
possible to account easily for censoring when there is a continuous outcome 
variable. The exclusion of women in the other follow-up status categories 
may bias the results. Second, I assumed that women who had private health 
insurance and were admitted to a public hospital (n= 8) were admitted as 
public patients. If these women were admitted as private patients the 
government receives some revenue. Hence the cost to government of these 
women's treatment would be overestimated. It could be argued that 
presenting smear is not a good measure of the severity of the abnormality 
since there was such poor correlation between presenting smear, colposcopy 
and histology. However, when this analysis was performed using histology 
instead of cytology, similar results were obtained (also including the 
interaction between age and level of abnormality).
The increasing costs of treatment for more severe levels of abnormality may 
be related to the increased chance of hospitalisation. Many gynaecologists in 
the ACT cannot treat women as an outpatient (for example, they do not have 
a CC>2 laser). These gynaecologists admit all women who require treatment 
to hospital. Such practices are likely to result in greater costs to government.
There is a suggestion that clinical practices may vary with different levels of 
abnormality for women of different ages. Women at younger ages appear to 
receive more intensive follow-up if they have minor abnormalities, while 
older women are more likely to have intensive treatment if they have severe 
abnormalities.
The increased cost of treating women older than 35 with CIN 3 may reflect 
the tendency for gynaecologists to undertake more radical treatment in the 
older age group. Four of the five women in this sample who had a 
hysterectomy were in the older age group. Conservation of reproductive 
function may be the rationale for less intensive treatment in the younger age 
groups. A sociological study based in an American hospital outpatient 
service which saw women with abnormal Pap smears, showed that clinicians 
were more likely to suggest hysterectomy to older women (Fisher 1986).
Explaining these differences requires further understanding of the world of 
the clinician. If an explanation for the increasing cost of treatment for women 
over 35 with CIN 3 is that they have radical treatment while younger women 
have more conservative treatment, why is this so? One answer might be that 
doctors think women over 35 are less likely to have further children and 
therefore use more radical treatment in the older age group. As discussed 
earlier, other studies have demonstrated that the treatment practices of 
clinicians vary with women's socio-demographic variables. For example, one 
Australian study showed that women with private health insurance were 
more likely to have a hysterectomy than women who only had public health 
insurance (Renwick 1991).
Why do younger women cost more when they have minor abnormalities? 
Younger women with no evidence of CIN have more visits than older 
women. Do the gynaecologists respond differentially to young women with 
minor lesions? If so, why? Are they more fearful of missing a significant 
lesion in a younger woman?
It is clear that the heterogeneity in the costs of treatment to government can 
not be adequately explained by clinicians making decisions on the basis of 
diagnosis alone. Other factors, such as a woman's age, influence clinical 
decision-making.
Containing the costs of current treatment could be improved if we had a 
better understanding of how diagnosis and other variables relating to both 
clinician and patient influenced cost. Clearly, factors other than diagnosis (as 
measured by presenting smear) explain the variation in costs.
Predicting costs to women
Like costs to government, the relationship between costs to women and 
presenting smear may be confounded by other factors such as age and health 
insurance status. Therefore, using multiple linear regression I examine the 
relationship between presenting smear and costs to women (after controlling 
for possible confounders), and explore other factors that may be associated 
with costs to women in this sample.
Methods
Cost to women is the outcome measure of interest. The assumptions of 
normality and constant variance of residuals were met by the following 
models. These assumptions were tested graphically.
In this analysis 328 cases were used. Only women in the discharged and not- 
attending categories were included. Women with missing values on any of 
the explanatory variables were not included in this analysis. A five per cent 
significance level was used.
Results
The frequencies of the categories for each of the variables used in this 
analysis were shown in Table 9.10.
Age and insurance status were entered into the model first. When presenting 
smear was added to this model it improved the predictive power of the 
model (F=4.94, df=3,322, p=0.002). The variable describing persistence of 
abnormalities was entered into the model next. This improved the model 
further (F=29.4, df=2,320, P<0.0001). The interaction between age and 
presenting smear, which was significant in the cost to government model, 
was not an important predictor of cost to women.
Another variable describing whether or not women had HPV of presenting 
smear was added to the model. This variable enhanced the model's 
predictive power a small amount (F=4.48, df=2,319, p=0.04). Parity and 
marital status did not explain the variation in costs to women in this sample.
Age, health insurance status, presenting smear and presence of FIPV 
explained 24 per cent of the variation of the costs to women in this sample. 
Table 9.13 shows this model.
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Whether or not women have persistent abnormalities after ablative or 
excisional treatment seems to exert influence over the costs women pay. 
Women with persistent abnormalities less than CIN pay, on average, $84 
more than other women, after controlling for the other variables. If a woman 
has persistent CIN after treatment then she pays $130 more. These women 
will be followed for longer, and may receive further treatment, because of 
their persistent abnormalities. The Mann-Whitney test shows that women 
with persistent minor abnormalities (no evidence of CIN) tended to have 
more visits than women who had normal smears and colposcopy following 
treatment (M-W Test, n=361, z=-3.23, p=0.0012). Women with CIN following 
treatment also attended a greater number of visits than women who had 
normal cytology or colposcopy following treatment (M-W test, n=366, z=- 
4.96, p<0.0001).
Table 9.13 Predicting costs to women
Variable ß($> 95% Cl P value
Age
<25 0.0
2 5 -3 4 -3.64 -23.59,16.31 0.71
>35 -29.15 -50.57, -7.73 0.008
Health  Insurance status
Public health insurance only 0.0
Private health insurance 3.46 -12.94, 19.84 0.68
Presenting sm ear
No CIN 0.0
CIN 1 8.30 -10.35, 26.95 0.49
CIN 2 30.50 11.84, 49.16 0.0015
CIN 3 20.95 -9.67, 51.57 0.18
H PV on presenting sm ear
NoHPV 0.00
HPV 18.48 1.39, 35.57 0.035
Persistence of abnorm alities
No recurrence 0.0
No CIN 83.95 37.97, 129.93 0.004
Evidence of CIN 130.26 90.96, 169.56 <0.0001
R2=0.244
F=11.46, df=9, 319 p<  0.0001
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Women older than 35 appear to pay less than younger women. There is no 
statistically significant difference in the effect of age for different categories of 
presenting smear. In the costs to government analysis women over 35 paid 
more for major abnormalities and less for minor abnormalities. However, 
most of the effect for major abnormalities may have been explained by an 
increasing risk of hospitalisation and more radical treatment in this age 
group. Because public hospital inpatient treatment does not cost women 
anything, the interaction between age and presenting smear is not important 
even though older women had more radical treatment than younger women 
for higher levels of abnormality. Instead, because younger women have 
more clinic visits, younger women had slightly greater out-of-pocket 
expenses than women over 35.
Women with HPV paid on average about $18 more than other women after 
controlling for other variables. However, there was not a statistically 
significant difference in the number of visits that women with HPV on 
presenting smear had compared with women with no evidence of HPV (M- 
W test, n=374, z=-1.58, p=0.11).
Women with CIN 2 and CIN 3 appear to pay about $30 more than other 
women after controlling for other variables. Compared with women with no 
evidence of CIN, women with CIN 2 have more clinic visits (M-W test, n=285, 
z=-4.00, p=0.0001). Women with CIN 3 also have more visits than women 
with no CIN (M-W test, n=209, z=-2.02, p=0.04). There was no statistically 
significant difference in the number of visits between women with CIN 1 and 
women with no evidence of CIN.
Conclusion
More severe abnormalities appear to cost women slightly more. A woman's 
age also influences how much she pays. Further exploration of how clinical 
practices differ in relation to age is required. Once such differences have 
been identified then possible explanations for such differences should be 
examined.
Factors which influence the number of visits (for example, age, presenting 
smear, persistent abnormalities and presence of HPV infection) are significant 
predictors of costs to women. Women who have persistent abnormalities 
appear to be followed longer, explaining why they pay more than other 
women in the study. Women with CIN 2 and CIN 3 on presenting smear
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have more visits, and hence have greater out-of-pocket expenses, than other 
women. If more were known about what factors are associated with 
increased length of follow-up, policy formulation could be more cognisant of 
such factors and, possibly, save women out-of-pocket expense.
Costs to women were more homogeneous with respect to category of 
presenting smear than costs to government. This is because most women had 
no out-of-pocket expenses for hospitalisation. Hence most of the costs to 
women were for outpatient treatment. The assumption that 15 women (in 
the multivariate analysis) with private health insurance were admitted to the 
public hospital as public patients may have biased these results considerably. 
If their expenses as private patients in a public hospital were included, this 
may have increased the cost estimates for the more severe levels of 
presenting smear.
However, this regression analysis of cost only included women who 
completed treatment' (i.e. were discharged or did not attend). Because 
women in other follow-up status groups were not included these results may 
be biased in unknown ways.
Discussion
CIN 1 or less made up over half the cost to government and women for this 
sample. There is no doubt that consistent recommendations regarding the 
appropriate approach to these minor abnormalities are necessary. If the 
Commonwealth recommendations are implemented they are likely to result 
in substantial cost savings in the short term. In the long term, the cost 
savings depend on the natural history of minor lesions. If the progression 
rates are low then substantial savings will also be realised in the long term. 
Whether the observational approach would realise savings over and above 
the active approach also rests on knowledge of the natural history of CIN 1.
In Chapter Three I suggest that, based on current diagnostic and referral 
practices, very few women who are referred for colposcopy currently would 
ever develop cervical cancer. Therefore, the new Commonwealth approach is 
also likely to result in savings in the long term.
There does appear to be a relationship between presenting smear and cost 
both to government and to women. With increasing severity the cost 
increases. This relationship is stronger for costs to government than costs to 
women. CIN 3 appears to cost government substantially more than any other
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lesion. This has implications for policy. If conservative approaches to the 
care of women who have minor lesions are adopted they may cost more to 
government in the future because they may progress to CIN 3 which is more 
expensive to treat. Again, whether this would negate the cost savings of the 
approaches advocated by Commonwealth requires further knowledge of the 
natural history of minor lesions.
However, the relationship between costs and presenting smear is not 
straightforward. The multivariate analyses of costs to government and costs 
to women suggest that factors other than diagnosis influence clinical practice. 
Age was an important factor in relation to costs. Women over 35 cost more to 
government when they had CIN 3 than other women, whereas women 
younger than 35 cost more to government when they had minor 
abnormalities. Women over 35 had fewer out-of-pocket expenses than other 
women.
This study only considered direct costs to women. The indirect costs of time 
off work, childcare and transportation also entail expense for women.
As this study was located in a private outpatient service, the findings in 
terms of costs to government and women are not relevant to the experience 
of women who attend public hospital outpatient colposcopy services which 
do not involve a direct cost to women.
However, at the clinic studied, women with any level of abnormality had 
significant out-of-pocket expenses. Indeed, many women commented on the 
expense of treatment in my interviews with them. In the next chapter, I 
examine what factors predict non-attendance for colposcopy clinic follow-up, 
and explore how the financial costs to women may constitute a barrier to 
some continuing participation in follow-up.
Unfortunately, few socio-demographic variables were collected in this study. 
Further exploration of the relationship between women's socio-demographic 
variables and cost might reveal more about the process of clinical decision­
making in relation to women who have abnormal Pap smears. A population 
data base linking women’s screening history and clinical data would enable 
examination of these relationships.
Policy is couched in terms that assume clinical decision-making is based on 
biomedical evidence alone. Instead, clinical decision-making is likely to be 
based on the world views of clinicians, which is partly based on clinical
findings. It would be useful to know how the world views of gynaecologists 
shape the recommendations they make about each woman's care. This 
suggests that what constitutes rational policy may be different from what 
constitutes rational clinical practice. Therefore, there may be difficulty in 
applying the simplified protocols of policy to the clinical situation. I return 
to the dissonances between public health policy-making and clinical practice 
in Chapter Eleven.
The multivariate analyses demonstrate the need to examine cost with real 
rather than hypothetical data. Hypothetical models, used to simulate the cost 
of various clinical practices, rely on simplistic assumptions about the nature 
of clinical decision-making. Such models reduce decision-making to a few 
variables, usually related to diagnosis, and fail to capture the complexity of 
the process.
This analysis suggests that substantial savings may be realised by instituting 
current policy initiatives. However, further cost savings might be achieved if 
policy was cognisant of the process of clinical decision-making. Recognition 
in policy of the ways clinicians make recommendations might also enable 
further accountability of clinicians as well as facilitate the delivery of a better 
service for women.
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Chapter Ten
Attendance for colposcopy clinic follow-up after referral for an
abnormal Pap smear
Not completing gynaecological follow-up may place women at greater risk of 
cervical cancer in the future. In this chapter I examine which categories of 
women are least likely to attend for colposcopy clinic follow-up. Twenty per 
cent of women in the CLC sample did not complete the follow-up 
recommended by their clinicians. By drawing on the findings of Part B and 
Chapter Nine of this thesis, I explore possible explanations for the different 
pattern of attendance.
Methods
The CLC sample was used for this study. Presenting smear was used as an 
indicator of the severity of the abnormality. For this analysis the women's 
presenting smear was divided into two groups: minor abnormalities (CIN 1 
or less including smears with HPV effect, minor atypia and inflammation), 
and major abnormalities (CIN 2 or 3).
Several proportions are calculated. First, the proportions of women who did 
not attend after one and two assessment visits are calculated. Second, I 
calculate the proportions of women who did not attend for one follow-up 
visit after they had ablative or excisional treatment and who did not attend 
after one or more follow-up visits after treatment. For these calculations the 
denominator was all women who were at risk of not attending at the 
subsequent visit. For example, for the first assessment visit the denominator 
included all those women who were not classified into any of the follow-up 
groups, other than 'did not attend', on the date of their assessment visit. That 
is, the denominator is comprised of all women who are at risk of being non- 
attenders for the second visit.
Unfortunately, no variables which indicate the sample group's socio­
economic status could be collected in this study. Flowever, income has a
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strong relationship to private health insurance status. Although fewer 
younger people have private health insurance, the relationship between 
income and private health insurance is strong across all age groups 
(Australian Bureau of Statistics 1993b). Young single-parent families are least 
likely to have private health insurance, whereas families where the major 
contributor is between 35 and 54 have the highest levels of insurance 
(Australian Bureau of Statistics 1993b).
Only those women who, after their first visit to their gynaecologist, were 
recommended for further gynaecological assessment or treatment, were 
included in this analysis. (Nine women were excluded because they were 
discharged after one visit.) Using Cox proportional hazards modelling 1 
examine how socio-demographic and clinical variables relate to non- 
attendance (Anderson, Auquier et al. 1980). This is a multivariate analytical 
technique, which is appropriate for follow-up data with a dichotomous 
outcome and censoring, and which provides estimates of relative risk.
Cox proportional hazards modelling produces unbiased estimates of the 
association between the variables recorded and women's non-attendance 
because it accounts for the time-dependent nature of women's follow-up 
status. The follow-up states — moved, discharged, still attending, and 
unknown — preclude women being categorised as 'not attending' at a later 
date. The frequency and distribution of days for each of the five follow-up 
states are shown on Table 8.4, pl74. For this analysis the outcome of interest 
is non-attendance. Women in the other discharge groups are censored on the 
date they receive their follow-up status code. This means that women not 
classified as non-attenders contribute to the analysis until they are 
discharged, move, change gynaecologists, or their follow-up status becomes 
unknown. Those still attending at the end of the case note audit contribute to 
the analysis for the time period they attend the clinic.
An underlying assumption of the method is that the relative risk or hazard 
for the outcome between the different covariate groups is constant over time. 
The models satisfied the assumptions of the proportional hazards analysis. 
Graphical techniques were used to test the proportional hazards assumption.
Treatment was entered into the model as a time-dependent variable. The 
women were assigned to the treatment category when they had ablative or 
excisional treatment to their cervix. Until they had treatment, they were in 
the 'no treatment' category.
230
Using the likelihood ratio test, which produces a chi-square statistic, new 
models are compared with previous models in the Cox proportional hazards 
analysis. In the multivariate analysis only cases for which there were no 
missing values on any of the variables were used. This means that 
comparisons between the different models could be made. A five per cent 
significance level was used. SPSS and EGRET were used for these analyses. 
(SPSS-X Inc 1988; Statistics and Epidemiology Research Corporation 1990).
Results
Twenty per cent of the women in this study did not continue to attend the 
clinic as recommended by their gynaecologist. This is a non-attendance rate 
of 2.2 women per 100 women months. Some of the women of unknown 
follow-up status may have been non-attenders. If these are reclassified as 
non-attenders, 29 per cent of the sample is lost to follow-up and the non- 
attendance rate is 3.1 per 100 women months. Only two women who had a 
major abnormality and evidence of persistent disease did not have 
appropriate treatment. Of the 102 women who were classified as non- 
attenders, 49 had a normal colposcopy and Pap smear on their last visit.
After one clinic visit, 1.4 per cent of women did not attend the subsequent 
visit (n=485). Of the women who had treatment, 6.1 per cent did not attend 
for the next follow-up visit (n=395). Reclassifying as non-attenders those 
women who were of unknown follow-up status on their assessment or 
treatment visit changes the proportion not attending after the first assessment 
and treatment visits to 1.9 and 6.3 per cent respectively. For those who did 
not have treatment, the proportion who did not attend after one follow-up 
visit was 21.7 per cent (n=297); if those women in the unknown category are 
reclassified as non-attenders, the proportion is then 30.9 per cent (n=307). 
Irrespective of whether a woman had treatment, the proportion who did not 
attend for subsequent visits after their second and third visits was 17.7 and 
23.5 per cent, respectively.
Predictors of non-attendance
The distribution of variables used in this analysis is detailed in Table 10.1.
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Table 10.1 Socio-demographic characteristics and clinical details of sample
Variable No. of women Percentage (%) No. not 
attending
Percentage not 
attending (%)
Presenting  sm ear (n=492)
Minor abnormality 294 59.8 62 21.1
Major abnormality 198 40.2 40 20.2
A ge (n=493)
<25 173 32.0 48 27.7
25- 34 179 37.3 33 18.4
>35 141 30.7 21 14.9
Health insurance status  
(n=439)
No private health insurance 213 43.8 59 27.7
Private health insurance 226 56.3 28 12.4
M arital status (n=446)
Ever married 348 77.8 68 19.5
Single 98 22.2 18 20.9
P arity (n=468)
Nulliparous 234 50.0 47 20.1
Parous 234 50.0 47 20.1
P revious Pap sm ear h istory  
(n=457)
Normal or never* 287 60.4 69 24.0
Abnormal 170 39.6 27 15.9
S elf-reported  Pap sm ear 
frequ en cy (n=442)
At least biennial 336 76.0 67 19.9
Less than biennial 106 24.0 26 24.5
Treatm ent** (n=493) 
No treatment 91 18.5 22 24.2
Treatment 402 81.5 80 19.9
* This group includes 32 women who had never previously had a smear as well as women who 
reported previously normal smears only
** Women were in the treatment group if they had treatment at any time during the study period. 
Because treatment is a time dependent co-variate those in the treatment category contributed to the 
estimates of the hazard ratio for the treatment category until they had treatment.
Bivariate analyses of the relationship between women's socio-demographic 
variables, treatment and presenting cytology, and non-attendance, produce 
estimates of the unadjusted relative risk for each of the variables. The results 
of the bivariate analyses are shown in Table 10.2.
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Table 10.2 Bivariate analyses of socio-demographic and clinical variables and non- 
attendance
Variable Relative risk 95% confidence intervals
A ge (n=493)*
<25 1.00 0.39, 0.96
25-34 0.62 0.30, 0.85
>35 0.51
Insurance status (n=439)*
No private health insurance 1.00
Private health insurance 0.46 0.30, 0.73
Parity  (n=468)
Nulliparous 1.00
Parous 0.96 0.64, 1.45
M arital status (n=446)
Ever married 1.00
Single
Self -reported  Pap sm ear frequency (n=442)
1.06 0.63, 1.79
Annual/Biennial 1.00
Less than biennial 1.18 0.75, 1.85
P revious Pap sm ear history (n=457)
Normal or never 1.00
Abnormal 0.66 0.43, 1.04
Presenting sm ear (n=492)
Minor abnormality 1.00
Major abnormality 0.78 0.52, 1.17
Treatm ent (n = 4 9 3 )"
No treatment 1.00
Treatment 2.30 1.25, 4.21
*Log rank test significant at the five per cent level.
"Treatment is a time-dependent co-variate which is coded zero before treatment and one after 
treatment. Since treatment is a time-dependent the significance of the co-variate can only be assessed
by using the Wald statistic (p=0.007) or the Log likelihood ratio test (A x2=8.32, df=1, p=0.004).
On the bivariate analyses, women with private health insurance were less 
likely to discontinue attending (relative risk 0.47,95% confidence intervals 
0.30 - 0.73, log rank test, x2 =11.82, df=l, p <0.001). Women were more likely 
to discontinue attending after treatment compared with before treatment 
(relative risk 2.30,95% confidence intervals 1.25-4.21, df=l, p=0.007). Non- 
attendance was also associated with age. Women between 25 and 34 (relative
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risk 0.62, 95 confidence intervals 0.39 - 0.96, p=0.03) and women 35 and older 
(relative risk 0.51, 95% confidence intervals 0.31 - 0.85, p=0.01) were at less 
risk of not attending than women less than 25 years of age.
However, the effect of private health insurance is likely to be confounded by 
other variables. In her Health Strategy paper, Sharon Willcox reports on the 
findings of an unpublished health insurance survey. (Willcox 1991). This 
survey showed that the factors people use to explain whether or not they 
have private health insurance include cost, beliefs about the adequacy of 
Medicare and their health status. Age, marital status and parity are also 
related to private health insurance status. (Australian Bureau of Statistics 
1993b). Presenting smear is also likely to be a confounder of women’s 
treatment status.
To assess the associations between variables collected in this study and non- 
attendance, and to enable control of confounding, the approach outlined by 
Kleinbaum et al. was used. (Kleinbaum, Küpper et al. 1982). All the variables 
were entered into the model (x2 =23.61, df=9, p =0.005). Using the forward 
selection procedure outlined by Kleinbaum et al. (1982), the significance of 
two-way interactions between the variables was then tested. Only an 
interaction between private health insurance and previous Pap smear history 
improved the model fit (x2 =10.34, df=l, p=0.001). Those women who had 
never had an abnormal Pap smear prior to the smear which resulted in their 
referral to the clinic, were less likely to attend if they did not have private 
health insurance. In contrast, the association between private health 
insurance status and non-attendance was not significant for women who had 
had abnormalities prior to referral. Neither marital status nor self-reported 
Pap smear frequency was a significant predictor of non-attendance, and did 
not change the estimates of the effects of any of the other variables. These 
were consequently dropped from the final model. Table 10.3 details the final 
model.
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Table 10.3 Multivariate Cox proportional hazards model and non-attendance
(n=337)
Variable Relative risk 95% confidence Intervals
Age
<25 1.00
25-34 * 0.49 0.26, 0.91
>35 0.47 0.21, 1.06
Parity
Nulliparous 1.00
Parous * 1.99 1.07, 3.69
Presenting sm ear
Minor abnormality 1.00
Major abnormality * 0.57 0.33, 0.97
Treatm ent
No treatment 1.00
Treatment * 3.13 1.42, 6.90
Previously normal Pap sm ears
No private health insurance 1.00 0.17, 0.66
Private health insurance * 0.34
Previously abnorm al Pap sm ears
No private health insurance 1.00 0.84, 6.55
Private health insurance 2.34
Deviance df
Initial Model 690.3 336
Final Model 657.5 328
C
M<
32.8 8
* Wald statistic significant at the five per cent level.
Unfortunately, many case notes were incomplete. Any case with missing 
values on any of the variables was excluded from the multivariate analyses 
so that comparisons between various models could be made. In the overall 
sample, 56 women (11%) did not have their private health insurance status 
recorded. Women for whom private health insurance status was recorded 
tended to be slightly younger (geometric mean age 26,95% confidence 
intervals 24.0-28.0) compared to the balance of the sample (geometric mean 
age 29,95% confidence intervals 28-30, t=2.78, p=0.006). These women were 
also less likely to have children (odds ratio 0.49,95% confidence intervals 
0.27-0.90, x2=5.52, df=l, p=0.02).
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Discussion
This study has demonstrated that a significant proportion of women do not 
complete the follow-up recommended by their clinicians after treatment. In a 
sample of women attending a private colposcopy clinic, I have shown that 
non-attendance was associated with age, parity, severity of smear and private 
health insurance status for women who had not previously had an abnormal 
Pap smear. In this sample, women who had had treatment were three times 
more likely not to attend than women who had not had treatment.
Most women attended the visit subsequent to their initial assessment visit. 
Most women who had treatment also attended a follow-up visit. For women 
who had treatment, most of the losses to follow-up occurred after the first 
follow-up visit after treatment. The new Australian guidelines recommend at 
least one colposcopy and Pap smear following treatment. It is suggested that 
a woman has a Pap smear 12 months after treatment. A colposcopy may also 
be performed 12 months following treatment. (Commonwealth Department 
of Human Services and Health 1994). However, this study was conducted 
before such guidelines were in place.
This study could only investigate the predictors of subsequent non- 
attendance for women who attend at least one clinic appointment. Also, 
some women may have attended other gynaecologists. However, as there 
are no public hospital clinics in Canberra, there is no financial reason to 
change gynaecologists unless other gynaecologists have different billing 
practices. If some women attended other clinics this study may overestimate 
the proportion of non-attenders. Some women in the unknown' follow-up 
status group are probably non-attenders. Censoring their observations at the 
time they receive their 'unknown' follow-up code would only bias the 
estimates obtained if the censoring was associated both with the explanatory 
variables and non-attendance. If censoring was only related to non- 
attendance, estimates of relative risk might lack precision but would still be 
unbiased.
Barriers to participation?
One way of considering possible explanations for non-attendance is to think 
in terms of structural or cultural barriers. Factors such as financial cost, 
travel and childcare might be considered structural barriers. Cultural 
barriers include the beliefs and understandings of women and their medical
236
practitioners towards their abnormal Pap smear. Below I discuss possible 
barriers and propose how they may operate to produce the pattern of 
attendance I have described in this chapter.
Structural barriers
I have shown that women with abnormal Pap smears face significant out-of- 
pocket of expenses for their gynaecological care. As discussed previously 
private health insurance status is related to income (Australian Bureau of 
Statistics 1993b). Young women and women with children may also 
experience economic disadvantage. Because most care is undertaken on an 
outpatient basis all women, insured or uninsured, face similar expenses. The 
clinic where this study was conducted has a policy of direct billing (charging 
at the same level as the Medicare benefit) women they perceive to be 
economically disadvantaged. But these women probably comprise only a 
small proportion of women who find cost a barrier to access.
Women who are admitted to hospital as private patients also face significant 
expense. To test whether cost might be an important explanation for non- 
attendance for these women, one would have to examine whether they were 
at greater risk of non-attendance prior to their admission to hospital.
If financial cost is an important barrier to follow-up for women in this study, 
the associations between private health insurance status, age and parity and 
attendance may be particularly strong in the ACT because there are no public 
hospital clinics. In other Australian cities, women have the option of 
attending public hospital clinics which do not entail a financial cost to them.
Lack of transport and child care may be barriers to participation in follow-up 
for some women. American women without private health insurance who 
had abnormal Pap smears were more likely to attend for follow-up if they 
were sent bus tickets to get to the clinic. In contrast, a health education 
intervention did not increase the attendance of uninsured women (Marcus 
1992).
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Cultural barriers
In the multivariate analysis, women who had treatment were three times 
more likely to discontinue attending than women who had not had 
treatment. In Chapter Five I discussed how some women's perceptions of 
their risk of cervical cancer and even death shifted after having treatment. 
After treatment, some women perceived themselves to be at similar risk of 
cervical cancer as other women. Many regarded themselves to be 'cured' of 
their abnormality after treatment. Hence, some women may have considered 
continued follow-up after treatment unnecessary because they were no 
longer at risk of cervical cancer or death. A longitudinal study that explored 
how women's perception of their risk of cervical cancer changed over the 
course of their diagnosis, treatment and follow-up may have thrown more 
light on this matter. Certainly, an indepth study with women who did not 
attend after treatment could explore this proposition further.
Socio-cultural differences between women patients and their gynaecologists 
may produce barriers to continuing attendance. Could socio-cultural 
differences explain the pattern of attendance described in this chapter? It 
may be that the categories of women described as non-attenders have less in 
common with their doctors than other women.
In Chapter Six I also explored how women made sense of their abnormality. 
Many sought explanations such as stress and lifestyle factors which were 
rooted in their own life circumstances. Some women considered that their 
gynaecologists were not cognisant of the meanings their abnormality held for 
them. Therefore, the high non-attendance rate could be partly attributable to 
the conflicts women experience between their own way of understanding 
their abnormal Pap smear and the gynaecological care they received.
Anthropologist, Emily Martin, found that middle class women tended to 
describe menstruation in the scientific terms of failed production. On the 
other hand, working class women's accounts of menstruation were 
phenomenologically based. Working class women's descriptions dealt with 
their own experiences as menstruators (Martin 1987). Similarly, in reporting 
a study with Italo-Australian women, Gifford (1994) suggests participants' 
ways of understanding cancer and menopause may constitute barriers to 
their attendance in cancer screening services (Gifford 1994). Basker (1983) 
demonstrated how conflicting meaning systems between lay women and the
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medical mediators for abortion and contraception resulted in communication 
difficulties.
Women may explain and understand their condition differently from their 
gynaecologists. These differences may be more obvious when the women do 
not share similar social positions or cultural backgrounds as their doctor. As 
the qualitative study was based on a small Canberra sample which was 
relatively homogeneous in terms of class and ethnicity, these differences 
could not be explored.
The way gynaecologists regard their patients may depend on the patients' 
social and cultural background. In a participant observation study based in 
hospital clinics for women with precancerous cervical lesions, Fischer (1986) 
found that poorer women and older women were more frequently 
recommended for hysterectomy than other women with similar complaints. 
Medical practitioners' recommendations were based on their feelings about 
individual patient and less on biomedical evidence. Sociological analysis 
suggests that the social order of society is reflected in and produced by 
medical interactions. For example, a participant observation study of some 
Canberra general practitioners and their clients revealed that the gender 
order of society also manifests in general practice medical encounters 
(Broom-Darroch 1978).
In the above discussion I have considered non-attendance in terms of barriers 
to participation rather than poor compliance. Compliance focuses attention 
on the individual. In doing so the problem is located in the individual and 
attention is directed towards developing strategies that encourage 
individuals to follow medical advice. Zola (1980) argues that patients should 
be allies in their own management plans.
In Chapter Six I proposed that if greater cognisance were given to women's 
understanding and meanings systems for cervical abnormalities, 
management plans more satisfactory both to gynaecologists and their women 
patients might be negotiated which would improve the experience for 
women.
In Chapter Seven I discussed how some women experienced pain or 
discomfort with their biopsy or treatment. Such experiences may explain 
why some did not attend subsequent visits. Women required further 
information about treatment and its after-effects.
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In Part B I argued that their was a need for greater information exchange 
between gynaecologists and women. In this chapter I suggest that this 
information exchange is not only necessary in terms of reducing the personal 
burden of this condition but may also improve attendance.
Screening history data
An effective cervical cancer screening program requires attention to all steps 
along the 'screening pathway'. The screening pathway is a concept used to 
describe six elements: screening of an identified population at designated 
intervals; the recruitment of women; provision of appropriate services for 
taking and processing Pap smears; ensuring the adequate follow-up of 
women who have abnormal Pap smears and continuing evaluation of the 
screening program; policy support; and co-ordination to ensure 
communication between all steps.
In Australia, we do not know which groups of women are at risk of not 
completing the screening pathway. This is partly because there is no 
population data base from which to examine this issue.
If screening and clinical data were linked, we could examine at what points 
along the screening pathway specific women were more at risk of being lost 
to follow-up. The report of the Steering Group on Quality Assurance in 
Screening for the Prevention of Cancer of the Cervix recommends that 
cervical cytology registries carry details of women's treatment as well as their 
colposcopy, cytology and histology findings. (Commonwealth Department 
of Human Services and Health 1993). If cervical cytology registries carried 
such details we could, using the methods used in this study, examine which 
categories of women are at risk of not completing at various points in the 
screening pathway, using a population data base. However, such data would 
be difficult to collect. Whether it is possible for cytology registries to gather 
data on the follow-up and treatment received by women who have abnormal 
Pap smears is currently being debated.
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Summary
In this chapter I have examined which groups of women were at risk of not 
attending colposcopy follow-up. I showed that age, parity, previous Pap 
smear history, health insurance status and treatment status were associated 
with non-attendance in this sample. I explored possible structural and 
cultural barriers to continued attendance. In doing so, I drew on the results 
of Part B of this thesis to suggest that dissonance between the meaning 
systems of gynaecologists and women patients may contribute to the low 
attendance rate. I suggested that the financial cost of treatment to women 
described in Chapter Nine may constitute a structural barrier to attendance.
Part D
Closing and balancing accounts
Chapter Eleven
Conclusion
This chapter considers the findings of the thesis in terms of the individual 
and aggregate costs of abnormal Pap smears. I propose a framework for 
interpreting these costs and suggest possible ways of reducing them. The 
thesis concludes with a discussion of future research directions.
The costs of current practice
Aggregate costs are the economic, social, and cultural consequences of 
abnormal Pap smears experienced by the community. Individual costs are 
the economic, personal and social costs that individuals with abnormal Pap 
smears experience. In this section the research findings of the thesis are 
considered in terms of these two costs.
In the colposcopy clinic studied for this research, a significant proportion of 
the economic costs to government come from investigating women who have 
CIN 1 or less. These costs would not be incurred in countries where 
colposcopy is only recommended for women with CIN 2 or 3. Women with 
CIN 1 or less paid over half the total out-of-pocket expenses paid by all 
women in the CLC sample.
How do aggregate social or cultural costs occur? Social practices shape how 
we understand ourselves and our world. For example, Metcalfe (1993) 
argues that health promotion strategies, designed to address high rates of 
cardiovascular morbidity and mortality among coalminers in the Cessnock 
region of New South Wales, transformed miners from being perceived as 
'...bad to being fat’. Coalfields people had been identified as suffering higher 
rates of cardiovascular morbidity and mortality than the rest of the Hunter 
region. They were shown to have a higher prevalence of cardiovascular risk 
factors such as obesity, smoking and high serum fats. A community-wide 
heart disease prevention program was launched. Metcalfe claims that the 
campaigns were developed within a healthist discourse which promotes
maximising one's own health. He argues that in the past coalfields people 
had been construed as bad, 'unable to train their minds', delinquent. Now 
they were defined as fat and lacking in willpower. 'Within the healthist 
discourse, they lack self-control which is demanded before people are 
granted the full rights to dignity' p40. Hence the health promotion 
campaigns, designed to address the poor health experiences of the coalfields 
people, had been 'used to reproduce miners and their inadequacy' p38. These 
definitions of the coalfields people might be considered a cultural cost of the 
health promotion campaign.
What do the research findings of this thesis tell us about how contemporary 
clinical and public health practice might construct women? And, how might 
abnormal Pap smears result in cultural costs?
The prevention of cervical cancer depends upon medical surveillance of 
women's cervices. In Chapter Three I suggest that if current referral patterns 
for colposcopy continue, most women will have a colposcopy in their 
lifetime. This means that more women may have colposcopy than is 
necessary to reduce the incidence of cervical cancer. What are the 
consequences of this intensive colposcopic investigation?
In Chapters Five and Six, I show that some women consider that their 
abnormality reflects the inherent disorderliness of women's reproductive 
systems. Their cervices require medical surveillance; women's reproductive 
organs are constitutionally deranged. This surveillance is necessary because 
of the troublesome nature of their cervix. Surveillance also reinforces its 
disorderly quality. This is a significant cultural cost. It might also be 
considered a personal or social cost for individual women.
Individual women also bear costs. This thesis has shown that individual 
women attending a private outpatient colposcopy service have significant 
out-of-pocket expenses. These are significant for all levels of their 
abnormality. In Chapter Ten, I advance the proposition that these out-of- 
pocket expenses may deter some women from completing the recommended 
follow-up.
In this thesis I have identified many possible personal and social costs for 
women. Individual women feel vulnerable and experience embarrassment, 
discomfort and pain because of examination and treatment. They feel 
stigmatised and anxious, and experience changes in their intimate
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relationships. The event redefines who they are. They have a different sense 
of their physical integrity. Their abnormality redefines them as having a 
cervix that is life-threatening. Some women feel out of control of their own 
health. Their attempts to re-assert control, evident in their narratives about 
stress and lifestyle, are not part of the clinical encounter. The marginalisation 
of women's accounts of what is happening to them exacerbates their distress.
No-one would want these costs to occur, so how do they come about?
A framework for understanding the costs
I suggest that two dynamics contribute to the high costs identified in this 
research: the clinician's concern to reduce clinical uncertainty, and the weak 
representation of women's perspectives in clinical and public policy decision­
making.
In this section I explore these dynamics and suggest that clinical protocols, 
developed within a policy framework, may not achieve the changes 
necessary in clinical practice to reduce costs. In making these arguments, I 
return to the notion, developed throughout the thesis, that abnormal Pap 
smears have three major stakeholders: clinicians, public health practitioners1 
and women who have abnormalities. Decisions about abnormal Pap smears 
occur in two settings: the clinical encounter and the formulation of public 
health policy. What is each stakeholder's perspective and what choices are 
available to them in the two settings?
The role of clinical uncertainty
The clinician’s concerns to reduce her or his uncertainty is well illustrated in 
the deliberations that went into the formulation of the document "Guidelines 
for the Management of Women with Screen Detected Abnormalities". 
(Commonwealth Department of Human Services and Health 1994). This 
document was produced after research for this thesis was conducted, and 
therefore had no influence on the activities studied in this research.
However, reviewing the development of the clinical protocols presented in 
the document reveals the differences between the perspectives of the 
clinicians and public health practitioners.
I I use the term public health practitioner to encapsulate those working from a public health 
perspective, including the health economist, the epidemiologist and the health bureaucrat.
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A working party was formed with the aim of achieving consensus about 
appropriate clinical recommendations for women who have abnormal Pap 
smears. To do this, a protocol was developed. The working party included 
three gynaecological oncologists, an epidemiologist, a cytopathologist, a 
medical educator, a consumer representative and a general practitioner. The 
working party was dominated numerically by practitioners working in 
clinical settings. The epidemiologist was the only public health practitioner 
(although some of the members with clinical expertise may have shared some 
of her perspectives). One woman — the 'consumer representative' — was to 
represent all women!
During the development of the Commonwealth guidelines, there was debate 
between members of the working party with population perspectives and 
those adopting a clinical perspective. Most of the disagreement concerned 
the approach to care of women with CIN l.2 From a population perspective, 
the concern was that referral and treatment of women with cytological 
evidence of CIN 1 would incur financial costs with little reduction in 
population morbidity or mortality.
Clinicians were concerned that some women with CIN 1 might have either a 
high-grade lesion or a rapidly-growing lesion, or that they might develop 
cervical cancer because of inadequate follow-up. The clinicians’ view 
prevailed and the guidelines recommend referral of all women with CIN 1 
for colposcopy and treatment if CIN 1 is confirmed.
This policy might be viewed as irrational by a public health practitioner 
because the financial costs are too high. Referring and treating all women 
with CIN 1 might reduce the incidence of cervical cancer slightly but would 
result in substantially higher financial costs to the community. This is 
confirmed again in the research findings of this thesis.
At the clinical level, the clinician is also conscious of the uncertainties with 
which she or he is working. How might the clinician decide whether to refer 
a woman for colposcopy? They are aware of the ambiguity of scientific 
knowledge, the incompleteness of their own knowledge, and the difficulty of
2 For example, draft protocols were discussed at the Annual Scientific Meeting of the 
Australian Society of Colposcopy and Cervical Pathology in Adelaide, in 1992, which I 
attended. Members of the working party were keen to obtain the support from the society 
for their position, which was to recommend colposcopic investigation and treatment for all 
women with cytological evidence of CIN 1. I also discussed the deliberations with 
employees of the Department of Human Services and Health.
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transferring general knowledge to a specific situation. Research has not 
defined clearly the natural history of cervical cancer. The role of various risk 
factors such as HPV is controversial, and the accuracy and comparability of 
pathology tests is poor, even in the best of circumstances.
What might clinicians consider when they make decisions about whether to 
refer a woman with an abnormal Pap smear for colposcopy? If a woman has 
a colposcopy and treatment is undertaken then her risk of future cancer is 
reduced. Alternatively, if the colposcopy reveals no abnormality, a higher 
degree of diagnostic certainty is achieved and the doctor and the woman may 
be reassured.
What are the costs of not referring? The individual woman may develop 
cancer. This would be a tragedy for the individual woman and the clinician 
would be distressed that they have failed to protect the woman's health. If 
the woman developed cancer they may also be at risk of litigation. The 
decision may be considered an error and the professional integrity and self- 
respect of the clinician might be undermined. A clinician who refers can be 
guaranteed that she or he will not be considered negligent in professional or 
legal terms. Katz (1984) argues that in clinical practice 'errors of commission 
are less reprehensible than errors of omission'. From the clinician's 
perspective, referring a woman with an abnormal Pap smear for colposcopy 
is likely to be conceived as the safest approach.
It is possible that gynaecologists are predisposed towards treatment after 
they have established that a woman has a low-grade lesion. Their reasons 
may be similar to the rationale for referring women with low-grade lesions 
for colposcopy in the first place. To treat ensures that an individual's risk of 
future cancer is minimised. One of the gynaecologists contacted during the 
course of the study told me that he was aware that treating women with 
minor abnormalities was of dubious value. Nevertheless he felt that omitting 
treatment was not an acceptable alternative.
The pathologist who reads the cytology and histology slides also requires 
consideration. What do they do when faced with a slide which is 
ambiguous? Do they call it abnormal? If they are unsure how to grade an 
abnormality are they likely to report it as a higher grade? Like the clinician 
who sees an individual patient, the pathologist who reports on cytology or 
histology specimens carries heavy responsibility, like the clinician, the 
pathologist might feel that it is best to be cautious. They may decide to call
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an ambiguous slide a higher grade and therefore ensure that the woman is 
investigated further, rather than risk misdiagnosing a high-grade lesion or 
cancer.
Contemporary clinical and pathology practices are resulting in large 
disparities between the population-based risks of cervical cancer and risk of 
referral for colposcopy. How might a change in clinical practice be 
accomplished? Clinical protocols are a possible avenue for modifying 
practice.
The application o f protocols in clinical practice
There is no doubt that consistent recommendations are required for the 
clinical care of women who have screen-detected abnormalities. The new 
Commonwealth protocol is a useful first step (Commonwealth Department of 
Human Services and Health 1994). The research conducted for this thesis 
suggests that even if all women with CIN 1 or above were referred for 
colposcopy, and the new guidelines were adopted in the clinic studied, there 
would still be a reduction in the number of women referred for colposcopy 
because women with abnormalities less than CIN would not be referred. 
However, I believe the new guidelines are unlikely to produce substantial 
changes in clinical practice because the appreciation of the costs and benefits 
of particular decisions in the clinical setting is different from that in the 
public health setting.
Previous research has demonstrated that protocols alone do not always 
change clinical practice. In light of an increasing tendency for Caesarean 
section in Canada, a consensus statement on Caesarean delivery was 
produced under the auspices of a specialty organisation. According to 
Lomas, Anderson et al. (1989), despite widespread acceptance of the 
statement amongst obstetricians, practices altered only slightly following the 
release of the guidelines. The authors conclude:
The results underscore the fact that the practices of physicians are 
influenced by many things besides research evidence, even when 
such research evidence is packaged in a set of clear concrete 
recommendations. In this case, there may have been other barriers 
to the implementation of the recommendations because of 
perceived threats of malpractice litigation from potentially 
dissatisfied patients, inadequate skills for the vaginal delivery of a 
baby in a breech presentation, economic and socioeconomic 
incentives to perform Caesarean section as opposed to vaginal
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delivery or even pressure from the women who were offered the 
opportunity to avoid a potentially painful and prolonged vaginal 
delivery. pl312
Even when there are no detailed protocols, health service organisations may 
have different priorities from those of clinicians. It may be difficult, or 
impossible, for hospital managers, for example, to produce changes in the 
behaviour of doctors. Fox (1991) found that policy recommendations for the 
organisation of surgery in the operating theatre (OT) were not implemented 
by clinicians. This was despite clinicians giving advice to hospital 
management when the policy was formulated. He suggests that 'any 
apparent shared interest between management and clinicians at the policy 
level is in fact illusory, based on differing conceptions and different meanings 
of the passage of the patient through the OT' p740. The clinicians and 
hospital managers defined 'success' in ways that represented their 
professional interests. For the hospital manager, success related to efficiency, 
while for the clinician, success was clinically defined. Despite the clinicians 
and management agreeing on policy regarding the workings of the operating 
theatre these were not realised in the OT where the clinician retained 
autonomy and could subvert the decisions of management. (Fox 1991).
This brings us back to the argument about how clinicians and public health 
practitioners conceptualise the costs and benefits of particular decisions. For 
the public health practitioner the relevant costs are the aggregate financial 
costs to government and to women, and the benefits are the total number of 
cancers averted. As discussed previously, for the clinician assessment of the 
costs and benefits of specific decisions relate to an individual. These might 
be considered micro-costs and -benefits. The public health policy discourses 
are concerned about cost efficiency. Within this discourse the clinicians 
managed to achieve a greater investment of resources for a given number of 
cancers prevented than the public health practitioner might regard as 
optimal. However, the clinician's concern for individual costs and benefits is 
not part of the policy making, just as the public health practitioner's concern 
for macro-level costs and benefits is not considered in the clinical encounter.
The clinical decision does not consider how much referring or treating a 
woman with a low-grade lesion contributes to aggregate costs and benefits. 
Instead it revolves around how treatment or referral might reduce an 
individual’s risk and therefore benefit the individual. From this perspective, 
it might even be considered appropriate to recommend referral or treatment
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for women with mild atypia or HPV. The protocol developed in the 
committee room, agreed to by all members of the committee who apparently 
share a common interest in maximising aggregate benefits and minimising 
aggregate costs, becomes more or less irrelevant in the clinic.
There is another problem with the Commonwealth guidelines. They reduce 
clinical decision-making to a mechanical process with a few distinct steps: a 
woman is found to have a particular abnormality, the abnormality is 
investigated further and, if necessary, treatment is undertaken. Such a 
protocol implies that clinical decision-making is driven by diagnosis alone. 
But, as we have seen in this thesis, other pressures and the clinician's concern 
about uncertainty — not identified in the policy document — may influence 
how clinicians make decisions and provide clinical care.
Marginalising women's accounts
Whatever the effect of protocols on clinical practice, one voice is silent. 
Women's perspectives have not been considered in the clinical or policy 
framework.
The title of the policy document released recently is revealing. It refers to 
women with screen-detected abnormalities being 'managed'. A woman can 
hardly be an autonomous agent within this construction. At the public health 
policy-making level the financial costs are the dominant consideration. The 
benefits are lives saved or cancer averted. What of the cultural consequences 
of naming and referring for colposcopy a large proportion of the female 
population with cervical abnormalities? How can accounts of these cultural 
costs be represented within the policy-making process?
It may be argued that the working party included a consumer representative 
whose responsibility was to articulate women's concerns in the committee 
room. Such an expectation is unrealistic, however. Let us compare the 
resources of the single consumer representative on the working party 
committee with those of the three gynaecological oncologists. As members of 
a professional college they have access to resources to consult and lobby.
They can draw upon an abundance of research and have extensive personal 
experience which they can legitimately bring to the working party. On the 
other hand, the consumer representative is meant to represent the views of all 
women who have abnormalities. She has a limited capacity to consult with 
other women and there is very little literature on women's experiences of
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abnormalities. She must imagine what it is like for other women.
Furthermore her lack of resources limits her capacity to speak with 
confidence and authority on the working party.
The policy attempts to incorporate women into the clinical decision-making 
process but it is the clinician's responsibility to achieve this. The policy 
suggests that women with abnormal Pap smears make decisions about the 
appropriate course of action in particular circumstances. It is proposed that 
the clinicians present the information to women and that the clinician and the 
woman with the abnormality take responsibility for ensuring adequate 
follow-up after referral and treatment of a screen-detected abnormality. The 
document does not address the question of litigation if a woman who is not 
referred or treated develops cervical cancer. The clinician still carries the 
responsibility for providing the information and for cancers missed under the 
current approach. This maintains their position of power and responsibility 
in the clinical decision-making process.
In the clinical setting, GPs and gynaecologists were important sources of 
medical information. Many women found this information unsatisfactory 
because it did not address the significance of their abnormality, the rationale 
for treatment or the reasons for the after-effects many experienced. A couple 
of women said they may not have had treatment if they had had fuller 
knowledge of the natural history of cervical abnormalities. Leslie stopped 
having medical treatment when she continued to have abnormalities despite 
treatment. Referral and treatment had not reduced her risk. Most women 
apparently did not make active decisions about whether referral or treatment 
should proceed.
A series of visits establishes the cervix as a possibly disordered organ and 
signals that medical treatment and surveillance are the only way to manage 
this unpredictable organ. Women did not have full access to the 
gynaecological accounts, they could not see their cervix (although most 
would have liked to), and they were not told enough about their abnormality.
When they were first informed of their Pap smear result, most women feared 
that they had or would get cancer. How was their anxiety about developing 
cancer experienced by clinicians? Perhaps one way was by referring and 
treating the women.
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Finally, women's ways of making sense of their abnormality could not be 
heard within the clinical encounter. For example, some women’s ways of 
managing their risk, through changes in their diet and lifestyle, could not be 
incorporated into their overall clinical care. In the clinical situation, medical 
treatment and surveillance were the only legitimate ways of approaching the 
abnormality and one's future risk of cervical cancer. I have previously 
proposed that such marginalising of women's experiences may contribute to 
some women's non-attendance for follow-up.
Clinicians and women with abnormalities might agree that the benefit of 
referral and treatment is the reduction of individual risk, but is either aware 
of the likely costs to the individual of referral and treatment? That is, are the 
out-of-pocket expenses to women and the emotional costs of having an 
abnormality considered?
Summary
Clinicians' ethical concern for the reduction in individual risk has meant that 
a large proportion of the female population will be diagnosed as having an 
abnormal Pap smear and will be referred for a colposcopy. This results in 
significant personal and cultural costs. Protocols for clinical practice may not 
achieve a change in practice because the costs and benefits of particular 
decisions are thought of differently in the committee room, where policy is 
made, and in clinical practice, where clinicians retain responsibility for 
decisions. Finally, women's experiences have remained peripheral both to 
clinical practice and public health policy. I maintain that having clinicians as 
the key players in this program results in significant costs, both aggregate 
and individual. So, how might this be different?
Women playing a more active role in decision-making
As stated previously, clinicians have the responsibility for making the 
decisions about the appropriate course of action in a particular situation or a 
particular category of situations. They manage the clinical uncertainty. If 
this responsibility was shared with the women who have abnormal Pap 
smears, the program might be more effective and result in lower costs. If 
individual women were better informed about the likely costs and benefits of 
particular courses of action, and consequently contributed more 
knowledgeably to decisions made about their care, things might change. The
responsibility for preventing future cancer would then be shared between 
clinicians and individual women with an abnormality. In this scenario, the 
fully informed woman could decide whether she wanted a colposcopy or 
treatment for her abnormality based on her appreciation of the probable costs 
and benefits of these options.
How might such a process be achieved? How could individual women with 
abnormalities become knowledgeable about the pros and cons of particular 
decisions? Although clinicians are an important source of such information 
they might present it in a way that preserves the status quo. Which costs 
would they discount and which would they emphasise? Other ways of 
providing the information might be developed. Resourcing workers in the 
women's health community to provide written and verbal information might 
be an alternative. The booklet "When a Pap smear isn't all clear", produced 
by the Women's Health Information Resource Collective in 1988, is an 
example of the written information that might be produced. It combines 
clinical information with accounts of several women's experiences of 
treatment. I gave this booklet to some of the women I interviewed, who 
found it useful. None of them had seen the booklet before. Clearly, such 
publications require wider circulation. Information provided by community 
organisations might create a greater scepticism among women about the 
value of medical intervention. Individual women could then make informed 
decisions about their care. By shifting the politics of clinical decisions, 
individual women's ways of making sense of their abnormality would 
become central rather than silenced. This might improve the follow-up rate.
How could the women's health community become more influential in policy 
development? Better documentation of women's experiences is required.
This would mean that the costs and benefits considered in the formulation of 
policy would not be only the dollar costs and cancers prevented. For 
example, the cultural consequences of particular forms of clinical practice 
such as those described in this thesis might be thought of as a cost and 
considered in the formulation of policy. Like the gynaecologists with their 
professional college which has in-built structures and resources to consult 
with colleagues, women's health advocates need the resources to develop a 
structure to consult. Such a structure was developed for consultation leading 
to the National Women's Health Policy. It is also available in small, poorly 
resourced, volunteer non-government organisations.
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Women have not been given a full account of how screening prevents cancer 
of the cervix. Health promotion messages have not addressed the 
mechanisms of prevention. Women are recruited into the cervical cancer 
screening program, but they are not informed about how it works and do not 
know the costs and benefits of making particular decisions about their care. I 
suggest that this should be changed and that this change might facilitate a 
reduction in both the individual and aggregate costs of the cervical cancer 
screening program.
Directions for future research
Two questions that arise from the analysis of costs could be subjects of 
further research. I have maintained that in the clinic and public health policy, 
women's accounts of what is happening to them individually and as a 
collective are not heard or are considered irrelevant. Future research might 
usefully document how this silencing occurs.
The second question that arises from this analysis is, how do some options 
become obvious courses of action?
Further investigation of these two issues would reveal the structures of 
current practices that uphold certain accounts and silence others. Such an 
approach would illuminate how clinical practice and public health policy 
currently operate and would enable the development of alternatives.
Individual interviews with clinicians and public health policy makers may 
help answer these questions. A study that observed clinical interactions and 
the public health policy-making process may also shed light on these queries.
Some of the research findings of the thesis also require further development.
The health economic study was based in one private outpatient service. 
Similar studies in public services and other private services would enable 
further elucidation of the distribution of economic costs according to level of 
abnormality and other variables such as age and socio-economic status. If 
cytology registries collect data on the follow-up and treatment of women 
who have abnormal Pap smears, future research could examine which 
categories of women do not complete the appropriate follow-up. Such 
information could then inform the delivery of services. Women and service 
providers could develop services that are more cognisant of women's needs.
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My interviews with women were conducted after the diagnosis of an 
abnormal Pap smear. These women came to experience their risk as part of 
themselves. Interviews with women before as well as after a diagnosis of an 
abnormal Pap smear might disentangle how the diagnosis per se shaped 
women's perception of their risk. Such research could explore how cervical 
cancer screening constructs women's perceptions of their risk of cervical 
cancer and clarify some of the non-dollar costs of abnormal Pap smears.
I have suggested that there are cultural consequences of current forms of 
practice; that cervical screening and the identification of women with cervical 
abnormalities perpetuates the construction of women as having reproductive 
organs that are inherently troublesome. This finding requires further 
elaboration. A qualitative study involving women who have had 
abnormalities as well as those who have not, could disentangle how cervical 
abnormalities shape this construction.
Concluding remark
It is now thirty years since cervical cancer screening was introduced in 
Australia. While there have been benefits, there have also been significant 
costs. When Phillipa was told that she had a positive Pap smear, she said:
You felt very demeaned by it all — and you think how could one 
little slip of paper make you feel so rotten?
Hopefully, in another thirty years the cervical screening program can 
produce the benefits without the burden of costs that women such as Phillipa 
experience today.
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Appendix A
Standard errors of Medicare estimates
Total number estimates
The standard errors of the total population estimates were calculated using 
the following formula:
standard error = -S.x  V l - f  
Vn
where s, the sample standard deviation, is given by:
and n = sample size, yi = the sample values, and since yi = 0 or 1,
The finite population correction (fpc) is 0.9 for the Medicare Samples. A fpc 
is only necessary if the sample fraction is equal to or above ten per cent 
(Kirkwood 1988).
i =  1
n
n -1
n n
I y i 2 = I y i
i = 1 i = 1
y = the sample mean, N = total population. (Cochran 1977) p24 
1 - f, the finite population 
correction, is given by:
N was calculated by determining the number of female Medicare enrollees 
for ACT and Australia for the financial year 1989/90. N was adjusted for the 
proportion of women who had had a hysterectomy in each age group.
Proportion estimates
se(proportion) = j ( l - f ) ' P^ . j ^
where p = sample estimate of the proportion. (Cochran 1977) p52
Ratio estimates
To calculate the variance of the ratio estimate the following formula was 
used:
n
Xyi
Given that the estimated ratio R = * ~ *n
X *i=l
the standard error of (R) =
n n n n
When yi and xi are equal to 0 or 1 then ^ y i  = ^  yi and ]Txi^ = ^ x i.
i = 1 i = 1 i = 1 i = 1
n  2 n  2When yi and xi have values other than 0 or 1 then ^ y i z and xiz cannot
i = 1 i = 1
be calculated because I only had access to aggregate Medicare data, 
n
The term 2R ^y ix i estimates the covariance of x and y. This is assumed to 
i = 1
be zero because it cannot be estimated without access to the individual data 
from the Medicare sample. This is a conservative assumption. In large 
samples, the normal distribution can be used to calculate the confidence 
limits of a ratio. (Cochran 1977) p31-32
VT-f i
xVn '
X y i 2 -2 R  X yix i+R2 X * i2
[ = 1 i = 1 i = 1
n -1
256
Appendix B
Interview schedule
Part A
Understanding of the condition 
Meaning of precancer 
Progression /  regression 
Probability of cure 
Severity/Risk of invasive disease 
Commonness
Role of viruses/sexual transmission
Possible complications/Interpretation of meaning of complicatio 
Meaning of cancer
Development of current understanding
Education /  reading
Contact with health care system
Other women/family/friends
GP/Gynaecologist/Primary health practitioner
Health promotion/Health education messages
Recommendations
Part B
Explanations for condition 
Relevance of life context 
Role of chance
Explanations for other illnesses
Relevance o f cervix/genitalia 
Description of cervix 
Attitudes/feelings/beliefs about cervix 
Effect of removal of cervix
Relationship between this experience and their life context
Effect on rest of life
Effect of life context on experience
Relationship to issues about control
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Appendix C
Pseudonyms
Adrienne: aged 41, lives with her male partner and works in the public 
service. She suffers from a chronic illness which she linked to 
her abnormality. At the time of interview Adrienne felt well. 
Adrienne had CIN 3 which was treated with laser.
Amanda: aged 30, lives with her husband and children. She works in 
the insurance industry. Amanda had CIN 3 which was 
treated with laser. At the time of interview Amanda still 
thought she had had cancer. Amanda found that the 
abnormality had made her more aware of her own mortality 
and the possibility that she may develop cancer. 
Unfortunately the tape recorder did not work for Amanda's 
interview so I wrote some quotes verbatim but I mainly noted 
the content of her answers.
Amy: aged 21, works in the public service and lives with her male 
partner. She had wart virus found on her smear six years 
previously. Recently she had CIN 2 and HPV and had laser 
treatment. One of Amy's main concerns was her mother's 
reaction to her wart virus infection. Her mother believed that 
wart virus was sexually transmitted and Amy felt her mother 
was angry at her for developing a sexually transmitted 
infection. Her mother worked in the health area.
Anna: aged 29, lives with her partner and works as a curator. She 
had CIN 3 on cervical biopsy and had laser treatment. Anna 
wanted much greater involvement in decisions about her 
gynaecological care.
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Brenda: aged 34, works in a library and lives alone. She had CIN 2 on 
Pap smear and had laser treatment. After a recurrence she 
had further laser treatment. She has recently divorced. Her 
partner had been unsupportive when she had the abnormality 
diagnosed and had treatment. Brenda was adamant that she 
should have much more information about the medical 
approach to abnormal Pap smears. She appreciated doctors 
who expressed their uncertainty and she questioned 
categorical statements about abnormal Pap smears and 
treatment. She was angered, and not reassured by, clinical 
staff who told her "not to worry".
Bronwyn: aged 22, works in marketing and lives with her male partner.
She has HPV affecting her vulva and on Pap smear. She had 
had two laser treatments and various topical treatments. 
Although her Pap smears no longer demonstrated HPV she 
has persistent wart virus infection of her vulva. Bronwyn felt 
a lot of pain with any sexual activity involving her genitals. 
She was concerned that she had "invented" her pain and that 
this was affecting her relationship.
Carmel: aged 37, lives with her husband and children. She works with 
preschool children. Carmel had CIN treated five years 
previously with a cone biopsy and it had recurred. She had 
laser treatment following the second abnormality. Her 
abnormality caused her to reflect upon her own mortality. 
Although she still feared her own death she appeared to feel 
more comfortable thinking about it than she had prior to the 
abnormality.
Gladys: aged 50, lives with her husband. Gladys has had abnormal 
Pap smears for 26 years. Her Pap smears have demonstrated 
inflammatory'and atypical changes. She had diathermy 11 
years ago and is currently deciding whether to have further 
ablative treatments. Gladys desired more information about 
her abnormality and her treatment options. She brought her 
case notes to the interview for me to read. These documented 
her Pap smear results and the treatments over many years.
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Gloria: aged 65, lives on her own. She retired from community
nursing several years ago. Gloria is a keen gardener and bush 
walker. Several years ago Gloria suffered from a lump in her 
breast and at the time she was concerned that it was 
malignant. Gloria had CIN 3 and a cone biopsy under general 
anaesthetic.
Heather: aged 24, is married and works in the public service. She 
studies part-time. She had CIN 2 and had laser treatment. 
Heather was initially concerned that she had cancer.
However, overall she felt her abnormal Pap smear was only a 
minor problem.
Jenny: aged 46, lives with her husband and children. She trained as a 
nurse. Jenny had CEN 2 found on her Pap smear and had laser 
treatment. Because of her abnormality Jenny thought more 
about her own death. She felt it had changed her approach to 
nursing, making her more sensitive to her patients' needs.
Judith: aged 53, works with books and lives with her husband. She 
had HPV found on her Pap smear and had had laser 
treatment. The main issue for Judith was how the diagnosis 
affected her relationship with her husband. Her husband felt 
she blamed him for her abnormality and she felt uncertain 
about why she developed the abnormality and was reluctant 
about sexual relations.
Julie: aged 29, lives with her husband and two children. Julie was 
studying for an arts degree part-time. She suffered from a 
chronic gastrointestinal disorder which she considered to be a 
much greater problem than her cervical abnormality. Julie 
had a minor cervical abnormality but was unsure of the grade. 
Julie thought the abnormality was a fairly insignificant health 
problem. She had one laser treatment.
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Leslie: aged 24, is a university student who has had cervical
abnormalities for several years. Initially she had CIN 1 and 
wart virus but her condition worsened, despite treatment, to 
CIN 3. Leslie had diathermy under general anaesthetic and 
when her condition recurred had laser treatment with a 
different gynaecologist. Following laser treatment she still 
had CIN 3 and used naturopathic treatment and made 
lifestyle changes. A colposcopy following her naturopathic 
treatment did not reveal any evidence of CIN or HPV. Leslie 
was angry because she felt she had not been fully informed 
about the various treatment options. She also thought that the 
possibilities of recurrences after treatment should have been 
explained.
Lorraine: aged 28, lives with her husband and two children. She had 
CIN 2-3 on colposcopic biopsy. Initially she tried various 
herbal treatments but her CIN persisted so she had laser 
treatment. At the time of her diagnosis Lorraine was 
experiencing considerable emotional trauma. The 
abnormality became part of her narrative about how difficult 
her life was at the time of diagnosis. She had a second 
treatment with laser six months after her first because her 
condition still persisted.
Louise: aged 36, lives with her husband and two children and works 
as an administrator part-time. She had CIN 1 and a diathermy 
under general anaesthetic. After treatment, a colposcopy 
revealed a recurrence of her CIN, however when she returned 
for treatment there was no evidence of CIN. Louise trusted 
her doctors to act in her best interest.
Maeve: aged 70, lives with her husband. She is retired and used to
work as a counsellor. She had CIN 1 and had laser treatment. 
Maeve had recently had an abdominal operation. Maeve read 
quite a lot about abnormal Pap smears. However, she felt she 
did not have adequate information to question clinicians' 
decisions nor make sense of the after-effects she experienced.
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Mary: aged 27, lives with her husband and children. Mary had CIN 
2 and diathermy under a general anaesthetic. For some time 
preceding the abnormal smear Mary had experienced health 
problems and had sought medical advice from several 
doctors. She was frustrated by the lack of diagnosis. Her Pap 
smear was one of the many tests that was done to investigate 
her symptoms. Initially she considered her abnormality might 
explain her symptoms. When the symptoms recurred after 
treatment she was upset that her problems had not been 
resolved.
Peggy: aged 46, lives with her male partner and works as an
administrative clerk. Peggy had CIN 1 and HPV and was 
treated with laser. She believed that without treatment she 
would develop cervical cancer and that the frequency of 
recurrences after treatment was low.
Penny: aged 37, works in the public service. She lives with her
children and male partner. On colposcopy her gynaecologist 
told her she had possible CIN and wart virus infection.
Several months later when she returned for another 
colposcopy there was no evidence of either CIN or wart virus 
infection. She related her abnormality to an emotionally 
difficult period in her life.
Phillipa: aged 36, lives with her husband and children and works as a 
school teacher. She had CEN and HPV on Pap smear and had 
laser treatment. Phillipa was very embarrassed about having 
wart virus infection. She felt stigmatised because she had a 
sexüally transmitted infection.
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Rosemary: aged 19, looks after her child at home. At the time of the 
interview Rosemary was living by herself. Her abnormal 
smear was found when she had a Pap smear at her post-natal 
visit to her obstetrician. She had not previously had a Pap 
smear. Rosemary had CIN 3 and laser treatment. Rosemary 
felt she had had cancer. Her mother, her main support 
person, also feared she would die. Rosemary felt unable to get 
support from her friends who she thought considered her 
abnormality related to sexual transmission and marked her as 
unclean.
Ruth: aged 30, lives with her male partner and works in an
administrative post. She had recently emigrated to Australia 
from the United Kingdom. CIN 1 was picked on her Pap 
smear and she had laser treatment. Several years ago Ruth 
had a cervical abnormality but did not have treatment for it. 
She feared cancer and linked it to the pressures of modem life. 
She believed that the chances of her developing cancer in the 
future were high.
Sally: aged 41, lives with her husband and child and works as a 
graphic artist. Sally had wart virus infection many years 
previously. On Pap smear she had CIN 1 and HPV infection 
and had laser treatment. Sally participated in the study 
because a health professional had previously told her that 
little was known about wart virus infection. She thought of 
her cervical abnormality as part of women's fate to experience 
reproductive afflictions.
Sarah: aged 27, works in the community sector and studies a health 
related degree part-time. Sarah shared a house with several 
other women. She had CIN 2 and a diathermy under general 
anaesthetic. She connected her abnormal Pap smear with a 
difficult period in her life and regrets that she did not adopt 
an expectant approach to the medical treatment for her 
abnormality. She felt this would have enabled her to address 
the other aspects of her life that she related to her abnormality.
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Sharon: aged 31, lives with her husband and works in the community 
sector in a health area. Sharon had CIN 1 and HPV and had 
laser treatment. Sharon's main concern related to the effect of 
the abnormality and treatment on her capacity to have 
children.
Valerie: aged 51, is a school teacher who lives with her husband. She 
had wart virus infection which was treated with laser on two 
occasions. There were still microscopic signs of wart virus 
infection after treatment. She felt that wart virus infection was 
difficult to eliminate. Her husband was also treated for wart 
virus infection.
Veronica: aged 34, is a public servant who lives with her male partner. 
Veronica has CIN 3 diagnosed on Pap smear and had laser 
treatment. Follow-up Pap smears have been normal.
Although she initially thought she had cancer and was 
concerned that she would die, she felt reassured by her GP 
and gynaecologist. Her partner was also supportive.
Winnie: aged 48, works in the public service and is studying part-time. 
She had an abnormal Pap smear 15 years ago which was 
treated with cryotherapy. Three years ago she had diathermy 
for a further recurrence. Recently she had CIN 1 and HPV 
found on her Pap smear and had laser treatment. Winnie felt 
able to ask doctors questions as she had medical friends and 
had some nursing training.
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Appendix D
Definitions of item numbers, DRG and ICD-9 codes
Item numbers
Table D.1 Item numbers*
Item Item description
number
104 Professional attendance at consulting rooms, hospital or nursing home by a 
specialist in the practice of his or her speciality where the patient is referred to him 
or her. INITIAL attendance in a course of treatment.
105 Each SUBSEQUENT attendance to the first in a single course of treatment.
35614 Examination of the lower female genital tract by a Hinselmann-type colposcope.
Benefits for this item are limited to the following circumstances: "(1) where a patient 
has had an abnormal cervical smear; (2) where there is a history of maternal 
ingestion of oestragen by the patient's mother during her pregnancy; or (3) where 
the patient has been referred by another medical practitioner because of suspicious 
signs of genital cancer.
35608 CERVIX, cauterisation (other than by chemical means), ionisation, diathermy or 
biopsy of, with or without dilatation of the cervix.
18200 REGIONAL OR FIELD NERVE BLOCK.
35539 COLPOSCOPICALLY DIRECTED C02 LASER THERAPY for previously
confirmed intraepithelial neoplastic changes of the cervix, vagina, vulva, urethra or 
anal canal, including associated biopsies • one anatomical site.
35542 As for 35539 except that laser is to two or more anatomical sites.
35545 COLPOSCOPICALLY DIRECTED C02 LASER THERAPY for condylomata,
unsuccessfully treated by other methods.
30071 BIOPSY OF SKIN OR MUCOUS MEMBRANE
30118 TUMOUR, CYST, ULCER OR SCAR, up to 3cm in diameter, removal from
cutaneous or subcutaneous tissue or mucous membrane, where removal is by 
surgical excision and suture.
73806______ Pregnancy test by one or more immunochemical methods._____________________
*AII number codes were converted to their equivalent in the Medicare Benefits Schedule Book
November 1992.
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Table D.1 Item numbers* (continued)
Item Item description
number
73806 Pregnancy test by one or more immunochemical methods.
72801 Histopathology examination of biopsy material including all the tissue processing,
staining and professional opinion or opinions.
73055 Cytological examination of smears from the cervix in association with the
management of previously detected abnormalities including precancerous or 
cancerous conditions, or the investigation of women with symptoms, signs or 
recent history suggestive of cervical neoplasia and smears repeated due to an 
unsatisfactory examination.
35646 CERVIX, colposcopy with radical diathermy of, with or without cervical biopsy, for 
previously confirmed intraepithelial neoplastic changes of the cervix, where 
performed in the operating theatre of a hospital or approved day facility.
35653 HYSTERECTOMY, ABDOMINAL, SUB-TOTAL or TOTAL, with or without removal
of the uterine adnexae.
35657_______ HYSTERECTOMY, VAGINAL, with or without uterine curettage._________________
*AII number codes were converted to their equivalent in the Medicare Benefits Schedule Book
November 1992.
Diagnostic related groups
Table D.2 DRGs
DRG code DRG description
360 Vaginal, cervical and vulval procedures
364 D&C, conization except for malignancy
358 Uterine and adnexal procedures for non-malignancy
369_________ Menstrual and other reproductive system disorders
ICD-9-CM procedure classification codes
Table D.3 ICD-9-CM procedure classification codes 
ICD-9 Code Description of code
67.2 Conization of the cervix
67.32 Destruction of tissue by cauterisation
68.4 Total abdominal hysterectomy
68.5 Vaginal hysterectomy
622.1 Dysplasia of the cervix (diagnostic code)
70.31 Hymenectomy
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Appendix E
Cost to government
Cost to government of outpatient treatment
Table E.1 Cost to government: item mix table
35614,
35608
73806 35545 35542 35539
1988/89
Estimated Total No. 21510 2570 160 310 3230
Average cost ($) 48.88 7.50 92.13 172.00 143.93
Standard error ($) 0.03 0.02 0.89 0.00 0.10
1989/90
Estimated Total No. 25530 2510 740 310 5330
Average cost ($) 50.46 8.12 98.32 177.94 150.66
Standard error ($) 0.04 0.02 0.13 0.61 0.24
1990/91
Estimated Total No. 23320 2320 560 350 5220
Average cost ($) 52.95 8.46 102.05 184.69 155.34
Standard error ($) 0.04 0.01 0.31 0.61 0.27
1991/92
Estimated Total No. 21360 2010 510 200 4720
Average cost ($) 55.13 8.65 105.57 188.98 159.02
Standard error ($) 0.03 0.00 0.23 1.02 0.13
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Table E.2 Cost to government: abatement table
Item
Abatement level*
18200**
A
30071# 
A
3 0 1 #
A
35608
A B C
35614
A B C
1988/89
Estimated total 60 530 530 28270 1010 380 58310 22680 590
Average cost ($) 47.60 26.75 64.12 32.62 16.35 8.20 32.67 16.36 8.19
Standard error ($) 0.00 0.03 0.03 0.01 0.02 0.00 0.01 0.00 0.01
1989/90
Estimated total 470 530 530 31800 980 550 66410 26730 760
Average cost ($) 49.12 27.86 67.22 33.78 16.95 8.47 33.81 16.90 8.46
Standard error ($) 0.07 0.06 0.19 0.01 0.04 0.01 0.01 0.00 0.01
1990/91
Estimated total 610 630 390 29210 740 330 69510 24580 510
Average cost ($) 51.59 28.96 70.27 35.33 17.83 8.97 35.43 17.69 8.92
Standard error ($) 0.20 0.07 0.25 0.02 0.05 0.03 0.01 0.01 0.03
1991/92
Estimated total 550 540 510 25840 710 250 66790 22370 380
Average cost ($) 53.47 30.07 73.15 36.78 18.40 9.19 36.85 18.42 9.21
Standard error ($) 0.11 0.08 0.16 0.01 0.03 0.03 0.01 0.01 0.02
* Items are rebated at 85 per cent of the 100, 50 and 25 per cent of the scheduled fee for levels A, B 
and C respectively.
**The multiple operation formula does not apply to 18200 which is always rebated at 100 per cent of the 
scheduled fee.
# Although items 30071 and 30118 were occasionally rebated at levels B and C in my clinic sample 
there were insufficient numbers in the ten per cent file to calculate costs. Therrefore, the cost to 
goverment was taken as 50 per cent and 25 per cent of the abatement A cost when they were rebated 
at levels B and C, respectively.
Table E.3 Cost to government of gynaecological consultations *
Item 104
Estimated
total
Average 
cost ($)
Standard 
error ($)
105
Estimated
total
Average 
cost ($)
Standard 
error ($)
1988/89 576530 44.00 0.00 693110 22.02 0.00
1989/90 588720 45.56 0.00 715920 22.77 0.00
1990/91 594180 47.50 0.01 691170 23.72 0.00
1991/92 596720 49.34 0.00 682800 24.66 0.00
Consultation item numbers are not affected, and do not affect, the multiple operation formulae. All 
consultation item numbers are rebated at 85 per cent of the scheduled fee. Other items charged with 
the consultation are subject to the multiple operation formula separately from the consultation item.
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Table E.4 Costs to government of pathology services*
Pap Smear** Biopsy*
1988/89
Total No. 1,404,324 764,827
Average cost ($) 14.82 67.19
1989/90
Total No. 1,542,957 938,176
Average cost ($) 16.20 69.77
1990/91
Total No. 1,687,936 1,020,0863
Average cost ($) 16.98 73.09
1991/92
Total No. 1,606,427 1,069,780
Average cost ($) 14.33 68.97
* Calculations for Pap smear and biopsy services used a 100% file of pathology services.
** The cost of Pap smear services was calculated using the following item numbers: 2051, 2052, 2053, 
2054, 2081, 2082, 2338, 2339, 73053, 73055, 73057. The item numbers for Pap smears changed over 
the time period of the study. Hence only a few of the above item numbers pertained in any one year.
# The cost of cervical biopsies taken as an outpatient was calculated using the following item numbers: 
2041, 2042, 72801. The item numbers for biopsies changed during the course of study. Hence not all 
of the above item numbers were relevant to any one year.
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Cost to government of public hospital treatment
Table E.5 Costs to governmennt of inpatient public hospital treatment
89/90* 90/91 91/92
Cone biopsy /average LOS 1.41 days)
Average cost per bed day 633.17 736.81 850.56
Total cost 892.77 1038.90 1199.29
Diathermv faveraae LOS 1.04 davsl
Average cost per bed day 750.98 865.63 1125.63
Total cost 781.02 900.26 1170.97
Total abdominal hysterectomv 
(average LOS 8.31 days) 
Average cost per bed day 323.75 348.07 418.90
Total cost 2691.01 2893.16 3481.90
Vaginal hysterectomy
(average LOS 10.30 days)
Average cost per bed day 323.75 348.07 418.90
Total cost 3333.98 3584.42 4313.83
Laser faveraae LOS 1.14 davsl
Average cost per bed day 750.98 865.63 1125.93
Total cost 856.12 986.82 1283.56
Hvmenectomv faveraae LOS 1.60 davsl
Average cost per bed day 750.98 865.63 1125.83
Total cost 1199.32 1382.41 1798.11
Other**faveraae LOS 2.19 days1#
Average cost per bed day 380.13 444.39 404.43
Total cost 832.48 973.21 885.42
LOS = Length of stay in days
* I use 89/90 estimate for 88/89 because there were no DRG cost estimates prior to 89/90
** The other category refers to two women who had unknown treatment in hospital and one woman 
who had a secondary haemorrhage.
# The length of stay in this category was calculated using the diagnostic ICD 9 code 622.1.
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Cost to government of private hospital treatment
Table E.6 Cost to government of private hospital inpatient treatment (medical 
expenses)
35618 35646 35653 35657
1 9 8 8 /8 9
E s tim a te d  total 1950 7960 15980 810
A v e ra g e  cost ($ ) 253.83 235.71 527.52 604.29
S ta n d a rd  e rro r ($ ) 5.23 2.47 3.14 11.54
1 9 8 9 /9 0
E s tim a te d  total 2080 6310 14250 2670
A v e ra g e  cost ($ ) 270.54 252.03 563.36 635.92
S ta n d a rd  erro r ($ ) 5.13 2.90 3.60 5.98
1 9 9 0 /9 1
E s tim a te d  total 2270 5630 12280 3890
A v e ra g e  cost ($ ) 272.55 271.61 582.06 674.72
S ta n d a rd  erro r ($ ) 4.17 3.33 3.98 6.22
1 9 9 1 /9 2
E s tim a te d  total 1990 3910 10870 4890
A v e ra g e  cost ($ ) 278.30 279.67 605.15 697.85
S ta n d a rd  erro r ($ ) 5.88 4.61 4.29 5.49
Appendix F
Cost to women
Cost to women of outpatient treatment
Table F.1 Cost to women: item mix table
35614 ,
3 5 6 0 8
7 3 8 0 6 35 5 4 5 35 54 2 3 5 5 3 9
1988/89
Estim ated total no. 2 1 5 1 0 2 5 7 0 160 31 0 32 30
A verage cost ($) 16 .19 2 .8 9 20.41 3 0 .9 4 38 .22
Standard  error ($) 0 .33 0 .0 3 4 .1 7 5 .47 3 .07
1989/90
Estim ated Total No. 2 5 5 3 0 25 1 0 740 31 0 5330
A verage cost ($) 19 .49 2 .5 8 4 0 .0 7 51 .55 4 2 .0 3
Standard  error ($) 0 .3 5 0 .0 2 2 .8 4 8 .5 0 2 .3 7
1990/91
Estim ated Total No. 2 3 3 2 0 2 3 2 0 560 35 0 5220
A verage cost ($) 2 1 .39 2 .7 4 3 7 .2 7 7 4 .95 4 9 .4 4
Standard  error ($) 0 .17 0 .0 3 4 .3 9 11 .10 1.72
1991/92
Estim ated Total No. 2 1 3 6 0 20 10 510 200 4 7 2 0
A verage cost ($) 2 1 .5 4 2 .7 7 39 .9 2 7 1 .27 4 9 .4 4
Standard  error ($) 0 .4 6 0.21 5 .33 14.01 3 .83
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Table F.2 Cost to women: abatement table
Item
Abatement level*
18200**
A
30071# 
A
30118# 
A
35608
A B C
35614
A B C
1988/89
Estimated total 60 530 530 28270 1010 380 58310 22680 590
Average cost ($) 16.40 12.95 19.64 10.62 4.73 1.79 11.59 5.50 3.44
Standard error ($) 3.39 1.83 2.55 0.19 0.24 0.39 0.15 0.11 0.36
1989/90
Estimated total 470 530 530 31800 980 550 66410 26730 760
Average cost ($) 26.88 10.82 18.61 12.07 5.75 4.70 13.41 6.37 3.90
Standard error ($) 1.71 1.74 2.89 0.20 0.59 0.43 0.16 0.11 0.40
1990/91
Estimated total 610 630 390 29210 740 330 69510 24580 510
Average cost ($) 33.56 17.32 22.50 13.60 6.12 3.56 14.69 7.13 4.03
Standard error ($) 1.16 2.12 3.57 6.12 0.74 0.30 0.18 0.15 0.45
1991/92
Estimated total 550 540 510 25840 710 250 66790 22370 380
Average cost ($) 34.14 15.00 20.88 13.61 7.81 2.51 14.87 7.17 4.03
Standard error ($) 1.52 2.31 3.49 0.27 0.93 0.53 0.19 0.15 0.51
* Items are rebated at 85 per cent of the 100, 50 and 25 per cent of the scheduled fee for levels A, B 
and C respectively.
**The multiple operation formula does not apply to 18200 which is always rebated at 100 per cent of the 
scheduled fee.
# Although items 30071 and 30118 were occasionally rebated at levels B and C in my clinic sample 
there were insufficient numbers in the 10 per cent file to calculate costs. Therefore, the cost to 
government was taken as 50 per cent and 25 per cent of the abatement A cost when they were rebated 
at levels B and C respectively.
Table F.3 Cost to women of outpatient gynaecological consultation*
Item 104
Estimated
total
Average 
cost ($)
Standard 
error ($)
105
Estimated
total
Average 
cost ($)
Standard 
error ($)
1988/89 576530 10.96 0.03 693110 5.83 0.02
1989/90 588720 12.65 0.03 715920 6.74 0.02
1990/91 594180 14.39 0.04 691170 7.77 0.02
1991/92 596720 15.53 0.04 682800 8.43 0.02
* Consultation item numbers are not affected, and do not affect, the multiple operation formulae. All
consultation item numbers are rebated at 85 per cent of the scheduled fee. Other items charged with 
the consultation are subject to the multiple operation formula separately from the consultation item.
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Table F.4 Costs of pathology services to women*
Pap smear** Biopsy#
1988/89
Total no. 1,404,324 764,827
Average cost ($) 3.05 18.15
1989/90
Total no. 1,542,957 938,176
Average cost ($) 3.55 18.29
1990/91
Total no. 1,687,936 1,020,0863
Average cost ($) 3.55 18.67
1991/92
Total no. 1,606,427 1,069,780
Average cost ($) 3.10 18.17
* Calculations for Pap smear and biopsy services used a 100 per cent file of pathology services.
** The cost of Pap smear services was calculated using the following item numbers: 2051,2052, 2053, 
2054, 2081, 2082, 2338, 2339, 73053, 73055, 73057. The item numbers for Pap smears changed over 
the time period of the study. Hence only a few of the above item numbers pertained in any one year.
# The cost of cervical biopsies taken as an outpatient was calculated using the following item numbers: 
2041, 2042, 72801. The item numbers for biopsies changed during the course of study. Hence not all 
of the above item numbers were relevant to any one year.
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Cost to women of private hospital treatment
Table F.5 Cost to women for private hospital treatment (medical expenses)
35618 35646 35653 35657
1988/89
Estimated total 1950 7960 15980 810
Average cost ($) 53.61 46.66 101.90 116.41
Standard error ($) 3.96 1.62 2.26 11.38
1989/90
Estimated total 2080 6310 14250 2670
Average cost ($) 56.20 60.24 131.52 109.10
Standard error ($) 3.71 2.62 2.97 7.14
1990/91
Estimated total 2270 5630 12280 3890
Average cost ($) 70.92 9.28 153.18 148.22
Standard error ($) 4.38 2.85 3.56 6.68
1991/92
Estimated total 1990 3910 10870 4890
Average cost ($) 67.43 85.10 174.33 180.43
Standard error ($) 4.43 4.32 4.00 6.70
Table F.6 Private hospital accommodation costs to women
1/5/90 to 30/9/90 
($)
1/11/90 ($)
Cone biopsy (median LOS 1 day) 5.00 20.00
Diathermy (median LOS 1 day) 5.00 20.00
Total abdominal hysterectomy
(Median LOS 8 days) 25.00 40.00
Women admitted on dates not included in the table did not have any accommodation expenses for their 
private hospital admission.
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